{"Topic 1": {"7499": "heart_failure_hf remains major public_health problem western country despite enormous progress diagnosis_treatment acute chronic decompensated hf leading medical cause hospitalization among people aged_year european country usa australia new zealand however study acute chronic decompensated hf european society_cardiology esc guideline subject published aim evaluate overall prevalence hospitalization due hf according subtypes comorbidities decompensating factor medical department central teaching hospital urban area method performed retrospective observational_study patient_admitted consecutively medical department via emergency room january june discharge casenotes admission reviewed diagnosis hf cardiovascular condition associated precursor hf analyzed case final diagnosis hf according criterion esc guideline included_study evaluated overall prevalence hf subtypes cardiac_dysfunction etiological risk_factor patient demographic characteristic decompensating factor comorbidity mean length hospital_stay hospital_mortality rate result identified patient_hf mean_age male aged female aged left_ventricular_systolic_dysfunction lvsd present_case preserved left_ventricular systolic_function valvular_heart_disease hypertension coronary_artery_disease main etiological risk_factor respectively atrial_fibrillation recorded patient_diabetes diagnosed anemia chronic_obstructive_pulmonary_disease one third infection predominantly respiratory main factor triggering decompensation followed uncontrolled hypertension supraventricular tachyarrhythmia admission patient nyha_class iii nyha_class iv hf_patient mean hospital_stay day slightly shorter mean overall stay patient_admitted medical department period day hospital_mortality hf_patient hf first cause admission medical department followed stroke conclusion_study confirms high_prevalence acute chronic decompensated hf_patient hospitalized medical department central teaching hospital urban area patient mainly elderly gender slightly higher proportion hf due lvsd patient nyha_class iii_iv mean hospital_stay longer patient_admitted period hospital_mortality rate low age_group affected high_prevalence multiple comorbidities emphasize need establish hf clinic multidisciplinary team manage patient health authority must made aware burden syndrome:0.0191563943613575", "106693": "background large_scale contemporary population_based study heart_failure incidence needed inform resource planning research prioritisation current evidence scarce aimed assess temporal trend incidence prevalence heart_failure large general_population cohort uk method population_based study used linked primary secondary electronic health record million individual clinical_practice research datalink cprd cohort representative uk population term age_sex eligible patient_aged_year older contributed data jan dec acceptable record according cprd quality control approved cprd hospital episode statistic linkage registered general practice least month patient incident heart_failure extracted recent measurement baseline_characteristic within_year diagnosis electronic health record well information comorbidities socioeconomic status ethnicity region calculated standardised rate applying direct age_sex standardisation european standard population inferred crude rate applying year specific age specific sex specific incidence uk census mid year population estimate assumed heart_failure_patient aged_year younger report total incidence prevalence age_year finding heart_failure incidence standardised age_sex decreased similarly men_woman per_person_year adjusted incidence ratio ci however estimated absolute number individual newly_diagnosed heart_failure uk increased largely due increase population size age estimated absolute number prevalent heart_failure case uk increased even study_period patient age multi morbidity first presentation heart_failure increased mean_age_year sd year adjusted difference year ci mean number comorbidities sd v adjusted difference ci socioeconomically deprived individual likely develop heart_failure affluent individual incidence_rate ratio ci earlier life affluent group adjusted difference year ci socioeconomic gradient age first presentation heart_failure widened socioeconomically deprived individual also comorbidities despite younger age interpretation despite moderate decline standardised incidence heart_failure burden heart_failure uk increasing similar four common_cause cancer combined observed socioeconomic disparity disease incidence age onset within nation point potentially preventable nature heart_failure still need tackled funding british heart foundation national institute health research:0.0184258479560014", "175466": "background atrial_fibrillation_af heart_failure_hf prevalent cardiovascular disorder frequently co occur exacerbating effect resulting adverse clinical_outcome despite well_established association condition paucity research examining af atrial flutter afl direct contributor hf_related mortality across various demographic region within united_state objective_study aim investigate pattern af afl related hf mortality u stratified age_gender race ethnicity urban rural classification geographic region method_retrospective analysis conducted utilizing data center disease control prevention wide ranging online data epidemiologic research cdc wonder database mortality data extracted death certificate identified af afl related hf primary contributing cause_death icd code age adjusted mortality_rate aamrs per individual calculated annual percentage change apc assessed_using joinpoint regression result death united_state attributed atrial_fibrillation flutter related heart_failure af afl hf age adjusted mortality_rate aamr rose significantly per population male consistently exhibited higher aamrs female v per respectively racial disparity evident non hispanic white highest cumulative aamr non hispanic asian pacific islander lowest geographic difference also prominent oregon recorded highest state level aamr hawaii lowest regionally west midwest highest cumulative aamrs place death trend showed shift toward home death became common location although aamrs increased sharply across subgroup rate stabilized conclusion af afl related heart_failure mortality increased substantially past year u marked disparity sex race ethnicity region urbanization recent_year seen plateau mortality_rate continued burden especially among vulnerable population underscore need equitable targeted public_health intervention improved access cardiovascular care:0.0177259772545763", "57591": "background_heart_failure_hf rapidly growing cardiac pathology industrialized country already primary cause hospital_admission elderly people outside field clinical_trial many study spain influence admission department diagnostic therapeutic management whether affect short_term long_term prognosis factor determine department patient_admitted objective analyze whether management prognosis patient_admitted heart_failure differ depending admission ward cardiology versus internal medicine geriatrics patient_method cross_sectional study_patient men_woman consecutively hospitalized hf cardiology n internal medicine geriatrics n ward hospital galicia recruited maximum period month main epidemiological clinical_variable recorded admission complication treatment clinical status recorded release result hf_patient mean_age_year woman year men year average hospitalization time day first admission total hospital_mortality fifty nine percent patient arterial_hypertension ischemic_heart_disease cardiac valve disease diabetes_mellitus chronic_obstructive_pulmonary_disease_copd patient_admitted cardiology ward younger v_year p frequently men v_p often first hospitalization v_p acute pulmonary_edema common v_p odds_ratio ci therapeutic diagnostic procedure relation admission ward reference group internal medicine geriatrics adjusted age_sex systolic_function number hospitalization history dementia hypertension copd ami valve disease ischemic_heart_disease echocardiogram catheterization admission intensive_care revascularization beta_blocker treatment difference hospital_mortality cardiology v internal medicine geriatrics average hospitalization time found department conclusion admission ward related clear difference hf management better adherence guideline use resource cardiologist unrelated difference hospital_mortality longer follow patient required evaluate impact therapeutic measure prognosis evolution hf well cost benefit relation elderly_patient population:0.0177149388986450", "143819": "objective throughout coronavirus disease covid pandemic multiple factor_associated poor_prognosis infected severe acute respiratory syndrome coronavirus sars_cov virus age obesity medical comorbidities linked poor_outcome including admission intensive_care_unit icu acute renal_failure stroke myocardial_infarction_mi mechanical_ventilation even death hospitalized covid patient although diabetes_mellitus dm also included set medical comorbidities inconsistency currently available body literature suggesting mortality_rate may may correlated elevated glycosylated hemoglobin hba_c level study_aim determine_whether correlation trend range hba_c value hospital_mortality among_patient admitted hospital covid diagnosis material_method study retrospective review electronic medical_record arrowhead regional medical_center colton ca patient age admitted hospital predetermined time frame either positive covid pcr test admission hospital_stay included_study medical chart reviewed hba_c value admission within three month prior admission hospital_mortality recorded medical_record available hba_c value hospital_discharge summary used delineate comorbidities including chronic_kidney_disease cerebrovascular_disease coronary_artery_disease congestive_heart_failure cancer history history deep vein thrombosis pulmonary_embolism among_patient included_study average hba_c value recorded mortality non mortality group statistical significance calculated result retrospective_study hba_c level compared mortality_rate among adult patient_admitted hospital concurrent covid diagnosis analysis conducted higher hba_c level increased rate hospital_mortality lower hba_c level decreased rate hospital_mortality comorbidity data confounding factor also reviewed excluded final analysis sars_cov vaccine also excluded confounder study selecting specific time frame data collection based result propose hba_c level likely little minimal correlation mortality_rate among hospitalized covid patient conclusion_study show hba_c level regardless concurrent comorbidities unlikely correlated mortality_rate among hospitalized covid patient hba_c level used marker whether patient_admitted hospital inpatient management discharged emergency_department:0.0173796560904113", "93205": "importance despite considerable improvement heart_failure care mortality_rate among_patient high income country changed little since early understanding reason underlying trend may_provide valuable clue developing targeted therapy public_health strategy objective investigate mortality_rate following new diagnosis heart_failure examine change time cause_death important patient feature design setting_participant population_based retrospective_cohort_study analyzed anonymized electronic health record individual received new diagnosis heart_failure january_december followed december clinical_practice research datalink link information primary_care secondary care national death registry subset uk population data analyzed january february main_outcome_measure cause cause specific mortality_rate year following diagnosis poisson regression_model used calculate rate ratio rrs confidence_interval comparing adjusting age_sex region socioeconomic status major comorbidities result participant woman white mean_sd age_year cause_mortality rate declined modestly time rr comparing ci underlying pattern presented explicit trend decline cardiovascular_mortality rr_ci offset increase noncardiovascular death rr_ci subgroup analysis_showed overall mortality_rate declined among_patient younger year rr_ci among older year rr_ci cardiovascular cause major cause_death neoplasm respiratory condition infection latter explaining observed increase noncardiovascular mortality conclusion relevance among_patient new heart_failure diagnosis considerable progress achieved reducing mortality young middle aged patient cardiovascular_mortality across age_group improvement overall mortality hindered high increasing rate noncardiovascular event finding challenge current research priority management_strategy call greater emphasis associated comorbidities specifically infection prevention present major opportunity improve prognosis:0.0171610421154985", "163305": "background covid caused sars_cov infection reached pandemic proportion since several clinical_characteristic associated poor_outcome study_aimed describe morbidity profile covid death portugal method_study performed including death certificated portugal covid icd u u coded underlying cause_death national e death certificate information system march december comorbidities derived icd code using charlson elixhauser index resident portuguese population estimate used result_study included death death rate death inhabitant predominantly male male_female mortality ratio male_female mortality_rate ratio however within age_group varied fold covid death portugal occurred mainly individual aged_year older predominantly public healthcare institution uncomplicated hypertension uncomplicated diabetes_mellitus congestive_heart_failure renal_failure cardiac_arrhythmia dementia cerebrovascular_disease observed among covid deceased patient prevalence higher high_prevalence zero morbidity registered using elixhauser charlson comorbidities list nevertheless high multimorbidity also identified time covid death higher multimorbidity level observed men increasing age_year old zero morbidity prevalence high multimorbidity prevalence varied throughout year seemingly elevated mortality wave peak suggesting variation according degree disease incidence given period conclusion_study provides detailed sociodemographic clinical information certificated death covid portugal showing complex extreme level morbidity zero morbidity v high multimorbidity dynamic first_year pandemic portugal:0.0171494689037242", "147554": "introduction atrial_fibrillation_af major increasing public_health problem worldwide clinical epidemiological difference men_woman however contemporary population level data incidence survival scarce aim evaluate sex specific contemporary trend incidence prevalence long_term_survival non valvular af real_world setting method af patient_diagnosed insured large state mandated health organization israel maccabi healthcare service included af diagnosed based registered diagnosis patient valvular disease active malignancy cardiac_surgery month recent pregnancy excluded annual incidence_rate period prevalence year_survival calendar year study_period calculated result_total eligible patient male_female identified male likely younger higher_rate underlying disease ischemic_heart_disease heart_failure chronic_obstructive_pulmonary_disease lower rate hypertension chronic_kidney_disease compared female patient study_period age adjusted incidence decreased men person_year p trend woman person_year p five year survival_rate significantly_higher among men v woman v respectively_p age adjusted prevalence increased significantly among men per_year p trend yet decreased among woman per_year p trend significant trend toward improved long_term_survival observed woman_men conclusion current study show significant sex related disparity incidence prevalence survival af_patient adjusted incidence decreased time prevalence mortality decreased significantly woman:0.0170731850045117", "114565": "objective describe characteristic prognosis_patient copd admitted hospital due sars_cov infection method semi covid registry ongoing retrospective cohort comprising consecutive covid patient_hospitalized spain since beginning pandemic march data demographic clinical_characteristic comorbidities laboratory test radiology treatment progress collected patient copd selected compared patient_without copd factor_associated poor_prognosis analyzed result_patient included semi covid registry may diagnosis copd patient copd older without copd year v_year frequently male comorbidities hypertension hyperlipidemia diabetes_mellitus atrial_fibrillation heart_failure ischemic_heart_disease peripheral vascular_disease kidney failure higher charlson comorbidity index v_p mortality_rate copd patient compared patient_without copd p male sex history hypertension_heart_failure moderate_severe chronic_kidney_disease presence cerebrovascular_disease sequela degenerative neurological disease dementia functional dependence higher charlson comorbidity index associated_increased mortality due covid copd patient survival higher among_patient copd treated hydroxychloroquine v_p macrolides v_p neither prone positioning non_invasive mechanical_ventilation high flow nasal cannula invasive mechanical_ventilation associated better prognosis conclusion copd patient_admitted hospital sars_cov infection severe disease worse prognosis non copd patient:0.0169992992409523", "164134": "background last two decade significant_increase number clostridioides difficile infection cdi case observed understandable attempt determine factor predict severity course infection identify_patient risk_death study_aimed analyze factor affecting incidence mortality cdi inpatient treatment university clinical hospital wroclaw method statistical analysis data obtained patient medical_record performed_patient symptom infection infection confirmed laboratory test enrolled study analyzing number death adult patient_died hospital ward included quantitative data including laboratory test used antibiotic nutritional risk screening nrs assessed also qualitative data sex year hospitalization occurrence diarrhoea admission hospital presence additional disease wee ad use antibacterial drug proton pump blocker ranitidine hospitalization analyzed result_total adult cdi patient woman_men enrolled people died woman_men mean_age patient_year entire period studied morbidity case per hospitalization mortality group deceased patient characterized older age_year longer duration hospitalization day reduced albumin level rho p_higher urea level use antibiotic higher_risk malnutrition nrs rho p_higher incidence sepsis heart_failure stroke hypothyroidism pneumonia diagnosed twice often also shown deceased patient significantly likely take penicillin fluoroquinolones conclusion_study morbidity lower mortality higher compared similar hospital poland cdi patient characterized older_age multimorbidity extended hospitalization use broad spectrum antibiotic risk_factor death included advanced age prolonged hospital_stay lower albumin higher urea malnutrition comorbidities like heart_failure stroke pneumonia sepsis hypothyroidism increased antibiotic use particularly penicillin fluoroquinolones associated_higher mortality_risk:0.0169262428432298"}, "Topic 2": {"170368": "background pathological cardiac_remodeling critical process leading heart_failure characterized primarily inflammation apoptosis matairesinol mat key chemical component podocarpus macrophyllus resin exhibit wide range pharmacological activity including anti hydatid antioxidant antitumor anti_inflammatory effect purpose_study aim investigate whether matairesinol alleviate cardiac_hypertrophy remodeling caused pressure_overload elucidate mechanism_action method vitro pressure loading model established using neonatal rat cardiomyocytes treated angiotensin_ii vivo model created using c mouse subjected transverse_aortic_constriction tac activate pi k akt foxo pathway y employed moreover small interfering rna sirna short hairpin rna shrna utilized silence prdx expression vitro vivo various technique including echocardiography wheat germ agglutinin wga staining staining psr staining masson trichrome staining used_assess cardiac_function cardiomyocyte cross_sectional area fibrosis level rat apoptosis myocardial_tissue vitro detected tunel assay reactive_oxygen_specie ro content tissue cell measured_using dhe staining furthermore affinity prdx mat pi k analyzed_using computer simulated molecular docking western blotting rt pcr utilized evaluate prdx level protein related apoptosis oxidative_stress well mrna level cardiac_hypertrophy fibrosis related indicator result mat significantly alleviated cardiac_hypertrophy fibrosis induced tac preserved cardiac_function markedly reduced cardiomyocyte apoptosis oxidative damage vitro mat attenuated ang_ii induced hypertrophy nrvms activation neonatal rat fibroblast notably activation pi k akt foxo pathway downregulation prdx expression observed tac mouse however effect reversed mat treatment furthermore prdx knockdown activated pi k akt foxo pathway leading exacerbation disease molecular docking indicated molecular docking indicated mat upregulated prdx expression binding thereby inhibiting pi k akt foxo pathway protecting heart restoring prdx expression_level conclusion matairesinol alleviates pressure_overload induced cardiac_remodeling vivo vitro upregulating prdx expression inhibiting pi k akt foxo pathway study highlight therapeutic potential matairesinol treatment cardiac_hypertrophy remodeling providing promising avenue future_research clinical_application:0.0181725712333593", "133528": "background diabetic_cardiomyopathy dcm increase_risk hospitalization heart_failure_hf mortality_patient diabetes_mellitus however specific therapy delay progression dcm identified mitochondrial_dysfunction oxidative_stress inflammation calcium handling imbalance play crucial role pathological process dcm ultimately leading cardiomyocyte apoptosis cardiac_dysfunction empagliflozin novel glucose lowering agent confirmed reduce_risk hospitalization_hf diabetic_patient nevertheless molecular_mechanism agent provides cardioprotection remain unclear aim investigate effect empagliflozin high glucose hg induced oxidative_stress cardiomyocyte apoptosis underlying molecular_mechanism method twelve week old db db mouse primary cardiomyocytes neonatal rat stimulated hg mmol_l separately employed vivo vitro model echocardiography used_evaluate cardiac_function flow cytometry tdt mediated dutp biotin nick end labeling staining used_assess apoptosis myocardial cell mitochondrial_function assessed cellular atp level change mitochondrial membrane potential furthermore intracellular reactive_oxygen_specie production superoxide dismutase activity analyzed real_time quantitative pcr used analyze bax bcl mrna expression western_blot analysis used measure phosphorylation amp activated protein_kinase ampk myosin phosphatase target subunit mypt well peroxisome proliferator activated receptor gamma coactivator alpha pgc alpha active caspase protein_level result vivo experiment db db mouse developed dcm however treatment db db mouse empagliflozin mg_kg wk substantially enhanced cardiac_function significantly_reduced myocardial apoptosis accompanied increase phosphorylation ampk pgc alpha protein_level well decrease phosphorylation mypt heart vitro experiment finding indicate treatment cardiomyocytes empagliflozin mum fasudil fa rock inhibitor mum overexpression pgc alpha significantly attenuated hg induced mitochondrial injury oxidative_stress cardiomyocyte apoptosis however effect partly reversed addition compound c cc cell exposed hg empagliflozin treatment increased protein_level p ampk pgc alpha protein decreasing phosphorylated mypt level change mitigated addition cc adding fa overexpressing pgc alpha cell exposed hg substantially increased pgc alpha protein_level addition sodium_glucose_cotransporter sglt protein_expression detected cardiomyocytes conclusion empagliflozin partially achieves anti oxidative_stress anti apoptotic effect cardiomyocytes hg condition activating ampk pgc alpha suppressing rhoa rock pathway independent sglt:0.0180639046222199", "151153": "background renin_angiotensin_system play crucial role development_heart_failure ang_ii angiotensin_ii act critical effector renin_angiotensin_system regulating cardiac_fibrosis however mechanism cardiac_fibrosis complex still fully understood igf r insulin like growth_factor receptor multiple function maintaining cardiovascular homeostasis low_dose igf treatment effective relieving ang_ii induced cardiac_fibrosis aimed investigate molecular_mechanism igf r ang_ii induced cardiac_fibrosis method_result using primary mouse cardiac microvascular endothelial_cell fibroblast vitro experiment performed using c bl j mouse clustered regularly interspaced short palindromic repeat crispr crispr associated ca mediated igf r heterozygous knockout igf r mouse cardiac_fibrosis mouse_model induced ang_ii week expression igf r examined quantitative reverse transcription polymerase chain reaction immunohistochemistry western_blot mouse heart histologic change evaluated_using masson picro sirius red staining fibrotic marker signal molecule indicating function akt protein_kinase b erk extracellular signal regulated kinase nuclear factor kappab pathway detected using quantitative reverse transcription polymerase chain reaction western_blot rna sequencing used explore igf r mediated target gene heart mouse association igf r g_protein coupled receptor kinase identified coimmunoprecipitation important blocking igf r signaling significantly suppressed endothelial mesenchymal transition primary mouse cardiac microvascular endothelial_cell mouse response transforming growth_factor beta ang_ii respectively deficiency inhibition igf r signaling remarkably attenuated ang_ii induced cardiac_fibrosis primary mouse cardiac_fibroblast mouse observed patient_heart_failure exhibited higher blood level igf igf r healthy individual moreover ang_ii treatment significantly_increased cardiac igf r wild_type mouse led slight downregulation igf r mouse interestingly igf r deficiency significantly alleviated cardiac_fibrosis ang_ii treated mouse mechanistically phosphorylation level akt erk upregulated ang_ii treated mouse whereas blocking igf r signaling mouse inhibited change akt erk phosphorylation concurrently phosphorylated p nuclear factor kappab exhibited similar alteration corresponding group mouse intriguingly igf r directly interacted g_protein coupled receptor kinase association decreased approximately igf r mouse addition grk deletion downregulated expression akt erk nuclear factor kappab signaling_pathway primary mouse cardiac_fibroblast conclusion igf r signaling deficiency alleviates ang_ii induced cardiac_fibrosis least partially inhibiting endothelial mesenchymal transition via akt erk nuclear factor kappab pathway interestingly g_protein coupled receptor kinase associate igf r signaling directly concurrently act igf r downstream effector study suggests promising potential igf r therapeutic_target cardiac_fibrosis:0.0179105701103170", "111256": "increase protein activity upregulation g_protein coupled receptor kinase grk hallmark cardiac stress heart_failure inhibition grk improved cardiac_function survival diminished cardiac_remodeling various animal heart_failure model aim present_study investigate effect grk cardiac_hypertrophy dissect potential molecular_mechanism mouse observed increased grk mrna protein_level following transverse_aortic_constriction tac conditional grk knockout mouse showed attenuated hypertrophic response preserved ventricular geometry week tac operation compared wild_type animal isolated neonatal rat ventricular cardiac_myocytes stimulation angiotensin_ii phenylephrine enhanced grk expression leading enhanced signaling via protein_kinase b pkb akt consecutively inhibiting glycogen synthase kinase beta gsk beta promoting nuclear accumulation activation nuclear factor activated cell nfat cardiac myocyte hypertrophy induced vitro grk overexpression increased cytosolic interaction grk phosphoinositide kinase gamma pi kgamma moreover inhibition pi kgamma well grk knock prevented akt activation resulting halted nfat activity reduced cardiac myocyte hypertrophy data show enhanced grk expression trigger cardiac_hypertrophy grk pi kgamma mediated akt phosphorylation subsequent inactivation gsk beta resulting enhanced nfat activity:0.0178599917074070", "184990": "pathological cardiac_hypertrophy involves multiple regulator several signal transduction pathway currently mechanism well understood differentially expressed fdcp homolog def reported participate immunity bone remodeling cancer effect def pathological cardiac_hypertrophy however yet fully characterized initially determined expression profile def found def upregulated hypertrophic heart cardiomyocytes vivo result revealed def deficiency mouse alleviated transverse_aortic_constriction tac induced cardiac_hypertrophy fibrosis dilation dysfunction left_ventricle conversely cardiomyocyte specific def overexpression aggravated hypertrophic phenotype mouse chronic pressure_overload similar animal experiment vitro data showed adenovirus mediated knockdown def remarkably inhibited phenylephrine pe induced cardiomyocyte hypertrophy whereas def overexpression exerted opposite effect mechanistically exploration signal pathway showed mitogen activated extracellular signal regulated kinase mek extracellular signal regulated kinase erk cascade might involved prohypertrophic effect def coimmunoprecipitation gst glutathione transferase pulldown analysis demonstrated def directly interact small gtpase ra related c botulinum toxin substrate rac rac activity assay revealed activity rac altered def expression tac cardiac_hypertrophy pe triggered cardiomyocyte hypertrophy end western_blot rescue experiment using rac inhibitor nsc constitutively active mutant rac g v verified requirement rac mek erk activation def mediated pathological cardiac_hypertrophy study substantiates def act deleterious regulator cardiac_hypertrophy activating rac mek erk signaling_pathway suggests def may potential treatment target heart_failure:0.0172709416096634", "174385": "background cardiac_fibrosis following myocardial_infarction_mi drive adverse ventricular_remodeling heart_failure cardiac_fibroblast cf playing central role gstm important member glutathione transferase gsts family play_important_role maintaining cell homeostasis detoxification study_investigated role mechanism gstm post_mi fibrosis method multi omics approach proteomics scrna seq identified gstm dysregulated target post_mi fibroblast using murine coronary ligation model assessed gstm dynamic via molecular profiling western blotting immunofluorescence real_time quantitative polymerase chain reaction aav mediated cardiac specific gstm overexpression achieved systemic delivery vitro study employed transforming growth_factor beta tgf_beta stimulated primary fibroblast sirna plasmid intervention mechanistic insight derived transcriptomics lipid peroxidation assay result expression gstm mouse cf mi significantly regulated transcriptional protein_level human dilated_cardiomyopathy_dcm patient_severe heart_failure gstm expression decreased alongside aggravated fibrosis overexpression gstm post_mi mouse improved cardiac_function significantly reducing infarct_size fibrosis compared control_group vitro model demonstrated gstm markedly attenuated collagen secretion activation fibroblast well suppressed proliferation migration study revealed gstm overexpression significantly inhibited generation intracellular mitochondrial reactive_oxygen_specie ro pathological condition suggesting gstm exerts antioxidative stress effect post infarction fibroblast investigation molecular_mechanism indicated gstm may suppress initiation progression fibrosis modulating lipid metabolism ferroptosis related pathway overexpression gstm significantly_reduced lipid peroxidation free ferrous iron level fibroblast mitochondrion markedly decreased ferroptosis related indicator alleviated oxidative lipid level hydroxyeicosapentaenoic acid hepe dihydroxy octadecenoic acid dhome fibrotic condition gstm enhanced phosphorylation stat thereby upregulating downstream expression glutathione peroxidase gpx reducing ro production mitigating fibroblast activation phenotypic transformation inhibiting lipid peroxidation conclusion_study identifies gstm key inhibitor fibroblast activation cardiac_fibrosis highlighting ability target ferroptosis redox regulation aav mediated gstm therapy demonstrates significant therapeutic potential improving outcome post_mi:0.0172497666042496", "193116": "loganin lg natural compound derived cornu officinalis sieb et zucc possesses diverse pharmacological property anti_inflammatory anti hypertrophic antioxidant effect however role lg pathogenesis heart_failure_hf remains_unclear current work aimed explore underlying_mechanism lg pressure_overload induced hf vivo vitro using transverse_aortic_constriction tac surgery isoproterenol iso administration following eight week tac surgery histological assessment including hematoxylin eosin staining wheat germ agglutinin staining tunel assay masson trichrome staining conducted evaluate extent cardiomyocyte remodeling additionally rt pcr wb analysis_performed detect level various target furthermore h_c cardiomyocytes treated iso induce hypertrophy effect lg cell viability alpha smooth_muscle actin alpha sma expression molecular target investigated finding revealed lg treatment mg_kg day significantly attenuated cardiac_dysfunction decreased left_ventricular collagen deposition interstitial perivascular space mechanistically lg mitigated iso induced toxicity h_c cardiomyocytes decreasing cellular hypertrophy alpha sma expression moreover observed downregulation sirtuin sirt molecular level accompanied reduced phosphorylation akt transforming growth_factor beta tgf_beta notably administration sirt inhibitor ex effectively abolished protective_effect lg therefore cardio protective_effect lg mediated activation sirt akt tgf_beta signaling_pathway leading reduced fibrosis improved cardiac_function:0.0171718900333008", "135515": "background heart_failure leading_cause_death worldwide cyclic nucleotide phosphodiesterases pdes degradation cyclic nucleotide play critical role cardiovascular biology disease preliminary screening study revealed pde upregulation diseased heart however role pde cardiovascular biology disease largely uncharacterized current study_aimed_investigate regulation function pde cardiac cell progression cardiac_remodeling dysfunction method_used isolated adult mouse cardiac_myocytes fibroblast well preclinical mouse_model hypertrophy heart_failure pde selective inhibitor tp global pde knock mouse used result found pde expression remains relatively low normal exercised heart tissue however pde significantly upregulated mouse human failing_heart vitro pde deficiency inhibiting pde selective inhibitor tp attenuated cardiac myocyte pathological hypertrophy induced angiotensin_ii phenylephrine isoproterenol affect cardiac myocyte physiological hypertrophy induced igf insulin like growth_factor tp also reduced tgf_beta transforming growth_factor beta stimulated cardiac_fibroblast activation proliferation migration extracellular_matrix synthesis tp treatment elevated camp cgmp level cardiac_myocytes cardiac_fibroblast consistent pde camp cgmp dual specific pde vivo global pde deficiency significantly attenuated myocardial hypertrophy cardiac_fibrosis dysfunction induced chronic pressure_overload via transverse aorta constriction chronic neurohormonal stimulation via angiotensin_ii infusion importantly demonstrated pharmacological effect tp specifically pde inhibition addition tp able reverse pre established cardiac_hypertrophy dysfunction rna sequencing bioinformatics analysis identified pde regualted transcriptome involved cardiac_hypertrophy fibrosis cardiomyopathy conclusion taken together study elucidates novel role pde regulation pathological cardiac_remodeling development_heart_failure given pde proven safe drug target pde inhibition may represent novel therapeutic_strategy preventing treating cardiac_disease associated cardiac_remodeling:0.0170323962469402", "73383": "rationale cardiac_fibrosis play critical role pathogenesis heart_failure excessive accumulation extracellular_matrix ecm resulting cardiac_fibrosis impairs cardiac contractile_function increase arrhythmogenicity current treatment_option cardiac_fibrosis however limited clear need identify novel mediator cardiac_fibrosis facilitate development better therapeutic exploiting coexpression gene network analysis rna sequencing data failing human_heart identified txndc thioredoxin domain containing cardiac_fibroblast cf enriched endoplasmic reticulum protein potential novel mediator cardiac_fibrosis completed experiment test hypothesis directly objective objective_study determine functional role txndc pathogenesis cardiac_fibrosis method_result rna sequencing western_blot analysis_revealed txndc mrna protein highly upregulated failing human left_ventricle hypertrophied failing mouse left_ventricle addition cardiac txndc mrna expression_level positively correlated transcript encoding transforming growth_factor beta ecm protein vivo txndc mrna protein increased human cf hcf transforming growth_factor beta stimulation vitro knockdown txndc attenuated transforming growth_factor beta induced hcf activation ecm protein upregulation independent smad smad family member whereas increasing expression txndc triggered hcf activation proliferation increased ecm protein production experiment showed txndc protein disulfide isomerase facilitated ecm protein folding depletion txndc led ecm protein misfolding degradation cf addition txndc promotes hcf activation proliferation enhancing c jun n_terminal kinase activity via increased reactive_oxygen_specie derived nad p h oxidase transforming growth_factor beta induced txndc upregulation hcf dependent endoplasmic reticulum stress activating transcription_factor mediated transcriptional control targeted disruption txndc mouse txndc revealed protective_effect isoproterenol induced cardiac_hypertrophy reduced fibrosis approximately markedly improved left_ventricle function post isoproterenol left_ventricular_ejection_fraction versus_p txndc versus wild_type mouse respectively_conclusion endoplasmic reticulum protein txndc promotes cardiac_fibrosis facilitating ecm protein folding cf activation via redox sensitive c jun n_terminal kinase signaling loss txndc protects beta agonist induced cardiac_fibrosis contractile dysfunction targeting txndc therefore could powerful new therapeutic_approach mitigate excessive cardiac_fibrosis thereby improving cardiac_function outcome patient_heart_failure:0.0170074224878177", "200374": "background hypertension induced cardiac_hypertrophy constitutes principal cause_heart_failure malignant arrhythmia sudden_cardiac_death nek never mitosis gene nima related protein_kinase member serine threonine kinase family multifunctional protein_kinase play crucial role regulating cell cycle mitosis inflammation role cardiac_hypertrophy remains_unclear method subjected aav ctnt si nek mouse pressure_overload mean transverse_aortic_constriction evaluated cardiac_function cardiac_hypertrophy inflammasome activation neonatal mouse cardiomyocytes treated ang angiotensin_ii effect si nek small interfering rna targeting nek nlrp nod like receptor family pyrin domain containing inhibition cardiomyocyte hypertrophy examined effect nek regulating cardiac_hypertrophy examined administering si mbnl muscleblind like splicing regulator tail vein knockdown transverse_aortic_constriction treated mouse result nek expression significantly upregulated transverse_aortic_constriction induced cardiac_hypertrophy model vivo ang_ii stimulated neonatal mouse cardiomyocytes vitro knockdown nek attenuated ang_ii induced cardiomyocyte hypertrophy inhibited activation nlrp inflammasome knockdown nek aav si nek significantly_improved cardiac_function reduced hypertrophy transverse_aortic_constriction mouse conversely nek overexpression exacerbated hypertrophy promoted nlrp inflammasome assembly leading pyroptosis via ro dependent pathway mechanistically nek directly bound nlrp prohypertrophic effect abrogated nlrp inhibition additionally mbnl rna binding protein bind nek mrna thereby regulating nek transcription affecting expression_level mbnl identified upstream regulator nek knockdown mbnl suppressing nek expression alleviating cardiac_hypertrophy vivo conclusion nek drive pathological cardiac_hypertrophy activating nlrp inflammasome promoting cardiomyocyte pyroptosis mbnl acting upstream regulator targeting mbnl nek nlrp axis may offer novel therapeutic_strategy preventing cardiac_hypertrophy heart_failure:0.0169726288844187"}, "Topic 3": {"150834": "sarcomeric hypertrophic_cardiomyopathy hcm prevalent genetic disorder characterised left_ventricular_hypertrophy myocardial disarray increased_risk heart_failure sudden_cardiac_death despite advance understanding pathophysiology treatment_option hcm remain limited narrative review aim provide comprehensive overview current clinical_practice explore emerging therapeutic_strategy sarcomeric hcm focus cardiac myosin inhibitor first discus conventional management hcm including lifestyle modification pharmacological therapy invasive intervention emphasizing limitation challenge next highlight recent advance molecular genetics potential application refining hcm diagnosis risk_stratification treatment delve emerging therapy gene editing rna based therapy targeted small molecule cardiac myosin modulators like mavacamten aficamten hold promise modulating underlying molecular_mechanism hcm mavacamten aficamten selective modulators cardiac myosin demonstrated encouraging result clinical_trial reducing left_ventricular outflow tract obstruction improving symptom patient obstructive hcm discus mechanism_action clinical_trial outcome potential implication future hcm management furthermore examine role precision medicine hcm management exploring individualised treatment_strategy including exercise prescription part management plan may optimise patient_outcome finally underscore importance multidisciplinary care patient centred approach address complex need hcm patient review also aim encourage research collaboration field hcm promoting development novel effective therapeutic_strategy cardiac myosin modulators hopefully improve quality_life outcome_patient sarcomeric hcm:0.0168024672215846", "160461": "acute myocarditis encompasses diverse presentation inflammatory cardiomyopathy infectious non infectious trigger clinical_presentation heterogeneous subtle symptom like mild chest_pain life_threatening fulminant heart_failure requiring urgent advanced hemodynamic support review provides comprehensive overview current state knowledge regarding pathogenesis diagnostic approach management_strategy direction future_research acute myocarditis pathogenesis myocarditis involves interplay inciting factor subsequent host immune response infectious cause especially cardiotropic virus frequently identified precipitant however autoimmune process independent microbial trigger well toxic myocardial_injury drug chemical metabolic derangement also contribute development myocarditis diverse mechanism furthermore medication like immune checkpoint inhibitor therapy increasingly recognized cause myocarditis elucidating nuance viral autoimmune hypersensitivity toxic subtypes myocarditis key guiding appropriate therapy heterogeneous clinical_presentation coupled non specific symptom creates diagnostic challenge multifaceted approach required incorporating clinical evaluation electrocardiography biomarkers imaging study endomyocardial_biopsy cardiovascular magnetic_resonance_imaging become pivotal non_invasive assessment myocardial inflammation fibrosis however biopsy remains gold_standard histological classification definitively establishing underlying etiology management relies supportive care disease specific therapy limited although patient recover well conservative measure severe fulminant myocarditis necessitates aggressive intervention mechanical_circulatory_support device transplantation immunosuppression beneficial certain histological subtypes clear evidence supporting antiviral immunomodulatory therapy majority acute viral myocarditis case remains insufficient substantial knowledge gap persist regarding validated diagnostic biomarkers optimal imaging surveillance strategy evidence_based medical_therapy risk_stratification schema deeper understanding immunopathological mechanism rigorous clinical_trial targeted therapy longitudinal outcome study imperative advance management improve prognosis across myocarditis spectrum:0.0165732701471224", "136821": "heart_failure_preserved_ejection_fraction_hfpef major public_health problem rising prevalence associated_high morbidity_mortality considered greatest unmet need cardiovascular medicine today general lack effective_treatment address challenging syndrome national heart lung blood institute convened working group made expert hfpef novel research methodology discus research gap prioritize research direction next decade summarize discussion working group followed key recommendation future_research priority uniform recognition hfpef highly integrated multiorgan systemic disorder requiring multipronged investigative approach human animal_model improve understanding mechanism treatment hfpef recognized advance understanding basic mechanism role inflammation macrovascular microvascular dysfunction fibrosis tissue remodeling needed ideally would obtained improved animal_model including large animal_model incorporate effect aging associated comorbid_condition repository deeply phenotyped physiological data human tissue made accessible researcher enhance collaboration research advance novel research method take advantage computational advance multiscale modeling analysis complex high density data across multiple domain working group emphasized need interaction among basic translational clinical epidemiological scientist across organ system cell type leveraging different area research focus research center network collaborative center accelerate basic translational clinical research pathobiological mechanism treatment_strategy hfpef discussed example strategy advance research progress resource would facilitate comprehensive deep phenotyping multicenter hfpef_patient cohort standardized protocol robust biorepository research priority outlined document meant stimulate scientific advance hfpef providing road map future collaborative investigation among diverse group scientist across multiple domain:0.0158401976344261", "198787": "background_objective heart_failure_preserved_ejection_fraction_hfpef emerged one challenging syndrome modern cardiology due complex pathophysiology diagnostic ambiguity lack effective targeted therapy unlike heart_failure_reduced_ejection_fraction_hfref hfpef encompasses highly heterogeneous patient_population unified preserved left_ventricular_ejection_fraction_lvef broad definition overlook important biological clinical difference leading inconclusive result large_scale therapeutic trial suboptimal patient_outcome recent_year advance data driven methodology unsupervised machine_learning cluster analysis latent class modeling enabled identification distinct hfpef phenotype phenotype often defined demographic clinical hemodynamic biomarker profile exhibit differential prognosis treatment response method systematic_review synthesizes finding study published examining phenotypic classification strategy clinical implication result despite methodological variation several recurring phenotype emerge including metabolic obese frail elderly atrial_fibrillation dominant cardiorenal pulmonary_hypertension right_heart phenotype present distinct pathophysiological mechanism risk profile highlighting inadequacy current one size fit treatment approach review also explores prognostic_value phenotype impact phenotypic variation treatment efficacy methodological challenge hinder translation clinical_practice inconsistent input variable lack external validation limited integration real_world data conclusion ultimately finding underscore need paradigm shift ejection_fraction based classification phenotype guided management hfpef embracing precision medicine framework could enable personalized treatment_strategy improve clinical_trial design enhance outcome diverse patient_population review concludes outlining future direction including development standardized phenotyping algorithm integration multi omic digital health data implementation pragmatic phenotype stratified clinical_trial:0.0156571299164241", "197950": "background management long_term cardiotoxicity become increasingly challenging despite growing utilization targeted therapy enhance progression free overall survival_rate although proliferation literature incidence mechanism cardiotoxicity induced targeted therapy comprehensive analysis publication landscape addressed unmet medical need area study_aimed characterize global research trend map collaborative network highlight unresolved issue cardiotoxicity management fill gap field inform future_research method_study conducted bibliometric analysis article concerning targeted therapy induced cardiotoxicity published web_science wos database using vosviewer citespace total publication country region research institution examined result number publication shown average annual increase article key research topic targeted therapy cardiotoxicity encompass breast_cancer heart_failure drug delivery cited publication guideline titled prevention monitoring cardiac_dysfunction survivor adult cancer american society clinical oncology clinical_practice guideline result indicate rising trend research tumor targeted therapy cardiotoxicity past two decade recent research trend future direction primarily focus two key area development novel nanocarriers aim enhance therapeutic efficacy reducing cardiac toxicity exploration mechanism_underlying cardiac injury caused targeted therapeutic drug crucial along investigates drug intervention counter mechanism application alternative technique prevention alleviation treatment cardiac injury conclusion_study provides comprehensive overview targeted therapy induced cardiotoxicity research identifying key research priority analysis address critical gap current knowledge future endeavor prioritize translational innovation multidisciplinary clinical framework enhance therapeutic safety:0.0153233507785722", "176918": "introduction testicular germ cell tumor tgct highly curable malignancy excellent survival_rate largely attributable advance cancer treatment consequently growing population long_term tgct survivor whose life expectancy approach general_population however survivor may experience acute late adverse_effect cancer treatment cardiovascular toxicity among serious potentially life_threatening method narrative review synthesizes current evidence cardiovascular toxicity testicular cancer survivor including clinical_manifestation pathophysiology cisplatin induced cardiovascular damage additional adverse_effect radiotherapy prevalence traditional cardiovascular_risk_factor key clinical guideline observational_study experimental finding analyzed identify trend knowledge gap opportunity improving survivorship care result multiple study consistently demonstrate increased_risk cardiovascular_disease_cvd among tgct survivor particularly following cisplatin based chemotherapy common clinical_manifestation include myocardial_infarction angina pectoris cerebrovascular event thromboembolism heart_failure highest risk occurs within first_year post treatment may persist recur even decade cisplatin induced cardiovascular toxicity involves vascular injury characterized endothelial_dysfunction oxidative_stress prothrombotic state myocardial damage driven oxidative_stress inflammation apoptosis furthermore tgct survivor exhibit higher_prevalence traditional cardiovascular_risk_factor smoking hypertension dyslipidemia diabetes obesity contributing overall elevated cvd risk discussion urgent need structured long_term survivorship care model tgct survivor cardiovascular_risk assessment prevention central component especially survivor treated cisplatin based chemotherapy early_detection treatment related toxicity combined lifestyle intervention regular monitoring essential future_research focus elucidating molecular_mechanism cardiovascular toxicity validating tgct survivor specific screening tool identifying early biomarkers cardiac injury exploring pharmacologic behavioral intervention conclusion protecting cardiovascular health tgct survivor requires proactive personalized multidisciplinary approach integrating cardiometabolic monitoring risk_factor modification tailored follow strategy survivorship care vital focused research clinical attention needed ensure long_term success cancer treatment compromised preventable cardiovascular_disease:0.0152567240909552", "194943": "hypertensive heart_disease hhd continues leading_cause cardiovascular morbidity_mortality worldwide necessitating evolution evidence_based management_strategy literature review examines recent update hypertension guideline issued european society hypertension esh european society_cardiology esc guideline compared previous key recommendation american college cardiology american heart_association guideline esc esh guideline updated recommendation reflect paradigm shift approach hypertension diagnosis management including stricter systolic_blood_pressure bp target mmhg underscore importance early precise bp control difference classification elevated bp hypertension esc versus esh guideline particularly regarding implication early_detection prevention hhd critically examined highlighting area clinical academic debate introduction new elevated bp category mmhg highlight proactive strategy aimed identifying risk individual earlier disease course prevent progression hhd additionally divergent role hypertension mediated organ damage hmod including hhd risk_stratification recommended esc esh discussed emphasising significance tailoring management approach patient resistant hypertension update also endorse innovative therapy renal denervation interventional procedure demonstrated significant promise managing treatment resistant case review synthesis update focusing implication clinical_practice diagnosing managing hhd emphasising aggressive intervention integration novel treatment modality review aim bridge existing gap earlier approach hypertension management critical evaluation guideline discrepancy evolving evidence seek provide clinician nuanced understanding optimise outcome_patient hhd particularly considering emerging therapeutic possibility stringent bp control target:0.0152511941378585", "173204": "rapid advancement next generation omics platform bioinformatic data analysis novel imaging technique transforming biomedical research especially pulmonary_hypertension cutting edge tool generate vast data leading innovative therapeutic diagnostic possibility personalized medicine patient specific risk_stratification however embracing new technology crucial integrate decade hypothesis driven research emerging discovery platform avoid redundant effort enhance scientific progress american thoracic society conference senior junior investigator vascular biology pulmonary_hypertension right_heart_failure engaged pro con debate research paradigm discussion explored evolving disease framework fit within context traditional research emphasizing balance newer multiomics approach classical hypothesis driven science three key objective addressed integrating unbiased analytic method traditional framework interpreting new multiomics finding within known pathobiological pathway reviewing modern imaging method right_ventricle improve disease understanding although omics approach offer broad integrative view support personalized medicine present challenge managing large datasets ensuring effective clinical translation conversely traditional reductionist approach focusing known genetic alteration signaling_pathway led significant breakthrough including development current therapy combining approach hold great potential drive future discovery develop effective_treatment pulmonary_hypertension goal achieved coordinated transdisciplinary team investigator diverse skillsets knowledge working together advance field:0.0152437075864936", "106231": "past decade seen many advance management heart_failure_hf improved survival quality_life patient living condition number gap remain understanding pathophysiology hf application emerging treatment_strategy exciting daunting challenge possible advance genetic evaluation cardiomyopathy provide refined approach characterizing hf syndrome whereas large_scale clinical_trial horizon clarify role novel pharmacologic agent invasive therapy cardiac repair regeneration hold great promise number pragmatic issue limit clinical_application near term replacing cardiac_function ventricular_assist_device represents significant progress management advanced disease however unacceptable rate complication cost need addressed broader use general hf population feasible ability personalize care limited optimal model disease_management canadian context remains uncertain emergence biomarker guided management remote monitoring technology might facilitate personalized approach care effort maintain health stability prevent worsening_hf ultimately greater understanding intervene setting acute_hf translate improved outcome highest risk subgroup patient review highlight key challenge management hf highlight progress toward ideal future state:0.0152152714988932", "198861": "introduction cardiovascular disorder cvds remain leading_cause global mortality surpassing chronic illness alarming rise cvd related death particularly among younger population intensified research effort better understand disease complication among myocardial_fibrosis play central role development cardiac_dysfunction heart_failure given multifactorial nature diverse therapeutic_strategy required manage progression effectively method comprehensive literature review conducted using database pubmed scopus elsevier clinicaltrials_gov peer reviewed english language study focusing molecular_mechanism therapeutic_strategy myocardial_fibrosis included irrelevant non english non peer reviewed source excluded data selected preclinical clinical investigation qualitatively synthesized result myocardial_fibrosis arises various pathological condition including ischemia hyperlipidemia genetic disorder promote maladaptive cardiac_remodeling although traditional treatment raas inhibitor beta_blocker offer symptomatic relief halt disease_progression recent evidence_suggests multiple molecular pathway involved development fibrosis opening opportunity explore alternative therapeutic_target discussion due complex pathophysiology myocardial_fibrosis cannot addressed monotherapy alone anti tgf_beta agent emerged promising candidate alongside newer therapy like sglt_inhibitor mmp inhibitor additionally regenerative approach stem_cell gene therapy offer future avenue though technical safety challenge accompany conclusion myocardial_fibrosis remains critical contributor heart_failure current treatment insufficient reverse course multifaceted therapeutic_approach targeting different molecular_mechanism hold key improved clinical_outcome continued translational research crucial advancing emerging therapy bench bedside:0.0152036779893309"}, "Topic 4": {"73266": "background eosinophilic myocarditis one fatal complication idiopathic hypereosinophilic syndrome given rarity form myocarditis often recognized describe young girl presented feature heart_failure knowledge first reported case eosinophilic myocarditis young sri lankan female case presentation previously healthy year_old sri lankan female admitted shortness breath week duration associated low grade fever profuse sweating mildly febrile dyspnoeic absent ankle oedema tachycardic elevated jugular venous pressure negative kussmaul sign blood_pressure mmhg clinically cardiomegaly heart sound slightly muffled gallop rhythm bilateral basal fine end inspiratory crackle mild hepatosplenomegaly noted laboratory examination showed leucocytosis severe eosinophilia abnormal cell esr troponin brain_natriuretic_peptide elevated normal crp electrocardiogram showed sinus tachycardia wide spread st depression heart_failure evident chest x_ray echocardiogram showed global left_ventricular hypokinesia ejection_fraction thin layer pericardial effusion mild hepatosplenomegaly without lymphadenopathy detected ultrasound scan bone_marrow biopsy showed hypereosinophilia evidence bone_marrow infiltration fip l pdgfra fusion transcript bcr abl transcript detected secondary cause hypereosinophilia excluded diagnosis idiopathic hypereosinophilic syndrome eosinophilic myocarditis made good response steroid clinically biochemically complete recovery left_ventricular_function steroid continued least month year conclusion eosinophilic myocarditis rare fatal disease left untreated hence clinician high index suspicion diagnose eosinophilic myocarditis clinical context heart_failure due myocarditis diagnosis eosinophilic myocarditis may often challenged especially poor recourse setting however available investigation used diagnose condition without delay early treatment systemic steroid may prevent fatal outcome therapy disease yet validated large prospective_study:0.0188218821376071", "129861": "background dissecting aneurysm sinus valsalva sov interventricular septum rare entity multilobulated form dissection rupturing left_ventricle lv never reported literature case summary year_old male presented dyspnoea palpitation wide pulse pressure peripheral sign distal run continuous murmur along left parasternal area echocardiography revealed dilated right coronary cusp rcc burrowed interventricular septum iv forming multi loculated cystic lesion ruptured lv associated restrictive ventricular septal_defect vsd severe aortic regurgitation computed_tomography ct angiography confirmed cm x cm x cm multiseptated aneurysm surgery involved excision aortic_valve av sinus ligation penetrating portion crest iv closure vsd av replacement postoperative echocardiography showed complete collapse iv component sov aneurysm normally functioning mechanical av discussion dissecting aneurysm iv rare variant sov aneurysm usually arising rcc mostly congenital origin wide variety presentation like congestive_heart_failure palpitation recurrent syncope chest_pain sudden cardiac_arrest infective_endocarditis cerebral infarction asymptomatic aortic regurgitation present_case conduction disturbance first degree block complete heart block common echocardiogram ct angio magnetic_resonance_imaging useful diagnosis surgical repair option treatment:0.0183680989577387", "145750": "background although systemic lupus erythematosus sle affect cardiovascular_system many way diverse presentation severe cardiogenic_shock secondary sle myocarditis infrequently described medical literature variable presenting feature sle myocarditis also make diagnosis challenging case_report allow learner consider sle myocarditis differential appreciate diagnostic uncertainty case presentation year_old filipino male presented acute dyspnea pleuritic chest_pain fever diffuse rash diagnosed sle six_month ago treated hydroxychloroquine lab notable leukopenia non nephrotic range proteinuria elevated cardiac biomarkers inflammatory marker low complement serology suggestive active sle broad spectrum iv antibiotic corticosteroid initiated sepsis sle activity blood culture positive mssa likely skin source electrocardiogram showed diffuse st_segment elevation without ischemic change ct chest demonstrated bilateral pleural pericardial effusion dense consolidation transthoracic transesophageal echocardiogram demonstrated reduced left_ventricular_ejection_fraction_lvef valvular pathology suggestive endocarditis although mssa bacteremia resolved patient rapidly developed cardiopulmonary decline repeat echocardiogram demonstrating lvef cardiac mri nondiagnostic study elucidate etiology decompensation given inability perform late gadolinium enhancement later cardiac catheterization revealed normal cardiac_output non obstructive coronary_artery_disease clear etiology explaining dramatic heart_failure endomyocardial_biopsy obtained demonstrating diffuse myofiber degeneration inflammation pathological finding addition skin biopsy demonstrating lichenoid dermatitis granular full house pattern consistent sle myocarditis furthermore aggressive sle directed therapy demonstrated near full recovery heart_failure conclusion although myocarditis sle flare well described cardiac manifestation progression cardiogenic_shock infrequent fatal sle myocarditis promptly considered given heterogenous presentation sle combination serologic evaluation advanced imaging myocardial biopsy helpful diagnostic uncertainty exists case highlight diagnostic method clinical_course de_novo presentation cardiogenic_shock sle myocarditis rapid improvement:0.0181219247900164", "138432": "infective_endocarditis ie serious bacterial infection endocardium heart valve carry considerable morbidity_mortality often presenting non specific symptom disease present many challenge emergency medicine practitioner year_old male pertinent medical_history presented emergency_department complaining shortness breath stated symptom persistent last three week associated malaise fatigue ct abdomen pelvis iv contrast revealed cm hypodensity spleen concerning abscess versus infarct denied trauma iv drug use follow ultrasound ordered characterized hypodensity splenic abscess echocardiogram recommended possible ie cardiology consulted transthoracic echocardiogram performed hospital day showed minimal mitral_valve thickening mild mitral_regurgitation interventional radiology ir service consulted splenic abscess order perform ct guided drainage ir drain successfully placed hospital day_day blood culture grew klebsiella pneumoniae hospital day patient transferred icu possible empyema formation sign respiratory distress patient_underwent ct chest showed development left_sided effusion patient also persistently tachycardic febrile high leukocytosis since admission worsening respiratory status transesophageal echocardiogram tee scheduled put hold due worsening respiratory status repeat tee scheduled five day later showed mitral_regurgitation increased size vegetation despite antibiotic therapy two day later scheduled mitral_valve repair reviewing case patient common uncommon aspect splenic abscess ie first despite respiratory symptom two week primary reason came hospital due new_onset fever febrile tachycardic significant leukocytosis continued fever despite antibiotic therapy ir drainage abscess history iv drug use history negative transthoracic_echocardiography lack immunocompromising condition blood culture gram negative rod ie became less_likely diagnosis establishing diagnosis ie proved exceptionally complicated especially setting covid pandemic notable challenge high index suspicion despite risk_factor patient previously healthy year_old male medical problem ie continues clinical challenge physician especially emergency_department due lack diagnostic criterion positive blood culture vegetation visualized echocardiographic study ie wide gamut presentation different level acuity diagnosis straightforward patient present obvious risk_factor many case one risk_factor may absent high index suspicion required especially patient additional finding splenic abscess embolic phenomenon focal neurologic deficit mycotic aneurysm decompensated_heart_failure new murmur pleural_effusion:0.0180836731597423", "192425": "year_old female hypertension depression asthma diagnosed chronic lymphocytic leukemia cll elevated beta microglobulin deletion q chromosome treated ibrutinib general weakness dyspnea fatigue shortness breath upper abdominal fullness discomfort splenomegaly ed oxygen saturation spo room air afebrile stable nasal oxygen l improved hypoxemia symptom exam showed bilateral crackle systolic murmur non tender abdomen splenomegaly lower extremity edema ct scan showed patchy ground glass opacity interlobular septal thickening bilateral pleural_effusion diuretic given patient condition worsened requiring icu bi level positive airway pressure bipap staphylococcus hominis found blood culture vancomycin started respiratory distress necessitated mechanical_ventilation intubation imaging suggested acute respiratory distress syndrome ards atypical pneumonia heart_failure_preserved_ejection_fraction transthoracic echocardiogram showed normal ejection_fraction severely increased pulmonary_artery_pressure transesophageal echocardiogram showed vegetation blood culture monitored gram positive bacteremia biofire isolating candida zeylanoides initially subsequent culture week period positive c zeylanoides cryptococcus neoformans chest ct revealed large mass lymph node mediastinal area thought causing pulmonary_hypertension compressing pulmonary_artery multidisciplinary discussion ibrutinib withheld drug induced pneumonitis suspected fungemia found immunocompromised patient infectious disease team prescribed voriconazole day changed amphotericin fluconazole due lack improvement eye examination showed sign endophthalmitis lumbar puncture showed central nervous_system cns fungal infection patient respiratory status worsened bronchoscopy bronchoalveolar lavage bal right middle lobe chest tube placement pleural_effusion done microbiological examination bal pleural_effusion revealed c neoformans klebsiella confirming disseminated c neoformans despite tough day hospital_stay patient discharged stable condition physical therapy nutrition optimization used enhance health case_report highlight rare serious complication cryptococcal disease patient using ibrutinib blood cancer early comprehensive diagnosis multi disciplinary involvement saved patient life:0.0178796322200520", "150142": "severe tricuspid_regurgitation especially caused pulmonary_hypertension primary tricuspid_regurgitation absence pulmonary_hypertension unknown etiology rare condition scarce data diagnosis_treatment follow particularity surgery indication outcome still clearly known year_old_woman medical_history coronary_artery_bypass_grafting three year ago presented shortness breath low limb edema physical_examination revealed prominent bilateral jugular turgescence hepatomegaly peripheral edema left midsternal border holosystolic murmur suggestive tricuspid_regurgitation echocardiogram confirmed diagnosis showed preserved right left_ventricular dimension function coronary_angiography showed new obstructive lesion patent surgical graft right cardiac catheterization revealed mild pulmonary_hypertension increased right atrium pressure cardiac_magnetic_resonance showed mild right_ventricular dilation normal systolic_function normal left chamber late gadolinium enhancement detected persistent symptom even optimization medical_therapy patient submitted tricuspid_valve replacement surgery immediately surgery patient_developed significant right_ventricular dysfunction need continuous hemodynamic support progressive clinical recovery confirmed serial echocardiogram showed improvement right_ventricular volume function patient discharged sign_symptom right_heart_failure histopathological examination showed significant diffuse myxomatous degeneration leaflet sign infection vegetation disruption strand observed report illustrates rare case symptomatic primary isolated severe tricuspid_regurgitation caused myxomatous degeneration leaflet thoroughly diagnostic workup presented histopathological analysis leaflet revealed etiologic process surgical treatment indicated onset right_ventricular failure essential patient full recovery:0.0175868291721535", "193090": "introduction hypocalcemia though rare lead heart_failure reduced_ejection_fraction dilated_cardiomyopathy may result various etiology manifestation range mild life_threatening cardiovascular_complication hypocalcemia include qt interval prolongation ventricular_arrhythmia heart_failure report rare case reversible hypocalcemic dilated_cardiomyopathy case_report present case_year_old woman secondary hypoparathyroidism following thyroidectomy treated levothyroxine calcitriol calcium vitamin supplement following covid infection may hypoparathyroidism decompensated leading severe hypocalcemia inadequately managed five month later presented worsening dyspnea orthopnea bilateral lower limb edema clinical examination revealed positive chvostek trousseau sign indicating severe hypocalcemia ecg showed sinus tachycardia qt prolongation echocardiography revealed dilated left_ventricle ejection_fraction_ef despite normal coronary_angiography ct scan showed bilateral pleural_effusion superior vena cava thrombosis laboratory finding confirmed hypocalcemia elevated phosphorus low parathyroid hormone level intravenous calcium correction heart_failure management led symptomatic improvement normalization serum calcium within one week echocardiography showed gradual recovery ef improving week month discussion calcium play critical role cardiac contractility deficiency severely impact myocardial function hypocalcemia following thyroidectomy known complication worsen systemic infection like covid hypocalcemia induced cardiomyopathy reversible proper treatment requires early recognition aggressive correction conclusion case highlight importance monitoring calcium level patient hypoparathyroidism especially context systemic infection prevent potentially life_threatening complication like hypocalcemic cardiomyopathy proper diagnosis_treatment hypocalcemia lead full recovery cardiac_function:0.0175639225436046", "99911": "background takotsubo syndrome uncommon acute reversible cardiomyopathy occurs primarily postmenopausal female clinical_presentation syndrome resembles acute_coronary_syndrome coronary_angiography reveals obstructive coronary_artery_disease rarely catecholamine surge due pheochromocytoma may induce takotsubo syndrome clinical_feature pheochromocytoma include paroxysmal hypertension headache palpitation profuse sweating however owing episodic rather continued symptom sign pheochromocytoma timely diagnosis pose challenge clinician report rare case long_term undetected pheochromocytoma leading takotsubo syndrome older male patient case presentation year_old_man presented paroxysmal chest distress chest_pain examination revealed acute_coronary_syndrome normal coronary_artery heart_failure reversible left_ventricular regional wall motion abnormality labile blood_pressure giant left adrenal mass extremely high_level metanephrine normetanephrine clinical_manifestation laboratory report imaging finding suggested diagnosis takotsubo syndrome caused pheochromocytoma supportive therapy administration alpha adrenergic receptor_blocker left adrenal mass resection resolved patient symptom histological examination confirmed presence pheochromocytoma reviewed history midbrain hemorrhage year prior found mass left adrenal region reviewing computed_tomography image lung also taken year prior pheochromocytoma evident conclusion case illustrates importance understanding link pheochromocytoma takotsubo syndrome diagnosis pheochromocytoma induced takotsubo syndrome considered differential diagnosis acute_coronary_syndrome especially patient labile blood_pressure normal coronary_angiography finding meanwhile assessment catecholamine metabolite abdominal computed_tomography scan performed right time clinician also alert potential pheochromocytoma patient unexplained cerebral hemorrhage even absence symptom catecholamine excess:0.0174936918397665", "71223": "case_year_old woman history hiv congestive_heart_failure secondary unknown congenital heart defect hypertension presented emergency_department worsening edema room air oxygen saturation percent l oxygen via nasal cannula oxygen saturation percent physical_examination notable central cyanosis facial lid edema ii vi holosystolic murmur across right chest radiating entire right back hemithorax decreased breath sound base pulmonary crackle clubbing finger edema bilateral lower extremity patient related lifelong knowledge congenital heart defect seen cardiologist adult asymptomatic yet sedentary one_year ago first multiple hospitalization acute_decompensated_heart_failure chest x_ray showed massive cardiomegaly right_sided calcified aortic arch patchy bilateral infiltrates transthoracic echocardiogram revealed severe right_ventricular hypertrophy ventricular septal_defect overriding aorta ejection_fraction percent consistent unrepaired tof utilized multimodality imaging technique including ct angiography cardiac mri defined cardiac anatomy finding consistent unrepaired tof pulmonary atresia pulmonary_artery arose directly aorta confluent fashion via large patent ductus arteriosus major aortopulmonary collateral artery arterialized pulmonary_artery aneurysmal dissection mural thrombus formation discussion case illustrates patient rare presentation unrepaired tof pulmonary atresia go undiagnosed adulthood early recognition utilizing multimodality imaging approach lead proper diagnosing hopeful surgical repair provide considerable improvement functional_status long_term_survival:0.0174884715686067", "136938": "importance virus infection widely described one common_cause myocarditis however less known cardiac_involvement complication severe acute respiratory syndrome coronavirus sars_cov infection objective describe presentation acute myocardial inflammation patient coronavirus disease covid recovered influenzalike syndrome developed fatigue sign_symptom heart_failure week upper respiratory tract symptom design setting_participant case_report describes otherwise healthy year_old_woman tested positive covid admitted cardiac care unit march acute myopericarditis systolic_dysfunction confirmed cardiac_magnetic_resonance_imaging week onset fever dry cough due covid patient show respiratory involvement clinical_course exposure cardiac_involvement covid main_outcome_measure detection cardiac_involvement increase level n_terminal_pro_brain_natriuretic_peptide nt_probnp high_sensitivity troponin echocardiography change diffuse biventricular myocardial edema late gadolinium enhancement cardiac_magnetic_resonance_imaging result otherwise healthy year_old white woman presented emergency_department severe fatigue described fever dry cough week afebrile hypotensive electrocardiography showed diffuse st elevation elevated high_sensitivity troponin nt_probnp_level detected finding chest radiography normal evidence obstructive coronary disease coronary_angiography based covid outbreak nasopharyngeal swab performed positive result sars_cov real_time reverse transcriptase polymerase chain reaction assay cardiac_magnetic_resonance_imaging showed increased wall_thickness diffuse biventricular hypokinesis especially apical segment severe left_ventricular_dysfunction left_ventricular_ejection_fraction short tau inversion recovery mapping sequence showed marked biventricular myocardial interstitial edema also diffuse late gadolinium enhancement involving entire biventricular wall circumferential pericardial effusion notable around right cardiac chamber finding consistent acute myopericarditis treated dobutamine antiviral drug lopinavir ritonavir steroid chloroquine medical treatment_heart_failure progressive clinical instrumental stabilization conclusion relevance case highlight cardiac_involvement complication associated covid even without symptom sign interstitial pneumonia:0.0174601823945475"}, "Topic 5": {"2079": "context result recent_study effect beta blockade patient_heart_failure demonstrated reduction total mortality however effect beta blockade frequency hospitalization symptom quality_life patient_heart_failure fully explored objective examine effect beta_blocker controlled release extended release metoprolol succinate metoprolol cr xl mortality hospitalization symptom quality_life patient_heart_failure design randomized double_blind controlled_trial preceded week single blind placebo run period conducted february october mean_follow year setting three hundred thirteen site country participant patient_n chronic_heart_failure new_york_heart_association nyha_functional_class ii iv ejection_fraction less stabilized optimum standard therapy intervention patient randomized metoprolol cr xl mg per day nyha_class ii mg per day nyha_class iii_iv titrated week target dosage mg per day n matching placebo n main_outcome_measure total mortality hospitalization time first event number hospitalization worsening_heart_failure change nyha_class intervention_group quality_life assessed substudy patient result incidence predefined end_point lower metoprolol cr xl group placebo group including total mortality cause hospitalization prespecified second primary_end_point v event risk reduction confidence_interval_ci_p total mortality hospitalization due worsening_heart_failure v event risk reduction ci_p number hospitalization due worsening_heart_failure v_p number day hospital due worsening_heart_failure v day_p nyha_functional_class assessed physician mcmaster overall treatment evaluation score assessed patient improved metoprolol cr xl group_compared placebo group_p p respectively conclusion_study patient symptomatic heartfailure metoprolol cr xl improved survival reduced need hospitalization due worsening_heart_failure improved nyha_functional_class beneficial_effect patient well:0.0312288911890948", "23718": "background beta blocking agent reduce_risk hospitalization death patient mild_moderate heart_failure little_known effect severe_heart_failure method evaluated patient symptom heart_failure rest minimal exertion clinically euvolemic ejection_fraction less percent double_blind fashion randomly_assigned patient placebo patient treatment carvedilol mean period month standard therapy heart_failure continued patient required intensive_care marked fluid retention receiving intravenous vasodilator positive inotropic drug excluded result death placebo group death carvedilol group difference reflected percent decrease risk_death carvedilol percent confidence_interval percent p unadjusted p adjusted interim analysis total_patient died hospitalized placebo group_compared carvedilol group difference reflected percent decrease combined risk_death hospitalization carvedilol percent confidence_interval percent p favorable effect end_point seen consistently subgroup examined including patient history recent recurrent cardiac decompensation fewer patient carvedilol group placebo group withdrew adverse_effect reason p_conclusion previously reported benefit carvedilol regard morbidity_mortality patient mild_moderate heart_failure also apparent patient_severe heart_failure evaluated trial:0.0277292350520399", "47773": "background stromal cell derived factor sdf promotes tissue repair mechanism cell survival endogenous stem_cell recruitment vasculogenesis stromal cell derived factor plasmid treatment patient_heart_failure stop hf phase ii double_blind randomized placebo controlled_trial evaluate safety_efficacy single treatment plasmid stromal cell derived factor psdf delivered via endomyocardial injection patient ischaemic heart_failure ihf method ninety three subject ihf stable guideline based medical_therapy left_ventricular_ejection_fraction_lvef completed minnesota living_heart_failure questionnaire mlwhfq min walk distance mwd randomized receive single treatment either mg dose psdf placebo via endomyocardial injection safety_efficacy parameter assessed month injection left_ventricular functional structural measure assessed contrast echocardiography quantified blinded independent core laboratory stromal cell derived factor plasmid treatment patient_heart_failure powered based change mwd mlwhfq month result subject profile baseline mean_sd age_year lvef left_ventricular end_systolic_volume lvesv ml n_terminal_pro_brain_natriuretic_peptide bnp ntprobnp pg_ml mlwhfq point mwd patient_year post recent myocardial_infarction study injection delivered without serious adverse_event subject sixty two patient_received drug unanticipated serious product related adverse_event primary_endpoint composite change mwd mlwhfq baseline month_follow primary_endpoint met p patient_treated psdf trend toward improvement lvef month placebo v mg v mg deltalvef v v_p pre specified analysis effect psdf based tertiles lvef entry revealed improvement ef lvesv lowest highest lvef patient first tertile ef received mg psdf demonstrated increase ef compared decrease placebo deltalvef p month also trend towards improvement lvesv treated patient demonstrating ml decrease compared ml increase placebo month deltalvesv ml_p change end_diastolic end_systolic_volume equated ml increase stroke_volume patient_treated mg psdf compared decrease ml placebo group deltasv ml_p addition mg treated cohort exhibited trend towards improvement ntprobnp compared_placebo month pg_ml p_conclusion blinded placebo controlled stop hf trial demonstrated safety single endocardial administration psdf failed demonstrate primary_endpoint improved composite score month treatment pre specified analysis stop hf trial demonstrates potential attenuating lv remodelling improving ef high_risk ischaemic cardiomyopathy safety profile support repeat dosing psdf degree left_ventricular remodelling suggests potential improved outcome larger future trial:0.0240839515358818", "103664": "background stem bark terminalia arjuna roxb ex dc wight arn arjuna used indian system medicine ayurveda treatment various cardiac_disease including heart_failure however well designed clinical_trial exploring efficacy_safety chronic_heart_failure_chf lacking purpose ascertain add efficacy_safety standardized water extract stem bark arjuna arjuna extract chf_patient standard pharmacotherapy study_design double_blind parallel randomized placebo controlled add clinical_trial method approval institutional ethic committee patient_chf new_york_heart_association nyha_functional_class ii standard pharmacotherapy echocardiographic left_ventricular_ejection_fraction_lvef consecutively recruited informed consent randomized arjuna extract mg matching placebo twice daily primary_outcome measure change lvef week secondary_outcome measure included change nyha_functional_class ii distance covered min walk test mwt iii quality_life qol determined kansa city cardiomyopathy questionnaire kccq iv plasma brain_natriuretic_peptide v plasma cytokine interleukin high_sensitivity c_reactive_protein tumour necrosis_factor alpha vi oxidative_stress marker serum thiobarbituric acid reactive substance tbars red blood_cell rbc superoxide dismutase sod rbc catalase rbc glutathione gsh week safety assessment done adverse_event monitoring laboratory investigation result expressed mean_sd median interquartile_range analysed intention treat principle using appropriate two sided statistical test p_value considered significant result arjuna extract well_tolerated change lvef versus_p secondary_outcome measure except preservation rbc catalase activity versus u g haemoglobin p compared_placebo significantly_greater percentage increase occurred distance covered mwt rbc sod rbc catalase rbc gsh symptom severity stability domain kccq patient arjuna extract versus placebo post_hoc analysis subgroup patient improved outcome conclusion arjuna extract improve lvef chf_patient week although improvement functional_capacity antioxidant reserve symptom related qol domain patient:0.0229548084015680", "494": "background study_evaluated short_term long_term effect angiotensin_ii type receptor_antagonist candesartan cilexetil hemodynamics neurohormone clinical symptom patient congestive_heart_failure_chf method multicenter double_blind parallel group study patient_chf new_york_heart_association_class ii_iii impaired left_ventricular_function ejection_fraction pulmonary_capillary wedge_pressure mm_hg randomly_assigned week treatment placebo n candesartan cilexetil mg n mg n mg n mg n daily week placebo run period hemodynamic measurement performed right_heart_catheterization hour period single day repeated month treatment study drug result regression_analysis time response curve single multiple dos candesartan cilexetil produced sustained significant dose dependent reduction pulmonary_capillary wedge_pressure short_term effect p long_term effect p mean pulmonary arterial_pressure short_term effect p long_term effect p systemic vascular_resistance showed trend toward decreasing dose short_term long_term treatment consistent change seen cardiac_index compensatory increase plasma renin activity angiotensin_ii level decrease aldosterone atrial natriuretic_peptide dose dependent significant candesartan cilexetil improved clinical symptom stabilized patient new_york_heart_association status compared_placebo judged efficacious treatment investigator patient_receiving placebo stopped trial prematurely adverse_event candesartan cilexetil group excess death treatment_group candesartan safe well_tolerated dosage conclusion candesartan cilexetil demonstrated significant short_term long_term improvement hemodynamic neurohormonal symptomatic status well_tolerated patient_chf:0.0228093057026590", "33923": "importance diastolic heart_failure ie heart_failure_preserved_ejection_fraction common condition without established therapy aldosterone stimulation may_contribute progression objective_assess efficacy_safety long_term aldosterone receptor blockade heart_failure_preserved_ejection_fraction primary objective determine_whether spironolactone superior placebo improving diastolic_function maximal exercise_capacity patient_heart_failure preserved_ejection_fraction design setting aldo dhf trial multicenter prospective randomized double_blind placebo controlled_trial conducted march april site germany austria included ambulatory patient mean_age sd year female chronic new_york_heart_association_class ii_iii heart_failure preserved left_ventricular_ejection_fraction greater evidence diastolic_dysfunction intervention patient randomly_assigned receive mg spironolactone daily n matching placebo n month_follow main_outcome_measure equally ranked co primary_end_point change diastolic_function e_e echocardiography maximal exercise_capacity peak_vo cardiopulmonary_exercise testing measured month result diastolic_function e_e decreased sd sd spironolactone increased sd sd placebo adjusted mean_difference ci_p peak_vo significantly change spironolactone v placebo sd ml_min kg sd ml_min kg sd ml_min kg sd ml_min kg respectively adjusted mean_difference ml_min kg ci ml_min kg p spironolactone induced reverse_remodeling left_ventricular mass_index declined difference g ci g p improved neuroendocrine activation n_terminal_pro brain type_natriuretic_peptide geometric mean ratio ci_p improve heart_failure_symptom quality_life slightly reduced minute walking distance ci_p spironolactone also modestly increased serum potassium level mmol_l ci_p decreased estimated_glomerular_filtration_rate ml_min ci ml_min p without affecting hospitalization conclusion relevance randomized_controlled_trial long_term aldosterone receptor blockade improved left_ventricular diastolic_function affect maximal exercise_capacity patient symptom quality_life patient_heart_failure preserved_ejection_fraction whether improved left_ventricular_function observed aldo dhf trial clinical significance requires investigation larger population trial_registration clinicaltrials_gov identifier isrctn eudra ct:0.0228055841350824", "70859": "aim determine tolerability optimal dose regimen soluble guanylate cyclase stimulator vericiguat patient_chronic_heart_failure preserved_ejection_fraction_hfpef method_result socrates preserved prospective randomized placebo controlled double_blind phase b dose finding study patient_hfpef ejection_fraction patient_received vericiguat daily mg fixed dos mg titrated mg starting dose placebo week two primary_endpoint change baseline log transformed n_terminal_pro_b_type_natriuretic_peptide nt_probnp left_atrial volume lav week patient_n woman mean_age_year baseline atrial_fibrillation randomized within week hf_hospitalization outpatient treatment intravenous diuretic hf vericiguat n placebo n pooled three highest dose arm change lognt probnp vericiguat log pg_ml n placebo log pg_ml n one sided p two sided p change lav vericiguat ml n placebo ml n one sided p two sided p different placebo vericiguat well_tolerated adverse_event vericiguat mg arm placebo low discontinuation rate group change blood_pressure mg compared_placebo pre specified exploratory endpoint kansa city cardiomyopathy questionnaire clinical summary score improved vericiguat mg arm mean point median interquartile_range baseline mean_difference placebo point conclusion vericiguat well_tolerated change nt_probnp lav week compared_placebo associated improvement quality_life patient_hfpef given encouraging result quality_life effect vericiguat patient_hfpef warrant study possibly higher dos longer follow additional endpoint:0.0225754985787058", "99839": "background increased iron availability modifies cardiorespiratory function healthy volunteer improves exercise_capacity quality_life patient_heart_failure pulmonary_hypertension hypothesised intravenous iron would produce improvement oxygenation exercise_capacity quality_life patient chronic_obstructive_pulmonary_disease_copd method performed randomised placebo controlled double_blind trial participant copd mean_sd age_year haemoglobin g l ferritin microg l transferrin saturation gold grade ii iv received single dose intravenous ferric carboxymaltose fcm mg_kg bodyweight saline placebo primary_endpoint peripheral oxygen saturation spo rest week secondary_endpoint included daily spo overnight spo exercise spo min walk distance symptom quality_life score serum iron index spirometry echocardiographic measure exacerbation frequency result spo unchanged week fcm administration difference group ci however secondary analysis exercise_capacity increased significantly fcm administration compared_placebo mean_difference min walk distance ci improvement observed iron treated placebo treated participant week p modified mrc dyspnoea scale score also significantly_lower fcm fewer participant reported score fcm group_compared placebo v_p significant_difference observed secondary_endpoint adverse_event rate similar group except hypophosphataemia occurred frequently fcm v_p conclusion fcm improve oxygenation week patient copd however treatment well_tolerated produced improvement exercise_capacity functional limitation caused breathlessness effect secondary_endpoint require confirmation future study trial_registration number isrctn:0.0224925883576722", "493": "background diuretic accepted first_line treatment refractory congestive_heart_failure_chf lack response frequent event randomized single blind study performed evaluate effect combination high_dose furosemide small volume hypertonic saline solution hs infusion treatment refractory new_york_heart_association_nyha_class iv chf normosodic diet follow material_method one_hundred seven patient woman_men age range year refractory chf nyha_class iv different etiology unresponsive high oral dos furosemide angiotensin_converting_enzyme_inhibitor digitalis nitrate enrolled inclusion_criterion included ejection_fraction_ef serum_creatinine level mg_dl blood urea nitrogen level mg_dl reduced urinary volume low natriuresis patient randomized group single blind patient_group woman_men received intravenous iv infusion furosemide mg plus hs ml nacl twice day minute patient_group woman_men received iv bolus furosemide mg twice day without hs period lasting day group received iv kcl meq prevent hypokalemia study entry patient_underwent physical_examination measurement body_weight bw blood_pressure bp heart_rate hr evaluation sign chf measurement control level serum na k cl bicarbonate albumin uric_acid creatinine urea glycemia daily hospitalization measurement daily output urine na k cl chest radiograph electrocardiogram echocardiogram obtained study entry hospitalization time discharge hospital treatment discharge daily dietary na intake mmol group versus mmol group fluid intake ml daily group assessment bw hour urinary volume serum urinary laboratory parameter performed daily patient reached compensated state iv furosemide replaced oral administration mg discharge hospital patient observed outpatient weekly first month subsequently month result group similar age_sex ef risk_factor treatment etiology chf_patient showed clinical improvement ten patient_group hyponatremia entry significant_increase daily diuresis natriuresis observed group significant group receiving hs p serum na level increased group decreased group_p serum k level decreased group_p bw reduced group_p group increase serum_creatinine level serum uric_acid level increased group bp value decreased hr corrected normal value group follow_period month patient_group readmitted hospital heart_failure group_patient readmitted hospital higher class discharge twenty four patient_group died follow versus patient_group p_conclusion treatment effective well_tolerated improves quality_life relief sign_symptom congestion may delay aggressive treatment_effect also beneficial long period mortality reduction v survival_rate clinical improvement:0.0220636777609524", "22314": "objective sought define therapeutic dose range levosimendan patient new_york_heart_association_class ii iv heart_failure ischemic origin background levosimendan calcium sensitizer treatment acute_decompensated_heart_failure method double_blind placebo controlled randomized multicenter parallel group study_included adult_patient levosimendan given min intravenous bolus microg kg followed h infusion microg kg_min respectively dobutamine comparative purpose given open label infusion microg kg_min primary efficacy variable proportion_patient achieving treatment_group least_one following increase stroke_volume sv h h decrease pulmonary_capillary wedge_pressure pcwp mm_hg h h increase cardiac_output co change heart_rate hr decrease pcwp two consecutive measurement result response rate levosimendan ranged lowest dose highest dose compared_placebo dobutamine dose response relationship demonstrated levosimendan increase co sv reduction pcwp infusion p headache nausea hypotension frequently reported adverse_event higher dosage conclusion dosing levosimendan min bolus microg kg followed infusion microg kg_min well_tolerated lead favorable hemodynamic effect:0.0218848705175980"}, "Topic 6": {"104089": "background transplanted heart dysfunction serious life_threatening condition pediatric transplant recipient several study focused echocardiographic detection early sign cardiac_dysfunction population evaluated advanced echocardiographic index cardiac_function large sample child young adult heart_transplant apparently normal cardiac_function method_study included_patient normal ejection_fraction transplantation performed pediatric age healthy_control subject patient control subject underwent complete transthoracic echocardiographic examination including tissue_doppler analysis dimensional speckle_tracking dimensional echocardiography two dimensional speckle_tracking analysis used obtain measure left_ventricular_lv radial circumferential longitudinal_strain derive lv twist torsion basal apical rotation three dimensional echocardiography used measure lv volume ejection_fraction evaluate lv systolic synchrony result difference observed group lv volume left_atrial diameter lv_ejection_fraction right_ventricular fractional area change however patient showed lower value longitudinal systolic excursion valvular plane mitral tricuspid_valve level well higher mitral e_e ratio cardiac radial strain similar group significant net reduction global left right_ventricular longitudinal_strain lv global circumferential strain could observed group_p addition reduced lv twist torsion found patient compared healthy_control subject p mainly owing significant_reduction basal rotation degree v degree p none control subject demonstrated lv dyssynchrony whereas systolic dyssynchrony observed heart_transplant recipient conclusion even absence sign graft failure presence normal ejection_fraction transplanted heart show significant_reduction biventricular function additional prognostic study_needed establish whether abnormality predict development overt heart_failure:0.0277788407972063", "99296": "background left_ventricular_lv diastolic_dysfunction main cause heart_failure_preserved_ejection_fraction_hfpef characterized lv stiffness relaxation abnormal lv global_longitudinal_strain gls frequently observed l hfpef shown useful identifying hfpef_patient high_risk cardiovascular_event cardiovascular magnetic_resonance cmr feature tracking cmr ft enables reproducible non_invasive assessment global strain cine cmr image however association gls invasively measured parameter diastolic_function investigated sought determine prevalence severity gls impairment patient_hfpef using cmr ft evaluate correlation gls measured cmr ft measured invasive diastolic functional index method eighteen patient_hfpef age_sex matched healthy_control subject studied subject underwent cine pre post contrast mapping late gadolinium enhancement cmr hfpef_patient invasive pressure volume loop obtained evaluate lv diastolic property gls quantified cine cmr extracellular volume fraction ecv quantified pre post contrast mapping known imaging biomarker predicting lv stiffness result gls significantly impaired patient_hfpef v_p thirty nine percent hfpef_patient showed impaired gls cut statistically significant_difference found ecv hfpef_patient control v_p hfpef_patient time constant active lv relaxation tau strongly correlated gls r_p global circumferential strain gc r_p global radial strain grs r_p multiple linear regression_analysis revealed gls independent_predictor altered tau beta_p among age lv_end_diastolic volume_index lv end_systolic volume_index lv mass_index gc grs gls conclusion cmr ft noninvasive approach enables identification subgroup hfpef_patient impaired gls cmr lv gls independently predicts abnormal invasive lv relaxation index tau measurement hfpef_patient finding_suggest feature tracking cmr analysis conjunction ecv may enable evaluation diastolic_dysfunction patient_hfpef:0.0273386939042384", "169003": "objective adhd one common neurodevelopmental disorder seen child adolescent often treated various pharmacological agent especially methylphenidate differing opinion literature regarding cardiovascular safety long_term methylphenidate use study suggest drug may increase_risk hypertension myocardial_infarction ventricular_arrhythmia sudden_cardiac_death cardiomyopathy heart_failure_hf pulmonary_hypertension stroke study_aimed compare clinical echocardiographic characteristic patient_diagnosed adhd using long acting methylphenidate extended period age_gender matched healthy volunteer material_method total_patient diagnosed adhd using long acting methylphenidate year healthy volunteer referred clinic included_study patient evaluated basic advanced technique motion mode mode two dimensional doppler speckle_tracking ste using transthoracic_echocardiography data evaluated instantly processing strain image analysis program result statistically significant_difference observed case control_group term body_mass_index_bmi systolic_blood_pressure sbp bmi negatively correlated sbp positively correlated methylphenidate use duration significant_difference group apical four chamber three chamber two chamber global_longitudinal_strain gls value obtained ste technique indicating early deterioration left_ventricular_lv lateral e value indicates diastolic_dysfunction lower drug group still within normal limit lateral lv e right_ventricular_rv e rv value showed significant negative correlation duration drug use remained within normal limit parameter evaluating systolic diastolic_function e_e left_ventricular_ejection_fraction_lvef myocardial performance index mpi tricuspid mitral annular plane systolic excursion tapse mapse differ significantly group within normal limit valve structure regurgitation also significantly_different two_group conclusion considering parameter conclude long_term use long acting methylphenidate cause cardiovascular dysfunction late adolescent early adult individual observed difference e lateral value case control_group well slight correlation lateral lv e rv e rv value duration use directly indicate cardiac_dysfunction:0.0263935351930594", "127832": "aim severity cardiac impairment acute_heart_failure_ahf predicts outcome challenge remain identify prognostically important non_invasive parameter cardiac_function left_ventricular_ejection_fraction_lvef relevant reduced lv systolic_function aimed assess standard advanced parameter left right_ventricular_rv function echocardiography predicting long_term_outcome ahf method_total consecutive ahf patient_presenting month prospectively recruited underwent bedside echocardiography within h recruitment retrospectively assessed rv lv echo parameter cardiac systolic_function predict year_mortality using guideline_directed study specific cutoff based maximum youden index via roc analysis rv tricuspid annular plane systolic excursion rv fractional area change tissue_doppler imaging tdi peak tricuspid annular systolic wave velocity peak end_systolic rv free wall global_longitudinal_strain rv gls strain rate mean rv glsr rv ejection_fraction rvef derived ellipsoid model ratio tapse systolic pulmonary_artery_pressure spap lv lvef mitral regurgitant deltap deltat mr dp_dt lateral mitral annular tdi peak systolic wave velocity lv gls lv glsr result_total parameter rv systolic_function predictive year outcome study cutoff like international guideline cutoff mean rv glsr associated_worse outcome compared hr_ci_p tapse spap cm mmhg v cm mmhg predicted worse outcome hr_ci_p way comparison year_mortality lvef european society_cardiology esc guideline criterion lvef prognostic v v_p parameter lv systolic_function mr dp_dt cutoff mmhg predictive adverse_outcome hr_ci_p_conclusion cutoff broadly like esc guideline identified rv dysfunction associated adverse prognosis whereas lvef could identify_patient risk:0.0260566676998548", "199048": "objective research investigated application real_time three dimensional speckle_tracking imaging rt sti evaluate left_atrial la function individual suffering hypertensive heart_disease hhd heart_failure_preserved_ejection_fraction_hfpef material_method retrospective_study included_patient hhd hfpef hospitalized august june hfpef group healthy individual undergoing physical_examination comprised control_group patient data_collected echocardiography performed measure la diameter lad left_ventricular_end_diastolic diameter lvedd interventricular septal thickness ivst left_ventricular posterior wall_thickness lvpwt left_ventricular outflow tract diameter lvotd early diastolic maximum velocity mitral_valve inflow mve late diastolic maximum velocity mitral_valve inflow mva early diastolic late diastolic velocity mitral annulus measured tissue_doppler ultrasound e tricuspid annular plane systolic excursion tapse left_ventricular_ejection_fraction_lvef la image analyzed_using ge software following parameter measured l emptying fraction laef la emptying volume laev lavolume onset contraction lavprea minimum la volume lavmin maximum la volume lavmax la strain reservoir phase lasr la strain contraction phase lasct la strain conduit phase lascd roc_curve adopted evaluate diagnostic value la parameter hfpef pearson correlation analysis examined relationship parameter n_terminal_pro_b_type_natriuretic_peptide nt_probnp result compared control_group blood_pressure hfpef group significantly_higher p lt hfpef group nt_probnp concentration significantly_greater observed control_group p lt statistically_significant variance detected lvef lvedd lvotd tapse mve mva ratio e wave velocity wave velocity e laev lavmin lavprea two_group p gt compared control_group hfpef group dramatically higher lad ivst lvpwt p lt hfpef group also lower e laef lasr lascd lasct e_e maximum la volume_index lav imax lavmax higher p lt lasr negatively associated nt_probnp r_p whereas significant_correlation found among lascd lasct nt_probnp p gt conclusion la strain parameter serve non_invasive method quantitatively assessing la dysfunction patient_hfpef:0.0258771689146550", "185660": "cardiac_resynchronization_therapy_crt induces left_ventricle reverse_remodeling however effect right_ventricular_rv volume function well described study_aimed assess effect crt rv patient_enrolled mean_age_year including male patient met criterion crt implantation followed month month interval standard dimensional dimensional echocardiography speckle_tracking analysis conducted assessment lv left_atrium la rv maximum diameter tricuspid lateral annular systolic velocity tricuspid annular plane systolic excursion fractional area change rv global rv chamber strain rv csl rv free wall strain rvfwsl addition echocardiographic assessment rv done crt implantation follow visit mean_follow period month total_patient lv responder lvr whereas rest nonresponders lvnr group similar baseline_characteristic risk_factor device implantation programming value lvr significant_reduction rv basal diameter together significant_improvement rv systolic performance systolic velocity fractional area change rv csl rvfwsl derived rv volume ejection_fraction compared baseline value addition pulmonary arterial systolic_pressure decreased lvr reduction tricuspid_regurgitation severity lv response percentage change rv csl la end_systolic volume_index la emptying fraction month_follow independent_predictor rv response multivariate_analysis reduced left_ventricular end_systolic_volume sensitivity_specificity conclusion crt induced rv reverse_remodeling improved rv arterial coupling effect associated left side response crt:0.0256201822336103", "104530": "objective aim_study investigate whether cluster analysis left_atrial left_ventricular_lv mechanical deformation parameter provide sufficient information doppler independent assessment lv diastolic_function background medical imaging produce substantial phenotyping data superior computational analysis could allow automated classification repetitive pattern patient_group similar behavior method author performed cluster analysis developed model lv diastolic_function initial exploratory cohort_patient subsequently tested prospective cohort patient_undergoing cardiac catheterization patient study group standard echocardiographic examination doppler derived assessment diastolic_function left_ventricle left_atrium tracked simultaneously using speckle_tracking echocardiography ste measuring simultaneous change left_atrial ventricular volume volume rate longitudinal_strain strain rate patient validation group also underwent invasive measurement pulmonary_capillary wedge_pressure lv_end_diastolic pressure immediately echocardiography similarity ste conventional dimensional doppler method diastolic_function investigated exploratory validation cohort result ste demonstrated strong correlation conventional index independently clustered patient_group conventional measurement verifying increasing severity diastolic_dysfunction lv filling_pressure multivariable linear regression_model also allowed estimation e_e pulmonary_capillary wedge_pressure ste validation cohort conclusion tracking deformation left_sided cardiac chamber routine cardiac ultrasound image provides accurate information doppler independent phenotypic characterization lv diastolic_function noninvasive assessment lv filling_pressure:0.0255692549303775", "143080": "right_ventricular_rv function adaptation increased afterload rv pulmonary arterial pa coupling crucial various type pulmonary_hypertension determining symptomatology outcome course disease_progression increasing afterload right_ventricle undergoes adaptive remodelling maintain right_sided cardiac_output increasing contractility exhaustion compensatory rv remodelling rv pa uncoupling finally lead maladaptation increase cardiac volume resulting heart_failure gold_standard measurement rv pa coupling ratio contractility end_systolic elastance ee afterload arterial elastance ea derived rv pressure volume loop obtained conductance catheterization optimal ee ea ratio rv pa coupling pulmonary_hypertension considerable reserve ee ea threshold uncoupling occurs estimated rv conductance catheterization invasive complex widely available multiple non_invasive echocardiographic surrogate ee ea investigated one first described best validated surrogate ratio tricuspid annular plane systolic excursion estimated pulmonary arterial systolic_pressure tapse pasp shown prognostic relevance left_sided heart_failure precapillary pulmonary_hypertension rv pa coupling surrogate formed replacing tapse different echocardiographic measure rv contractility peak systolic tissue velocity lateral tricuspid annulus rv fractional area change speckle_tracking based rv free wall longitudinal_strain global_longitudinal_strain three dimensional rv ejection_fraction pasp independent surrogate also studied including ratio rv end_systolic area index rv area change rv end_systolic area stroke_volume end_systolic_volume limitation non_invasive surrogate include influence severe tricuspid_regurgitation cause distortion longitudinal measurement underestimation pasp angle dependence tapse pasp detection early rv remodelling may require isolated analysis single component rv shortening along radial anteroposterior ax well longitudinal axis multiple non_invasive method may need applied depending level rv dysfunction review explains mechanism rv mal adaptation load describes invasive assessment rv pa coupling provides overview study non_invasive surrogate parameter highlighting recently published work field large_scale prospective_study including gold_standard validation needed study date retrospective single centre design small number participant validation gold_standard ee ea rarely performed:0.0254972548559162", "74975": "right_ventricular_rv function significantly important factor determination prognosis chronic thromboembolic pulmonary_hypertension cteph patient speckle_tracking echocardiography ste angle independent new technique quantifying myocardial deformation capable providing data multiple parameter including longitudinal transverse information myocardium present study_aimed study advantage ste derived parameter identifying rv dysfunction cteph patient sixty cteph patient mean_age_year year male normal control mean_age_year year male enrolled study rv free wall rvfw systolic peak longitudinal_strain l including basal mid apical segment basal longitudinal transverse displacement basal dl basal dt measured ste global l gls rv calculated averaging l value segment rvfw clinical_data cteph patient collected cteph patient_divided subgroup according world health organization function classification clinical right_heart_failure rhf defined presence symptom heart_failure sign systemic circulation congestion hospitalization apical segment l rvfw lower basal mid segment control_group p significant_difference found among segment l cteph group_p used cutoff value recommended american society echocardiography guideline identify abnormal rv function cteph patient tricuspid annular plane systolic excursion tapse patient fractional area change fac patient rv index myocardial performance rvimp patient_patient gls determined abnormal rv function respectively among multiple rv function indicator tapse fac gls basal dl n_terminal pronatriuretic b_type_natriuretic_peptide showed significant_difference cteph patient mild ii severe symptom iii_iv p rvimp basal dt showed significant_difference p_p_respectively pearson correlation analysis_showed gls correlation spap evaluated echocardiography cteph patient r_p weak moderate correlation ra area r_p rv diameter r_p rvfw thickness r_p receiver_operating_characteristic analysis gls largest area_curve identify rhf cutoff value sensitivity_specificity separately study_demonstrated depression regional l rvfw pronounced basal middle segment cteph patient also longitudinal movement much important transverse movement evaluating rv systolic_function compared conventional parameter rvfw gls showed sensitivity identify abnormal rv function largest auc identifying rhf additionally gls showed correlation spap weak correlation right_heart morphological parameter cteph cohort:0.0251615128271948", "79926": "background right_ventricular_rv systolic_function critical role determining clinical_outcome success using left_ventricular_assist_device lvads patient refractory heart_failure tissue_doppler mode measurement tricuspid systolic motion tricuspid tricuspid annular plane systolic excursion tapse currently used method quantification rv longitudinal function rv deformation analysis speckle_tracking echocardiography ste recently allowed analysis global rv longitudinal function using cardiac catheterization reference standard study_aimed exploring correlation rv longitudinal function ste rv stroke work index rvswi patient referred cardiac_transplantation method_result right side heart catheterization transthoracic echo doppler simultaneously performed_patient referred cardiac_transplantation evaluation advanced systolic_heart_failure thermodilution rv stroke_volume invasive pulmonary pressure used obtain rvswi rv longitudinal_strain rvls ste assessed averaging segment apical chamber view global rvls averaging rv free wall segment free wall rvls tricuspid tapse also calculated significant_correlation found tapse tricuspid rvswi r r respectively close negative correlation global rvls free wall rvls rvswi found r r respectively_p furthermore free wall rvls demonstrated highest diagnostic accuracy area receiver_operating_characteristic roc_curve good sensitivity_specificity respectively predict depressed rvswi using cutoff value less conclusion group_patient referred heart_transplantation tapse tricuspid correlate invasively obtained rvswi rv longitudinal deformation analysis ste correlated well rvswi providing better estimation rv systolic performance:0.0251576226608411"}, "Topic 7": {"91662": "background end life may time high service utilisation older_adult transition care setting occur frequently may produce little improvement symptom control quality_life patient ensuring patient experience co ordinated care move occur individual need rather system imperative crucial patient well containing health_care cost objective aim_study understand experience influence consequence transition setting older_adult end life three condition focus study chosen represent differing disease trajectory setting england participant thirty patient_aged_year last year life diagnosed heart_failure lung cancer stroke caregiver decedent aged_year died heart_failure lung cancer stroke chronic_obstructive_pulmonary_disease selected cancer provider commissioner service primary_care hospital hospice social care ambulance service design method mixed method_study composed four part depth interview older_adult qualitative interview structured questionnaire bereaved carers older_adult decedent telephone interview care commissioner provider using case scenario derived interview carers analysis linked hospital episode statistic he mortality data relating hospital_admission heart_failure lung cancer england result transition care setting last year life common component end life care across data set made study many move made shortly death patient carers experience transition disjointed system organisational process prioritised individual need many case family carer co ordinator provider care home excluded participation institutional care lacking information support extend role confidence general practitioner gp valued central figure end life care across setting though discipline critical gps expertise adherence guideline hour service care home identified many contributor unnecessary transition good relationship communication professional different setting sector recognised family one important influence transition rarely acknowledged staff conclusion development shared understanding professional carer role end life transition may one effective way improving patient experience patient carers manage many aspect end life care identifying way extend skill strengthen voice particularly hospital setting would welcomed may reduce unnecessary end life transition experience carers appear changed little despite implementation range relevant policy important question answered recommendation future_research include relationship policy intervention experience end life carers identification way harmonise understanding carers role strengthen voice particularly hospital setting identification way reduce influence interprofessional tension end life care development intervention enhance patient experience across transition funding national institute health research health service delivery research programme:0.0235837781470343", "90982": "medical management chronic illness consumes percent every health_care dollar spent united_state provision economical accessible high quality chronic_disease care continuing concern across health_care setting type_diabetes hypertension hyperlipidemia congestive_heart_failure prime example common chronic_disease cause substantial morbidity_mortality require long_term medical management support disease condition majority care occurs outpatient setting well_established clinical_practice guideline used guide treatment decision despite availability guideline practice recommendation often implemented contributes suboptimal clinical_outcome shortage primary_care clinician outpatient care setting identified barrier provision comprehensive chronic_disease care provides impetus develop test strategy expanding role responsibility member interdisciplinary team help meet continually increasing need chronic_disease care effort serve veteran improve quality efficiency chronic_disease care department veteran affair va implementing patient aligned care team pact model primary_care transformation build widely disseminated effort chronic care model va pact adaptation patient centered medical home includes following core principle wide ranging team based care patient centered orientation toward whole person care coordinated across element health_care system patient community enhanced access care us alternative method communication system based approach quality safety va pact clinical team may include nurse registered nurse rn licensed practical nurse lpn well primary_care provider clinical pharmacist behavioral health specialist clinic facilitator organizing principle care team utilize personnel highest level skill set institute medicine recommended expansion nurse role responsibility allow practice full extent education training report contribution nurse improving access quality care patient selected chronic_condition using detailed structured protocol developed consultation physician began late robust evidence supporting effectiveness nurse providing patient education chronic_disease treatment self_care management secondary_prevention strategy well ability nurse practitioner np provide effective cost_effective primary_care largest segment health_care workforce nurse ideally suited collaborate professional meeting increasing demand chronic care nurse experienced accustomed working multidisciplinary team clearly defined clinical protocol additional training safely practice beyond usual scope practice may well able order relevant diagnostic test adjust routine medication regimen appropriately refer complicated unstable patient medical evaluation va process developing protocol policy expanding nurse role member pact team protocol contains series action accordance current clinical guideline standard practice implemented nurse manage patient condition va emerging interest allowing nurse practice expanded role includes medication initiation titration guideline protocol lack certainty regarding outcome associated use clinical protocol non np nurse expanded role led va commission evidence synthesis thus synthesized current literature describe effect nurse managed protocol outpatient management adult high impact chronic_condition type_diabetes hypertension hyperlipidemia congestive_heart_failure_chf:0.0235485864892027", "87792": "background north america industrialized country heart_failure_hf become national public_health priority study indicate significant heterogeneity approach treat manage hf suggest targeted change health_care delivery needed reduce unnecessary health_care utilization optimize patient_outcome recent published study reported care hf_patient tertiary care hospital perspective non specialist stakeholder hf management general practitioner clinic hospital administrator rarely considered study explores current state community based hf care canada experienced various healthcare stakeholder providing coordinating care hf_patient method_study employed qualitative exploratory research design consisting semi structured telephone interview conducted health_care provider health_care administrator working outside tertiary care four populous canadian province modified thematic analysis process used different data source triangulated finding collectively interpreted author result twenty eight participant recruited study eight cardiologist five general practitioner family physician eight nurse practitioner registered nurse four hospital pharmacist three health_care administrator director participant reported lack stakeholder engagement throughout continuum care hinders implementation coordinated approach quality hf care four substantive theme emerged indicated challenge gap optimal treatment management hf community setting challenge risk_assessment early_diagnosis hf challenge ensuring efficient consistent transition acute care setting community challenge primary_care provider optimally treat manage hf_patient challenge promoting holistic approach hf management conclusion health system evolve tertiary based care community based outpatient service management chronic_disease study finding pinpoint challenge observed canadian context stimulate orient dialogue toward solution coordinated approach improve care hf_patient reduce pressure healthcare system:0.0232000374248134", "93493": "background_heart_failure_hf associated_high rate hospitalization morbidity_mortality cost remote patient monitoring mobile health mhealth show promise improving self_care hf management thus increasing quality care reducing hospitalization cost however limited information exists regarding perception older_adult hf mhealth use objective study_aimed compare perspective older_adult hf randomized either mhealth equipment connected hour call center digital home equipment standard_care regard ease satisfaction equipment provider communication engagement ability self monitor manage disease method performed pilot study using mixed method descriptive design pre postsurveys following participant week augmented data semistructured qualitative interview learn feasibility satisfaction communication self_management result enrolled patient_hf aged_year male non hispanic white multiple comorbid_condition baseline rated health fair poor often always frustrated discouraged health baseline monitor weight monitor blood_pressure monitor symptom post intervention equipment group home monitored daily technology anxiety indicated technology made nervous reported fear technology without significant_change post intervention technology usability post intervention scored high reflecting ease use majority indicated health_care provider managing health reported one trust question provider moreover believed better seek professional help caring oneself post intervention mhealth user relied mirrored home equipment standard_care group participant satisfied communication engagement provider yet many described access problem distressing symptom unpredictable prevailed week provider visit visit emergency_department nurse call center received reading completed telephone call participant narrative data revealed following main theme traditional communication engagement provider prevailed delaying access care home monitoring technology described useful mhealth user felt secure knowing someone observing equipment group felt confident self monitoring managing finally uncertainty frustration persistent health problem conclusion mhealth equipment feasible potential improve patient centered outcome increase self_management older_adult hf:0.0231742129382747", "167000": "background nonadherence diet medical_therapy heart_failure_hf contributes poor hf outcome mobile apps may promising way improve adherence increase knowledge behavior change via education monitoring well designed apps input health_care provider hcps lead successful adoption apps practice however little_known hcps perspective use mobile apps support hf management objective aim_study determine hcps perspective need motivation challenge use mobile apps support patient_hf management method qualitative descriptive study using one one semistructured interview informed diffusion innovation theory conducted among hf hcps including cardiologist nurse nurse practitioner transcript independently coded researcher analyzed_using content analysis result hcps cardiologist n nurse n nurse practitioner n identified challenge opportunity app adoption across theme participant perceived factor affect app adoption include patient age technology savviness technology access ease use improved delivery care apps support remote care collect share assess health information identify adverse_event prevent hospitalization limit clinic visit facilitating patient engagement care apps provide feedback reinforcement facilitate connection communication patient hcps support monitoring track self_care providing patient support education apps provide hf_related information ie diet medication participant view app feature patient hcps felt useful apps would reminder alarm participative element gamification food scanner quiz conclusion hcps positive view use mobile apps support patient_hf management finding inform effective development implementation strategy hf management apps clinical_practice:0.0229384071595015", "35483": "background disease_management shown great promise mean reorganizing chronic care optimizing patient_outcome nevertheless disease_management program widely heterogeneous lack shared definition disease_management limit ability compare evaluate different program address problem american heart_association disease_management taxonomy writing group developed system classification used categorize compare disease_management program inform effort identify specific factor_associated effectiveness method aha writing group began conceptual model disease_management component subsequently validated model wide range disease_management program systematic medline search performed term heart_failure diabetes depression together disease_management case management care management search encompassed article published english selected study incorporated intervention designed improve_outcome reduce medical resource utilization patient_heart_failure diabetes depression clearly defined protocol least prespecified component traditionally associated disease_management analyzed study protocol used qualitative research method develop disease_management taxonomy conceptual model organizing framework result final taxonomy includes following domain patient_population characterized risk status demographic profile level comorbidity intervention recipient describes primary target disease_management intervention includes patient caregiver physician allied healthcare provider healthcare delivery system intervention content delineates individual component patient education medication management peer support form postacute care included disease_management delivery personnel describes network healthcare provider involved delivery disease_management intervention including nurse case manager physician pharmacist case worker dietitian physical therapist psychologist information system specialist method communication identifies broad range disease_management delivery system may include person visitation audiovisual information packet form electronic telecommunication technology intensity complexity distinguish frequency duration exposure well mix program component respect target disease_management environment defines context disease_management intervention typically delivered includes inpatient hospital affiliated outpatient program community home based program combination factor clinical_outcome include traditional frequently assessed primary secondary_outcome well patient centered measure adherence medication self_management caregiver burden conclusion statement present taxonomy disease_management describes critical program attribute allows comparison across intervention routine application taxonomy may facilitate better comparison structure process outcome_measure across range disease_management program promote uniformity design conduct study seek validate disease management_strategy:0.0226918420764571", "187232": "background uganda limited healthcare access created significant burden patient living_heart_failure increasing use mobile phone digital health tool could offer accessible platform individualized care support multi national team adapted mobile phone based program heart_failure self_care ugandan context found patient using system showed improvement symptom quality_life approximately ugandan residing rural community medly uganda program provide greater benefit community rural area limited access care support implementation program within rural community study worked partnership two remote clinic northern uganda identify cultural service level requirement program method using principle community based research user centered design conducted mixed method_study composed participatory consensus cycle semi structured interview ssi iterative co design meeting two remote cardiac clinic patient survey also completed ssi collect data related cell phone access community support geographic barrier qualitative data analyzed_using inductive thematic analysis indigenous method two eyed seeing also embedded within analysis help promote local perspective regarding community care result five theme identified burden travel recognized largest barrier care patient travelling km motorbike clinic visit despite mixed view traditional medicine patient often turned healer due cost medication transport patient owning non smartphone n participant valued use digital tool improve equitable access care however sustain program usage integrating role village health team vhts support community follow ups medication delivery recognized pivotal conclusion use mobile phone based digital health program help reduce barrier geography empowering remote hf self_care leveraging trusted role vhts within delivery program help enable culturally informed care closer home supplementary information online version contains supplementary material available:0.0225258746829555", "163579": "background mobile apps potential support patient_heart_failure facilitate disease self_management area research recent rapidly evolving inconsistent result efficacy far published study_evaluated feasibility specific app assessed quality apps available app store research needed explore patient clinician perspective guide app development evaluation implementation model care objective_study aim explore patient primary_care clinician perspective facilitator barrier using mobile apps well desired feature support heart_failure self_management method qualitative phenomenological study involving face face semistructured interview interview conducted general practice clinic sydney australia eligible participant adult patient_heart_failure health_care professional provided care patient clinic patient need previous experience using heart_failure mobile apps eligible study interview audio recorded transcribed analyzed_using inductive thematic data analysis nvivo result_total participant interviewed patient mean_age sd year clinician interview lasted minute main facilitator use apps support heart_failure self_management communication ability personalized feedback education automated self monitoring patient mentioned chat like feature ability share audio visual information helpful getting support outside clinical appointment clinician considered helpful send motivational message patient ask sign_symptom heart_failure decompensation overall participant highlighted importance personalization particularly term feedback educational content automated self monitoring wireless device seen alleviate burden tracking measure weight blood_pressure desired feature included tool monitor patient_reported outcome support patient mental health well main barrier identified_patient unwillingness engage new strategy manage condition using app particularly case low digital literacy however clinician mentioned barrier could potentially overcome introducing app soon exacerbation patient might willing improve self_management avoid rehospitalization conclusion use mobile apps support heart_failure self_management may facilitated feature increase usefulness utility app communication ability consultation personalized feedback also important facilitating ease use supporting automated self monitoring integration wireless device future_research consider feature co design testing heart_failure mobile apps patient clinician:0.0224750603468963", "198383": "objective heart_failure important health problem patient generally older several comorbidities multidisciplinary heart_failure care therefore recommended however little evidence real_world setting involve primary_care health professional evaluate programme main objective_study integrate evaluate several disease_management intervention primary_care setting design prospective non randomised observational implementation study mixed method process evaluation conducted year setting primary_care practice two regional hospital one tertiary one secondary leuven region belgium serving approximately inhabitant participant general practitioner gps practice participated total_patient included disease_management programme inclusion_criterion patient_included high_risk status heart_failure_hf readmission based clinical criterion exclusion criterion explicitly defined participation required informed consent intervention four intervention implemented online hf education gps reimbursed natriuretic_peptide np testing patient education trained primary_care hf educator structured transitional care protocol posthospital discharge primary secondary_outcome measure primary_outcome included gp self efficacy hf management np testing rate hf registration electronic health record patient self efficacy item european heart_failure self_care behaviour scale ehfscb secondary_outcome included_patient quality_life short form questionnaire sf hospital readmission_rate provider satisfaction result gps felt competent management hf online education eight point increase self efficacy score month_follow ci_p gps conducted reimbursed np test half scored age specific threshold referral initiation significant_increase np testing bayes factor total rate test per patient_year proportion registered hf_patient aged_year older gps electronic health record increased patient_included disease_management programme inclusion followed transitional protocol discharge hf significant_improvement patient self efficacy month_follow ehfscb score change point ci significant_change quality_life sf score change point ci adherence transitional protocol depended presence specialist hf nurse admission patient seen within_day discharge general practitioner time trend analysis_revealed increase hf secondary rather primary cause admission participating healthcare professional reported satisfaction programme conclusion impact b study_demonstrated integrated disease_management programme hf could implemented assessed routine clinical_practice programme resulted increased awareness registration hf primary_care increased self management_patient improved follow discharge although result interpreted cautiously given uncontrolled pre post study_design trial_registration trial_registration nct clinicaltrials_gov:0.0223685123000079", "139905": "introduction despite evidence cardiac_rehabilitation cr essential component care people heart_failure uptake low centre based format known barrier suggesting home based programme might improve accessibility aim scot rehabilitation enablement chronic_heart_failure reach hf assess implementation reach hf home based cr intervention context national_health service nh scotland paper present design protocol observational implementation study specific objective scot reach hf assess service level facilitator barrier implementation reach hf compare real_world patient caregiver outcome seen prior clinical_trial estimate economic health social impact implementing reach hf scotland method analysis reach hf intervention delivered partnership four beacon site across six nh scotland health board covering rural urban area health professional site trained facilitate delivery week programme people heart_failure caregiver patient caregiver outcome assessed baseline month_follow assessment include minnesota living_heart_failure questionnaire mlhfq five dimension euroqol l hospital anxiety depression scale caregiver burden questionnaire qualitative interview conducted health professional involved programme delivery eg cardiac nurse physiotherapist facilitator patient consultation audio recorded assessed fidelity integrative analysis address key research question fidelity context cr participant related outcome scot reach hf finding inform future potential roll reach hf scotland ethic dissemination study given ethical approval west scotland research ethic service reference w approved march written informed consent obtained participant study listed isrctn registry study id isrctn research team ensure study_conducted accordance general data protection regulation university glasgow research governance framework finding reported funder shared beacon site facilitate service evaluation planning good practice broaden interest understanding reach hf seek publish peer reviewed scientific journal present stakeholder event national international conference:0.0221618388599675"}, "Topic 8": {"86141": "recent advance medical device therapy heart_failure improved survival patient_heart_failure however due limited availability suitable heart donor left_ventricular_assist_device lvads become important tool bridge heart_transplantation patient refractory heart_failure singapore report experience heartmate ii hmii lvad thoratec corporation pleasanton ca usa bridge heart_transplant center retrospective review consecutive patient_underwent hmii lvad_implantation center may december patient classified interagency registry mechanically assisted circulatory_support intermacs level underwent lvad_implantation bridge heart_transplant male_female patient mean_age_year old range etiology heart_failure included ischemic_heart_disease idiopathic dilated_cardiomyopathy viral myocarditis chemotherapy induced cardiomyopathy nine patient intermacs level patient level two_patient level patient successfully underwent hmii lvad_implantation mortality within first postoperative day postoperative complication included stroke full neurological recovery mediastinal infection cardiac tamponade mediastinal collection requiring reopening chest cardiac_arrhythmia pump thrombosis pump replacement patient discharged hospital lvad_implantation three patient_experienced driveline infection outpatient follow readmission due following condition sub therapeutic anticoagulation gastrointestinal bleeding suspected pump thrombosis transient_ischemic_attack arrhythmia congestive cardiac_failure due severe aortic regurgitation right_ventricular failure rhabdomyolysis hematuria post lvad_implantation patient functionally new_york_heart_association_nyha_class reported nyha iii symptom three_patient successfully bridged heart_transplantation one_patient successfully explanted month lvad_implantation two mortality follow_period average duration lvad support day range day heartmate ii lvad proven effective asian population driveline infection rate remains low even tropical hot humid climate singapore patient ending extended period lvad support increased emphasis detection management long_term complication ventricular_assist_device needed:0.0290094020370164", "18907": "objective levitronix centrimag ventricular_assist_device vad centrifugal pump designed short_term extracorporeal support cardiogenic_shock aim_study report clinical experience levitronix centrimag uni biventricular support method july december patient supported using levitronix centrimag device nineteen male mean_age range year indication support implantation cardiogenic_shock included end_stage_heart_failure ill undergo transplantation questionable neurologic status subject right_ventricular failure left vad lvad_implantation subject post cardiotomy status subject acute donor graft failure heart_transplantation subject result post vad day survival patient mean support time day patient range day mean support time levitronix biventricular vads range day mean support time levitronix lvads range day highest survival_rate levitronix support donor graft failure cardiotomy levitronix right vad rvad support long_term lvad insertion incurred hospital_mortality survived patient discharged home vad support remain alive date two_patient bridged primary another bridged repeat heart_transplantation five patient weaned recovery operation bleeding occurred_patient clinical evidence cerebral thromboembolism overwhelming sepsis aortic thrombus formation clot formation tubing observed_patient necessitating emergent replacement bedside successful conclusion levitronix centrimag system reliable facile temporary circulatory_support system bridge decision patient refractory acute cardiogenic_shock:0.0279464887919051", "73038": "background heart_transplantation gained recognition gold_standard therapy advanced_heart_failure scarcity donor organ become important concern evolution surgical alternative ventricular_assist_device vads allow recovery myocardium ensure patient survival heart_transplantation becomes possible report elaborates role vads bridge heart_transplantation infant child year_old end_stage_heart_failure method_retrospective review medical_record heart_transplant recipient may september identified child mean_age_year old iqr year advanced_heart_failure supported vad left vad lvad biventricular vad bvad bridge heart_transplantation fourteen patient less year_old child cardiac_arrest underwent cardiopulmonary resuscitation patient also requiring extracorporeal_membrane_oxygenation ecmo support prior implantation vad aetiology heart_failure primarily cardiomyopathy dilative restrictive endocardial fibrosis idiopathic toxic induced reported patient vads employed primarily berlin heart excor r n heartware n berlin heart incor r n toyobo n result mean duration vad support day range day iqr day donor heart became available primary complication encountered patient bridged transplant mediastinal bleeding main indication pump exchange thrombus formation valve incidence technical failure blood pump driving system component skin infection around cannulae occurred adverse neurological symptom thromboembolism cerebral haemorrhage occurred permanent neurological sequela could detected clinical examination study mean duration follow year iqr year cumulative survival_rate patient bridged transplantation vad day year respectively statistically significant_difference p survival_rate patient bridged heart_transplantation vad compared underwent primary heart_transplantation post transplant survival_rate stratified according type vad implanted number ventricle supported statistically different p respectively addition post transplant survival_rate significantly_different age_gender diagnosis adjusted furthermore statistically significant_difference found post transplant survival_rate child episode rejection compared episode rejection conclusion_result series demonstrate vads satisfactorily support paediatric patient_advanced_heart_failure variety aetiology heart_transplantation data suggests patient bridged vads comparable long_term post transplant survival undergoing primary heart_transplantation:0.0278522965603504", "80594": "child heart_failure unresponsive medical_therapy left option survival ventricular_assist_device vads life saving option patient allowing bridge transplantation cardiac recovery retrospective review case may october undertaken fourteen patient_underwent implantation vads refractory heart_failure mean_age_year range year weight kg range kg indication support end_stage cardiomyopathy n myocarditis n univentricular failure n congenital_heart_disease postcardiotomy n level limitation time implant included critical cardiogenic_shock six progressive decline eight extracorporeal_membrane_oxygenation used bridge vad five patient preimplant variable patient requiring mechanical_ventilation mean day hyperbilirubinemia acute renal_insufficiency device selection systemic vad biventricular assist_device three berlin heart excor used eight patient six patient_received thoratec implantable vad paracorporeal vad mean duration support day range day overall survival ten patient successfully bridged transplantation three died device one remains support patient weaned vad child supported single ventricle heart_failure survival none currently bridged transplantation complication included bleeding requiring reoperation n stroke n driveline infection n two_patient total six pump exchange performed thrombus formation survival pediatric patient age excellent using current device technology majority patient successfully bridged transplantation morbidity acceptably low considering severity illness significant challenge exist long_term extracorporeal support due lack donor availability high incidence preformed alloantibody especially failing single ventricle:0.0273531193372812", "78412": "recent outstanding clinical advance new mechanical circulatory system mc led additional strategy treatment end_stage heart_failure_hf heart_transplantation htx postponed certain patient even replaced smaller implantable left_ventricular_assist_device_lvad mechanical support failing left_ventricle enables appropriate hemodynamic stabilisation recovery secondary organ failure often seen severely ill patient new device may great help bridge patient suitable cardiac allograft available also discussed definitive treatment_patient qualify transplantation main indication lvad_implantation bridge recovery bridge transplantation destination therapy lvad may important tool patient expected prolonged period waiting list instance blood group_b body_weight kg potentially reversible secondary organ failure pulmonary_artery hypertension however lvad_implantation mean additional heart operation inherent peri operative risk complication waiting period finally cardiac_transplantation patient prior implantation lvad represents surgical challenge review summarises current knowledge lvad continuous_flow device especially since latter increasingly used worldwide recent_year review also based institutional experience berne university_hospital apart short_term device impella cardiac assist deltastream ecmo used approximately case pulsatile long_term lvad rvad bi vad non pulsatile lvad mainly heartmateii heartware implanted initial learning curve one year_mortality dropped last patient:0.0271022030479873", "135161": "total artificial heart tah form mechanical_circulatory_support involves resection native ventricle followed placement device restore total pulmonary systemic flow given increasing burden congestive_heart_failure cardiovascular_disease number people need cardiac replacement_therapy continue grow despite aggressive effort expand donor pool number heart_transplant united_state u plateaued less per_year addition increasing recognition long_term complication current generation left_ventricular_assist_device progressive aortic insufficiency complication related blood trauma early delayed right_ventricular failure factor may serve expand role tah treatment_patient end_stage_heart_failure particularly new generation device developed durable improved safety profile totally implantable purpose_review review role current evidence use tah management advanced_heart_failure discus development recent tahs may impact field near future recent_finding many patient receive heart_transplant bridged mechanical support device commonly left_ventricular_assist_device_lvad however small subset patient profound biventricular bv failure structural abnormality preclude lvad placement require support biventricular assist_device bivad tah numerous study showing efficacy tah bridging transplantation also recent_study shown equal rate bridging transplantation patient_receiving tah compared bivad however bivad support higher incidence stroke addition complication related native heart arrhythmia valve dysfunction currently multiple new generation artificial heart preclinical development clinical_trial bridge transplant destination therapy tah shown effective circulatory_support select patient end_stage_heart_failure current lvads associated significant long_term complication related retention native heart pump design many complication may addressed increased use cardiac replacement_therapy e total artificial heart multiple generation pulsatile advanced design continuous_flow tah development potential expand role tahs:0.0268264085510035", "112319": "background end_stage_heart_failure major cause morbidity_mortality prevalence expected rise ageing population suitable patient orthotopic heart_transplantation remains gold_standard therapy however paucity donor organ led development left_ventricular_assist_device_lvad device utilized either bridge transplant btt alternative heart_transplantation device prolong life improve quality_life associated significant number adverse_event aim systematically review literature quantify survival incidence adverse_event following implantation continuous_flow lvads cf lvad method systematic_review performed determine outcome following implantation cf lvad primary_outcome survival frequency adverse_event bleeding infection thrombosis stroke right_ventricular failure secondary_outcome included quality_life assessment functional_status result sixty three study reported clinical_outcome patient survival cf lvad varied study industry funded trial generally reported better overall survival single multi center case series showed significant variation largest registry report documented twelve twenty four forty eight month survival_rate respectively commonly reported adverse_event gastrointestinal bleeding gib device related infection neurological event right_heart_failure rhf bleeding rhf infection frequent complication experienced supported cf lvad occurring patient respectively quality_life measured_using kansa city cardiomyopathy questionnaire kccq functional_status measured minute_walk test mwt improved cf lvad_implantation decline evident two year implantation conclusion paucity donor heart led development left_ventricular_assist_device btt destination therapy dt outcome cf lvad_implantation excellent short_term survival comparable heart_transplantation long_term_survival remains limited due incidence post implantation adverse_event despite complication quality_life functional_status improve significantly post implantation remain improved long_term study demonstrates potential benefit cf lvad therapy whilst also identifying adverse_event area increased morbidity_mortality:0.0267092224453908", "183893": "left_ventricular_assist_device_lvad therapy well_established treatment end_stage cardiac_failure indication bridge transplant btt bridge candidacy btc bridge recovery btr destination therapy dt durability adverse_event ae rate lvads improved year however due donor shortage duration support btt population increased tremendously similarly dt patient device long time consequently number readmission long_term lvad patient increased case severe aes intensive_care_unit icu treatment necessary infectious complication common ae furthermore embolic hemorrhagic stroke occur due foreign surface acquired von willebrand syndrome anticoagulation treatment another consequence coagulative status combination continuous_flow gastrointestinal bleeding event moreover patient isolated lvad implanted involves risk late right_heart_failure adjustment pump speed optimization volume status help solve issue malignant arrhythmia pre_existing de_novo lvad_implantation life_threatening ae antiarrhythmic medical_therapy ablation potential treatment_option specific lvads medtronic heartware ventricular_assist_device hvad manufactured distributed currently however patient still device pump thrombosis occur wherein thrombolytic therapy first_line treatment_option additionally hvad fail restart controller exchange due technical issue precaution must taken momentum trial showed superior survival without pump exchange disabling stroke patient_treated heartmate r hm abbott abbott park il usa device comparison heartmate ii hmii however case twisted graft bio debris formation outflow graft bend relief could observed causing outflow graft obstruction patient lvads still heart_failure_patient many case comorbidities therefore many situation occur requiring icu treatment ethical aspect always focus taking care patient:0.0266917821082144", "48043": "introduction heartmate ii hmii thoratec corporation pleasanton calif united_state continuous_flow pump approved food drug administration fda bridge transplantation btt since destination therapy dt since herein present postoperative outcome hmii implantation due end_stage_heart_failure center method twenty eight patient mean_age_year female implanted hmii august august indication dilated n ischemic n cardiomyopathy intended treatment btt dt patient preoperative clinical status international registry mechanical_circulatory_support intermacs patient respectively procedure performed via conventional sternotomy cardiopulmonary bypass heparin acetylsalicylic acid warfarin used postoperative anticoagulation result mean duration support day median three patient_underwent heart_transplantation remain pump support one patient_died discharge due respiratory_failure others died following cerebral bleeding day postoperatively respectively survival_rate month respectively temporary right_ventricular failure observed_patient two_patient pump thrombosis treated anticoagulation management pump exchange whereas another patient aortic root thrombosis underwent reoperation removal thrombus discussion mechanical_circulatory_support hmii axial flow pump seems effective may_provide good survival_rate compared optimum medical management old generation device patient_selection timing implantation crucial success:0.0266062196713245", "107974": "background interagency registry mechanically assisted circulatory_support intermacs joint effort among national heart lung blood institute food drug administration center medicare medicaid service others established university alabama birmingham registry examined clinical_outcome quality_life metric patient_received food drug administration approved durable mechanical_circulatory_support mc device treat advanced_heart_failure january intermacs database became part society thoracic surgeon national database providing additional resource quality assessment improvement scientific advancement method intermacs database annual report summarizes outcome_patient year_age underwent durable mc implant june december outcome presented patient_underwent isolated continuous_flow left_ventricular_assist_device cf lvad support cf lvad support concomitant right_ventricular assist_device rvad implant total artificial heart implant analysis patient cf lvads stratified axial flow centrifugal flow configuration association era outcome survival analysis restricted isolated cf lvads implanted era result adult_patient mc reported intermacs received cf lvads rvad cf lvad received total artificial heart received isolated rvad cf lvads mean_age_year listed transplantation cardiogenic_shock profile preoperatively cf lvads included axial flow centrifugal flow device intermacs patient phenotype evolved time include patient profile versus fewer patient profile versus patient better marker preoperative renal hepatic function patient_received implant destination therapy versus indication centrifugal flow implant approximated axial flow device mean cf lvad support duration month patient_year one_year survival isolated cf lvads year_survival one_year survival centrifugal versus axial flow device respectively patient required concomitant rvad support year_survival respectively freedom cause readmission month year_year stroke occurred_patient centrifugal flow patient axial flow support p gastrointestinal bleeding affected patient centrifugal flow device patient axial flow device p pump related infection occurred_patient centrifugal flow device versus patient axial flow device p neurologic dysfunction death multisystem organ dysfunction common cause_death conclusion evolution mc patient phenotype outcome also changing time cf lvad support increasingly used less ill patient phenotype patient supported destination therapy mean survival approaching year adverse_event especially neurologic event continue detrimental impact success cf lvad support:0.0264299426479660"}, "Topic 9": {"75826": "background previous clinical_trial reported ivabradine effectively treat heart_failure_hf however systematic_review explored efficacy_safety hf systematic_review aim evaluate efficacy_safety ivabradine treatment patient_hf method search literature following electronic database inception january cochrane central register controlled_trial embase mediline web_science cumulative index nursing allied health literature allied complementary medicine database chinese biomedical literature database china national knowledge infrastructure vip information wanfang data randomized_controlled_trial rcts ivabradine hf fully considered inclusion without restriction additionally grey literature including clinical_trial registry dissertation reference list included_study conference abstract also searched two researcher review literature extract data assess risk bias included rcts separately data pooled either fixed effect model random_effect model meta_analysis conducted appropriate result primary_outcome cause_mortality secondary_outcome comprise change body_weight urine output change serum sodium adverse_event conclusion result_study summary provide dated evidence assessing efficacy_safety ivabradine hf ethic dissemination necessary acquire ethical approval systematic_review individual patient data used study result systematic_review published peer reviewed journal systematic_review registration prospero crd:0.0278179519451448", "172536": "background_heart_failure_hf global health concern affecting million individual worldwide leading significant morbidity_mortality despite advance conventional therapeutic_strategy prognosis hf_patient remains challenging constant search novel therapeutic_option among panax quinquefolius saponin pqs demonstrated promising pharmacological property may benefit hf however efficacy_safety pqs hf comprehensively evaluated objective systematic_review_meta_analysis aim provide reliable estimation efficacy_safety pqs hf help clinician make informed decision regarding potential use pqs managing hf_patient method comprehensively systematically searched published randomized_controlled_trial rcts following eight electronic database pubmed cochrane_library embase web_science wos china national knowledge infrastructure cnki china science technology journal database vip wanfang data china biology medicine database cbm database inception march cochrane risk bias rob assessment tool used quality assessment review manager revman version used meta_analysis mean_difference md credible interval ci relative_risk rr estimate calculated random_effect model also used grade profiler gradepro version analyze quality outcome addition protocol registered international platform registered systematic_review_meta_analysis protocol inplasy registry number result_study included nine rcts involving total patient_hf result meta_analysis random_effect model showed adjuvant pqs therapy significantly_increased lvef md ci_p mwtd md ci_p decreased bnp nt_pro_bnp md ci_p lvedv md ci_p lvedd md ci_p lvesv md ci_p patient_hf conclusion evidence provided systematic_review suggests adjunctive pqs therapy hf improved clinical efficacy hold potential advantage improving cardiac_function increasing exercise_tolerance however given limitation inherent review conclusion_study interpreted cautiously therefore clinical_practice recommended physician tailor treatment_strategy according specific circumstance individual patient systematic_review registration http inplasy com:0.0274818899660104", "187598": "introduction chronic_disease self_management cdsm vital component congestive_heart_failure_chf programme recent chf guideline downgraded cdsm programme citing lack gold_standard evidence protocol describes aim method systematic_review collate synthesise published research evidence determine effectiveness cdsm programme intervention patient_treated chf method medline pubmed_embase central cinahl cochrane central register controlled_trial psycinfo scopus web_science science citation index register clinical_trial searched addition reference list shortlisted article reviewed randomised controlled_trial case management intervention cdsm chf reported major_adverse_cardiovascular_event_mace extracted analysed restriction language study protocol template developed cochrane collaboration reporting adheres preferred reporting item systematic_review_meta_analysis protocol guideline systematic_review_meta_analysis two independent author apply inclusion exclusion criterion limit article search assess bias certainty evidence rating data extraction study description included_study include quality appraisal study quantitative synthesis data undertaken ascertain evidence study_aim subgroup_analysis conducted different cdsm programme primary_outcome significant_change mace parameter intervention control arm meta_analysis conducted using statistical software feasible ethic dissemination ethic approval sought study collecting primary patient data result_study disseminated peer reviewed scientific journal also presented audience meeting scientific conference prospero registration number crd:0.0270329555358074", "99215": "background sacubitril_valsartan first class angiotensin_receptor neprilysin_inhibitor used treat heart_failure evidence novel medication largely based one pivotal phase iii trial stopped early due significant clinical_benefit shown however potential limitation trial design highlighted recent literature necessitating thorough review evidence sacubitril_valsartan method review conducted using prisma reporting guideline relevant randomised controlled_trial rcts sacubitril_valsartan systematically searched medline pubmed_embase cochrane_library google scholar web_science toxline scopus clinical_trial registry searched eight grey literature database addition unpublished clinical_study report csrs relevant trial requested european medicine agency ema clinical_study data request database study_included involve randomising adult patient_heart_failure either sacubitril_valsartan usual_care either active comparator placebo control heart_failure subtype nyha_class included relevant clinical safety outcome reviewed particularly hospitalisation due heart_failure cardiovascular_mortality two reviewer assess eligibility selected study inclusion data extraction performed separately trial publication clinical_trial registry csrs using piloted form methodological quality included trial published source assessed separately using cochrane risk bias tool rob narrative synthesis included_study conducted appropriate meta_analysis clinical efficacy_safety outcome discussion review collate available rct data sacubitril_valsartan including published unpublished source order obtain complete picture evidence base sacubitril_valsartan registration protocol registered prospero reference crd:0.0269591707456347", "198324": "objective_evaluate whether remdesivir associated cardiac adverse_event caes addressing concern raised basic experiment clinical case_report observational_study design systematic_review_meta_analysis data source medline embase searched january_december study selection randomised controlled_trial rcts comparing remdesivir placebo standard_care patient covid primary focus cardiac safety eligibility criterion selecting study_included rcts evaluated safety remdesivir patient covid eligible study compared remdesivir placebo standard_care adult patientscovid inclusion_criterion emphasised safety outcome particularly caes primary_endpoint data extraction synthesis two reviewer independently extracted data reporting followed preferred reporting item systematic_review_meta_analysis prisma harm guideline risk bias rob assessed_using cochrane collaboration tool random_effect model used data synthesis grading recommendation assessment development evaluation grade approach applied assess certainty evidence primary_outcome incidence caes defined composite reported cardiac related harm secondary_outcome included specific caes arrhythmia heart_failure myocardial disorder result identified study seven rcts met inclusion_criterion comprising total participant rob assessed across multiple domain four rcts showing low_risk three showing moderate risk specific area pooled analysis_revealed significant_association remdesivir use caes rr_ci_p subgroup analysis_showed consistent finding across different patient demographic comorbidities grade assessment indicated moderate certainty overall caes low certainty arrhythmia heart_failure due imprecision study level bias low certainty myocardial disorder due small sample size indirectness conclusion contrary preliminary concern case_report meta_analysis found evidence statistically_significant association remdesivir caes among_patient covid finding provide reassurance clinician regarding safety profile remdesivir patient_population supporting use antiviral therapy treatment covid research warranted validate finding clarify whether remdesivir may neutral potentially protective_effect cardiac outcome prospero registration number crd:0.0261255786297786", "118575": "background heart_failure end_stage heart_disease prevalence incidence condition rapidly increasing although heart_transplantation one type surgical treatment people end_stage_heart_failure donor availability limited implantable ventricular_assist_device vads therefore offer alternative treatment heart_transplantation although two study reported beneficial_effect exercise based cardiac_rehabilitation cr functional_capacity quality_life qol performing systematic_review_meta_analysis systematic_review included_study limited design e_g non randomised retrospective_study participant implantable extracorporeal vads objective_determine benefit harm exercise based cr people implantable vads search method searched cochrane central register controlled_trial central cochrane_library medline embase psycinfo conference proceeding citation index science cpci web_science cinahl lilac october limitation date language publication status also searched two clinical_trial register august checked reference list primary study review article selection criterion randomised controlled_trial rcts regardless cluster individual randomisation full text study published abstract unpublished data eligible however individually rcts full text publication included data collection analysis two review author independently extracted outcome data included_study double checked data entered correctly comparing data presented systematic_review study report dichotomous data analyse used mean_difference standardised mean_difference confidence_interval_ci continuous data furthermore assessed quality evidence relates study contribute data meta_analysis prespecified outcome using gradepro software main result included two study total participant review exercise based cr consisted aerobic resistance training three time per week six eight week exercise intensity oxygen_consumption vo reserve ranged heart_rate reserve two serious adverse_event observed one trial participant complete study due infection furthermore total four participant group required visit emergency_department although participant complete study summary score item short form health survey sf kansa city cardiomyopathy questionnaire kccq measured quality_life one trial reported kccq summary score improved point exercise group_compared point usual_care group trial reported sf total score improved point exercise group_compared point usual_care group large difference quality_life observed group end follow standardised mean_difference ci participant study low quality evidence however evidence effectiveness exercise based cr due young age participant high_risk performance bias small sample size wide confidence_interval resulted low quality evidence furthermore able determine effect exercise based cr mortality rehospitalisation heart_transplantation cost outcome reported author conclusion evidence currently inadequate assess safety_efficacy exercise based cr people implantable vads compared usual_care amount rct evidence limited low quality addition training duration short_term six eight week high quality well reported rcts exercise based cr people implantable vads needed trial need collect data event mortality rehospitalisation patient related outcome including quality_life cost_effectiveness:0.0257433662565322", "17284": "background cardiac_rehabilitation important component recovery coronary event uptake adherence programme recommended level aim update previous non cochrane systematic_review examined intervention may potentially improve cardiac patient uptake adherence rehabilitation component concluded insufficient evidence make specific recommendation objective_determine effect intervention increase patient uptake adherence cardiac_rehabilitation search strategy previous systematic_review identified study published prior june searched cochrane central register controlled_trial central cochrane_library issue medline january embase january cinahl january psycinfo january web_science isi proceeding april nh centre review dissemination crd database health technology assessment hta database abstract review effect dare january reference list identified systematic_review randomised control trial rcts also checked additional study selection criterion adult myocardial_infarction coronary_artery_bypass graft percutaneous transluminal coronary angioplasty heart_failure angina coronary_heart_disease eligible cardiac_rehabilitation randomised quasi randomised trial intervention increase uptake adherence cardiac_rehabilitation component part study reporting measure adherence included data collection analysis title abstract identified reference screened eligibility two reviewer independently full paper potentially relevant trial obtained checked included_study assessed risk bias two reviewer main result ten study identified three intervention improve uptake cardiac_rehabilitation seven intervention increase adherence meta_analysis possible due multiple source heterogeneity three intervention targeting uptake cardiac_rehabilitation effective two seven study intended increase adherence significant effect one study reported non significant effect intervention cardiovascular_risk_factor study reported data mortality_morbidity cost health_care resource utilisation author conclusion evidence suggest intervention increase uptake cardiac_rehabilitation effective practice recommendation increasing adherence cardiac_rehabilitation made time intervention targeting patient identified barrier may increase likelihood success high quality research needed:0.0256511046877656", "174892": "objective sympathetic crashing acute pulmonary oedema scape menacing medical emergency severe form acute_heart_failure requires urgent intervention nitroglycerin ntg commonly_used scape management optimal dosing remains uncertain meta_analysis compared efficacy_safety high_dose v low_dose ntg scape patient assessing mechanical_ventilation need symptom resolution hospital_stay major_adverse_cardiovascular_event_mace design systematic_review_meta_analysis conducted per preferred reporting item systematic_review_meta_analysis guideline registered prospective register systematic_review crd data source comprehensive search pubmed europe pmc sciencedirect november reference list included_study also reviewed eligibility criterion randomised controlled_trial rcts observational_study comparing high_dose ntg mcg min low_dose ntg mcg min scape patient_included key inclusion_criterion acute dyspnoea hour systolic_blood_pressure sbp mmhg mean arterial_pressure map mmhg respiratory rate rr breath min sympathetic activation exclusion criterion included non cardiogenic pulmonary oedema immediate intubation ntg contraindication pregnancy acute_coronary_syndrome data extraction synthesis two author independently screened title abstract identified study eligibility full text potentially relevant article reviewed discordance disagreement resolved discussion final decision made consensus risk bias assessed_using newcastle ottawa scale meta_analysis performed using stata review manager mantel haenszel method applied dichotomous outcome inverse variance approach continuous outcome heterogeneity assessed via squared random_effect model applied needed result four study one rct three observational scape patient met inclusion_criterion high_dose ntg reduced mechanical_ventilation need rr_ci_p high certainty increased symptom resolution within hour rr_ci_p moderate certainty hospital_stay shorter md hour ci_p low certainty significant_difference found mace risk rr_ci_p low certainty hypotension incidence group_conclusion high_dose ntg improved clinical_outcome scape reducing mechanical_ventilation need symptom duration hospital_stay without increased adverse_event finding_suggest high_dose ntg promising treatment_strategy large_scale study_needed optimise dosing protocol:0.0255310038545242", "160535": "background patient_heart_failure high rehospitalisation rate poor cardiovascular_outcome home based monitoring hbm emerged promising result different setting however long_term effect patient recently admitted acute_decompensated_heart_failure adhf remain uncertain method systematically searched pubmed_embase cochrane_library randomised controlled_trial rcts comparing hbm usual_care uc published database inception june included_study patient_admitted adhf previous month minimum follow month excluded study_patient hospitalised reason adhf study disproportional education intervention arm statistical analysis_performed using r software version pooled risk_ratio rr mean_difference md confidence_interval_ci categorical continuous outcome respectively cochrane collaboration tool assessing risk bias rcts rob used_assess study quality publication bias assessed via funnel plot egger test heterogeneity assessed statistic sensitivity_analysis protocol systematic_review_meta_analysis registered international prospective register systematic_review prospero crd finding included rcts comprising patient randomised hbm men follow ranged six fifteen month compared uc hbm significantly_reduced cause_mortality rr_ci_p cause hospitalisation rr_ci_p cardiovascular_cv mortality rr_ci_p hospitalisation heart_failure rr_ci_p cv hospitalisation rr_ci_p significant_difference length hospital_stay md day ci_p interpretation patient recently admitted adhf hbm significantly reduces long_term cause_mortality hospitalisation cv mortality hospitalisation hospitalisation heart_failure compared uc support implementation hbm standard practice optimise patient_outcome following admission adhf however future study warranted evaluate efficacy_safety implementing hbm real_world setting funding none:0.0254768031900124", "69622": "background chronic_heart_failure_chf one important cardiovascular_disease worldly high morbidity_mortality fuling sini decoction fsd used management chf widely china effective evidence clear systematic_review_meta_analysis evaluate fsd chf lacking hence propose protocol systematic evaluation efficacy_safety chf method search following electronic database inception october including embase cochrane center registration controlled_trial cochrane_library pubmed medline international clinical_trial registry platform china biomedical literature database cbm china national knowledge infrastructure cnki chinese scientific journal database vip wan fang database randomized_controlled_trial rcts fsd alone combined management chf included two independent reviewer screen literature extract data according cochrane handbook method assessment bias risk data synthesis subgroup_analysis meta_analysis finally meta_analysis performed using revman v software result systematic_review provide high quality evidence may first evaluate efficacy_safety fsd treatment chf conclusion systematic_review provide evidence judging whether fsd effective management chf prospero registration number crd:0.0252685032288411"}, "Topic 10": {"143240": "purpose advanced lung cancer inflammation index ali novel inflammatory nutritional index exerts prognostic_value various type cancer previous_study demonstrated ali discharge could predict prognosis patient_acute decompensated_heart_failure adhf however long_term prognostic_value ali admission elderly heart_failure_hf inpatient remains_unclear material_method retrospectively collected hf inpatient year_old hospitalized cardiology center whole year ali calculated body_mass_index_bmi x serum albumin alb neutrophil lymphocyte ratio nlr patient_divided two_group optimal cutoff value ali predicting cause_mortality using time dependent receiver_operating_characteristic roc_curve spearman rank correlation coefficient computed evaluate correlation ali geriatric nutritional risk index gnri kaplan_meier curve cox survival analysis time dependent roc analysis net reclassification improvement nri analysis used_assess prognostic effect ali cause_mortality cardiovascular_mortality result month median_follow cause cardiovascular_mortality occurred_patient respectively optimal cutoff value ali predicting cause_mortality year spearman correlation coefficient showed moderate positive linear correlation ali gnri r_p kaplan_meier analysis_revealed cumulative incidence cause cardiovascular_mortality significantly_higher patient lower ali log_rank test cause_mortality p cardiovascular_mortality p multivariate cox_proportional_hazard analysis indicated ali independent_predictor cause_mortality hr_ci_p cardiovascular_mortality hr_ci_p time dependent roc analysis_showed ali comparable gnri predicting long_term cause_mortality auc ali gnri p cardiovascular_mortality auc ali gnri p year however estimated nri indicated addition ali could significantly improve risk_stratification base model cause_mortality categorical nri p continuous nri p cardiovascular_mortality categorical nri p continuous nri p_conclusion higher ali significantly_associated lower cause cardiovascular_mortality elderly hf_patient ali admission could competent nutrition inflammation marker independent predictive_value evaluating long_term_mortality hf elder population:0.0230403712076698", "162994": "background recent_study fibroblast growth_factor fgf first recognized regulator glucose lipid metabolism found level serum fgf associated prognosis many cardiovascular_disease relationship acute_heart_failure_ahf patient remains unknown study_aimed_investigate whether circulating fgf could predict short_term prognosis ahf patient_method four hundred two ahf patient healthy_control recruited prospective_cohort_study blood sample participant collected tube without anticoagulant within first h hospital_admission serum fgf level detected enzyme linked immunosorbent assay elisa patient_followed least month discharge primary_endpoint cause_death secondary_endpoint composite_endpoint death heart_failure readmission mortality composite end_point event analyzed_using kaplan_meier curve roc_curve compared difference fgf nt_probnp predicting month mortality time event data evaluated_using kaplan_meier estimation cox_proportional_hazard_model result present_study serum fgf concentration significantly_higher ahf patient_enrolled compared healthy_control p average age_year male participant divided two_group according median fgf level pg_ml high fgf group_n fgf pg_ml low fgf group_n fgf pg_ml fgf positively correlated nt_probnp bun ast creatinine cholesterol negatively correlated alb hdl median_follow day high fgf group higher mortality composite_endpoint event compared low fgf group hr_ci_p even adjusting nt_probnp hr_ci_p roc analysis show fgf better nt_probnp predicting death auc v_p month auc v conclusion high baseline fgf level associated adverse clinical_outcome ahf patient serum fgf might potential predictive biomarker ahf patient:0.0220084695800885", "93871": "background clinical assessment treatment guidance heart_failure depends variety biomarkers objective_study investigate prognostic predictive_value growth differentiation factor gdf n_terminal prohormone brain_natriuretic_peptide nt_probnp assessing hospitalized_patient acute_heart_failure_ahf method total_patient admitted ahf first affiliated hospital nanjing medical university enrolled april may medical_history blood sample collected within h admission primary_endpoint cause_mortality within_year patient_divided survival group death group based endpoint established mortality risk_factor serum gdf level receiver operator characteristic roc analysis_performed cox_regression_analysis used analyze combination value nt_probnp gdf result baseline gdf nt_probnp significantly_higher amongst deceased survivor p roc analysis area_curve auc gdf predict year_mortality confidence_interval_ci_p nt_probnp ci_p statistically significant_difference found two marker p based optimal cut offs gdf ng_l nt_probnp ng_l combination gdf nt_probnp increased auc year_mortality prediction auc ci_p_conclusion gdf prognostic marker patient ahf inferior nt_probnp combining two marker could provide early recognition high_risk_patient improve prediction value ahf long_term prognosis clinical_trial registration chictr onc http_www chictr org cn:0.0215124238496347", "167281": "introduction previous_study shown fibroblast growth_factor fgf involved ventricular_remodeling process heart_failure_preserved_ejection_fraction_hfpef hypothesized high_level fgf correlated ventricular_remodeling heart_failure_patient mildly reduced hfmref reduced_ejection_fraction_hfref method_total participant hfmref hfref enrolled followed june june subject without heart_failure_hf underwent physical_examination time selected control_group primary_endpoint occurrence major_adverse_cardiovascular_event_mace defined cause cardiac mortality rehospitalization decompensation serum fgf level measured early next morning admission using enzyme linked immunosorbent assay elisa result fgf level significantly_higher patient hfmref hfref control_group pg_ml pg_ml v pg_ml_p serum_level fgf n_terminal_pro_b_type_natriuretic_peptide nt_probnp higher endpoint event group non endpoint event group regardless hfmref hfref group_p spearman correlation revealed fgf positively correlated left_ventricular end_systolic diameter left_ventricular_end_diastolic diameter left_ventricular mass_index p moreover negative correlation fgf left_ventricular_ejection_fraction addition relative wall_thickness p area receiver_operating_characteristic roc_curve auc fgf optimal cut value fgf determined roc_curve pg_ml kaplan_meier analysis demonstrated low fgf level group increased mace free survival_rate compared high fgf level group univariate multivariate cox analysis seen serum fgf nt_probnp independent_predictor poor_prognosis hf_patient conclusion baseline level fgf nt_probnp related ventricular_remodeling patient mildly reduced reduced_ejection_fraction fgf nt_probnp good prognostic_value mace heart_failure_patient mildly reduced reduced_ejection_fraction:0.0214074849320898", "196986": "background_objective heart_failure_hf one common initial presentation cardiovascular_disease_cvd patient type_diabetes_mellitus_dm different cardiac biomarkers related pathophysiological mechanism hf dm current research aim identify additional biomarkers could improve diagnosis prognosis hfpef currently assessed_using nt_pro bnp_level nt_pro_bnp valuable tool diagnosing heart_failure may always correlate clinical symptom severity present normal level certain case obesity biomarkers like fgf galectin could provide greater insight heart_failure severity especially diabetic_patient main objective current study assess performance nt_probnp fgf galectin copeptin discriminate advanced mild hf material_method total_patient enrolled study divided two_group patient nyha_functional_class ii mild hf_patient nyha iii_iv advanced hf nt_pro_bnp fgf galectin copeptin serum_level determined elisa method receiver_operating_characteristic roc analysis binomial logistic_regression_analysis used measure ability studied biomarkers distinguish advanced mild hf_patient result_patient dm advanced hf serum fgf level significantly positively correlated egfr rho p triglyceride rho p significantly negatively correlated serum_level hdl cholesterol rho p rv ra gradient rho p_patient mild hf serum fgf level significantly negatively correlated nt_probnp_level rho p e_e ratio rho p tr velocity rho p rv ra gradient rho p fgf auc ci nt_probnp auc ci demonstrated significant predictive_value discriminate dm patient_advanced hf mild hf elevated value fgf ng_ml ntprobnp pg_ml significantly_associated increased odds advanced hf adjusting demographic clinical covariates conclusion ntpro bnp fgf similar ability discriminate dm patient_advanced hf mild hf univariable multivariable logistic model showed fgf ntprobnp independent_predictor advanced hf_patient preserved mildly reduced_ejection_fraction dm:0.0208389590576222", "60242": "background risk_stratification elderly_patient presenting heart_failure_hf emergency_department ed unmet challenge prospectively investigated prognostic performance different biomarkers unselected older_patient ed method consecutively enrolled non surgical patient_year presenting ed wide range cardiovascular non cardiovascular comorbid_condition n_terminal_pro_b_type_natriuretic_peptide nt_probnp mid regional pro adrenomedullin mr proadm mid regional pro atrial natriuretic_peptide mr proanp c terminal pro endothelin ct proet ultrasensitive c terminal pro arginine vasopressin copeptin u high_sensitivity cardiac_troponin h ctnt measured admission two cardiologist independently adjudicated final diagnosis hf reviewing available baseline data using circulating nt_probnp_level final diagnosis hf found patient_patient followed cardiovascular_death within following month order test prognostic performance investigated biomarkers used boosting model age_sex mandatory covariates boosting statistical learning technique built variable selection developed obtain sparse interpretable prediction_model result follow complete median_follow time day interquartile_range iqr day patient_aged_year cardiovascular_death patient_hf nine hf diagnosed prior admission boosting model selected mr proadm h ctnt predictor cardiovascular_death median value mr proadm h ctnt presentation significantly_higher patient cardiovascular_death compared surviving patient follow nmol l iqr v nmol l iqr p ng_l iqr v ng_l iqr p one unit increase log transformed mr proadm level associated fold risk_death confidence_interval_ci_p second marker h ctnt showed increased predicted risk significantly correlated event free_survival hazard_ratio ci_p_conclusion within different biomarkers mr proadm predictor cardiovascular_death unselected older_patient presenting ed:0.0206207407469609", "111549": "background systematic inflammation nutritional status cardiovascular function associated outcome acute exacerbation chronic_obstructive_pulmonary_disease aecopd patient_heart_failure_hf however value relevant biomarkers predicting mortality well defined yet aimed investigate prognostic_value circulating biomarkers including c reaction protein crp albumin alb neutrophil lymphocyte ratio nlr platelet lymphocyte ratio plr n_terminal_pro_brain_natriuretic_peptide nt_probnp aecopd patient_hf method_retrospective study carried second clinical college jinan university january january total case aecopd complicated hf enrolled classified survivor group_n non survivor group_n baseline_characteristic crp alb ratio nlr plr serum_level nt_probnp indicator collected predictor prognosis analyzed multivariate logistic_regression ability predict day_mortality evaluated receiver_operating_characteristic_curve roc area_curve auc result_patient non survivor significantly_higher level crp crp alb nlr pct nt_probnp lower alb level compared survivor v mg l v_v v_v ng_ml v ng_ml v g l p respectively significant_difference plr found two_group p logistic analysis_revealed crp alb ci_p nt_probnp ci_p nlr ci_p independent_risk_factor predicting day_mortality auc roc_curve crp alb pct crp nt_probnp alb nlr respectively combination crp alb nlr nt_probnp biomarkers shown better accuracy predicting prognosis auc ci_p higher specificity specificity compared single biomarkers conclusion high_level nlr crp alb nt_probnp may clinical usefully predictor death aecopd patient_hf combination nlr crp alb nt_probnp provide higher accuracy predicting day_mortality patient:0.0205745491030836", "29073": "aim investigate use biomarkers providing independent information regarding physiology acutely decompensated_heart_failure adhf assessment risk method_result prospective_study patient_hospitalized adhf mean_age_year_male left_ventricular_ejection_fraction blood sample collected presentation measure soluble st high_sensitivity troponin hstnt amino terminal pro b_type_natriuretic_peptide nt_probnp_level clinical follow obtained patient median period day cause_mortality registered concentration sst per ng_ml hazard_ratio_hr_confidence_interval_ci_p hstnt per ng_ml hr_ci_p nt_probnp per pg_ml hr_ci_p predictive higher_risk death bootstrapped model biomarker retained independent predictive_value mortality_patient three biomarkers optimal cut presentation free death follow whereas elevation three biomarkers died elevated marker adjusted analysis suggested tripling risk_death elevated marker hr_ci_p integrated discrimination analysis indicated use three marker multimarker approach uniquely improved prediction death conclusion biomarkers reflecting remodelling sst myonecrosis hstnt myocardial stretch nt_probnp provide complementary prognostic_information patient adhf used together novel marker provide superior risk_stratification:0.0205627807185135", "106979": "background patient end_stage_renal_disease esrd prone severe heart_failure_hf several life_threatening event therefore ability assess disease prognosis risk short_term event death great importance role soluble st sst potential new prognostic marker esrd patient yet known aim_study assess prognostic_value sst esrd patient hemodiafiltration hdf compare nt_probnp established prognostic marker hf renal_disease method esrd patient hdf prospectively followed date sst nt_probnp measurement death maximally day patient_divided low sst group ng_ml high sst group ng_ml according measured sst concentration start study kaplan_meier survival curve cox regression_model roc analysis used statistical analysis result follow patient_died cause_mortality median iqr sst serum concentration survivor deceased ng_ml respectively kaplan_meier survival analysis_showed survival_rate high sst group statistically_significant lower low sst group_p cox regression_model sst using dichotomized cut ng_ml hazard_ratio hr_ci_p continuous approach log transformed value univariate hr_ci_p multivariate_analysis hr_ci_p showed sst alone combination nt_probnp predict cause_mortality conclusion sst confirmed prognostic_value independent renal_function hdf treatment could useful independent prognostic marker stratifying esrd patient hdf high_risk life_threatening event hospitalisation death especially combination nt_probnp:0.0204679223123353", "154489": "background elevated fibroblast growth_factor fgf level associated mortality adult heart_failure_hf data fgf level paediatric hf limited prospective_cohort_study aimed assess prognostic_value fgf child chronic_hf method prospectively enrolled child chronic_hf matched healthy_control patient complete diagnostic workup performed including transthoracic_echocardiography evaluate cardiac systolic diastolic_function serum fgf renal_function test parathyroid hormone serum calcium phosphate measured patient control n_terminal probrain natriuretic_peptide nt_probnp measured patient severity symptom assessed_using modified ross hf classification child patient_followed year clinical worsening event death hf hospitalisation recorded result patient_hf significantly_higher fgf level compared_control pg_ml pg_ml respectively_p three patient_died admitted hf comparison patient_without clinical worsening event patient exhibited significantly_higher fgf level pg_ml pg_ml respectively_p fgf positively correlated nt_probnp left_ventricular_end_diastolic diameter negatively correlated ejection_fraction fractional_shortening ability fgf predict clinical worsening event patient analysed using receiver_operating_characteristic_curve optimal cut point pg_ml sensitivity_specificity positive predictive_value negative predictive_value area_curve auc multivariable regression_analysis revealed fgf independent_predictor clinical worsening event child chronic_hf conclusion fgf level elevated child chronic_hf increased significantly ross score class increased fgf level increased patient_experienced clinical worsening event:0.0203270490386645"}, "Topic 11": {"199978": "cardiac_amyloidosis though rare clinical entity increasingly recognized important etiology heart_failure cardiac_arrhythmia deposition misfolded amyloid fibril myocardium lead restrictive cardiomyopathy progressive cardiac_dysfunction two main precursor protein implicated cardiac_amyloidosis transthyretin ttr synthesized liver immunoglobulin light chain al usually associated plasma cell dyscrasia lymphoma given substantial difference treatment prognosis ttr al amyloidosis accurate differentiation subtypes critical delivering optimal patient care report case_year_old man progressive dyspnea atrial flutter found severe concentric left_ventricular_hypertrophy characteristic cherry top strain pattern echocardiography technetium pyrophosphate pyp scan demonstrated grade uptake concurrent abnormal igm spike serum electrophoresis prompted hematologic evaluation bone_marrow biopsy revealed low grade b cell lymphoma without amyloid deposition endomyocardial_biopsy mass spectrometry confirmed wild_type ttr amyloidosis patient_underwent atrial flutter ablation initiated tafamidis clinical improvement knowledge represents first reported case coexisting attr cardiac_amyloidosis b cell lymphoma diagnosed simultaneously case highlight diagnostic challenge hematologic malignancy cardiac_amyloidosis coexist underscore importance endomyocardial_biopsy definitive typing emphasizes role multidisciplinary approach guiding management optimizing outcome:0.0555376486187041", "196467": "cardiac_amyloidosis ca serious condition result infiltrative cardiomyopathy heart_failure_preserved_ejection_fraction_hfpef caused extracellular deposition amyloid fibril within heart tissue many important feature ca known year prevalence elderly patient_hf increasingly recognized plasma cell produce monoclonal immunoglobulin light chain result formation aggregation amyloid fibril responsible al amyloidosis ca classified originating either transthyretin attr light chain al amyloidosis attr ca may result genetic mutation ttr gene inherited attrv age related deposition wild_type attr attrwt cardiac_involvement al amyloidosis attributed either two mechanism extracellular deposition amyloid fibril myocardium direct cardiotoxicity fibril aggregate typing amyloid fibril critical determinant therapy also improved wider availability laser capture mass spectrometry histologic specimen specific accurate evaluation ca possible using cardiac_magnetic_resonance_imaging bone scintigraphy tracer survival ca improved markedly novel chemotherapy agent become available challenge remain advanced disease broadening amyloid specific therapeutic landscape include rna inhibitor fibril formation stabilizer inhibitor immunotherapeutic targeting amyloid deposit hold promise may_improve outcome systemic cardiac amyloidoses treatment_strategy ca recently undergone transformative change leading progress outcome certain patient discus basic feature ca well emergence novel disease modifying strategy recently evaluated clinical_trial treatment ca:0.0553630412914274", "136352": "cardiac_amyloidosis recognized potentially fatal cause_heart_failure cardiovascular manifestation caused deposition misfolded precursor protein fibrillary amyloid deposit cardiac_tissue two primary subtypes systemic amyloidosis causing cardiac_involvement immunoglobulin light chain al plasma cell dyscrasia transthyretin attr subdivided hereditary subtype caused gene mutation attr protein age related wild_type occurs absence gene mutation clinical recognition requires high index suspicion inclusive extracardiac manifestation subtypes diagnostic workup includes screening serum urine monoclonal protein suggestive immunoglobulin light chain along serum cardiac biomarker measurement performance cardiac imaging finding consistent amyloid infiltration modern cardiac imaging technique including use nuclear scintigraphy bone seeking radiotracer noninvasively diagnose attr cardiac_amyloidosis reduced reliance gold_standard endomyocardial_biopsy disease modifying therapeutic_approach evolved significantly particularly attr pharmacologic therapy slow halt disease_progression becoming available canadian cardiovascular society canadian heart_failure society joint position statement provides evidence_based recommendation support early recognition optimal diagnostic approach management_strategy patient cardiac_amyloidosis includes recommendation symptomatic management heart_failure cardiovascular_complication arrhythmia risk_stratification follow surveillance use attr disease modifying therapy optimal clinical care setting patient complex multisystem disease:0.0520615451445915", "121427": "cardiac_amyloidosis amyloid cardiomyopathy acm commonly resulting extracellular deposition amyloid fibril consisted misfolded immunoglobulin light chain al transthyretin ttr protein underestimated cause_heart_failure cardiac_arrhythmia among three type cardiac_amyloidosis wild_type familial ttr light chain wild_type wt ttr related amyloidosis attr increasingly recognized cause heart_failure_preserved_ejection_fraction_hfpef amyloidosis considered differential diagnosis heart_failure group_patient recent advance diagnosis drug treatment acm ushered new era early disease detection better management_patient certain clue cardiac extracardiac manifestation acm may heighten clinical suspicion guide confirmatory testing newer noninvasive imaging method strain echocardiography cardiac_magnetic_resonance bone scintigraphy may obviate need endomyocardial_biopsy attr patient newer targeted therapy may alter adverse prognosis_patient early recognition acm crucial halting disease process irreversible organ damage occurs chemotherapy stem_cell transplantation combined immunomodulatory therapy may_also favorably affect course prognosis light chain acm finally select patient end_stage disease heart_transplantation may render result comparable non acm patient issue herein reviewed:0.0517332096701480", "112115": "amyloidosis disorder characterized misfolded precursor protein form deposition fibrillar aggregate abnormal cross beta sheet conformation known amyloid extracellular space several tissue although known amyloidogenic protein hereditary non hereditary cardiac_amyloidosis ca typically arises either misfolded transthyretin attr amyloidosis immunoglobulin light chain aggregation al amyloidosis prevalence common previously thought especially among patient_heart_failure preserved_ejection_fraction_hfpef aortic_stenosis clinical suspicion ca focused echocardiography laboratory screening presence monoclonal protein serum urinary electrophoresis immunofixation serum free light chain ratio cardiac scintigraphy technetium labeled bone tracer sensitive specific initial diagnostic test case advanced invasive technique necessary last several year treatment_option al ca attr ca rapidly expanded important note aim therapy different systemic al amyloidosis requires treatment targeted abnormal plasma cell clone whereas therapy attr ca must targeted production stabilization ttr molecule likely multistep treatment approach optimal al ca attr ca additionally treatment ca includes management restrictive cardiomyopathy preserved reduced_ejection_fraction addition treating amyloid deposition future study necessary define optimal management_strategy al ca attr ca confirm cardiac response therapy:0.0515568921435418", "123878": "cardiac_amyloidosis ca rare progressive infiltrative restrictive cardiomyopathy characterized extracellular deposition insoluble amyloid fibril form misfolded endogenous protein heart common type ca transthyretin ttr immunoglobulin light chain al amyloidosis ttr ca subdivided wild_type wtttr ca mutant mttr ca form ca long thought rare disease however clinical_practice frequently overlooked increasingly recognized cause heart_failure_preserved_ejection_fraction_hfpef patient ca show poor_prognosis early_diagnosis novel therapeutic_option shown significantly improve prognosis novel diagnostic modality nuclear scintigraphy allow earlier diagnosis ttr ca without biopsy report present_case wtttr ca rare overlooked underlying etiology hfpef left_ventricular_hypertrophy:0.0515440542194538", "114619": "cardiac_amyloidosis ca infiltrative restrictive cardiomyopathy caused accumulation heart interstitium amyloid fibril formed misfolded protein common ca type light chain amyloidosis al caused monoclonal immunoglobulin light chain transthyretin amyloidosis attr caused either mutated wild_type transthyretin aggregate previously considered rare disease ca increasingly recognized among_patient may misdiagnosed undifferentiated heart_failure_preserved_ejection_fraction_hfpef paradoxical low flow low gradient aortic_stenosis otherwise unexplained left_ventricular_hypertrophy progress diagnosis due refinement cardiac echocardiographic technique speckle_tracking imaging magnetic_resonance mapping mostly due advent bone scintigraphy enabled noninvasive diagnosis attr limiting need endomyocardial_biopsy importantly proper management ca start early recognition suspected case among high_prevalence population followed advanced diagnostic evaluation confirm diagnosis typing preferentially experienced amyloidosis center differentiating attr type amyloidosis especially al critical emerging targeted attr therapy offer potential improve outcome_patient previously treated palliatively:0.0514508472637985", "179443": "transthyretin amyloidosis attr progressive disease characterized tissue deposition transthyretin ttr derived amyloid fibril commonly involving heart joint ligament however deposition less common site bone_marrow also reported clinical significance remains_unclear year_old_man presented mild heart_failure amyloid initially detected synovial tissue carpal tunnel release surgery prompted technetium pyrophosphate mtc pyp scintigraphy endomyocardial_biopsy confirmed wild_type attr cardiomyopathy cm due elevated serum free light chain ratio bone_marrow biopsy performed exclude immunoglobulin light chain al amyloidosis myeloma revealing amyloid deposit positive ttr negative anti kappa anti lambda antibody indicating attr type deposition ttr stabilizer initiated shortly diagnosis although biomarker level b_type_natriuretic_peptide troponin echocardiographic finding consistent mild disease presentation gradually worsened subsequent year parallel increasing heart_failure_symptom case highlight ttr amyloid deposition less common site e_g bone_marrow even initial clinical finding mild may reflect advanced stage wild_type attr cm:0.0513831080149050", "193681": "background amyloidosis multisystem disease characterized deposition amyloid fibril leading organ dysfunction cardiac_amyloidosis suspected essential screen light chain amyloidosis al transthyretin amyloidosis attr two common subtypes case presentation report patient_advanced_heart_failure mild kidney dysfunction initial symptom preliminary testing revealed slightly abnormal light chain ratio strong positive tc pyrophosphate pyp scan biopsy heart bone_marrow kidney confirmed amyloidosis immunofluorescence mass spectrometry analysis identified immunoglobulin g lambda light chain deposit patient_diagnosed multiple myeloma heavy light chain amyloidosis ahl initiated treatment cyclophosphamide bortezomib dexamethasone rather tafamidis oral transthyretin kinetic stabilizer used attr conclusion ahl amyloidosis rare subtype case demonstrates positive pyp scan even intense uptake entirely specific attr tissue confirmation essential definitive diagnosis particularly light chain disease rare form suspected al ahl attr distinct treatment prognosis may coexist:0.0510537079125530", "170296": "cardiac_amyloidosis ca infiltrative restrictive cardiomyopathy caused deposition amyloid fibril myocardium presenting primarily transthyretin cardiac_amyloidosis attr immunoglobulin light chain cardiac_amyloidosis al attr classified wild_type attrwt hereditary attrv based transthyretin gene mutation disease increasingly recognized significant cause_heart_failure advance diagnostic modality including electrocardiography echocardiography cardiac_magnetic_resonance_imaging technetium pyrophosphate scintigraphy revolutionized non_invasive diagnosis ca attr often diagnosed scintigraphy al typically requires histological confirmation review explores diagnostic tool emphasizing role early_detection quantification disease burden crucial timely treatment prognostication comprehensive overview aim aid clinician efficiently diagnosing ca ultimately improving patient_outcome:0.0505285777626699"}, "Topic 12": {"194293": "background early prediction heart_failure_hf acute_myocardial_infarction_ami essential personalized treatment aimed use interpretable machine_learning ml method develop risk prediction_model hf ami patient_method retrospectively included_patient initially ami received percutaneous_coronary_intervention_pci hospital november february primary_endpoint occurrence hf within_year operation developing predictive model hf_risk ami patient least absolute shrinkage selection operator lasso regression used feature selection four ml algorithm including random forest rf extreme gradient boost xgboost support vector machine svm logistic_regression lr employed develop model training set performance evaluation prediction_model carried training set testing set utilizing metric including auc area receiver_operating_characteristic_curve calibration plot decision curve analysis dca addition used shapley additive explanation shap value determine importance selected feature interpret optimal model result_total ami patient included_patient developed hf follow among four evaluated ml model xgboost model exhibited exceptional accuracy auc value shap method showed left_ventricular_ejection_fraction_lvef left_ventricular end_systolic diameter lvds lactate dehydrogenase ldh identified three important characteristic predict hf_risk ami patient individual risk_assessment performed using shap plot waterfall plot analysis conclusion research demonstrates potential ml method early prediction hf_risk ami patient furthermore enhances interpretability xgboost model shap analysis guide clinical decision_making:0.0349713521468925", "195038": "background sepsis induced coagulopathy sic fatal complication icu patient yet early risk prediction remains challenging study_aimed develop interpretable machine_learning model predicting sic within seven day icu admission method clinical_data model development retrieved medical information mart intensive_care iv mimic iv database feature selection performed using three distinct algorithm least absolute shrinkage selection operator lasso regression random forest recursive feature elimination rf rfe boruta method ten machine_learning model underwent training employing fold cross validation training subset subsequent evaluation validation subset encompassing discrimination calibration clinical utility metric optimal model underwent interpretability analysis shapley additive explanation shap elucidate variable contribution directional effect external validation conducted using electronic intensive_care_unit collaborative research database eicu crd finally best performing model implemented web based shiny application featuring interactive interface result among_patient mimic iv developed sic within_day post icu admission lightgbm model thirteen variable demonstrated optimal performance achieving area receiver_operating_characteristic_curve auroc confidence_interval_ci internal validation set ci external eicu crd cohort key predictive variable included prothrombin time international normalization ratio inr platelet count sequential organ failure assessment sofa lactate systolic_blood_pressure sbp red cell distribution width rdw bicarbonate phosphate hemoglobin age presence heart_failure_hf ischemic_heart_disease ihd use continuous renal replacement_therapy crrt model deployed clinician oriented web application providing accessible interface http shatao shinyapps io sepsis induced coagulopathy conclusion model demonstrated strong predictive ability clinical interpretability enabling early sic identification targeted intervention:0.0349192307622764", "199656": "introduction bleeding serious complication cardiac_surgery especially among_patient receiving combined anticoagulant antiplatelet therapy current prediction_model rarely include undergoing valve surgery coronary_artery_bypass_grafting cabg account postoperative factor dual antithrombotic therapy limiting clinical utility aim_study aimed develop validate machine_learning model individualized prediction bleeding event within three month discharge patient_receiving warfarin plus aspirin following combined cabg valve surgery method data adult patient_underwent cardiac_surgery received combined anticoagulant antiplatelet therapy june december retrospectively analyzed patient randomly_assigned training internal validation cohort eleven key bleeding predictor selected using least absolute shrinkage selection operator lasso method seven machine_learning algorithm logistic_regression decision tree random forest rf support vector machine extreme gradient boosting xgboost light gradient boosting machine lightgbm k nearest neighbor subsequently trained using predictor model performance evaluated based area receiver_operating_characteristic_curve auc accuracy sensitivity_specificity positive predictive_value ppv negative predictive_value npv f score brier score external validation performed temporally independent cohort_patient model interpretability assessed shapley additive explanation shap used visualize global individual risk contribution result eleven clinical_variable including anemia diabetes heart_failure atrial_fibrillation age postoperative drainage previous bleeding stroke body_mass_index estimated_glomerular_filtration_rate intraoperative bleeding identified predictor among model rf algorithm demonstrated best performance internal validation auc accuracy sensitivity_specificity ppv npv f score external validation rf model maintained strong performance auc accuracy sensitivity_specificity ppv npv f score decision curve analysis confirmed clinical utility model shap visualization provided transparent interpretation individualized bleeding risk conclusion_study demonstrates feasibility clinical utility ml based prediction short_term bleeding risk cardiac_surgery patient dual antithrombotic therapy rf model enables individualized risk_assessment shap interpretation supporting clinical applicability:0.0348847495562739", "182984": "objective risk_stratification patient congestive heart_failure_hf vital clinical_practice aim_study construct machine_learning model predict hospital cause_mortality intensive_care_unit icu patient_hf method extreme gradient boosting algorithm xgboost used construct new prediction_model xgboost model medical information mart intensive_care iv database mimic iv training set eicu collaborative research database dataset eicu crd used external validation test set xgboost model performance compared logistic_regression_model existing model get guideline heart_failure model mortality test set area receiver_operating_characteristic cure brier score employed evaluate discrimination calibration three model shapley additive explanation shap value applied explain xgboost model calculate importance feature result_total_patient congestive hf training set test set respectively included_study hospital cause_mortality occurred_patient respectively training set feature highest predictive_value selected model lasso regression acute physiology score iii aps iii age sequential organ failure assessment sofa strongest predictor shap external validation xgboost model performance superior conventional risk predictive method area_curve confidence_interval brier score evaluation clinical effectiveness machine_learning model brought positive net benefit threshold probability prompting evident competitiveness compare two model model translated online calculator accessible freely public http nkuwangkai app mortality prediction app mhkf streamlit app conclusion_study developed valuable machine_learning risk_stratification tool accurately assess stratify risk hospital cause_mortality icu patient congestive hf model translated web based calculator access freely:0.0331717314058202", "192758": "background currently paucity literature addressing personalized risk_stratification using multimodal data_patient symptomatic aortic_stenosis heart_failure_preserved_ejection_fraction_hfpef following transcatheter aortic_valve_replacement tavr objective study_aimed enhance performance risk_assessment model patient_population developing predictive model adverse_outcome using various machine_learning ml technique method multicenter cohort_study included_patient diagnosed severe hfpef underwent tavr january_december patient allocated training n independent validation n set based hospital affiliation dual phase feature selection process combining least absolute shrinkage selection operator logistic_regression boruta algorithm used_identify relevant variable multimodal dataset total ml model decision tree k nearest neighbor random forest support vector machine extreme gradient boosting used construct visualization explainable predictive framework elucidate model decision_making process result primary feature identified included age n_terminal_pro_brain_natriuretic_peptide fasting blood glucose triglyceride high density_lipoprotein cholesterol ratio triglyceride glucose index triglyceride glucose bmi index atherogenic index plasma index apolipoprotein b among model support vector machine demonstrated best predictive performance major_adverse cardiovascular cerebrovascular event patient_severe hfpef following tavr achieving area_curve ci independent validation set model exhibited good calibration robust predictive power training validation set demonstrated highest net benefit decision curve analysis compared model extract significant variable influencing algorithm ensure model appropriateness interpreted cohort personalized model prediction using shapley additive explanation value conclusion ml based multimodal model incorporating readily accessible predictor demonstrated robust predictive capability month major_adverse cardiovascular cerebrovascular event risk model used_identify high_risk individual hfpef following tavr potentially aiding risk_stratification personalized treatment_strategy:0.0330788512497589", "197911": "background currently heart_failure become one major complication advanced stage various cardiovascular_disease numerous predictive model developed estimate mortality_rate heart_failure_patient however model often require measurement multiple indicator inclusion various scoring system critically_ill patient often unsuitable extensive diagnostic test many primary_care hospital lack comprehensive diagnostic equipment contrast blood test simpler also reflect overall health_status body therefore using simpler method predict mortality intensive_care_unit icu patient become focus study method_total case eicu database utilized model development case mimic iv database employed external testing patient primarily diagnosed heart_failure data included demographic information blood oxygen saturation white blood_cell red blood_cell platelet hemoglobin electrolyte lactate glucose biochemical physiological indicator collected icu stay enhance accuracy data analysis improve universality model data underwent rigorous preprocessing prior training combined data standardization utilized variety machine_learning algorithm modeling purpose including logistic_regression lr support vector machine svm decision tree random forest gradient boosting machine gbm xgboost neural network performance model assessed cross validation evaluated_using f score conclusion feature selection key variable ultimately identified among nine machine_learning model evaluated multilayer perceptron mlp demonstrated best overall performance predicting mortality e deceased population mlp achieved f score recall precision relatively high f score mlp highlight potential clinical_application value:0.0324885473903998", "127217": "objective_study aim construct validate several machine_learning ml algorithm predict long_term_mortality identify risk_factor unselected patient post cardiac_surgery method medical information mart intensive_care mimic iii database used perform retrospective administrative database study candidate predictor consisted demographic comorbidity vital sign laboratory test result scoring system treatment information first day icu admission four year_mortality set study outcome used ml method logistic_regression lr artificial neural network nnet naive bayes nb gradient boosting machine gbm adapting boosting ada random forest rf bagged tree bt extreme gradient boosting xgb prognostic capacity clinical utility ml model compared using area receiver_operating_characteristic_curve auc calibration curve decision curve analysis dca result_patient mimic iii included final cohort total_patient died year_follow among variable extracted database total predictor selected using recursive feature elimination included subsequent analysis ada model performed best among eight model discriminatory ability highest auc goodness fit visualized calibration curve moreover dca show net benefit rf ada bt model surpassed ml model almost threshold probability value additionally ada technique determined red blood_cell distribution width rdw blood urea nitrogen bun sap ii anion gap ag age urine output chloride creatinine congestive_heart_failure sofa top predictor feature importance ranking conclusion ada model performs best predicting year_mortality cardiac_surgery among eight ml model might significant application development early warning system patient following operation:0.0324191367120720", "190772": "introduction heart_failure_hf may induce bowel hypoperfusion leading hypoxia villa bowel wall occurrence clostridioides difficile infection cdi however risk_factor development cdi hf_patient yet fully illustrated especially lack evidence real_world data method clinical_data survival situation hf_patient cdi admitted icu extracted medical information mart intensive_care mimic iv database developing model predict day cause_mortality hf_patient cdi recursive feature elimination cross validation rfe cv method_used feature selection nine machine_learning ml algorithm including logistic_regression lr decision tree bayesian adaptive boosting random forest rf gradient boosting decision tree xgboost light gradient boosting machine categorical boosting applied model construction training hyperparameter optimization model grid search fold cross validation performance model evaluated area_curve auc accuracy sensitivity_specificity precision negative predictive_value f score furthermore shapley additive explanation shap method_used interpret optimal model result_total hf_patient cdi included_study case experienced death within_day eighteen variable selected model construction algorithm model construction among ml model considered rf model emerged optimal model achieving accuracy f score auc value respectively net benefit model surpassed model threshold probability based decision curve analysis according importance feature rf model red blood_cell distribution width blood urea nitrogen simplified acute physiology score ii sequential organ failure assessment white blood_cell count highlighted five influential variable conclusion developed ml model predict day cause_mortality hf_patient associated cdi icu effective conventional lr model rf model best performance among ml model employed may_useful help clinician identify high_risk hf_patient cdi:0.0323280431321666", "174187": "background_heart_failure_hf rank among foremost cause_mortality globally exhibiting particularly high_prevalence significant impact within intensive_care_unit icu study sought develop validate deploy time dependent machine_learning model aimed predicting one_year cause_mortality risk icu patient_diagnosed hf thereby facilitating precise prognostic evaluation risk_stratification method_study encompassed cohort icu patient_hf sourced medical information mart intensive_care iv mimic iv database version latest version database added data basis version covering data therefore data spanning n designated training set data n reserved test set primary_endpoint interest one_year cause_mortality least absolute shrinkage selection operator lasso regression employed select predictive feature initial pool candidate variable including demographic characteristic vital sign comorbidities complication therapeutic_intervention routine laboratory data disease_severity score four predictive model developed compared cox_proportional_hazard random survival forest rsf cox_proportional_hazard deep neural network deepsurv extreme gradient boosting xgboost model performance assessed_using concordance index c index brier score model interpretability addressed shapley additive explanation shap time dependent survival shapley additive explanation survshap result_study revealed one_year mortality_rate within population investigation training set lasso effectively identified feature model test set xgboost model exhibited superior predictive performance evidenced c index brier score outperforming cox model c index brier score rsf model c index brier score deepsur model c index brier score decision curve analysis validated clinical utility xgboost model across broad spectrum risk threshold feature importance analysis identified red cell distribution width albumin ratio rar charlson comorbidity index simplified acute physiology score ii sap ii acute physiology score iii aps iii age bilirubin inr creatinine abic score top five predictive factor consequently online risk prediction tool based model developed publicly accessible conclusion time dependent xgboost model demonstrated robust predictive capability evaluating one_year cause_mortality risk critically_ill hf_patient model offered useful tool early risk identification supported timely intervention:0.0321791924375031", "167191": "background_heart_failure_hf combined hypertension extremely important cause hospital_mortality especially intensive_care_unit icu patient however intense working pressure medical staff easily overwhelmed large number clinical signal generated icu may_lead treatment delay sub optimal care even wrong clinical decision individual risk_stratification essential strategy managing icu patient_hf combined hypertension artificial intelligence especially machine_learning ml develop superior model predict prognosis_patient study_aimed develop machine_learning method predict day_mortality icu patient_hf combined hypertension method enrolled critically_ill patient_hf combined hypertension medical information mart intensivecare database iv mimic iv v eicu collaborative research database eicu crd subsequently mimic iv divided training cohort testing cohort ratio eicu crd designated external validation cohort least absolute shrinkage selection operator lasso cox_regression internal tenfold cross validation used data dimension reduction identifying valuable predictive feature day_mortality based accuracy area_curve auc best model validation cohort selected addition utilized shapley additive explanation shap method highlight importance model feature analyze impact individual feature model output visualize individual shapley value result_total patient_hf combined hypertension mimic iv eicu crd included_patient including male median q q age_year selection total clinical parameter extracted develop machine_learning model among four constructed model neural network nn model performed best predictive performance auc test cohort external validation cohort respectively addition simplified model including seven variable built based nn also good predictive performance auc feature importance analysis_showed age mechanical_ventilation mechvent chloride bun anion gap paraplegia rdw rdw hyperlipidemia peripheral capillary oxygen saturation spo respiratory rate cerebrovascular_disease heart_rate white blood_cell wbc international normalized ratio inr mean corpuscular hemoglobin concentration mchc glucose aid mean corpuscular volume mcv n_terminal_pro_brain_natriuretic_peptide npro bnp calcium renal replacement_therapy rrt partial thromboplastin time ptt top feature nn model greatest impact finally hyperparameter optimization shap plot employed make nn based model interpretable analytical description constructed model visualizes prediction death conclusion developed predictive model predict day_mortality icu patient_hf combined hypertension proved superior traditional logistic_regression_analysis shap method enables machine_learning model interpretable thereby helping clinician better understand reasoning behind outcome assess hospital outcome critically_ill patient:0.0319380217534967"}, "Topic 13": {"130454": "background left bundle_branch area pacing lbbap emerged promising technique deliver cardiac_resynchronization_therapy_crt however safety_efficacy ventricular_arrhythmia sensing via left bundle implantable_cardioverter_defibrillator_icd recipient remain unclear sought evaluate feasibility single lbbap lead connected dual chamber icd patient indicated crt implantation method cross left pilot study prospectively included consecutive_patient reduced_ejection_fraction complete left_bundle_branch_block indicated prophylactic crt df lead implanted right_ventricular_rv apex lbbap lead interventricular septum ventricular fibrillation induced implantation conventional rv left bundle_branch area sensing configuration latter final sensing configuration patient implanted dual chamber df icd connected atrial lead ra port lbbap lead rv port defibrillation lead rv df port pin capped atrioventricular delay optimized ensure fusion lbbap native conduction right bundle patient_followed month result difference configuration observed regarding r wave sensing sinus_rhythm p ventricular fibrillation median interval detection p total induced episode duration p lbbap resulted significant_reduction median qrs width m p median ventricular sensing significantly_improved implantation mv month p median lvef also significantly_improved month p_conclusion ventricular_arrhythmia sensing defibrillation performed via single lbbap lead connected dual chamber icd associated significant electromechanical reverse_remodeling clinical_trial registration number nct patient_presenting left_bundle_branch_block left_ventricular_systolic_dysfunction left bundle_branch area pacing lead connected df dual chamber implantable_cardioverter_defibrillator provides safe ventricular_arrhythmia sensing efficient electro mechanical resynchronization:0.0276994793264774", "188647": "background patient_heart_failure non left_bundle_branch_block non lbbb qrs pattern limited response biventricular_pacing bvp objective personalized cardiac_resynchronization_therapy_crt implantation approach guided real_time electrocardiographic imaging ecgi studied method twenty patient left_ventricular_ejection_fraction_lvef qrs_duration m non lbbb right bundle_branch_block intraventricular conduction delay recruited crt implantation right_atrial right_ventricular coronary sinus bundle left bundle lead inserted total activation time tat different pacing combination measured real_time implantation ecgi configuration producing shortest tat chosen clinical response defined new_york_heart_association_class improvement echocardiographic response defined left_ventricular end_systolic_volume reduction lvef improvement month result ecgi guided crt implantation lvef improved p new_york_heart_association_class improved p clinical echocardiographic response rate ecgi approach resulted better acute electrical resynchronization bvp measured tat reduction v_p percentage tat reduction found strong predictor echocardiographic response area_curve receiver_operating_characteristic_curve confidence_interval strong positive correlation percentage tat reduction percentage lvef improvement pearson r_p found conclusion ecgi guided crt implantation patient_non lbbb generates superior acute electrical resynchronization compared bvp associated favorable clinical echocardiographic outcome:0.0274383181494429", "41895": "background_aim cardiac_resynchronization_therapy_crt improves ventricular dyssynchrony associated improvement symptom quality_life prognosis patient_severe heart_failure intraventricular conduction delay different pacing modality produce variable activation pattern may cause different haemodynamic change aim_study investigate acute haemodynamic change different crt configuration optimization procedure method_study included_patient severe left_ventricular_systolic_dysfunction left_bundle_branch_block wide qrs ef qrs m new_york_heart_association iii_iv implanted crt device whole group_patient severe mitral_regurgitation order measure dp_dt implantation discharge patient_underwent optimization procedure guided doppler echocardiography left right_ventricular pre ejection interval lvpei rvpei interventricular mechanical delay ivd maximal rate ventricular pressure rise early systole max dp_dt measured left biventricular_pacing three different atrioventricular av delay result crt device optimization optimal av delay crt mode defined left_ventricular pre ejection interval changed p rvpei p ivd p dp_dt p_conclusion patient_receiving crt echocardiographic assessment acute haemodynamic response crt useful tool optimization procedure variability doppler parameter different crt modality emphasizes necessity individualized approach optimization procedure:0.0270359007535606", "123344": "background cardiac_resynchronization_therapy_crt based conventional biventricular_pacing biv crt technique sometimes result broad qrs complex suboptimal response objective aimed assess feasibility outcome crt based left bundle_branch area pacing lbbap lieu right_ventricular lead combined coronary venous left_ventricular pacing international multicenter study method lbbap optimized crt lot crt attempted nonconsecutive patient crt indication addition lbba coronary venous lead discretion implanting physician guided suboptimal paced qrs complex clinical ground result lot crt successful patient baseline_characteristic follows mean_age_year female left_ventricular_ejection_fraction left_ventricular_end_diastolic diameter mm n_terminal_pro_b_type_natriuretic_peptide level pg_ml left_bundle_branch_block nonspecific intraventricular conduction delay right_ventricular pacing right bundle_branch_block procedure characteristic follows mean fluoroscopy time minute lbbap capture threshold v m r wave amplitude mv lot crt resulted significantly_greater narrowing qrs complex m baseline m p biv crt m p lbbap m p follow month ejection_fraction improved left_ventricular_end_diastolic diameter decreased mm n_terminal_pro_b_type_natriuretic_peptide level decreased pg_ml pacing parameter stable clinical improvement noted patient new_york_heart_association_class v conclusion lot crt feasible safe provides greater electrical resynchronization compared biv crt could alternative especially suboptimal electrical resynchronization obtained biv crt randomized_controlled_trial comparing lot crt biv crt needed:0.0268050158319898", "107902": "background cardiac_resynchronization_therapy_crt established therapy_patient cardiomyopathy left_bundle_branch_block heart_failure bundle pacing hbp may_also improve clinical_outcome narrowing qrs_duration qrs narrowing hbp may always optimal aim_study determine crt could optimized sequential hbp followed left_ventricular_lv pacing optimized crt hot crt maximize electrical resynchronization method attempted permanent hbp patient left_bundle_branch_block intraventricular conduction defect right_ventricular pacing referred crt addition lv lead hbp followed lv pacing delay equal ventricular interval qrs_duration baseline hbp biventricular_pacing hot crt measured echocardiographic_parameter new_york_heart_association_functional_class assessed baseline follow result hot crt successful patient age_year men ischemic qrs_duration baseline m significantly narrowed m biventricular_pacing p m hbp p m hot crt p mean_follow month lv_ejection_fraction improved p new_york_heart_association_functional_class changed twenty one_patient clinical responder showed echocardiographic response conclusion feasibility cohort hot crt resulted improved electrical resynchronization hot crt may_improve clinical echocardiographic outcome advanced heart_failure_patient requiring crt:0.0267854048825145", "113956": "aim present_study evaluate feasibility clinical_outcome left bundle_branch area pacing lbbap cardiac_resynchronization_therapy_crt indicated patient method_result lbbap performed via transventricular septal approach patient rescue strategy patient failed left_ventricular_lv lead placement primary strategy remaining patient pacing parameter procedural characteristic electrocardiographic echocardiographic data assessed implantation follow enrolled crt indicated patient left_bundle_branch_block lbbb right bundle_branch_block rbbb intraventricular conduction delay ivcd ventricular pacing dependence qrs_duration qrsd significantly shortened lbbap intrinsic m v lbbap m p mean_follow month new_york_heart_association_functional_class improved baseline p left_ventricular_ejection_fraction_lvef increased baseline p lv_end_diastolic dimension lvedd decreased mm baseline mm p significant_improvement v_p lvef patient lbbb conclusion present_study demonstrates clinical feasibility lbbap crt indicated patient left bundle_branch area pacing generated narrow qrsd led reversal remodelling lv improvement cardiac_function lbbap may alternative crt patient failure lv lead placement first_line option selected patient lbbb heart_failure:0.0260630094657642", "93459": "background cardiac_resynchronization_therapy_crt via biventricular_pacing demonstrated clinical_benefit patient_heart_failure_hf ventricular dyssynchrony approach crt little_known objective purpose_study assess feasibility safety_efficacy left bundle_branch area pacing lbbap patient_hf left_bundle_branch_block lbbb method eleven consecutive patient_hf reduced left_ventricular_ejection_fraction lbbb indicated crt recruited lbbap achieved via transventricular septal approach characterized narrower qrs_duration shortened peak left_ventricular activation time right bundle_branch conduction delay electrocardiogram electrocardiogram echocardiogram cardiac_function evaluated baseline follow interventricular mechanical delay dimensional tissue synchronization imaging lbbap intrinsic lbbb status measured echocardiography follow result lbbap significantly shortened qrs_duration baseline m m p left_ventricular activation time baseline m m p interventricular mechanical delay standard_deviation tissue synchronization imaging left_ventricular_lv segment significantly shorter lbbap intrinsic lbbb status p mean_follow period month new_york_heart_association_functional_class plasma_level b_type_natriuretic_peptide lv end_systolic diameter left_ventricular_ejection_fraction significantly_improved p v baseline conclusion_study demonstrates lbbap clinically feasible patient systolic hf lbbb lbbap new crt technique correct lbbb provide ventricular synchrony improve clinical symptom lv reverse_remodeling:0.0260562320301707", "173525": "cardiac_resynchronization_therapy_crt using biventricular biv pacing standard treatment heart_failure_hf_patient reduced left_ventricular_ejection_fraction_lvef electrical dyssynchrony however one three_patient remains non responder left bundle_branch area pacing lbbap could represent physiological alternative effectiveness limited case atypical left_bundle_branch_block lbbb intraventricular conduction delay ivcd left bundle_branch pacing optimized cardiac_resynchronization_therapy lot crt integrates lbbap coronary sinus c lead pacing improve electrical synchrony clinical_outcome review evaluates feasibility advantage disadvantage clinical_outcome lot crt additionally describe center experience propose evidence_based implantation algorithm review published study investigating lot crt conducted comparing effectiveness biv crt lbbap alone using qrs narrowing lvef improvement left_ventricular remodeling new_york_heart_association_nyha_class change nt_probnp_level found lot crt outperforms biv crt lbbap alone selected population cost higher clinical skill longer procedural time specific device setup randomized_trial underway define role clinical_practice:0.0260297600039938", "63626": "cardiac_resynchronization_therapy_crt established therapeutic_option symptomatic heart_failure reduced_ejection_fraction evidence left_ventricular_lv conduction delay qrs width m especially typical left_bundle_branch_block present rationale behind crt restoration aberrant lv electrical activation considerable heterogeneity lv electrical activation pattern among crt candidate individualized approach targeting lv lead region latest electrical activation avoiding scar tissue may enhance crt response echocardiography electro anatomic mapping cardiac_magnetic_resonance_imaging late gadolinium enhancement helpful guide targeted lv lead placement however important limitation remains anatomy coronary sinus often allow concordant lv lead placement optimal region epicardial lv lead placement minimal invasive surgery endocardial lv lead placement transseptal punction may overcome limitation obviously increased complication risk furthermore recent pacing algorithm suggest superiority lv versus biventricular_pacing patient preserved atrio ventricular av conduction typical lbbb pattern finally pacing one lv site might overcome wide electrical dispersion often seen patient lv conduction delay therefore multisite pacing gained significant interest improve crt response use multiple lv lead may potentially lead favorable reverse_remodeling improved functional_capacity quality_life crt candidate adverse_event shorter battery span frequent extra lead use one multipolar lv lead increase number pacing configuration within coronary sinus side branch within small distance without use additional lead small observational_study suggest effective resynchronization achieved approach finally many reason non effective crt delivery carefully selected patient adequately implanted device multidisciplinary post implantation care inside dedicated crt clinic ensures optimal crt delivery improves response rate considered standard_care:0.0260070810706998", "165330": "background cardiac_resynchronization_therapy_crt biventricular_pacing well_established therapy left bundle_branch area pacing lbbap safe technique providing physiological pacing lbbap optimized crt lot crt shown provide better electrical resynchronization traditional crt however report shock lead placement left bundle_branch area lbba crt defibrillator crt implantation case summary year_old_woman heart_failure dilated_cardiomyopathy presented left_bundle_branch_block pattern qrs_duration m left_ventricular_ejection_fraction cardiac_resynchronization_therapy defibrillator implantation performed due worsening symptom reshaping agilis hispro catheter adding septal curve shock lead placed deep ventricular septum narrowing qrs_duration m left_ventricular activation time m defibrillation threshold test confirmed successful treatment without adverse_event month_follow left_ventricular_ejection_fraction improved patient condition improving new_york_heart_association_class iii class discussion reported qrs narrowing crt related long_term_mortality lot crt decreased qrs_duration compared lbbp biventricular_pacing increased response rate combining lbbap coronary sinus pacing potentially achieve superior electrical resynchronization lack suitable tool direct shock lead placement lbba necessitated additional lbbap lead conventional lot crt successful lot crt procedure minimal number lead agilis hispro catheter reshaping enabled direct lbba shock lead placement:0.0258982382318767"}, "Topic 14": {"73022": "importance prior study_demonstrated lower cause_mortality individual overweight compared normal body_mass_index_bmi whether may come cost greater burden cardiovascular_disease_cvd unknown objective calculate lifetime risk estimate incident cvd subtypes cvd estimate year lived without cvd weight status design setting_participant population_based study used pooled individual level data adult baseline age_year across large u prospective cohort million person year_follow participant free clinical cvd baseline available bmi index cvd outcome data data analyzed october july exposure world health organization standardized bmi category main_outcome_measure total cvd cvd subtype including fatal nonfatal coronary_heart_disease stroke congestive_heart_failure cvd death height weight measured directly investigator study bmi calculated weight kilogram divided height meter squared performed modified kaplan_meier analysis estimate lifetime risk adjusted competing cox model estimate joint cumulative risk cvd noncardiovascular death irwin restricted mean estimate year lived free cvd result person examination included_study mean_sd age_year men year woman patient female compared individual normal bmi defined bmi lifetime risk incident cvd higher middle aged adult overweight obese group_compared normal weight among middle aged men_woman competing hazard_ratio incident cvd ci_ci respectively overweight bmi ci_ci obesity bmi ci_ci morbid obesity bmi higher bmi strongest association incident heart_failure among cvd subtypes average year lived cvd longer middle aged adult overweight obese group_compared adult normal bmi group similar pattern observed younger older_adult conclusion relevance study obesity associated shorter longevity significantly increased_risk cardiovascular morbidity_mortality compared normal bmi despite similar longevity compared normal bmi overweight associated significantly increased_risk developing cvd earlier age resulting greater proportion life lived cvd morbidity:0.0335865328261464", "138687": "high office blood_pressure variability obpv midlife increase_risk cardiovascular_disease_cvd impact obpv older_adult without previous cvd unknown conducted post_hoc analysis aspree trial aspirin reducing event elderly participant aged_year older u minority without history cvd event baseline examine risk incident cvd associated long_term visit visit obpv cvd prespecified adjudicated secondary end_point aspree estimated obpv using within individual sd mean systolic bp baseline first annual visit cox_proportional_hazard regression used calculate hazard_ratio hr_ci association cvd event participant survived year without event highest tertile obpv increased_risk cvd event adjustment multiple covariates compared participant lowest tertile hr_ci_p similar increased_risk observed ischemic_stroke hr_ci_p heart_failure_hospitalization death hr_ci_p cause_mortality hr_ci_p finding consistent stratifying participant use antihypertensive drug sensitivity_analysis suggested increased_risk especially individual whose bp uncontrolled obpv estimation period finding support increased obpv risk_factor cvd event healthy older_adult without hypertension event previously registration url http_www clinicaltrials_gov unique identifier_nct url http_www isrctn com unique identifier isrctn:0.0335604113329473", "105066": "importance coronary_artery calcium cac associated coronary_heart_disease chd cardiovascular_disease_cvd however prognostic data cac limited younger adult objective_determine cac adult aged_year associated incident clinical chd cvd cause_mortality year_follow design setting_participant coronary_artery risk development young adult cardia study prospective community based study recruited black white participant aged_year march june cohort surveillance year cac measured n n n year recruitment mean_follow period incident event year_year computed tomographic scan august main_outcome_measure incident chd included fatal nonfatal myocardial_infarction acute_coronary_syndrome without myocardial_infarction coronary revascularization chd death incident cvd included chd stroke_heart_failure peripheral arterial disease death included cause probability developing cac age_year estimated using clinical risk_factor measured year apart age_year result year study among participant mean_sd age_year men_woman individual cac geometric mean agatston score interquartile_range participant followed year incident chd event incident cvd event observed adjusting demographic risk_factor treatment cac experienced fold increase chd event hazard_ratio hr_ci fold increase cvd event hr_ci within cac score stratum hr chd ci_ci ci_ci respectively cac score incidence death per participant hr_ci death participant cac score adjudicated chd event risk_factor cvd early adult life identified median risk developing cac applied selective cac screening strategy could reduce number people screened cac number imaged needed find person cac conclusion relevance presence cac among individual aged_year associated_increased_risk fatal nonfatal chd year_follow cac score associated early death adult younger year cac even low score identified computed tomographic scan elevated risk clinical chd cvd death selective use screening cac might considered individual risk_factor early adulthood inform discussion primary_prevention:0.0315706522924712", "35588": "objective_assess prospective association metabolic_syndrome mets cardiovascular_disease_cvd older people evaluate effect lowering threshold impaired fasting glucose ifg prevalence ifg mets risk cvd design prospective_cohort_study setting four field center u community participant three thousand five hundred eighty five subject cardiovascular health study free diabetes_mellitus cvd baseline mean_age female black measurement baseline measure mets component adjudicated incident cvd event mets defined first using original criterion third adult treatment panel report national cholesterol education program following large waist circumference woman cm men cm elevated triglyceride mmol_l low high density_lipoprotein cholesterol men mmol_l woman mmol_l elevated fasting glucose mmol_l high blood_pressure mmhg self_reported use medication hypertension subject also classified according revised definition mets applies lower threshold fasting glucose mmol_l result follow median year coronary_heart_disease chd stroke congestive_heart_failure_chf event occurred age race adjusted hazard_ratio_hr chd stroke chf confidence_interval_ci ci_ci woman ci_ci ci_ci men respectively overall woman_men mets likely experience cvd event subject without mets using lower cut point ifg resulted near tripling ifg prevalence additional classified mets hr similar estimated original mets criterion high blood_pressure component strongly_associated incident chd conclusion result_study elderly population_based cohort provide support earlier investigation primarily middle aged population link presence mets development cvd underscore importance recognizing treating individual component particularly high blood_pressure:0.0314698982443701", "182386": "importance long_term relative_risk antihypertensive treatment regard mortality_morbidity well understood objective_determine long_term posttrial risk primary secondary_outcome among trial participant randomized either thiazide type diuretic calcium_channel blocker ccb angiotensin_converting_enzyme ace_inhibitor year_follow design setting_participant prespecified secondary analysis antihypertensive lipid lowering treatment prevent heart attack trial allhat multicenter randomized double_blind active controlled clinical_trial followed participant aged_year older diagnosis hypertension least coronary_heart_disease risk_factor year february december trial participant linked administrative database posttrial mortality n morbidity outcome n statistical analysis_performed january october intervention participant randomly_assigned receive thiazide type diuretic n ccb n ace_inhibitor n planned trial follow approximately year posttrial passive follow year main_outcome_measure primary_end_point mortality due cardiovascular_disease_cvd secondary_outcome included cause_mortality combined fatal nonfatal morbidity cvd mortality_morbidity coronary_heart_disease stroke_heart_failure end_stage_renal_disease cancer result_total participant mean_sd age_year men black participant followed cause_mortality subgroup participant mean_sd age_year woman black participant followed fatal nonfatal cvd mean_sd follow year maximum follow year cardiovascular_disease mortality_rate per person diuretic ccb ace_inhibitor group respectively year randomization adjusted_hazard_ratio ahr ci ccb v diuretic ahr ci ace_inhibitor v diuretic long_term risk secondary_outcome similar among group_compared diuretic group ace_inhibitor group increased_risk stroke mortality ahr ci increased_risk combined fatal nonfatal hospitalized stroke ahr ci_conclusion relevance secondary analysis randomized_clinical_trial adult population hypertension coronary_heart_disease risk_factor cvd mortality similar group ace_inhibitor increased_risk stroke outcome compared diuretic effect persisted well beyond trial period trial_registration clinicaltrials_gov identifier_nct:0.0313853975056744", "73997": "background iris trial insulin_resistance intervention stroke demonstrated pioglitazone reduced risk cardiovascular_event diabetes_mellitus insulin resistant patient however concern remains pioglitazone may increase_risk heart_failure_hf susceptible individual method iris patient insulin_resistance without diabetes_mellitus randomized pioglitazone placebo within_day ischemic_stroke transient_ischemic_attack followed year identify_patient higher hf_risk pioglitazone performed secondary analysis iris participant without hf history entry hf episode adjudicated external review treatment_effect analyzed_using time event method baseline hf risk_score constructed cox model estimated using stepwise selection baseline patient feature individually summarized risk_score postrandomization event examined possible modifier effect pioglitazone net cardiovascular benefit estimated composite stroke myocardial_infarction hospitalized hf result among_patient mean_age_year_male year hf_risk differ treatment pioglitazone placebo risk hospitalized hf low significantly_greater pioglitazone compared_placebo group versus_p older_age atrial_fibrillation hypertension obesity edema high c_reactive_protein smoking risk_factor hf however effect pioglitazone differ across level baseline hf_risk hazard_ratio ci pioglitazone versus placebo patient low moderate high_risk interaction p_value hf_risk increased patient versus without incident myocardial_infarction group pioglitazone versus placebo versus_p edema dyspnea weight gain trial predict hf_hospitalization led study drug dose reduction lower mean dose pioglitazone versus placebo mg versus mg p pioglitazone reduced composite_outcome stroke myocardial_infarction hospitalized hf hazard_ratio p_conclusion iris surveillance dose adjustment pioglitazone increase_risk hf conferred net cardiovascular benefit patient insulin_resistance cerebrovascular_disease risk_hf pioglitazone modified baseline hf_risk iris experience may instructive maximizing net benefit therapy clinical_trial registration url http_www clinicaltrials_gov unique identifier_nct:0.0311496732362167", "181068": "importance education social determinant health quantifying association lifetime cardiovascular_disease_cvd risk public_health importance objective calculate lifetime risk estimate incident cvd cvd subtypes estimate year lived without cvd education design setting_participant included community based cohort_study adjudicated cardiovascular_event used pooled individual level data prospective_cohort_study study team assessed association education lifetime cvd risk modified kaplan_meier cox model accounting competing risk noncardiovascular death study team estimated year lived without cvd education irwin restricted mean utility adding educational attainment cvd risk_assessment participant baseline year_old year_old without cvd baseline complete education cardiovascular_risk_factor prospective cvd outcome data data analyzed january september exposure educational attainment less high school high school completion college college graduate main_outcome_measure cardiovascular_event fatal nonfatal coronary_heart_disease heart_failure stroke cvd related death total cvd encompassing event result participant female mean_sd age_year male year female compared college graduate less high school high school completion higher lifetime cvd risk among middle aged men competing hazard_ratio_hr cvd event ci_ci ci_ci less high school high school college respectively compared college completion among woman competing hr_ci ci_ci individual higher education longer duration life prior incident cvd education provided limited contribution toward enhancing cvd risk prediction conclusion relevance lower education associated lifetime cvd risk across adulthood higher education translated healthy longevity educational policy initiative may associate long_term health benefit:0.0310515325327371", "136490": "importance american heart_association ideal cardiovascular health cvh score associated risk cardiovascular_disease_cvd mortality however unclear whether number year spent ideal cvh associated morbidity_mortality objective_evaluate whether living longer higher cvh score midlife associated_lower risk hypertension_diabetes chronic_kidney_disease cvd subtypes coronary_heart_disease stroke congestive_heart_failure peripheral artery disease cause_mortality later life design setting_participant prospective_cohort_study used data participant participated community based framingham heart study offspring investigation conducted massachusetts cvh score participant assessed examination cycle respectively individual excluded analysis association duration cvh score outcome outcome interest seventh examination median_follow approximately year data analyzed april october cvh score category poor score intermediate score ideal score composite score derived based smoking status diet physical_activity resting blood_pressure level body_mass_index fasting blood glucose level total serum cholesterol level main_outcome_measure number event number risk main outcome including incident hypertension_diabetes chronic_kidney_disease cvd cause_mortality seventh examination result eligible participant mean_sd age_year woman number event number risk main outcome seventh examination incident hypertension_diabetes chronic_kidney_disease cvd cause_mortality seventh examination participant mostly poor intermediate cvh score antecedent examination cycle year duration participant intermediate ideal cvh less_likely develop adverse_outcome hazard_ratio ci incident hypertension ci diabetes ci chronic_kidney_disease ci cvd ci cause_mortality relative living amount time poor cvh referent group effect modification observed age_sex conclusion relevance result_suggest time spent better cvh midlife may salutary cardiometabolic benefit may associated_lower mortality later life:0.0310404517044466", "163054": "background patient_heart_failure_hf high_risk atherosclerotic cardiovascular_disease study atherothrombotic treatment population disappointing date icosapent ethyl reduced risk atherosclerotic cardiovascular_disease among broad array statin treated patient elevated risk atherosclerotic cardiovascular_disease whether treatment benefit icosapent ethyl consistent among hf unknown method_result reduce reduction cardiovascular_event icosapent ethyl intervention trial randomized participant including patient history hf icosapent ethyl n placebo n primary_end_point composite cardiovascular_death nonfatal myocardial_infarction nonfatal stroke coronary revascularization unstable_angina used cox_regression estimate risk outcome participant without hf estimated placebo controlled change triglyceride h crp high_sensitivity c_reactive_protein baseline year among patient_hf median_age_year median body_mass_index kg men icosapent ethyl reduced triglyceride median reduction mg_dl p h crp p compared_placebo similar patient_without hf p_interaction treatment_effect primary_end_point patient_hf history hazard_ratio hr_ci consistent effect observed patient_without hf history hr_ci_p interaction conclusion reduce icosapent ethyl provided similar improvement triglyceride level h crp well similar cardiovascular_risk reduction patient_without hf registration url http_www clinicaltrials_gov unique identifier_nct:0.0309675214808252", "119595": "importance little_known regarding association level blood_pressure bp young adulthood cardiovascular_disease_cvd event middle age objective_assess whether young adult developed hypertension defined american college cardiology acc american heart_association aha bp guideline age_year higher_risk cvd event compared maintained normal bp design setting_participant analysis conducted prospective cohort coronary_artery risk development young adult cardia study started march cardia enrolled african_american white participant aged_year u field center birmingham alabama chicago illinois minneapolis minnesota oakland california outcome available august exposure using highest bp measured first examination examination closest age_year participant categorized normal bp untreated systolic bp sbp mm_hg diastolic bp dbp mm_hg n elevated bp untreated sbp mm_hg dbp mm_hg n stage hypertension untreated sbp mm_hg dbp mm_hg n stage hypertension sbp mm_hg dbp mm_hg taking antihypertensive medication n main_outcome_measure cvd event fatal nonfatal coronary_heart_disease chd heart_failure stroke transient_ischemic_attack intervention peripheral artery disease pad result final cohort included adult mean_age follow outcome began year sd woman african_american taking antihypertensive medication median_follow_year incident cvd event occurred chd stroke_heart_failure pad cvd incidence_rate normal bp elevated bp stage hypertension stage hypertension ci_ci ci_ci ci_ci per_person_year respectively multivariable adjustment hazard_ratio cvd event elevated bp stage hypertension stage hypertension v normal bp ci_ci ci_ci respectively_conclusion relevance among young adult elevated blood_pressure stage hypertension stage hypertension age_year defined blood_pressure classification american college cardiology american heart_association acc aha guideline significantly_higher risk subsequent cardiovascular_disease event compared normal blood_pressure age_year acc aha blood_pressure classification system may_help identify young adult higher_risk cardiovascular_disease event:0.0307947911711700"}, "Topic 15": {"159667": "background worsening heart_failure_hf often requires hospitalization case may managed outpatient emergency_department ed setting predictor clinical significance ed visit without admission v hospitalization unclear method ascend hf trial included u patient_hospitalized hf reduced preserved_ejection_fraction clinical_characteristic compared_patient subsequent cause ed visit ed discharge within_day v cause readmission within_day factor_associated type care assessed multivariable model multivariable model landmarked day evaluated association type care subsequent day_mortality result day follow patient ed discharge readmission neither urgent visit patient ed discharge v readmission similar respect age_sex systolic_blood_pressure ejection_fraction coronary_artery_disease whereas ed discharge patient modestly lower creatinine p among_patient either event within_day higher creatinine prior hf_hospitalization associated_higher likelihood readmission compared ed discharge p landmarked day rate death subsequent day patient readmitted patient discharged ed compared_patient readmitted ed discharge independently_associated lower day_mortality adjusted hazard_ratio_confidence_interval p_conclusion cohort u patient_hospitalized hf worse renal_function prior hf_hospitalization associated_higher likelihood early postdischarge readmission compared ed discharge although subsequent mortality high discharge ed risk mortality significantly_lower patient readmitted hospital:0.0274692105900664", "155220": "aim impact mitral_regurgitation mr patient_hospitalized acute_heart_failure_ahf well_established assessed role mr patient_enrolled relaxin acute_heart_failure relax ahf trial method_result patient_enrolled relax ahf available data regarding mr status included analysis baseline_characteristic hospital data clinical_outcome day follow evaluated impact moderate_severe mr assessed among ahf patient known mr status patient moderate_severe mr compared_patient mild mr moderate_severe mr likely history heart_failure_hf prior hf_hospitalization comorbidities symptom sign hf lower left_ventricular_ejection_fraction higher n_terminal_pro_b_type_natriuretic_peptide level moderate_severe mr associated longer length hospital_stay higher_rate residual dyspnoea increased jugular venous pressure index hospitalization higher unadjusted risk composite cardiovascular cv_death rehospitalization hf renal_failure rf day crude hazard_ratio_hr_confidence_interval_ci_p association moderate_severe mr poorer outcome maintained multivariable model including several covariates interest adjusted hr_ci_p similar finding observed hf rf rehospitalization alone conclusion_patient ahf moderate_severe mr associated_worse clinical profile independent prognostic impact clinical_outcome:0.0261498596650050", "185946": "aim sex difference long_term_outcome following hospitalization heart_failure_hf across ejection_fraction_ef subtypes well described study_evaluated risk mortality rehospitalization among male_female across spectrum ef year_follow following index hf_hospitalization event method_result patient_hospitalized hf january_december american heart_association get guideline heart_failure registry available year_follow using medicare part claim data included association sex risk mortality readmission year_follow period hf subtype hf reduced ef hfref ef hf mildly reduced ef hfmref ef hf preserved ef hfpef ef assessed_using adjusted cox model effect modification hf subtype association sex outcome assessed including multiplicative interaction term model total_patient median_age_year female included year_follow male_female comparably poor survival post_discharge however female v male greater year_survival lost hf compared median age_sex matched u population hfpef v_year hfref v_year hfmref v year_age group year adjusted analysis female v male lower_risk year_mortality adjusted_hazard_ratio ahr confidence_interval_ci_p risk difference pronounced among_patient hfref ahr ci_p interaction sex hf subtype female v male higher adjusted risk_hf readmission year_follow ahr ci_p risk difference pronounced among_patient hfpef ahr ci_p interaction sex hf subtype conclusion female v male lower adjusted mortality female experienced significantly_greater loss survival time median age_sex matched u population greater risk rehospitalization year following hf_hospitalization:0.0256714870245175", "111786": "background hospitalization heart_failure_hf associated_increased_risk death among_patient chronic_hf degree hospitalization_hf distinct biologic entity independent prognostic_value versus marker higher_risk chronic hf_patient unclear method excluding patient new_onset hf ascend hf trial acute study clinical effectiveness nesiritide decompensated_heart_failure included_patient hospitalized worsening chronic_hf reduced preserved_ejection_fraction present analysis compared_patient presence absence prior hf_hospitalization within_month timing prior hf_hospitalization relative index hospitalization association day cause_mortality assessed including adjustment prespecified clinical factor result overall patient_hf hospitalization within prior month mortality_rate day respectively unadjusted analysis prior hf_hospitalization associated_increased_risk day_mortality hr_ci_p adjustment point estimate attenuated association statistically_significant hr_ci_p similarly adjustment compared patient_without prior hospitalization prior hf_hospitalization associated mortality irrespective timing month hr_ci_p month hr_ci_p month hr_ci_p month hr_ci_p_conclusion cohort patient_hospitalized worsening_hf prior hf_hospitalization associated day_mortality comprehensively accounting patient_characteristic measured index patient visit clinical confounders measured point care may explain previously observed association prior hf_hospitalization mortality clinical factor may direct mean predicting patient survival registration url http_www clinicaltrials_gov unique identifier_nct:0.0255431266908687", "108942": "aim regional difference patient_characteristic management outcome hospitalized patient_heart_failure_hf aim_study_evaluate clinical_characteristic outcome japanese patient_hospitalized hf basis left_ventricular_ejection_fraction_lvef stratum method_result retrospectively conducted multicentre cohort_study hospitalized_patient decompensated hf_patient lvef hf reduced_ejection_fraction_hfref median_age_year male lvef hf mid range ef hfmref year male lvef hf preserved ef hfpef year male primary_outcome death cause secondary_outcome cardiac_death hospitalization due worsened hf hospital_discharge high proportion non ischaemic cardiomyopathy hfref_patient coronary_artery_disease hfmref patient valvular disease hfpef_patient frequency intravenous diuretic natriuretic_peptide administration hospitalization respectively median hospital_stay overall population day length_stay day patient hospital_mortality different among lvef group hfref hfmref hfpef median_follow_month range month patient discharged alive died hospitalized hospital_discharge significant_difference mortality hospital_discharge among three lvef group hfref hfmref hfpef difference cardiac_death hospitalization due worsened hf hospital_discharge among lvef group cardiac_death hfref hfmref hfpef hospitalization due worsened hf hfref hfmref hfpef multivariable adjusted analysis_showed hfmref hfref group_compared hfpef group associated_increased_risk hospital death death hospital_discharge non cardiac cause_death hospitalization hospital_discharge accounted respectively_conclusion result revealed different clinical_characteristic similar mortality_rate hfref hfmref hfpef group common cause_death hospitalization hospital_discharge hf non cardiac cause also contributed prognosis integrated management approach required hf_patient:0.0252052865256590", "73293": "objective largest acute_heart_failure_ahf trial conducted date global ascend hf acute study clinical effectiveness nesiritide decompensated_heart_failure trial database presented opportunity systematically describe relationship among time hospital presentation clinical profile inpatient management outcome among_patient admitted ahf background time hospital presentation shown impact outcome among_patient hospitalized many condition however association among time presentation patient_characteristic management clinical_outcome among_patient hospitalized ahf well characterized method post_hoc analysis ascend hf trial performed enrolled patient_hospitalized ahf patient_divided based presented hospital regular hour defined pm monday friday hour defined pm monday friday weekend clinical_characteristic outcome compared time presentation result overall patient_presented hour hour patient likely orthopnea v respectively rale v respectively regular hour patient hour patient likely receive intravenous iv nitroglycerin v respectively iv loop_diuretic v respectively initial therapy reported greater relief dyspnea h odds_ratio confidence_interval_ci_p regular hour patient adjustment hour presentation associated significantly_lower day_mortality ci_p day_mortality hazard_ratio hr_ci_p similar day rehospitalization rate p_conclusion ahf trial patient_admitted hour exhibited distinct clinical profile experienced greater dyspnea relief lower post_discharge mortality regular hour patient finding implication future ahf trial:0.0251589942467038", "33227": "aim chronic_obstructive_pulmonary_disease_copd common heart_failure_hf_patient yet population poorly characterized associated conflicting outcome data aimed evaluate clinical_characteristic outcome hf_patient systolic_dysfunction copd large acute_hf registry method_result optimize hf organized program initiate lifesaving treatment hospitalized patient_heart_failure performance improvement registry patient_hospitalized hf n included pre specified subgroup patient_n day follow performed retrospective analysis clinical_characteristic outcome length_stay hospital day_mortality patient systolic_dysfunction according baseline copd status copd present patient_patient co_morbidity compared patient_without copd less_likely receive beta_blocker angiotensin_converting_enzyme_inhibitor hospitalization discharge p copd associated_increased median length_stay day interquartile_range v day interquartile_range p increased hospital cause non cardiovascular_cv mortality_rate v_p v_p respectively two endpoint similar day_mortality v_p risk adjustment hospital non cv mortality remained increased odds_ratio_confidence_interval p_conclusion presence copd hf_patient systolic_dysfunction associated_increased burden co_morbidity lower use evidence_based hf medication longer hospitalization increased hospital non cv mortality similar post_discharge mortality:0.0249023704551201", "71753": "difference clinical_course congestion underlying ejection_fraction_ef well characterized acute_heart_failure_ahf post_hoc analysis_performed using pooled data diuretic optimization strategy evaluation acute_heart_failure cardiorenal rescue study acute_decompensated_heart_failure renal optimization strategy evaluation acute_heart_failure trial patient_admitted primary diagnosis ahf patient grouped reduced ef borderline ef preserved ef multivariable cox_regression_analysis used_assess association among measure congestion composite unscheduled outpatient visit rehospitalization death mean_age_year_male patient preserved ef older likely female less_likely ischemic etiology hf higher_prevalence atrial_fibrillation flutter chronic_obstructive_pulmonary_disease compared_patient reduced ef preserved ef patient lower amino terminal pro b_type_natriuretic_peptide level baseline e reduced pg_ml v borderline pg_ml v preserved pg_ml experienced smaller change hospitalization general difference ef group clinical_course congestion measured sign_symptom hf body_weight change net fluid loss adjusting potential confounders greater improvement global visual analog scale associated_lower risk unscheduled outpatient visit rehospitalization death day hazard_ratio per mm increase confidence_interval relation differ ef p_conclusion among_patient hospitalized ahf difference hospital trajectory prognostic_value routine marker congestion ef:0.0247629036358103", "106023": "aim patient_hospitalized heart_failure_hf high_risk day_readmission study sought examine timing cause readmission within_day hf_hospitalization method_result timing cause readmission ascend hf acute study clinical effectiveness nesiritide decompensated_heart_failure trial assessed early late readmission defined admission occurring within_day day post_discharge respectively patient_died hospital remained hospitalized day post randomization excluded patient compared timing cause readmission logistic cox_proportional_hazard regression_analysis used_identify independent_risk_factor early v late readmission association day outcome_patient ascend hf population included analysis patient readmitted within_day cause overall readmission non hf cause median time rehospitalization day interquartile_range day rehospitalizations occurred day rehospitalization within_day independently_associated increased_risk day cause_death hazard_ratio_hr_confidence_interval_ci_p risk day cause_death differ according early v late readmission hr_ci_p_conclusion hospitalized hf trial population significant majority day_readmission non hf cause one third readmission occurred first day early late readmission within_day timeframe associated similarly increased_risk death continued effort optimize multidisciplinary transitional care warranted improve rate early readmission:0.0246130102017288", "159792": "background acute decompensation heart_failure_hf often marked fluid retention weight_loss marker successful diuresis examined relationship hospital weight_loss post_discharge outcome patient_hf method_conducted propensity_score matched study patient_hospitalized decompensated hf medicare linked organized program initiate lifesaving treatment hospitalized patient_heart_failure optimize hf registry patient weight_loss group_patient weight_loss group balanced baseline_characteristic defined weight_loss admission discharge weight_loss kilogram defined weight_loss weight gain loss kilogram hazard_ratio_hr_confidence_interval_ci outcome associated weight_loss estimated result_patient mean_age_year woman african_american median weight_loss weight_loss group interquartile_range kilogram hr_ci day cause_mortality cause readmission hf readmission associated weight_loss respectively respective day hr_ci association attenuated lost significance month_follow conclusion among older patient_hospitalized decompensated hf hospital weight_loss associated_lower risk mortality hospital_readmission finding_suggest hospital weight_loss marker successful diuresis decongestion also marker improved clinical_outcome:0.0245133630660254"}, "Topic 16": {"1184": "background_aim present_study assess early clinical_outcome following primary coronary angioplasty elderly_patient aged_year compared younger patient_year method_study population included consecutive_patient mean_age_year acute st elevation myocardial_infarction_mi underwent primary percutaneous_coronary_intervention_pci within hour symptom onset elderly_patient accounted patient primary pci performed using balloon coronary stent well glycoprotein iib iiia inhibitor primary_endpoint hospital incidence major_adverse_cardiac_event including death stroke reinfarction target vessel revascularization new_onset heart_failure result elderly_patient frequently female v_p comorbid disease prior stroke v_p extensive cardiovascular_disease previous acute mi v_p multivessel disease v_p significantly_lower ejection_fraction v_p despite similar rate timi flow presentation v_p n similar use stent v_p glycoprotein iib iiia inhibitor infusion v_p comparable angiographic residual stenosis v_p n final rate timi flow significantly_lower elderly population v_p although hospital ischemic event_rate age significantly_different hospital_mortality higher elderly compared younger patient v_p even patient cardiogenic_shock time admission excluded v_p furthermore patient aged hospital heart_failure v_p whole population multivariate_analysis identified baseline killip class iii_iv independent_predictor event elderly_patient multivariate_analysis identified baseline killip class iii_iv time onset chest_pain pci independent_predictor event conclusion data_suggest elderly_patient acute st elevation mi primary pci yield positive result successful reperfusion achieved high proportion elderly_patient mortality_rate lower reported non pci registry high killip class late reperfusion therapy predict unfavorable outcome elderly patient_treated primary pci:0.0320060994909469", "156009": "objective goal retrospective_study reveal prevalence angiographic characteristic clinical_presentation long_term_outcome non st_segment_elevation_myocardial_infarction nstemi patient wellens syndrome background procedural result percutaneous_coronary_intervention_pci acute_coronary_syndrome_ac improved recent_year however still paucity available clinical_trial data wellens syndrome even though well_known high_risk ac method among total_patient ac underwent angioplasty cardiovascular center beijing friendship hospital nstemi patient culprit left_anterior_descending lad vessel enrolled study according electrocardiographic criterion wellens syndrome patient_divided wellens group_n non wellens group_n primary_endpoint cardiac_death secondary_endpoint main adverse cardiovascular cerebrovascular event macces composite cause_death cardiac_death heart_failure target lesion revascularization recurrent myocardial_infarction_stroke medical follow data obtained institutional database result incidence wellens syndrome ac patient among_patient wellens syndrome nstemi proportion significant_decrease percentage preexisting coronary_heart_disease chd prior myocardial_infarction previous pci p wellens group_compared non wellens group coronary_angiography single vessel lesion common wellens group_v_p almost patient_received drug eluting stent notably wellens group higher proportion early pci non wellens group_v_p month statistically significant_difference cardiac_death p two_group macces comparable wellens v non wellens p age_year largest independent_risk_factor adverse prognosis conclusion early recognition aggressive intervention wellens syndrome longer risk_factor adverse prognosis_patient nstemi current pci era:0.0298047367298197", "178491": "background aimed compare clinical_outcome immediate staged complete revascularization primary percutaneous_coronary_intervention_pci treating st_segment_elevation_myocardial_infarction stemi multivessel disease mvd method total_patient enrolled prospective randomized multicenter registry immediate revascularization defined one time pci culprit non culprit lesion initial procedure staged revascularization defined pci non culprit lesion later date mean day interquartile_range following initial culprit revascularization end_point major_adverse_cardiovascular_event_mace composite total death recurrent myocardial_infarction revascularization individual component mace cardiac_death stent thrombosis stroke month result follow year mace occurred_patient immediate revascularization group_patient staged revascularization group hazard_ratio_hr_confidence_interval_ci incidence total death numerically higher immediate group staged group_v hr_ci significant_difference group risk individual component mace cardiac_death stroke hospital complication need transfusion bleeding acute renal_failure acute_heart_failure study prematurely terminated due halt production everolimus eluting stent manufactured promus element boston scientific natick massachusetts conclusion due limited power definite conclusion drawn regarding complete revascularization strategy present_study large randomized_clinical_trial would warranted confirm optimal timing complete revascularization patient stemi mvd:0.0288555264593879", "43933": "objective sought compare outcome st_segment_elevation_myocardial_infarction stemi patient_undergoing primary percutaneous_coronary_intervention_pci without previous coronary_artery_bypass graft cabg background limited information exists regarding procedural success clinical_outcome stemi patient cabg undergoing primary pci method apex ami assessment pexelizumab acute_myocardial_infarction trial randomized placebo controlled_trial pexelizumab stemi patient planned primary pci patient prior cabg clinical procedural characteristic culprit vessel infarct related artery ira day clinical_outcome compared result_patient previous cabg frequently men older higher incidence comorbidities multivessel disease patient versus without prior cabg pci performed less frequently versus prior cabg receiving pci thrombolysis myocardial_infarction timi flow grade also restored less often versus_p prior cabg nearly even designation ira bypass graft n versus native vessel n ira post pci timi flow grade achieved versus respectively_p prior cabg patient increased day death composite day death congestive_heart_failure shock excess death remained significant multivariable adjustment hazard_ratio_confidence_interval_p prior cabg patient stratified type ira discrimination increased day death bypass graft n versus native vessel n p respectively_conclusion prior cabg patient stemi less_likely undergo acute reperfusion worse angiographic outcome following primary pci higher day_mortality finding especially applicable ira bypass graft:0.0287248697531887", "175571": "background_aim beneficial_effect pre treatment unfractionated heparin ufh first medical contact fmc primary percutaneous_coronary_intervention ppci comer st_elevation_myocardial_infarction stemi remains uncertain method help pci investigator initiated randomized_controlled_trial conducted clinical centre china patient stemi presenting h symptom onset undergoing ppci randomly_assigned intravenous administration ufh u kg fmc cath lab catheter sheath primary_endpoint thrombolysis myocardial_infarction flow grade tfg infarct related artery ira diagnostic angiography ppci secondary_outcome complete epicardial myocardial reperfusion ppci major_adverse cardiac cerebrovascular event macce defined composite cause_death cardiac_death heart_failure_hospitalization infarction stent thrombosis unplanned revascularization stroke month safety outcome day bleeding academic research consortium barc type bleeding result_total_patient stemi undergoing ppci randomly_assigned receive either ufh administration fmc n cath lab n pre treated population fmc showed higher frequency tfg ira compared cath lab group_v odds_ratio_confidence_interval p significant_difference secondary_endpoint safety endpoint including month macce complete epicardial myocardial reperfusion major_bleeding conclusion pre treatment loading dose ufh fmc associated improvement spontaneous reperfusion ira without increasing risk major_bleeding:0.0286537113222694", "90645": "influence preinfarction angina pectoris ap long_term clinical_outcome patient st_segment_elevation_myocardial_infarction stemi underwent primary percutaneous_coronary_intervention_pci remains controversial patient acute_myocardial_infarction_ami enrolled coronary revascularization demonstrating outcome study kyoto ami registry present_study population consisted patient stemi underwent primary pci within hour symptom onset data preinfarction ap available preinfarction ap defined ap occurring within hour hospital arrival present patient_patient preinfarction ap younger often anterior ami longer total ischemic time whereas less often history heart_failure atrial_fibrillation shock presentation infarct_size estimated peak creatinine phosphokinase significantly smaller patient patient_without preinfarction ap median interquartile_range iu l v iu l p cumulative year incidence death significantly_lower patient preinfarction ap v_p median_follow interval day adjusting confounders preinfarction ap independently_associated lower risk_death hazard_ratio_confidence_interval_p lower_risk year_mortality patient preinfarction ap consistently observed across subgroup stratified total ischemic time initial thrombolysis myocardial_infarction flow grade hemodynamic status infarct location diabetes_mellitus conclusion preinfarction ap independently_associated lower year_mortality patient stemi underwent primary pci:0.0283642902346626", "103584": "background examined whether efficacy early invasive strategy fibrinolysis st_segment_elevation_myocardial_infarction stemi differs relation initial troponin status method trial routine angioplasty stenting fibrinolysis enhance reperfusion acute_myocardial_infarction transfer ami patient stemi presenting non percutaneous_coronary_intervention_pci capable hospital received fibrinolysis randomized either pharmacoinvasive standard strategy subsequent angiography pci post_hoc subgroup_analysis compared efficacy strategy relation initial troponin status hospital presentation primary composite end_point mortality reinfarction recurrent ischemia heart_failure cardiogenic_shock day assessed heterogeneity treatment_effect initial troponin status using breslow day test tested interaction adjustment baseline global registry acute_coronary event grace risk_score result among_patient abnormal initial troponin level n older worse killip class longer time symptom onset fibrinolysis higher grace thrombolysis myocardial_infarction risk_score patient abnormal troponin level higher_rate primary_end_point v_p cumulative mortality reinfarction year v_p stratified analysis pharmacoinvasive management reduced primary_end_point among_patient normal initial troponin status however significant treatment heterogeneity p_interaction initial troponin status treatment assignment adjusting grace risk_score conclusion_patient stemi abnormal initial troponin level worse short_term long_term_outcome accounting overall baseline risk grace risk_score troponin status modulate efficacy pharmacoinvasive management:0.0283315419870252", "77513": "objective aimed assess sex difference invasive parameter acute microvascular reperfusion injury infarct characteristic cardiac mri st_segment_elevation_myocardial_infarction stemi method_patient stemi undergoing emergency percutaneous_coronary_intervention_pci prospectively enrolled index microcirculatory resistance imr coronary flow reserve cfr measured culprit artery post pci contrast enhanced mri used_assess infarct characteristic microvascular obstruction myocardial haemorrhage day month post stemi prespecified outcome follows cause_death first heart_failure hospitalisation ii cardiac_death non_fatal myocardial_infarction urgent coronary revascularisation major_adverse_cardiovascular_event_mace year median_follow result_patient stemi woman mean_age_year men mean_age_year woman anterior stemi less often fewer prescription beta_blocker discharge higher baseline n_terminal_pro_b_type_natriuretic_peptide level p following emergency pci fewer woman_men thrombolysis myocardial_infarction timi myocardial perfusion grade v_p woman lower corrected timi frame count v_p however imr cfr microvascular obstruction myocardial haemorrhage infarct_size myocardial salvage index left_ventricular remodelling ejection_fraction differ significantly sex female_sex associated mace cause_death first heart_failure hospitalisation conclusion sex difference microvascular pathology patient_acute stemi woman less anterior infarct men beta_blocker therapy discharge prescribed less often woman trial_registration number nct:0.0281757111778074", "12661": "background controversy ideal type revascularization context primary angioplasty percutaneous_coronary_intervention_pci acute_myocardial_infarction_ami presence additional stenosis especially complex impact prognosis objective_evaluate medium term year prognosis according presence complex additional stenosis primary pci population method_retrospective study consecutive_patient admitted unit st_segment elevation ami underwent primary pci patient_followed year divided group without complex additional stenosis n year male complex additional stenosis n year male p n evaluated demographic characteristic risk_factor coronary_artery_disease previous cardiac history sign heart_failure admission angiographic characteristic medication pci outcome also evaluated impact variable combined end_point death reinfarction myocardial revascularization year assessed result angiographic success rate twenty four percent patient_aged_year total population killip class iv admission anterior ami slightly common non complex additional stenosis group_v_p inferior ami complex additional stenosis group_v_p one vessel disease prevalent group without complex additional stenosis expected v_p stent implantation also frequent group_v_p difference variable death reinfarction revascularization frequent group complex additional stenosis v_p sixty seven per cent event occurred first day follow year univariate predictor outcome killip class timi flow infarct related vessel pci non use glycoprotein iib iiia receptor_antagonist beta_blocker statin multivessel disease presence complex additional stenosis log_rank_p using multivariate regression_analysis independent_predictor outcome year killip class ci_p presence complex additional stenosis ci_p_conclusion presence complex additional stenosis primary pci worse prognosis year suggesting need intervention stabilize plaque particularly first day ami:0.0280584706817796", "119133": "background patient_presenting st_elevation_myocardial_infarction stemi complicated cardiogenic_shock c extremely high mortality_rate objective sought assess impact prior revascularization either coronary_artery_bypass graft surgery cabg percutaneous_coronary_intervention_pci hospital month outcome compare revascularization naive patient method_result total consecutive_patient admitted institution stemi c defined new_york state percutaneous_coronary_intervention reporting system pcirs underwent primary pci baseline clinical angiographic procedural characteristic well hospital outcome prospectively collected among_patient undergoing primary pci part new_york state pcirs data collection patient history prior bypass graft surgery older history heart_failure hypertension dyslipidemia diabetes left_anterior_descending coronary_artery usually culprit vessel post pci revascularization naive patient whereas vein graft patient prior history surgical bypass hospital_mortality rate different three_group significant_difference major_adverse cardiac cerebrovascular event_rate among three group_p notably revascularization naive patient higher_rate major_bleeding complication p multivariable_analysis age ci prior history congestive_heart_failure ci dyslipidemia ci independent_predictor month mortality prior revascularization impact rate stroke death macce conclusion_patient acute stemi c similar hospital one year_mortality stroke major_adverse cardiac cerebrovascular event_rate irrespective prior revascularization status:0.0279274760428884"}, "Topic 17": {"146064": "importance million people living either mitral aortic_valve disease worldwide heart valve replacement surgery performed year u transcatheter valve repair emerged important therapeutic_option patient candidate heart valve replacement observation transcatheter valve therapy involve multidisciplinary team interventional cardiologist cardiothoracic surgeon radiologist echocardiographers nurse social worker termed heart team determine optimal approach managing patient transcatheter aortic_valve implantation tavi aortic_valve_replacement procedure performed percutaneously currently approved patient_severe symptomatic aortic_stenosis surgical risk category tavi procedure performed using balloon expandable self expanding valve low_risk cohort_patient partner placement aortic transcatheter valve trial rate death cause stroke rehospitalization patient_receiving tavi patient_undergoing surgical aortic_valve_replacement decision_making regarding therapy choice based individual anatomy including number leaflet annular size peripheral arterial anatomy comorbidities including concomitant coronary_artery_disease aortopathies patient preference guide mitral transcatheter edge edge repair device approved u food drug administration high_risk_patient degenerative functional mitral_regurgitation excellent safety_efficacy population coapt cardiovascular_outcome assessment mitraclip percutaneous therapy heart_failure_patient functional mitral_regurgitation trial annualized rate hospitalization_heart_failure among_patient underwent transcatheter edge edge repair received medical_therapy compared among_patient medical_therapy alone group transcatheter tricuspid_valve repair replacement trial ongoing show promise treatment_patient tricuspid_regurgitation previously limited therapeutic_option multimodality imaging includes transthoracic_echocardiography transesophageal echocardiography computed_tomography intracardiac echocardiography important preprocedural planning device selection optimal outcome conclusion relevance approximately tavi procedure transcatheter mitral_valve repair take place yearly u treat patient_severe symptomatic aortic_stenosis mitral_regurgitation respectively transcatheter valve therapy expanded therapeutic_option patient including previously viable surgical option:0.0304233932121744", "194398": "background management recurrent mitral_regurgitation mr relevant iatrogenic mitral_valve mv stenosis mitral transcatheter edge edge repair teer emerges increasingly relevant clinical issue surgery teer associated_higher morbidity_mortality electrosurgical leaflet laceration stabilization implant elasta clip followed transcatheter mitral_valve replacement tmvr innovative less invasive treatment_option patient teer failure objective author sought evaluate early result elasta clip followed transapical tmvr patient symptomatic failed teer defined persistent recurrent mr iatrogenic mv stenosis method data symptomatic patient failed teer underwent elasta clip followed compassionate use commercial transapical tmvr using abbott tendyne system retrospectively collected tertiary care center country safety_efficacy procedure assessed year according mitral_valve academic research consortium mvarc criterion result_total_patient mean_age_year female high surgical risk euroscore ii sts score symptomatic residual mr n iatrogenic mv stenosis n failed teer followed median period q q month elasta clip procedure transseptal transapical followed tmvr successful patient technical success according mvarc achieved patient_without left_ventricular outflow tract obstruction conversion sternotomy day patient paravalvular leak progression ischemic_stroke occurred_patient baseline mr reduced grade less patient durable result p nyha_functional_class significantly_improved ii discharge p last follow p day patient alive three_patient rehospitalized heart_failure uncontrolled atrial_fibrillation case underwent reintervention valve retensioning conclusion transapical tmvr elasta clip feasible less invasive option management failed teer performed acceptable result carefully selected patient_population particular attention required avoid paravalvular leakage measure minimize risk periprocedural cerebrovascular event need implemented future larger scale prospective_study longer term follow:0.0294258246055925", "75906": "valvular_heart_disease one frequent cause_heart_failure degenerative disease aortic mitral_valve well dysfunctional tricuspid_valve disease result worse clinical_outcome severe minimal invasive surgical catheter based structural heart_disease shd intervention recently seen dramatic increase transcatheter aortic_valve implantation tavi severe aortic_stenosis disruptive technology next generation device careful patient_selection minimize limitation tavi paravalvular leak conductance disturbance ischemic_stroke vascular complication indication tavi continues shift toward lower_risk patient_patient complex anatomy bicuspid native pure aortic regurgitation successful clinical result tavi generated considerable interest transcatheter technology targeting mitral_regurgitation mr also toward tricuspid_regurgitation tr efficacy_safety edge edge without annuloplasty leaflet repair mimicking surgical repair confirmed technical improvement device development emerging study transcatheter mitral_valve implantation might alternative strategy patient symptomatic severe mr favorable anatomy possible interventional treatment approach tr gained attention improvement development shd intervention enabled patient receive minimally invasive heart valve intervention procedure prolonged life improved quality_life many patient previously considered unsuitable surgery continued technical device improvement accumulated evidence expand possibility future shd intervention:0.0289550835386881", "91737": "objective many patient_severe symptomatic mitral_valve regurgitation denied surgical valve replacement repair due high operative risk describe early series case transcatheter implantation cardiaq mitral_valve via transapical approach method three consecutive_patient society thoracic surgeon sts mortality score selected transcatheter mitral_valve implantation tmvi compassionate ground patient elderly severe mitral_regurgitation mr class iv heart_failure deemed unsuitable mitraclip two_patient functional mr setting ischaemic cardiomyopathy left_ventricular_ejection_fraction_lvef deemed remaining patient chordal rupture extensive anterior leaflet flail preserved lvef comorbidities included previous coronary_artery_bypass surgery n severe pulmonary_hypertension n moderate_severe chronic renal_failure n cardiaq mitral_valve implanted using fluoroscopy transoesophageal tee guidance via standard transapical approach result accurate prosthesis positioning deployment immediate elimination mr achieved case two_patient made full clinical recovery discharged home post procedural tee performed day_day showed good valve function stable valve position minimal lvot gradient one_patient expired postoperative day due pneumonia conclusion tmvi using cardiaq device via transapical approach feasible effective:0.0289376993144121", "81799": "report first case mitral stenosis following mitra clip insertion patient symptomatic nyha iv heart_failure secondary severe mitral_regurgitation mr year_old female history prior aortic_valve_replacement underwent percutaneous mitral_valve mv repair single clip advanced coaxially onto mv toe guidance anterior posterior leaflet clipped together p toe confirmed significant_reduction mr grade grade despite initial symptomatic relief represented month later similar symptom repeat toe confirmed well positioned mitra clip mild residual mr however possibility significant mitral stenosis raised due presence significant turbulence bi orifice valve peak gradient mm_hg addition evidence severe functional tricuspid_valve tv regurgitation elevated pulmonary_artery_pressure pap mm_hg confirmed subsequent right_heart_catheterization repeated heart team discussion failure optimal medical_therapy despite logistic euroscore minimally invasive surgical replacement mv simultaneous tv repair undertaken via right thoracotomy despite procedural success initial good postoperative response patient_died subsequently combination hospital acquired pneumonia significant gastrointestinal bleeding post operative day mitra clip promising novel approach mv repair establishment clinical echocardiographic based selection criterion help identify correct patient treatment:0.0286416253018350", "95387": "background mitral_valve surgery patient failing bioprosthesis annuloplasty ring patient_advanced mitral annular calcification mac associated_high morbidity_mortality rate percutaneous antegrade transseptal transcatheter mitral_valve implantation tmvi recently successfully performed_patient high prohibitive surgical risk data patient_treated tmvi sparse study sought evaluate short midterm outcome_patient treated tmvi site clinical_practice method_result october february seven patient six woman one man high prohibitive surgical risk underwent tmvi site three procedure performed tmvi failed mitral_valve bioprostheses tmvi viv valve valve one procedure performed tmvi failed mitral annuloplasty ring tmvi r three procedure performed tmvi advanced native mitral annular calcification tmvi mac mean_age population treated year mean log euroscore patient edward sapien transcatheter heart valve implanted toe fluoroscopic guidance using transvenous transseptal access indication tmvi presence advanced_heart_failure symptom patient nyha_class iii_iv predominant dysfunction mitral_valve treated severe regurgitation n severe stenosis n patient tmvi technically successful procedure clinical success functional improvement least_one nyha_class procedure compared procedure also achieved patient median nyha_class improved significantly procedure tmvi p mitral_valve regurgitation reduced trace mild one_patient showed moderate mr tmvi mac patient prosthesis mismatch lvot obstruction occurred tmvi two patient_underwent interventional asd closure hospital course due large persisting atrial septal_defect transseptal access one patient_underwent pacemaker implantation due complete av block tmvi one patient_died hospital day procedure due severe hospital acquired pneumonia sepsis hospital_mortality rate high_risk population hospital_discharge death occurred clinical improvement according nyha_functional_class remained stable one year_follow conclusion small single_center series tmvi appears promising patient_high prohibitive surgical risk either failing mitral bioprostheses annuloplasty ring native mitral_valve dysfunction combination advanced mac gaining experience tmvi new valve improve safety_efficacy new treatment_option:0.0282927664017029", "148007": "introduction paravalvular leak pvl common serious complication associated prosthetic valve implantation objective aim_study report single_center experience retrospective review analyze possible predictor success method performed percutaneous pvl closure patient female mean_age_year mitral prosthesis studied previously transesophageal echocardiography tee aortic prosthesis tee tee fluoroscopy used assessment planning guidance intervention twelve patient also underwent computed_tomography angiography better characterization anatomic detail result eighteen patient_admitted due heart_failure new_york_heart_association nyha iii_iv seven heart_failure hemolysis one due hemolysis regarding leak aortic mitral prosthesis mechanical biological prosthesis transcatheter aortic_valve implant aortic patient_severe aortic regurgitation furthermore mitral patient one moderate_severe severe mitral_regurgitation closure successful patient partially successful four unsuccessful five procedure nyha ii hemolysis worsened three_patient despite successful closure required valvular surgery two died regarding angiographic echocardiographic procedural success analyzed age_gender type prosthesis mechanical biological location aortic mitral clinical_data maximum leak diameter anatomic regurgitant orifice leak location anterior posterior inferior lateral mitral leak left right non coronary sinus aortic leak number device plug used closure parameter presented significant relationship success excepting previous hemolysis relationship clinical improvement reduction pvl p follow cardiac related event new hospital_admission cardiac valvular surgery need transfusion frequent patient partially successful unsuccessful closure p relationship cardiac related event death p_conclusion percutaneous pvl closure emerged alternative treatment pvl predictor procedural success difficult establish survival related reduction regurgitation improvement nyha_functional_class:0.0273189974583422", "104075": "background symptomatic mitral_regurgitation mr associated_high morbidity_mortality ameliorated surgical valve repair replacement despite many patient mr undergo surgery transcatheter mitral_valve replacement tmvr may option selected patient_severe mr objective study_aimed examine effectiveness safety tmvr cohort_patient native valve mr high_risk cardiac_surgery method patient_underwent transcatheter transapical delivery self expanding mitral_valve prosthesis examined prospective registry short_term day outcome result thirty patient age_year men grade mr underwent tmvr mr etiology secondary n primary n mixed pathology n society thoracic surgeon predicted risk mortality successful device implantation achieved patient_acute death stroke myocardial_infarction one patient_died day tmvr hospital acquired pneumonia prosthetic leaflet thrombosis detected patient follow resolved increased oral anticoagulation warfarin day transthoracic_echocardiography showed mild central mr patient residual mr remaining patient valve situ left_ventricular_end_diastolic volume_index decreased ml baseline v ml follow p left_ventricular end_systolic volume_index ml v ml_p seventy five percent patient_reported mild symptom follow new_york_heart_association_functional_class ii successful device implantation free cardiovascular_mortality stroke device malfunction day conclusion tmvr effective safe therapy selected patient symptomatic native mr evaluation tmvr using prosthesis specifically designed mitral_valve warranted intervention may_help address unmet need patient high_risk surgery early feasibility study tendyne mitral_valve system global feasibility study nct:0.0265269707064190", "180501": "background degenerative mitral_regurgitation dmr associated substantial morbidity_mortality left untreated surgical repair remains gold_standard mitral transcatheter edge edge repair teer established alternative patient_high surgical risk however recurrent mr initial teer remains therapeutic challenge associated poor_outcome case summary year_old patient_presented recurrent heart_failure_symptom due mr prior carillon r device implantation secondary mr external hospital september transoesophageal echocardiography revealed degenerative mitral_valve disease characterized complex combination posterior leaflet prolapse anterior leaflet flail resulting severe eccentric regurgitant jet patient_underwent successful teer mitraclip r system december june patient_hospitalized recurrent heart_failure_symptom imaging revealed severe recurrent mr originating lateral implanted device redo teer performed using pascal r system requiring careful navigation narrow residual lateral orifice procedure resulted durable reduction mild mr sustained clinical stability month_follow discussion case illustrates anatomical challenge dmr demonstrates feasibility durability redo teer high surgical risk patient recurrent mr emphasizes importance individualized anatomical assessment tailored device selection complex valve anatomy:0.0262721713259570", "196457": "background symptomatic high_risk patient_severe mitral_valve regurgitation mr eligible surgery transcatheter edge edge repair teer transcatheter mitral_valve replacement tmvr may option especially surgical mitral_valve repair annuloplasty performed earlier tmvr appropriate anticoagulation regimen still matter debate case presentation report year_old frail lady heart_failure atrial_fibrillation underwent surgical reconstruction mitral_valve nine year ago due high surgical risk heart team discussion tmvr using transcatheter aortic_valve prosthesis valve ring concept performed successfully via transapical access route several month later excellent result could confirmed since surgical excision left_atrial appendage carried first surgery oral anticoagulation withdrawn two month later patient_presented massive la thrombus mass severe stenosis mitral_valve prosthesis requiring surgery conclusion management anticoagulation patient atrial_fibrillation successfully performed laa excision still matter debate particular transcatheter heart valve implantation mitral position tmvr device may thrombogenic thus caution used whenever discontinuing oral anticoagulation patient despite lack evidence withdrawal anticoagulation avoided especially absence bleeding complication left_atrial appendage closure excision influence decision:0.0261373110231795"}, "Topic 18": {"128775": "aim body roundness index bri obesity related anthropometric index combine waist circumference height better reflect body fat study_aim prospectively explore relationship bri risk heart_failure_hf based community based cohort method_result total individual without tumour hf baseline included kailuan cohort_study demographic information anthropometric parameter biochemical index collected measured participant followed december death diagnosed hf whichever came first cox_proportional_hazard_model used calculate hazard_ratio_hr_confidence_interval_ci incident_hf restricted cubic spline analysis applied evaluate possible non linear dose response relationship bri risk_hf median_follow period year identified hf event participant grouped four group according quartile bri q q q q adjustment potential confounders compared group participant lowest quartile bri adjusted hr_ci ci_ci ci_ci subject q q q group respectively standard_deviation bri increasing risk_hf increased hr_ci subgroup_analysis indicated association bri hf prominent younger people hr_ci older hr_ci_p interaction significant linear dose response relationship bri hf also observed p non linearity conclusion_study suggests higher bri associated_increased_risk hf finding replicated population future study need examine whether lowering bri may lower_risk incident_hf:0.0376398588869495", "197506": "background depression recognized leading global contributor disease burden mortality etiology depression involves complex interplay biological psychological social factor precise pathophysiological mechanism remain incompletely understood albumin bilirubin albi score originally developed objective measure hepatic function demonstrated prognostic_value diverse clinical context including liver_disease brain tumor chronic_heart_failure however relationship albi score depression systematically investigated study_aim examine association albi score depression nationally representative cohort method population_based cross_sectional_study utilized data national_health nutrition examination survey nhanes spanning seven survey cycle albi score calculated using established formula albi log bilirubin mumol l x albumin g l x depression assessed_using patient health questionnaire phq weighted multivariable logistic_regression_model constructed analyze association albi depression adjusting potential covariates nonlinear relationship explored using restricted cubic spline rcs robustness result validated subgroup_analysis relationship albi depression symptom severity evaluated via anova prognostic analysis cox_proportional_hazard regression_model assessed link albi clinical_outcome complemented kaplan_meier k survival curve rcs plot illustrate trend result weighted multivariable logistic_regression_model revealed significant_association elevated albi score depression risk participant higher albi albi demonstrated increased odds depression compared reference albi adjusted ci_p restricted cubic spline analysis confirmed linear relationship continuous albi score depression risk subgroup_analysis stratified age_gender race education smoking drinking diabetes consistently identified high albi independent_risk_factor depression analysis variance revealed significant dose response relationship albi depression symptom severity p cox_proportional_hazard_model revealed significant_association albi increment mortality_risk depression cohort cause_mortality unit albi elevation associated_increased_risk adjusted hr_ci_p cancer related mortality showed risk escalation per albi unit hr_ci_p non cancer death exhibited stronger association increased_risk hr_ci_p_conclusion analyzing data seven cycle nhanes database study identified positive association albi score depression among u adult albi score also linked severity depressive_symptom associated cause_mortality cancer related mortality individual depression trial_registration clinical_trial number applicable:0.0349916927864393", "180310": "background_heart_failure_hf major global public_health problem identifying modifiable environmental risk_factor important prevention evaluated association blood cadmium level risk_hf u adult method analyzed data national_health nutrition examination survey nhanes total adult complete information blood cadmium hf status included weighted multivariable logistic_regression_model used_assess relationship blood cadmium self_reported hf restricted cubic spline rcs regression two piecewise linear model applied explore potential dose response relationship result cohort u adult nhanes dataset analyzed including individual diagnosed hf fully adjusted weighted logistic_regression_model elevated blood cadmium level significantly correlated increased prevalence hf specifically mug l increment blood cadmium associated_higher likelihood hf odds_ratio confidence_interval_ci_p participant highest quartile blood cadmium level exhibited threefold increase odds hf compared lowest quartile ci_p significant linear trend observed across quartile p rcs analysis demonstrated monotonic positive relationship apparent inflection point approximately mug l beyond risk continued escalate association generally consistent across various subgroup notably stronger among smoker p_interaction conclusion elevated blood cadmium independent_risk_factor hf united_state finding_suggest reducing cadmium exposure may novel strategy hf prevention prospective_study warranted clarify causal relationship underlying_mechanism:0.0343808738109639", "190150": "background triglyceride glucose tyg index emerging surrogate indicator insulin_resistance demonstrated risk_factor various cardiovascular_disease including coronary syndrome stent restenosis heart_failure however association tyg index incident aortic dissection ad aortic aneurysm aa remains investigated method_study included participant without baseline ad aa large_scale prospective uk biobank cohort primary_outcome incident ad aa comprising ad aa multivariable adjusted cox_proportional_hazard regression_model restricted cubic spline rcs analysis applied assess relationship tyg index onset ad aa addition association tyg index incident ad aa examined within subgroup defined age_gender smoking status drinking status diabetes hypertension bmi result median_follow period year ad aa case occurred incidence ad aa rose along elevated tyg index rcs curve showed linear trend tyg index risk incident ad aa tyg index positively associated risk incident ad aa adjusting age_gender smoking status drinking status bmi hypertension ldl c hba_c adjusted hr reference ci_ci ci_ci tyg index quartile respectively especially participant highest tyg index quartile highest risk developing aa adjusted hr_ci conclusion tyg index independently_associated higher_risk incident ad aa indicating importance using tyg index risk_assessment ad aa especially aa:0.0333623859617929", "197901": "background functional deficiency vitamin b prevalent condition among heart_failure_hf_patient despite specific sensitive marker deficiency study methylmalonic acid mma context hf infrequent method seven hundred forty seven individual hf incorporated cross_sectional_study participated national_health nutrition examination survey nhanes two period hazard_ratio_hr_confidence_interval_ci risk cause_mortality estimated using weighted multivariable cox_proportional_hazard_model non linear association mma level cause_mortality investigated using restricted cubic spline rcs analysis result_among hf participant death recorded follow_period year elevated serum mma level significantly_associated increased_risk cause_mortality tertile compared tertile adjusted hr_ci_p demonstrating dose response pattern increased mortality_risk per unit increase lnmma b intake diet significantly_associated mortality_risk p although minor statistically_significant association observed serum b level mortality p disappeared multivariate regression_analysis moreover correlation mma mortality_risk prominent hf population poorer health_status advanced age current smoker hypertension_diabetes overweight low estimated_glomerular_filtration_rate egfr conclusion_study indicated higher mma level associated_increased cause_mortality risk_hf population particularly aged current smoker hypertension_diabetes overweight insufficient physical_activity lower egfr_ml_min:0.0332606327403294", "192089": "background_aim uric_acid hdl cholesterol ratio uhr novel marker metabolism inflammation investigated various disease however potential association incidence cardiovascular_disease_cvd dyslipidemia remain unclear study_aimed examine relationship uhr incidence cvd dyslipidemia primary objective_evaluate role uhr predicting cvd dyslipidemia whereas secondary objective analyze predictive effect uhr different subgroup method_conducted cross_sectional analysis using data national_health nutrition examination survey nhanes included adult aged_year weighted binary logistic_regression subgroup analysis_performed evaluate independent association uhr risk various cardiovascular condition including overall cvd congestive_heart_failure myocardial_infarction angina coronary_heart_disease dyslipidemia investigate potential nonlinear relationship uhr outcome restricted cubic spline modeling applied elucidate association result_among participant included_study diagnosed cvd elevated uhr value strongly_associated greater incidence cvd subtypes including congestive_heart_failure myocardial_infarction angina coronary_heart_disease p accounting weighted factor participant higher uhr quartile presented progressively higher_rate cvd quartile quartile quartile quartile nonlinear relationship uhr risk developing cvd identified restricted cubic spline rcs analysis among subgroup participant dyslipidemia multivariable linear regression_analysis demonstrated significant positive association uhr dyslipidemia ci association remained robust even adjusting covariates ci rcs analysis confirmed nonlinear nature relationship subgroup analysis_revealed significant interaction uhr overall cvd cvd related variable congestive_heart_failure myocardial_infarction angina coronary_heart_disease however dyslipidemia bmi showed significant interaction indicating positive association uhr dyslipidemia risk influenced participant bmi conclusion high uhr associated_increased_risk various cardiovascular condition dyslipidemia incorporation routine uhr monitoring clinical_practice support early identification high_risk individual facilitate timely intervention reduce burden cardiovascular metabolic disease:0.0331456646914682", "79814": "aim examined relationship forced expiratory volume fev airflow obstruction incident heart_failure_hf black white middle aged men_woman four u community method_result lung volume standardized spirometry information covariates collected atherosclerosis risk community aric cohort participant incident_hf ascertained hospital record death certificate eligible participant average follow year participant developed new_onset hf age height adjusted hazard_ratio_hr hf increased monotonically descending quartile fev gender race group smoking status multivariable adjustment traditional cardiovascular_risk_factor height hr confidence_interval_ci hf comparing lowest highest quartile fev white woman white men black woman black men association weakened remained statistically_significant additional adjustment systemic marker inflammation multivariable adjusted incidence hf higher fev forced vital capacity v hr_ci among men among woman consistent positive association hf seen self_reported diagnosis emphysema chronic_obstructive_pulmonary_disease asthma conclusion large population_based cohort long_term_follow low fev obstructive respiratory disease strongly independently_associated risk incident_hf:0.0330486757735043", "170118": "background limited data_available regarding association serum transferrin saturation tsat level heart_failure_hf method utilized data national_health nutrition examination survey nhanes analysis data tast hf covariates extracted analyzed weighted logistic_regression subgroup_analysis used explore independent association tsat hf furthermore interaction test also carried evaluate stratum difference subsequently assessed whether non linear relationship using restricted cubic spline rcs threshold effect model result_total participant identified hf among total population participant hf significantly_lower tsat level compared_without hf v_p fully adjusting potential confounders weighted multiple logistic_regression_model revealed reduced risk_hf unit tsat increased also negative association elevated tsat developed risk_hf quartile group q q ci q ci q ci subgroup_analysis result remained consistent across stratum strong negative correlation tsat hf interaction test showed dependence gender age body_mass_index race diabetes hypertension hyperlipidemia ratio family income poverty education negative association tsat hf p_interaction rcs threshold effect model indicated linear negative correlation tsat hf pronounced tsat conclusion overall finding_suggest consistent negative association tsat level presence hf among middle aged older_adult united_state:0.0328280777682546", "156229": "background well_established obesity associated risk heart_failure_hf however data relationship visceral fat risk_hf limited aim aim evaluate association visceral obesity assessed visceral adiposity index vai incident_hf left_ventricular_lv structure_function atherosclerosis risk community aric study method included participant aged_year free history hf coronary_heart_disease baseline aric study used multivariable cox hazard regression_model assess association vai incident_hf explored effect vai lv geometry function among participant echocardiographic data using multivariable linear regression_analysis multinomial logistic_regression result median_follow_year total participant developed hf adjustment traditional hf risk_factor unit increase baseline vai associated_higher_risk incident_hf hazard_ratio_hr_confidence_interval_ci result similar participant categorized vai tertiles compared participant lowest tertile vai second tertile third tertile greater risk incident_hf hr_ci respectively analysis hf subtypes higher vai associated risk_hf preserved_ejection_fraction hf reduced_ejection_fraction addition greater vai associated_worse lv diastolic_function abnormal lv geometry including concentric remodelling concentric hypertrophy eccentric hypertrophy conclusion_study show higher vai independently_associated increased_risk incident_hf abnormal lv geometry lv diastolic_dysfunction:0.0328233822355192", "175602": "background c_reactive_protein triglyceride glucose index cti emerged innovative composite marker evaluating metabolic inflammatory dysregulation integrating marker insulin_resistance systemic inflammation however association cti cardiovascular_disease_cvd mortality rarely studied study sought examine cti association cvd mortality cvd incidence cause_mortality method_study included adult national_health nutrition examination survey nhanes cti derived ln crp mg l ln tg mg_dl x fpg mg_dl participant categorized quartile employed kaplan_meier curve cox_proportional_hazard_model logistic_regression_analysis restricted cubic spline rcs evaluate cti association cvd mortality total cvd incidence cause_mortality across sex stratified age specific glycemic subgroup result_study cti significantly positively associated cvd mortality total cvd incidence cause_mortality cti significantly predicted cvd mortality hr cause_mortality hr additionally cti index correlated risk total cvd ci congestive_heart_failure ci coronary_heart_disease ci angina pectoris ci heart attack ci stroke ci specifically association similar male_female similar young participant elderly participant different glycemic status high_level cti found linked increased_risk cvd individual without diabetes_mellitus dm however association observed individual dm conclusion analysis_revealed elevated cti level significantly_associated cvd incidence mortality cti may emerge unique predictive marker cvd risk:0.0327386879063012"}, "Topic 19": {"20194": "background cardiac resynchronisation therapy crt become valuable therapeutic tool patient_advanced chronic_heart_failure_chf search optimal method assessment crt efficacy still underway aim evaluate impact implantation crt device patient_chf adaptation circulatory respiratory system maximal exercise assessed cardiopulmonary_exercise test cpx minute walking test mwt method investigated patient male_female year crt device implanted due advanced chf resulted ischaemic dilated_cardiomyopathy patient implantation underwent echocardiography cpx expired gas analysis mwt investigation repeated month crt implantation cpx evaluated peak oxygen_uptake peak_vo oxygen pulse maximal minute ventilation carbon dioxide production vco max slope vco slope vo slope vo anaerobic threshold cardiac respiratory reserve mwt evaluated walking distance heart_rate blood_pressure response exercise result noted statistically higher mean peak_vo crt implantation studied group_v ml_kg_min p v l_min p_higher value expired co v l_min p pulse rose ml beat p also observed significant_reduction vco slope crt crt p significant_decrease vo slope p vco max fell p_patient estimated dyspnoea borg scale peak exercise point crt point p crt patient could walk longer distance mwt crt v_p conclusion cardiac resynchronisation therapy improves exercise_tolerance measured mean cpx mwt improves respiratory system efficiency restores adaptive mechanism exercise patient_advanced chf better exercise adaptation crt may objectively measured cpx parameter correlate improvement clinical symptom cpx seems helpful tool assessing result crt:0.0365012401856584", "124350": "objective cardiopulmonary function patient chronic_heart_failure_chf severely limited holistic integrative exercise pathophysiology still unclear method signed consent form eighty three patient_severe chf october october fuwai hospital performed ramp incremental loading program cardiopulmonary_exercise testing cpet normal subject served control cpet performed according standard harbor ucla mc circulatory respiratory metabolic parameter cpet measured analyzed result peak oxygen_uptake peak_vo chf ml_min kg pred significantly_lower control ml_min kg pred core parameter cpet anaerobic threshold peak oxygen pulse oxygen_uptake efficiency platform ouep lowest carbon dioxide output ventilation ratio lowest vco carbon dioxide output ventilation slope vco slope chf significantly_different control_group p core parameter lung function forced expiratory volume first second fev forced vital capacity fvc fev fvc carbon monoxide diffusion dlco significantly_decreased p systolic_blood_pressure stage cpet chf significantly_lower control_group p heart_rate peak recovery stage significantly_lower control p minute ventilation tidal volume respiratory frequency rest warm significantly_higher control p tidal volume recovery significantly_higher control p vo peak recovery stage chf significantly_higher control p oxygen pulse peak significantly_higher control p pulse oxygen saturation stage cpet chf significantly_lower control p_conclusion decreased holistic functional_capacity cardiogenic chf dominantly due circulatory limitation secondly due respiratory metabolic limitation:0.0353261531418022", "46496": "objective_study sought discover key determinant exercise_capacity maximal oxygen_consumption oxygen_uptake vo ventilatory efficiency ventilation carbon dioxide output vco slope assess prognostic potential metabolic exercise testing hypertrophic_cardiomyopathy hcm background intrinsic mechanism leading reduced functional tolerance hcm unclear method_study sample included hcm patient consecutively enrolled january january complete clinical assessment including rest stress echocardiography cardiopulmonary_exercise test cpet impedance cardiography patient also followed composite_outcome cardiac related death heart_transplant functional deterioration leading septal reduction therapy myectomy septal alcohol ablation result abnormality cpet response frequent n sample showing reduced exercise_tolerance vo max predicted n characterized impaired ventilatory efficiency vco slope variable strongly_associated exercise_capacity expressed metabolic equivalent peak cardiac_index r_p age r_p male sex r_p indexed right_ventricular end_diastolic area r_p resulting r_p peak cardiac_index main predictor peak_vo r_p variable strongly related vco slope e_e r_p indexed left_atrial volume_index lavi r_p model r composite_endpoint occurred_patient exploratory analysis variable independently_associated composite_outcome mean_follow month peak_vo predicted hazard_ratio confidence_interval_ci_p vco slope hazard_ratio_ci_p lavi ml hazard_ratio ci_p_conclusion hcm peak cardiac_index main determinant exercise_capacity significantly related ventilatory efficiency peak_vo ventilatory inefficiency lavi associated_increased_risk major event short_term follow:0.0351577553961691", "23835": "purpose_study investigates relationship ventilatory expired gas cardiac parameter measured exercise testing patient_heart_failure method twenty five subject male_female diagnosed compensated heart_failure underwent symptom limited exercise testing ventilatory expired gas analysis metabolic cardiac measure interest collected testing result mean peak oxygen_consumption vo minute ventilation carbon dioxide production vco slope percentage age predicted maximal heart_rate achieved exercise testing apmhr peak respiratory exchange ratio ml_kg_min respectively vco slope significantly correlated following apmhr r_p peak_vo r_p vo ventilatory threshold r_p dead space tidal volume ratio vd vt r_p ability peak_vo apmhr predict vco slope significant r r p_conclusion study demonstrates importance analyzing multiple exercise test parameter including metabolic measure patient_heart_failure:0.0347024829770676", "157348": "background cardiopulmonary_exercise testing cpx essential assessment exercise_capacity patient chronic_heart_failure_chf respiratory gas hemodynamic parameter ventilatory efficiency vco slope peak oxygen_uptake peak_vo heart_rate recovery established diagnostic prognostic marker clinical population previous_study suggested clinical value metric related respiratory gas collected recovery peak exercise particularly recovery time peak_vo current study explores metric detail recovery peak exercise chf method patient_chf referred cpx healthy individual without formal diagnosis assessed inclusion subject performed cpx cycle ergometer volitional exhaustion monitored least five minute recovery cpx data analyzed overshoot respiratory exchange ratio rer vco vo ventilatory equivalent oxygen vo end tidal partial pressure oxygen peto peak_vo vco result thirty two patient_chf control included peak_vo differed significantly patient control v ml_kg_min p mean left_ventricular_ejection_fraction_lvef patient_chf compared control_group vo vco significantly_higher patient control p overshoot peto vo rer significantly_lower patient control p recovery metric significantly correlated peak_vo chf_patient lvef conclusion patient_chf significantly blunted recovery peak exercise reflected delay vo vco peto rer vo reflecting greater energy required return baseline abnormal respiratory gas kinetics chf negatively correlated peak_vo baseline lvef:0.0344725776378720", "7248": "background rate heart_rate recovers exercise recently shown strong predictor mortality_patient suspected coronary disease prognostic_value patient_heart_failure_hf explored sought assess prognostic utility heart_rate recovery hrr patient_hf method eighty seven subject diagnosed compensated hf underwent cardiopulmonary_exercise testing cpx mean_age ejection_fraction year respectively heart_rate minute post cpx subtracted maximal heart_rate exercise test produce measure hrr beat per minute subject followed combined death hospitalization end_point year cpx result mean peak respiratory exchange ratio peak oxygen_consumption vo minute ventilation carbon dioxide production vco slope hrr ml_kg_min beat min respectively although three variable significant univariate predictor composite end_point p multivariate cox_regression_analysis retained vco slope chi p hrr residual chi p equation hazard_ratio subject abnormal vco slope hrr beat min value ci_p_conclusion result indicate hrr provides additional prognostic_information patient_hf undergoing cpx moreover given independent prognostic_value hrr variable alone may_provide valuable clinical information ventilatory expired gas analysis available:0.0343888630630517", "17566": "background cardiopulmonary_exercise testing ventilatory expired gas analysis cpet proven valuable tool assessing patient chronic_heart_failure_chf maximal oxygen_uptake peak v used risk_stratification patient_chf minute ventilation carbon dioxide production relationship vco slope recently demonstrated prognostic significance patient_chf method january_december performed cpet pt f mean_age_year stable chf coronary_artery_disease dilated_cardiomyopathy nyha_functional_class ii n iii n left_ventricular_ejection_fraction_lvef ability peak_vo vco slope predict cardiac related mortality cardiac related hospitalization within_month evaluation examined result peak_vo vco slope demonstrated univariate cox_regression_analysis significant_predictor cardiac related mortality hospitalization p respectively non survivor lower peak_vo ml_kg_min v ml_kg_min p steeper vco slope v_p survivor multivariate survival analysis_revealed vco slope added additional value vo peak independent prognostic_factor chi relative_risk ci_p result kaplan_meier analysis_revealed year cardiac related mortality_patient vco slope vco slope log_rank chi p_patient peak_vo ml_kg_min peak_vo ml_kg_min log_rank chi p one_year cardiac related hospitalization patient vco slope vco slope log_rank chi p_patient peak_vo ml_kg_min peak_vo ml_kg_min log_rank chi p vco slope demonstrated receiver_operating_characteristic_curve analysis equivalent peak_vo predicting cardiac related mortality v although area receiver_operating_characteristic_curve vco slope greater peak_vo predicting cardiac related hospitalization v difference statistically_significant p_conclusion result add present body knowledge supporting use cpet chf_patient vco slope index ventilatory response exercise excellent prognostic parameter improves risk_stratification chf_patient easier obtain parameter maximal exercise_capacity equivalent prognostic importance peak_vo:0.0342977372004654", "10210": "background cardiopulmonary_exercise testing cpet variable provide valuable prognostic_information heart_failure_hf population purpose present_study assess ability resting end tidal carbon dioxide partial pressure petco predict cardiac related event patient_hf method subject diagnosed compensated hf underwent cpet outpatient basis mean_age ejection_fraction year respectively resting p et co determined immediately prior exercise test seated position peak oxygen_consumption vo minute ventilation carbon dioxide production vco slope also acquired cpet result cardiac related hospitalization cardiac related death year following cpet mean resting p et co peak_vo vco slope mmhg ml_kg_min respectively univariate cox_regression_analysis revealed resting p et co chi square p peak_vo chi square p vco slope chi square p significant_predictor cardiac related event multivariate cox_regression_analysis revealed resting p et co added prognostic_value vco slope predicting cardiac related event residual chi square p peak_vo add additional value removed residual chi square p_conclusion result indicate resting ventilatory expired gas variable possesses prognostic_value independently combination established prognostic marker cpet resting p et co may therefore valuable objective measure obtain non exercise exercise evaluation patient_hf:0.0342761561262707", "28511": "aim_study aim validate cardiopulmonary_exercise testing cpet parameter recommended european society_cardiology guideline risk_assessment heart_failure_hf esc predictor verify predictive role supplementary cpet predictor parameter method_result followed hf_patient cardiovascular_death urgent heart_transplantation year patient cardiac_event esc predictor peak oxygen_consumption vo slope minute ventilation v carbon dioxide production vco exertional oscillatory ventilation related outcome univariate multivariable_analysis esc prototype based esc predictor presented harrell c concordance index likely chi predictor predicted peak_vo peak oxygen pulse peak respiratory exchange ratio peak circulatory power peak vco vco slope normalized peak_vo vo efficiency slope ventilatory anaerobic threshold detection peak end tidal co partial pressure peak heart_rate peak systolic arterial blood_pressure sbp linked outcome univariate_analysis individually added esc prototype peak sbp peak pulse significantly_improved model discrimination ability esc peak sbp prototype harrell c index reached highest likely chi p_conclusion evaluated longest list cpet prognostic parameter yet studied hf esc predictor independent_predictor cardiovascular_event esc prototype showed convincing predictive capacity whereas none predictor enhanced prognostic performance except peak sbp:0.0340145455972763", "125159": "background advanced heart_failure_hf levosimendan increase peak oxygen_uptake vo investigated whether peak_vo increase linked cardiovascular respiratory muscular performance change method_result twenty patient_hospitalized advanced hf underwent shortly levosimendan infusion different cardiopulmonary_exercise test personalized ramp protocol repeated arterial blood gas analysis standard spirometry including alveolar capillary gas diffusion measurement rest peak exercise b step incremental workload cardiopulmonary_exercise testing continuous near infrared spectroscopy analysis cardiac_output assessment bioelectrical impedance analysis levosimendan significantly_decreased natriuretic_peptide improved peak_vo interquartile_range ml_kg_min p decreased minute ventilation carbon dioxide production relationship slope p parallel spirometry showed minor increase forced expiratory volume whereas peak exercise dead space ventilation unchanged however exercise smaller edema formation observed levosimendan infusion inferable change diffusion component membrane diffusion capillary volume end tidal pressure co isocapnic buffering period increased levosimendan mm_hg mm_hg p exercise cardiac_output increased parallel vo levosimendan total oxygenated tissue hemoglobin deoxygenated hemoglobin increased exercise phase conclusion advanced hf levosimendan increase peak_vo decrease formation exercise induced lung edema increase ventilation efficiency owing decrease reflex hyperventilation increase cardiac_output muscular oxygen delivery extraction:0.0339809796502354"}, "Topic 20": {"178045": "background_heart_failure_hf common complication patient end_stage_renal_disease esrd also major cause_death although clinical_study shown close relationship mechanism occurrence unclear aim_study explore molecular_mechanism hf esrd comprehensive bioinformatics analysis providing new perspective crosstalk two disease method hf esrd datasets downloaded gene_expression omnibus geo database identified analyzed common differentially expressed gene degs first gene ontology go kyoto encyclopedia gene genome kegg gene set variation analysis gsva applied explore potential biological function construct protein protein interaction ppi network also four algorithm namely random forest rf boruta algorithm logical regression selection operator lasso support vector machine recursive feature elimination svm rfe used_identify candidate gene subsequently diagnostic efficacy hub gene hf esrd evaluated_using extreme gradient boosting xgboost algorithm cibersort used analyze infiltration immune cell thereafter predicted target micrornas mirnas using database mirtarbase tarbase enocri transcription_factor tfs identified using chea database cytoscape software applied construct mrna mirna tf regulatory network finally drug signature database dsigdb used_identify potential drug candidate result_total common degs identified enrichment analysis result_suggest immune response inflammatory factor may common feature pathophysiology hf esrd total four hub gene bcl ccl cnn pcnt validated using rf lasso boruta svm rfe algorithm auc value greater immune infiltration analysis_showed immune cell macrophage neutrophil nk cell altered hf myocardial_tissue neutrophil significantly correlated four hub gene finally target mirnas tfs obtained mirna mrna tf regulatory network construction performed addition gene targeted drug discovered conclusion_study revealed important crosstalk hf esrd common pathway pivotal gene may_provide new idea clinical treatment experimental study:0.0567997017721561", "128151": "background heart_failure health burden responsible high morbidity_mortality worldwide dilated_cardiomyopathy_dcm one common cause_heart_failure dcm disease heart muscle characterized enlargement dilation least_one ventricle alongside impaired contractility left_ventricular_ejection_fraction also associated abnormality cytoskeletal protein mitochondrial atp transporter microvasculature fibrosis however pathogenesis potential biomarkers dcm remain investigated aim investigate candidate gene pathway involved dcm patient_method two expression datasets gse gse downloaded gene_expression omnibus database differentially expressed gene degs dcm patient healthy individual identified using r package linear model microarray data pathway common degs analyzed via gene ontology go kyoto encyclopedia gene genome kegg gene set enrichment analysis moreover protein protein interaction network ppi constructed identify hub gene module microrna database applied predict micrornas mirnas targeting hub gene additionally immune cell infiltration dcm analyzed_using cibersort result_total degs upregulated downregulated identified go analysis_showed degs mainly enriched response growth_factor extracellular_matrix extracellular_matrix structural constituent kegg pathway analysis indicated degs mainly enriched protein digestion absorption interleukin il signaling_pathway ppi network suggested collagen type iii alpha chain col col contribute pathogenesis dcm additionally visualization interaction mirnas hub gene revealed hsa mir hsa mir interacted col col thus mirnas might play_role dcm immune cell infiltration analysis_revealed dcm patient infiltrated plasma cell fewer infiltrated b memory cell follicular helper cell resting dendritic cell conclusion col col targeting mirnas hsa mir hsa mir may play critical role pathogenesis dcm closely related il signaling_pathway acute inflammatory_response result may_provide useful clue diagnosis_treatment dcm:0.0565184460020547", "122213": "introduction heart_failure_hf heterogeneous clinical syndrome affect million people world hf occurs cardiac overload injury worldwide complaint aim_study screen verify hub gene involved developmental hf well explore active drug molecule method expression profiling high throughput sequencing gse dataset downloaded gene_expression omnibus geo database contained sample including heart_failure sample non heart_failure sample raw data integrated find differentially expressed gene degs analyzed bioinformatics analysis gene ontology go reactome enrichment analysis_performed via toppgene protein protein interaction ppi network degs constructed based data hippie interactome database module analysis_performed target gene mirna regulatory network target gene tf regulatory network constructed analyzed hub gene validated molecular docking study performed result_total degs including regulated gene regulated gene observed degs significantly enriched biological adhesion extracellular_matrix signaling receptor binding secretion intrinsic component plasma membrane signaling receptor activity extracellular_matrix organization neutrophil degranulation top hub gene esr pyhin ppp r b lck tp pclaf cftr tk ect fkbp identified ppi network module analysis_revealed hf associated adaptive immune system neutrophil degranulation target gene mirnas tfs identified target gene mirna regulatory network target gene tf regulatory network furthermore receiver_operating_characteristic roc_curve analysis rt pcr analysis_revealed esr pyhin ppp r b lck tp pclaf cftr tk ect fkbp might serve prognostic diagnostic biomarkers therapeutic_target hf predicted target active molecule confirmed conclusion current investigation identified series key gene pathway might involved progression hf providing new understanding underlying molecular_mechanism hf:0.0560280979005728", "173969": "background_heart_failure_hf end_stage various cardiovascular_disease identifying new biomarkers essential early_diagnosis prognosis treatment study applied bioinformatics identify potential hf biomarkers explore role immune microenvironment method gene_expression data obtained gene_expression omnibus geo database differential expression analysis weighted gene co expression network analysis wgcna used_identify key gene gene ontology go kyoto encyclopedia gene genome kegg gene set enrichment analysis_performed feature gene determined using two machine_learning algorithm random forest rf least absolute shrinkage selection operator lasso diagnostic accuracy assessed via receiver_operating_characteristic roc_curve nomogram screen hub gene external datasets used validation quantitative reverse transcription polymerase chain reaction rt qpcr used validate expression_level hub gene clinical sample single sample gene set enrichment analysis cibersort algorithm applied evaluate immune cell infiltration hf relationship hub gene result differential analysis identified differentially expressed gene degs wgcna revealed blue module showing significant_correlation hf integration degs blue module gene identified common gene kegg pathway enrichment analysis suggested gene may involved cytoskeleton muscle cell pathway lasso rf algorithm confirmed key gene potential biomarkers hf analysis using roc_curve identified hub gene good diagnostic value namely high mobility group_n hmgn myosin heavy chain myh high temperature requirement htra microfibrillar associated protein mfap validated external dataset rt qpcr immune infiltration analysis_revealed significant infiltration immune cell hf cell nk cell monocyte macrophage play_important_role development hf hub gene closely associated multiple immune cell type conclusion_study identifies hmgn htra mfap myh novel diagnostic biomarkers potential therapeutic_target hf gene closely related immune microenvironment providing new insight early diagnosis_treatment mechanistic exploration hf:0.0545794868960338", "193804": "background previous research established chronic_kidney_disease_ckd heart_failure_preserved_ejection_fraction_hfpef often coexist although preliminary understanding potential correlation hfpef ckd underlying pathophysiological mechanism remain unclear study_aimed elucidate molecular_mechanism associated ckd hfpef bioinformatics analysis method datasets hfpef ckd obtained gene_expression omnibus geo database r software package limma employed conduct differential expression analysis functional annotation performed using kyoto encyclopedia gene genome kegg gene ontology go conducted weighted gene co expression network analysis wgcna correlation analysis autophagy ferroptosis immune related process well transcriptional regulation analysis immune infiltration analysis diagnostic performance evaluation finally diagnostic potential identified hub gene ckd hfpef assessed_using roc_curve analysis gse result differential expression analysis_revealed overlapping gene comprised regulated regulated gene go kegg analysis indicated enriched pathway relevant disorder wgcna identified gene associated ckd comparison differentially expressed gene degs identified three hub gene klf scd sel l linked autophagy ferroptosis immune process condition additionally mirna mrna regulatory network involving mirnas transcription_factor tfs constructed roc_curve analysis_performed evaluate diagnostic utility hub gene ckd hfpef conclusion_study elucidated shared pathogenic mechanism identified diagnostic marker common hfpef ckd identified hub gene show promise potential tool early_diagnosis treatment_strategy condition:0.0545747184181765", "166566": "background present_study investigated differential expressed gene gegs ischemic_cardiomyopathy icm construct regulation network study correlation myocardial_infarction risk method data set downloaded gene_expression omnibus geo screen messenger rna mrna long non coding rna lncrna differentially expressed icm sample normal sample gene ontology go function analysis kyoto encyclopedia gene genome kegg pathway analysis_performed differentially expressed mrna lncrna analyzed bioinformatics method_used predict analyze microrna mirna competing endogenous rna hub gene regulatory network constructed using limma software package r language degs icm screened non heart_failure donor control_group condition differential expression ratio less time corrected p_value clusterprofiler software package used go enrichment analysis kegg enrichment analysis search tool retrieval interacting gene protein string online database used screen key gene protein protein interaction ppi network analysis result go function analysis kegg pathway analysis_showed degs significantly enriched metabolic pathway oxidative phosphorylation extracellular_matrix receptor interaction pathway closely related fibrosis collagen catabolic process inflammatory_response function hub gene regulatory network related icm lncrna constructed bioinformatics method_used effectively analyze degs icm hub gene regulatory network icm successfully constructed conclusion_study identified certain risk correlation icm susceptibility gene myocardial_infarction:0.0537077283658978", "193757": "background diabetic_cardiomyopathy dcm severe complication among_patient type_diabetes significantly increasing heart_failure risk mortality despite various implicated mechanism effective dcm treatment remain elusive study_aimed construct comprehensive competing endogenous rna cerna network dcm using bioinformatics analysis material_method three expression profile datasets gse gse gse collected gene_expression omnibus database integrated identification differentially expressed gene degs gene ontology kyoto encyclopedia gene genome pathway analysis gene set enrichment analysis gsea employed functional analysis protein protein interaction ppi network hub gene also identified cerna regulatory network constructed based interaction long noncoding rna lncrna degs microrna mirna degs predicted public available database result_total degs including upregulated downregulated gene identified associated dcm functional enrichment analysis_showed fatty_acid metabolism pathway inflammatory_response significantly enriched dcm total interaction mirna degs interaction lncrna mirna predicted besides cerna network includes mrna mirna lncrna constructed among cdh cacna hub gene ppi network conclusion identified hub gene cerna network component provide valuable insight dcm biology offer potential diagnostic biomarkers therapeutic_target investigation experimental validation clinical_study warranted translate finding clinical_application:0.0536188542804912", "170819": "background non alcoholic fatty liver_disease nafld heart_failure_hf related condition increasing incidence however mechanism_underlying association remains_unclear study_aimed explore shared pathogenic mechanism common biomarkers nafld hf bioinformatics analysis experimental validation method nafld hf_related transcriptome data extracted gene_expression omnibus geo database gse gse differential analysis_performed identify common differentially expressed gene co degs nafld hf gene ontology go kyoto encyclopedia gene genome kegg gene set enrichment analysis gsea conducted explore function regulatory pathway co degs protein protein interaction ppi network support vector machine recursive feature elimination svm rfe method_used screen common key degs diagnostic value common key degs assessed receiver_operating_characteristic roc_curve validated external datasets gse gse finally expression biomarkers validated mouse_model result_total co degs screened nafld hf_patient go kegg gsea analysis indicated co degs mainly enriched immune related pathway ppi network revealed key degs svm rfe model eventually identified two gene cd ccr common key degs nafld hf expression analysis_revealed expression_level cd ccr significantly regulated hf nafld patient roc_curve analysis_showed cd ccr good diagnostic value hf nafld single gene gsea suggested cd ccr mainly engaged immune response inflammation experimental validation indicated unbalanced macrophage polarization hf nafld mouse_model expression cd ccr significantly regulated conclusion_study identified polarization impairment characterized decreased expression cd ccr common pathogenic pathway nafld hf downregulation cd ccr may reflect key pathological change development progression nafld hf suggesting potential diagnostic therapeutic_target:0.0532417066125861", "159182": "background hypoplastic left heart syndrome hlhs one complex congenital cardiac malformation molecular_mechanism heart_failure_hf hlhs still elusive method integrative bioinformatics analysis_performed unravel underlying gene mechanism involved hf hlhs microarray dataset gse screened differentially expressed gene degs gene ontology go kyoto encyclopedia gene genome kegg functional enrichment analysis carried using metascape protein protein interaction ppi network generated module hub gene identified cytoscape plugin integrated network transcription_factor tf degs mirna degs constructed respectively result_total degs identified including regulated regulated gene functional enrichment analysis degs pointed towards mitochondrial related biological process cellular component molecular function signaling_pathway ppi network constructed including node well edge hub gene ndufb uqcrq sdhd atp h identified based three topological analysis method mitochondrial component function relevant furthermore integrating network interaction construction tfs nfkb rela hif vhl gata ppar gamma etc well several mirnas hsa mir_p hsa mir_p hsa mir_p hsa mir_p etc detected indicated possible involvement nf_kappab signaling_pathway mitochondrial_dysfunction hlhs conclusion present_study applied integrative bioinformatics analysis_revealed mitochondrial related key gene regulatory pathway tfs mirnas underlying hf hlhs improved understanding disease mechanism development novel therapeutic_target:0.0529809388440248", "176811": "purpose_study explores lactylation pivotal role disease_progression heart_failure_hf method gse dataset encompassing hf sample normal control ctl sourced gene_expression omnibus geo differentially expressed gene hf ctl group underwent enrichment analysis using gene ontology go kyoto encyclopedia gene genome kegg pathway weighted correlation network analysis wgcna unsupervised clustering employed identify hf associated gene module subtypes intersected lactate related gene lrgs curated molecular signature database genecards pinpoint hub gene implicated lactylation mediated hf lcy hf least absolute shrinkage selection operator lasso xgboost boruta algorithm protein protein interaction ppi network utilized identify hub gene diagnostic potential biological significance hub gene hf progression assessed_using receiver_operating_characteristic roc_curve gene set enrichment analysis gsea immune infiltration analysis result comparison hf ctl sample upregulated downregulated gene identified primarily enriched inflammatory_response pathway intersecting lrgs curated database pinpointed six hub gene implicated lcy hf gata hbb jak stat stat war immune infiltration analysis_revealed lcy hf hub gene associated macrophage polarization conclusion lactylation play crucial role pathogenesis hf gene gata hbb jak stat stat war emerging potential lactylation biomarkers hf identification lactylation macrophage polarization inflammation axis stand pivotal mechanism driving hf progression:0.0528101622905286"}, "Topic 21": {"108496": "diabetes_mellitus major risk_factor cardiovascular_cv disease conversely cv disease responsible majority death patient_diabetes many drug trial concentrated blood glucose hemoglobin c reduction strategy reducing microvascular outcome like nephropathy neuropathy little effect reducing macrovascular event like heart attack stroke_heart_failure postulated hypoglycemia may counterbalance beneficial_effect anti hyperglycemic agent proven trial evidence thiazolidinediones rosiglitazone pioglitazone showed increased_risk heart_failure raised concern increased myocardial_infarction heightened awareness potentially harmful cv effect otherwise effective hypoglycemic drug resulted regulatory mandate cv outcome trial ascertain safety newer anti hypoglycemic agent appearing market three new class anti hyperglycemic agent introduced recent_year dipeptidyl peptidase dpp inhibitor exhibited increased heart_failure_hospitalization savor timi trial evaluating saxagliptin secondary analysis examine trial alogliptin effect glucagon like peptide glp analog sodium_glucose co transporter sglt_inhibitor cv outcome diabetes largely positive leader sustain trial evaluating safety_efficacy glp analog liraglutide semaglutide respectively showed statistically_significant reduction primary_outcome major_adverse_cardiac_event mace cv_death myocardial_infarction_stroke secondary combined outcome compared_placebo result tecos trial sitagliptin however neutral net cv benefit harm questioning class effect glp analog result sglt_inhibitor trial uniform empa reg evaluating empagliflozin canvas evaluating canagliflozin showed reduction mace end_point dapagliflozin net neutral effect mace declare timi three sglt_inhibitor however showed significant_reduction heart_failure_hospitalization although initially designed keep potentially harmful anti hyperglycemic agent market cv outcome trial provided clinician new set anti hyperglycemic drug proven cv benefit patient_diabetes cv disease thus expanding field cv secondary_prevention need inculcate glp analog sglt_inhibitor reduce major cv_event heart_failure_hospitalization alongside lifestyle management metformin treatment_patient diabetes cv disease:0.0407356545363565", "116865": "cardiovascular_disease_cvd major challenge management type_diabetes_mellitus glucose lowering agent reduce_risk major cardiovascular_event would considered major advance recently reported liraglutide semaglutide glucagon like peptide receptor_agonist empagliflozin canagliflozin sglt sodium_glucose_cotransporter type inhibitor dpp dipeptidyl peptidase inhibitor present review devoted cv effect new oral glucose lowering agent dpp inhibitor gliptins showed positive cardiac vascular effect preliminary study initial data phase clinical_trial suggested reduction major cardiovascular_event however subsequent cv outcome trial alogliptin saxagliptin sitagliptin showed noninferiority failed demonstrate superiority compared_placebo patient type_diabetes_mellitus high cv risk unexpected higher_risk hospitalization_heart_failure reported saxagliptin sglt_inhibitor gliflozins promote glucosuria thus reducing glucose toxicity body_weight enhance natriuresis thus lowering blood_pressure two cv outcome trial type_diabetes_mellitus patient mainly secondary_prevention showed remarkable positive result empagliflozin empa reg outcome empagliflozin cardiovascular_outcome event type_diabetes_mellitus patient reduced major cardiovascular_event cv mortality cause_mortality hospitalization_heart_failure canvas canagliflozin cardiovascular assessment study reduction cv mortality canagliflozin failed reach statistical significance despite similar reduction major cardiovascular_event underlying protective mechanism sglt_inhibitor remain unknown hemodynamic metabolic explanation proposed cvd real study comparative effectiveness cardiovascular_outcome new user sodium_glucose_cotransporter_inhibitor limitation observational approach suggested favorable result may considered class effect shared sglt_inhibitor including dapagliflozin extrapolated larger population patient type_diabetes_mellitus primary_prevention ongoing cv outcome trial dpp linagliptin sglt dapagliflozin ertugliflozin inhibitor provide additional information cv effect pharmacological class:0.0404025216522986", "188879": "primary treatment autoimmune diabetes_mellitus type_diabetes_mellitus_dm insulin therapy unfortunately multitude clinical case demonstrated use insulin sole therapeutic_intervention fails address issue comprehensively therefore non insulin adjunct treatment investigated shown successful result clinical_trial various hypoglycemia inducing drug metformin glucagon like peptide glp receptor_agonist dipeptidyl peptidase dpp inhibitor amylin analog sodium_glucose cotransporters sglt_inhibitor developed good outcome_patient dm currently sglt_inhibitor remarkably improved treatment_patient diabetes preventing cardiovascular_event heart_failure_hospitalization progression renal_disease however pharmacological potential explored enough thus substantial interest sglt_inhibitor sglt underline present review begin overview carrier mediated cellular glucose uptake evidencing insulin independent transport system contribution glucose homeostasis essential role sodium_glucose cotransporters pharmacological property sglt detailed leading potential application treating dm patient automated insulin delivery aid system result several study_demonstrated improvement glycemic control increase time range tir decrease glycemic variability reduced daily insulin requirement without increasing hyperglycemic event benefit weight management however advantage counterbalanced increased_risk particularly concerning diabetic ketoacidosis dka several clinical_trial reported higher incidence dka patient dm received sglt_inhibitor sotagliflozin empagliflozin hand patient dm body_mass_index_bmi kg treated dapagliflozin showed similar reduction hyperglycemia body_weight insignificantly increased dka incidence compared overall trial population additional multicenter randomized study required establish safer effective long_term strategy based patient_selection education continuous ketone body monitoring optimal integration sglt_inhibitor dm therapeutic protocol:0.0400259838219507", "67327": "randomized_controlled_trial rcts intensive glucose control patient type_diabetes lead modest reduction major cardiovascular_event mace associated reduction kidney event reduction eye event fda issued guidance led conduct numerous cardiovascular_outcome cvot trial assess cardiovascular safety new antihyperglycemic therapy_patient type_diabetes result trial show insulin glargine three different dipeptidyl peptidase dpp inhibitor saxagliptin alogliptin sitagliptin lixisenatide glucagon like peptide receptor_agonist produce significant_difference cvot compared usual_care placebo trial newer diabetes drug including empagliflozin canagliflozin two sodium_glucose co transporter inhibitor liraglutide semaglutide two glp receptor_agonist succeeded demonstrating cv benefit people type_diabetes last two decade equation diabetes equal myocardial_infarction contributed development preventive therapy risk_factor diabetes primary secondary_prevention diabetic_patient high rate statin aspirin treatment improved cv outcome compared_non user drug used reduce glucose level patient type_diabetes seem important ultimate cardiovascular_outcome combination intensive glycemic control safely attainable newer diabetes drug empagliflozin canagliflozin liraglutide semaglutide may decrease incidence mace nephropathy retinopathy moreover depending drug used cv mortality heart_failure may_also reduced:0.0400088869793546", "144234": "pharmacotherapy type_diabetes_mellitus_dm markedly evolved last two decade classical antidiabetic agent sulphonylureas metformin insulin competition new glucose lowering medication alpha glucosidase inhibitor thiazolidinediones glitazones able replace older agent insufficient efficacy poor tolerability safety contrast incretin based therapy dipeptidyl peptidase inhibitor dpp gliptins oral agent glucagon like peptide receptor_agonist glp_ra subcutaneous injection major breakthrough management dm associated hypoglycaemia weight gain dpp tend replace sulphonylureas add metformin glp_ra tend replace basal insulin therapy failure oral therapy furthermore placebo controlled cardiovascular_outcome trial demonstrated neutrality dpp cardiovascular protection glp_ra patient dm high cardiovascular_risk recently sodium_glucose_cotransporter_inhibitor sglt gliflozins oral agent also showed cardiovascular protection especially reduction hospitalization_heart_failure well renal protection patient_without dm high cardiovascular_risk established heart_failure chronic_kidney_disease thus glp_ra sglt considered preferred drug dm patient high_risk atherosclerotic cardiovascular_disease whereas sglt specifically recommended patient_risk heart_failure renal albuminuric disease_management dm moving glucocentric approach broader strategy focusing risk_factor including overweight obesity organ disease targeted personalized approach:0.0395878338217777", "123773": "type_diabetes_mellitus_dm highly prevalent associated two fold increased mortality mostly explained cardiovascular_disease trial evidence older glucose lowering agent metformin sulfonylurea limited term cardiovascular efficacy since rosiglitazone observed increase_risk myocardial_infarction heart_failure_hf cardiovascular_outcome trial cvots required regulator licensing new glucose lowering agent following cvots dipeptidyl peptidase inhibitor dpp shown safe improve mortality_morbidity except saxagliptin increased_risk hf several glucagon like peptide receptor_agonist glp_ra sodium_glucose_cotransporter_inhibitor sglt demonstrated reduce_risk cardiovascular_mortality morbidity sglt shown class effect reduction risk_hf event patient dm leading trial testing efficacy_safety hf regardless dm dapa hf emperor reduced trial dapagliflozin empagliflozin respectively improved cardiovascular_mortality morbidity patient_hf reduced_ejection_fraction_hfref without dm therefore drug key part hfref pharmacotherapy soloist whf sotagliflozin reduced cardiovascular_mortality morbidity patient dm recent acute episode hf regardless ejection_fraction_ef emperor preserved empagliflozin reduced cv mortality_morbidity patient_heart_failure mildly reduced hfmref preserved hfpef ef regardless comorbid dm deliver currently testing dapagliflozin patient hfmref hfref strong renal protective role sglt also emerged trial enrolling patient_without dm:0.0386533219065193", "107325": "patient type_diabetes_mellitus_dm substantially increased_risk heart_failure_hf hf mortality despite lack evidence tight glycemic control reduces incidence cardiovascular cv_event growing body evidence_suggests choice glucose lowering agent may influence outcome including hf thiazolidinediones associated significant risk_hf metformin sulphonylureas insulin little data_available indicate impact hf glucagon like peptide glp agonist liraglutide semaglutide shown reduce major cv_event affect rate hospitalization_hf clinical_trial demonstrated diverse effect dipeptidyl peptidase dpp inhibitor hf saxagliptin showed increased_risk hf admission alogliptin associated_higher rate new hf admission sitagliptin neutral effect sodium_glucose_cotransporter sglt_inhibitor empagliflozin canagliflozin recently shown reduce incidence hf cardiovascular_mortality patient_without history hf review summarize key finding impact glucose lowering agent cv safety hf associated outcome present available data underlying_mechanism benefit sglt_inhibitor hf discus strategy improve outcome_patient dm high cv risk:0.0386439645889994", "145593": "type_diabetes leading_cause chronic_kidney_disease worldwide continues increase prevalence turn significant implication healthcare provision economy recent_year multiple advance glucose lowering agent available treatment diabetes modify disease also important benefit term associated cardiovascular_outcome cardiovascular_outcome trial agent glucagon like peptide receptor_agonist glp_ra sodium_glucose_cotransporter_inhibitor sglt demonstrated significant benefit reducing major_adverse_cardiovascular_event admission heart_failure case mortality secondary analysis trial also indicated significant renoprotective benefit canagliflozin renal outcome type_diabetes_mellitus nephropathy credence renal specific trial shown major benefit canagliflozin renal outcome diabetic kidney_disease similar trial sglt_inhibitor either underway awaiting analysis article_review current goal treatment diabetes implication advancing renal impairment choice treatment area discussed include diagnosis diabetic kidney_disease current treatment_strategy diabetic kidney_disease ranging lifestyle modification glycaemic control review_focus role glp_ra sglt_inhibitor treating diabetes chronic_kidney_disease illustrative case clear agent considered first choice combination metformin diabetes increased cardiovascular_risk reduced renal_function preference class dipeptidyl peptidase dpp inhibitor sulphonylureas:0.0384053451787653", "135656": "type_diabetes_mellitus_dm common patient_heart_failure_hf associated considerable morbidity_mortality significant advance recently occurred treatment dm evidence several new glucose lowering medication showing either neutral beneficial cardiovascular effect however agent safety characteristic strong practical implication hf e dipeptidyl peptidase dpp inhibitor glucagon like peptide receptor_agonist glp_ra sodium_glucose co transporter type sglt_inhibitor regarding safety dpp inhibitor saxagliptin recommended hf greater risk_hf hospitalisation compelling evidence excess hf_risk dpp inhibitor glp_ra overall neutral effect hf outcome however signal harm suggested two small trial liraglutide patient reduced_ejection_fraction indicates role remains defined established hf sglt_inhibitor empagliflozin canagliflozin dapagliflozin shown consistent reduction risk_hf hospitalisation regardless baseline cardiovascular_risk history hf accordingly sglt_inhibitor could recommended prevent hf hospitalisation patient dm established cardiovascular_disease multiple risk_factor recently completed trial dapagliflozin shown significant_reduction cardiovascular_mortality hf event patient_hf reduced_ejection_fraction without dm several ongoing trial assess whether result observed dapagliflozin could extended sglt_inhibitor treatment hf either preserved reduced_ejection_fraction regardless presence dm position paper aim summarise relevant clinical_trial evidence concerning role safety new glucose lowering therapy patient_hf:0.0375444497003919", "145382": "purpose_review review summarizes recent cardiovascular_outcome trial cvots glucose lowering drug recent_finding majority recent cvots glucose lowering drug tested dipeptidyl peptidase inhibitor dpp glucagon like peptide receptor_agonist glp_ra sodium_glucose_cotransporter_inhibitor sglt study also performed agent including thiazolidinediones insulin cvots dpp glp_ra sglt demonstrated cardiovascular_cv safety agent compared usual_care however certain glp_ra liraglutide subcutaneous semaglutide albiglutide dulaglutide sglt empagliflozin canagliflozin demonstrated cv benefit showing significant_reduction composite cardiovascular_outcome furthermore sglt also significantly_decreased risk hospitalization_heart_failure result_study altered clinical guideline worldwide resulted new indication glucose lowering drug patient high_risk cvd glp_ra sglt proven cardiovascular benefit recommended irrespective glycemic control:0.0375228506728838"}, "Topic 22": {"27496": "objective investigate effect beta adrenoceptor beta_ar antagonist sr cardiac_function left_ventricular remodeling rat_model heart_failure induced isoproterenol iso probe mechanism method eight rat randomly selected serve control male adult wistar rat heart_failure model reproduced twenty remain rat randomly divided iso group_n sr group sr group_n iso group received intraperitoneal injection ml saline twice day sr group received intraperitoneal injection nmol sr ml saline twice day control_group received treatment parameter determined included echocardiogram expression nitric_oxide synthase enos left_ventricle technique reverse transcription polymerase chain reaction rt pcr western blotting cyclic guanosine monophosphate cgmp level enzyme linked immunosorbent assay elisa ratio left_ventricular weight body_weight lvw bw ratio lung weight body_weight pw bw result compared control_group left_ventricular end_systolic pressure lvesp maximum minimum first derivative left_ventricular pressure dp dtmax significantly_decreased p heart_rate hr left_ventricular_end_diastolic pressure lvedp significantly_increased p iso group_compared iso group lvesp dp dtmax markedly higher p_p_respectively whereas hr lvedp markedly lower p_p sr group difference hr sr group control_group p lvedp higher r group control_group p level enos mrna protein cgmp significantly_lower sr group_compared iso group_p addition compared iso group lvw bw ratio pw bw ratio sr group also decreased p_conclusion beta_ar antagonist sr block beta_ar no cgmp pathway improve cardiac_function heart_failure rat administered long_term sr also improve left_ventricular remodeling certain degree:0.0321682831782630", "196818": "ethnopharmacological significance therapeutic efficacy ershen zhenwu decoction eszwd famous formulation xin patient_chronic_heart_failure heart kidney yang deficiency chf hkyd well_established still underlying molecular_mechanism clear aim_study study_investigated mechanism eszwd suppresses cardiac pathology including myocardial_fibrosis chf hkyd model rat ang_ii stimulated cardiac_fibroblast cf material_method component eszwd analyzed ultra high performance liquid chromatography coupled quadrupole time flight mass spectrometry uhplc q tof m chf hkyd model established male sprague dawley rat bilateral thyroidectomy intraperitoneal administration doxorubicin dox twice weekly week subsequently chf hkyd model rat randomly categorized model eszwd l g kg eszwd eszwd g kg eszwd eszwd h g kg eszwd sac val mg_kg sacubitril_valsartan group treated daily week control sham surgery group sham used primary cardiac_fibroblast cf categorized control model eszwd sac val group cf stimulated ang_ii eszwd sac val group incubated different concentration drug containing serum effect cf viability assessed via cck assay eszwd sac val group received drug containing serum concentration determined cck assay result cardioprotective_effect eszwd determined using echocardiography hematoxylin eosin h e staining masson staining sirius red staining enzyme linked immunosorbent assay elisa eszwd effect ra homolog gene family member rhoa rho associated coiled coil kinase rock signaling_pathway myocardial_fibrosis assessed western blotting quantitative real_time pcr qrt pcr analysis immunofluorescence used observe fibrotic marker cf result eszwd treatment improved cardiac_function chf hkyd rat significantly reducing myocardial_fibrosis ventricular_remodeling eszwd treatment increased rat body temperature b h urine volume left_ventricular_ejection_fraction_lvef lv fractional_shortening lvfs decreased lv internal systolic diameter lvids lv internal diastolic diameter lvidd heart weight body_weight hw bw compared model group comparison model rat eszwd treatment decreased serum_level b_type_natriuretic_peptide precursor nt_probnp tumor_necrosis_factor alpha tnf_alpha interleukin il il eszwd treatment significantly regulated protein mrna expression_level collagen alpha sma rhoa rock rock heart tissue chf hkyd rat ang_ii stimulated cf conclusion eszwd significantly_improved cardiac_function attenuated myocardial_fibrosis inflammation chf hkyd rat inhibiting rhoa rock signaling_pathway:0.0321233797730344", "118175": "present_study investigated role parathyroid hormone pth non ischemic_cardiomyopathy cm underlying_mechanism total sprague dawley male rat randomly divided control_group n experimental group_n induce cm rat experimental group mg_kg adriamycin adr administered intraperitoneally equal injection every third day followed weekly injection resulting cumulative dose mg_kg following establishment model rat experimental group subdivided pth untreated cm group received daily normal saline subcutaneous injection day three treated cm group received daily subcutaneous injection microg kg recombinant pth day rat control_group accordingly received intraperitoneal subcutaneous injection normal saline blood sample analysis_revealed b_type_natriuretic_peptide_bnp troponin c_reactive_protein crp creatinine phosphorus concentration increased pth untreated cm group_compared control_group whereas pth calcium concentration decreased administration pth dose dependently decreased bnp crp creatinine phosphorus level increased pth calcium level notably significant_difference pth bnp troponin crp creatinine calcium phosphorus level among rat five group_p cardiac ultrasonography result indicated left_ventricular_ejection_fraction_lvef significantly_decreased rat treated adr compared rat control_group p however lvef gradually recovered elevated pth treatment dos overall difference lvef left_ventricular end_systolic_volume five experimental group statistically_significant p furthermore dose dependent increase lv mass left_ventricular_end_diastolic volume pth treated rat however difference two_group reach statistical significance p immunohistochemical staining western_blot analysis using anti pth polyclonal antibody performed evaluate protein_expression level pth myocardial_tissue mrna expression_level pth bnp measured_using reverse transcription quantitative polymerase chain reaction result demonstrated mrna protein_expression level pth myocardial_tissue significantly_decreased adr treated rat compared level control_group rat injection recombinant pth significantly_increased pth expression reduced bnp expression dose dependent manner p finding demonstrated pth improve cardiac_function rat adr induced cm suggesting potential therapeutic application pth non ischemic cm:0.0318140151004117", "103006": "objective investigate effect renal denervation rdn left_atrial fibrosis rat chronic_heart_failure method sixty healthy male sprague dawley rat randomly_assigned control_group n intraperitoneal injection mg_kg normal saline daily consecutive week sham group_n rdn group_n rat sham rdn group intraperitoneally injected mg_kg isoproterenol daily consecutive week rdn sham rdn procedure implemented week renal artery vein isolated nerve left intact sham group experiment ended week cardiac_function diastolic interventricular septal thickness ivsd left_atrial dimension lad evaluated echocardiography baseline week rat three_group sacrificed week left_atrial tissue used following analysis fibrosis detected masson staining plasma bnp measured elisa kit protein_expression angii tgf_beta mmp collagen determined western_blot result cardiac_function compared control_group lvef decreased p ivsd p lad p increased significantly sham rdn group week compared sham group week lvef ivsd significantly_improved p lad tended smaller p rdn group degree left_atrial tissue fibrosis masson staining collagen volume fraction cvf showed significantly_decreased fibrosis left_atrial tissue rdn group_compared sham group_p plasma bnp_level elisa assay revealed plasma bnp sham group significantly_increased compared control_group p similar rnd group control_group week protein_expression angii tgf_beta mmp collagen rat left_atrial western_blot analysis demonstrated expression angii tgf_beta mmp collagen significantly regulated rdn group_compared sham group_p still significantly_higher control_group p_conclusion rdn effectively attenuate left_atrial fibrosis rat isoproterenol induced chronic_heart_failure attenuation left_atrial fibrosis rdn rat may attributed improved cardiac_function downregulated pro fibrogenic factor angii tgf_beta mmp collagen:0.0313998533167887", "108927": "objective_study change short chain acyl coa dehydrogenase scad heart_failure_hf myocardial_infarction_mi effect aerobic exercise scad method healthy male sprague dawley sd rat divided sham operation group sham group sham operation swimming group sham swim group hf model group lad group hf swimming group lad swim group random number table method rat group left_anterior_descending branch coronary_artery lad ligated establish rat_model hf mi sham group one loose knot threaded left coronary_artery rest operation lad group rat sham swim group lad swim group given swimming test week operation minute st day minute th day given swimming endurance training nd week onwards minute daily time weekly week row tail artery systolic_pressure sbp measured swimming endurance training every week end th week ten week swimming training echocardiography performed measure cardiac_output co stroke_volume sv left_ventricular_ejection_fraction_lvef shortening fraction f left_ventricular end_systolic diameter lvesd left_ventricular_end_diastolic diameter lvedd left_ventricular end_systolic_volume lvesv left_ventricular_end_diastolic volume lvedv morphological change heart observed masson staining apoptosis myocardial cell detected transferase mediated deoxyuridine triphosphate biotin nick end labeling stain tunel apoptosis index ai calculated reverse transcription polymerase chain reaction rt pcr western_blot used detect mrna protein_expression myocardial scad respectively addition enzyme activity scad content adenosine triphosphate atp free fatty_acid ffa serum myocardium detected according kit instruction step result compared sham group sham swim group showed sbp change significantly obvious eccentric hypertrophy increased myocardial contractility lad group showed persistent hypotension obvious mi thinning left_ventricle decreased myocardial systolic diastolic_function compared lad group sbp systolic diastolic_function mi lad swim group significantly_improved sbp mmhg mmhg kpa v week v week v week v week co ml_min v sv mul v lvef v f v lvedd mm v lvesd mm v lvedv mul v lvesv mul v ai v_p compared sham group mrna protein_expression myocardium scad activity scad sham swim group significantly_increased content atp slightly increased content serum ffa significantly_decreased content myocardial ffa slightly decreased conversely mrna protein_expression myocardium scad activity scad content atp lad group significantly_decreased content serum myocardial ffa significantly_increased compared lad group mrna protein_expression myocardium scad content atp significantly_increased lad swim group scad mrna deltadeltact v scad gapdh fold increase sham group_v atp content mumol g v_p content serum myocardial ffa significantly_decreased serum ffa nmol l v myocardial ffa nmol g v_p activity scad slightly increased ku g v_p conclusion expression scad hf significantly regulated expression significantly regulated aerobic exercise intervention indicating swimming may_improve severity hf regulating expression scad:0.0309956370502616", "73225": "objective observe effect moxibustion cardiac_function expression b cell lymphoma bcl bcl associated x bax fa fa ligand fasl cardiomyocytes chronic_heart_failure_chf rat explore underlying_mechanism preventing treating chf method sd rat randomly divided normal control model moxibustion captopril moxibustion captopril c group_n rat group chf model established intraperitoneal injection adriamycin adr mg_kg every day_day mild moxibustion applied bilateral feishu bl xinshu bl rat captopril group treated gavage captopril suspension mg ml ml kg c group treated combined two method treatment given day week general condition behavior rat observed left_ventricular mass_index lvmi right_ventricular mass_index rvmi detected assessing cardiac performance morphological change myocardium observed staining enzyme linked immunosorbent assay elisa used detect concentration b_type_natriuretic_peptide_bnp precursor n_terminal_pro_brain_natriuretic_peptide nt_pro_bnp serum expression_level bcl bax fa fasl left_ventricle heart detected western_blot result modeling pathological change myocardium myocardial cell swelling vacuole myocardial fibre breakage etc obvious lvmi rvmi serum bnp nt_pro_bnp concentration myocardial bax fa fasl protein_expression level significantly_increased model group_compared normal group_p expression_level bcl significantly regulated p following intervention myocardial_injury reduced lvmi rvmi serum bnp concentration bax fa fasl expression_level three treatment_group serum nt_pro_bnp concentration moxibustion c group significantly_decreased p_p myocardial bcl protein_level three treatment_group significantly_increased relevant model group_p comparison among three treatment_group showed effect moxibustion captopril significantly superior simple moxibustion simple captopril suppressing chf induced increased expression myocardial bax fa fasl lessening chf induced decrease bcl level p_p significant_difference found among three treatment_group regulating lvmi rvmi serum bnp content p_conclusion moxibustion reduce myocardial_injury improve cardiac_function chf rat may related effect regulating expression myocardial bax fa fasl protein regulating expression bcl protein inhibit cardiomyocyte apoptosis:0.0307234446425561", "138072": "objective_study effect yixintai pill myocardial cell apoptosis rat adriamycin adr induced heart_failure_hf mechanism_action method sixty healthy male wistar rat randomly divided control model captopril yixintai pill group rat_model adr induced hf constructed intraperitoneal injection adr mg_kg control_group given equal volume normal saline yixintai pill captopril group given corresponding mediation mg_kg lavage week treatment fasting blood collected detect content plasma rennin activity pra angiotensin_ii angii aldosterone ald b ultrasound used detect heart structure heart weight body_weight hw bw ratio calculated pathology myocardial_tissue observed staining apoptosis myocardial cell detected tunel assay expression_level tumor_necrosis_factor alpha tnf_alpha interleukin il serum analyzed elisa protein_expression level protein_kinase b akt phosphorylated p akt glycogen synthase kinase beta gsk beta_p gsk beta myocardial_tissue measured western blotting result compared control_group pra angii ald left_ventricular posterior wall_thickness end systole lvpws left_ventricular posterior wall_thickness end diastole lvpwd interventricular septal thickness end systole ivss interventricular septal thickness end diastole ivsd hw bw tnf_alpha il model group increased significantly p pra angii ald lvpws lvpwd ivss ivsd hw bw tnf_alpha il yixintai pill captopril group significantly_lower model group_p significant_difference index yixintai pill captopril group_p model group lamellar necrosis vacuolar degeneration increased myocardial fiber lamellar dissolution myocardial cell found myocardial_tissue however myocardial cell control_group neatly arranged clearly structured one underwent fibrosis mild myocardial_fibrosis vacuolar degeneration yixintai pill captopril group degeneration hyperplasia myocardial fiber obviously relieved compared control_group apoptosis index ai model group increased significantly p ai value yixintai pill captopril group significantly_lower model group_p compared control_group expression_level p akt p gsk beta model group decreased significantly p expression_level p akt p gsk beta yixintai pill captopril group significantly_higher model group_p whereas former group similar result p_conclusion yixintai pill may inhibit myocardial cell apoptosis ventricular_remodeling rat regulating pi k akt gsk beta signal thus protecting heart_function:0.0307178655198337", "42842": "objective_study evaluated effect growth hormone gh morphology myogenic regulatory factor mrf gene_expression skeletal_muscle rat ascending aortic_stenosis aa induced chronic_heart_failure design male g wistar rat subjected thoracotomy aa created placing stainless steel clip ascending aorta twenty five week surgery rat treated daily subcutaneous injection recombinant human gh mg_kg day aa gh group saline aa group day sham operated animal served control left_ventricular_lv function assessed treatment igf serum_level measured elisa anesthesia soleus muscle frozen liquid nitrogen histological section stained picrosirius red calculate muscle fiber cross_sectional area collagen fractional area respectively mrf myogenin myod expression analyzed reverse transcription pcr result body_weight similar group aa aa gh group presented dilated left_atrium left_ventricular_lv hypertrophy lv mass_index control aa aa gh g kg p aa aa gh v control reduced lv posterior wall shortening velocity soleus muscle fiber area significantly_lower aa control aa gh group difference aa gh control_group collagen fractional area significantly_higher aa control aa gh differ control aa group serum igf level decreased aa compared_control myod mrna significantly_higher aa gh aa difference aa gh control_group myogenin mrna level similar group_conclusion rat aortic_stenosis induced_heart_failure growth hormone administration increase myod gene_expression non treated animal level preserve muscular trophism attenuates interstitial fibrosis result_suggest growth hormone may potential role adjuvant therapy chronic_heart_failure:0.0300213010805506", "154334": "objective explore effect tanshinone ii myocardial remodeling ischemia_reperfusion r induced_heart_failure rodent model method vivo sd rat randomly divided sham operation heart_failure tanshinone ii treatment_group rat group r model established ligating left coronary_artery st_segment elevation minute ligation removed hour reperfusion sham operation group rat chest opened without artery ligation three day model establishment tanshinone ii mg_kg given intraperitoneal injected tanshinone ii group week two_group normal saline administrated way behavioral manifestation rat group observed hemodynamic index evaluated masson staining performed observe degree myocardial_fibrosis enzyme linked immunosorbent assay elisa used detect content galectin myocardial_tissue quantitative reverse transcription polymerase chain reaction qrt pcr used detect expression collagen iii collagen matrix metalloproteinase mmp tissue inhibitor metalloproteinase timp vitro rat primary cardiac_fibroblast extracted isolated divided blank control_group angiotensin_ii group mmol_l angiotensin_ii angiotensin_ii tanshinone ii group mmol_l angiotensin_ii mmol_l tanshinone ii hour hour culture cell proliferation group detected methyl thiazolyl tetrazolium mtt expression collagen iii collagen mmp timp detected qrt pcr content galectin cardiac_fibroblast detected elsia result vivo rat activity status hair conformity food intake ranked good bad order sham operation group tanshinone ii group heart_failure model group_compared sham operated group heart_rate hr rat heart_failure model group significantly_decreased heart_function significantly impaired mrna protein_expression collagen collagen iii timp galectin content significantly_increased mrna protein_expression mmp significantly_decreased compared heart_failure model group rat tanshinone ii group showed significantly_higher hr improved cardiac_function significantly_lower mrna expression collagen collagen iii significantly_lower mrna protein_expression timp galectin significantly_higher mrna protein_expression mmp obvious change th week modeling collagen mrna deltadeltact v collagen iii mrna deltadeltact v timp mrna deltadeltact v timp gapdh v galectin ng_l v mmp mrna deltadeltact v mmp gapdh v_p masson staining showed myocardial_tissue fibrosis obvious heart_failure group degree fibrosis tanshinone ii group reduced vitro compared blank control_group proliferation rate collagen collagen iii timp expression galectin content myocardial fibroblast significantly_increased mmp expression significantly_decreased angiotensin group h h culture compared angiotensin group proliferation rate cardiac_fibroblast expression collagen collagen iii timp content galectin significantly_decreased expression mmp mrna significantly_increased angiotensin tanshinone ii group significant_change hour culture proliferation rate v collagen mrna deltadeltact v collagen iii mrna deltadeltact v timp mrna deltadeltact v galectin ng_l v mmp mrna deltadeltact v_p conclusion tanshinone ii improve cardiac_function inhibit myocardial_fibrosis improve myocardial remodeling rat r induced_heart_failure:0.0298399341347615", "73571": "objective elucidate association large conductance calcium activated potassium channel bk ca paraventricular hypothalamic nucleus pvn sympathetic outflow rat chronic_heart_failure_chf method male wistar rat week old randomized sham operated group chf group coronary_artery ligation two week operation bk ca inhibitor iberiotoxin ibtx infused pvn osmotic minipumps rat divided following group sham acsf chf acsf sham low_dose ibtx nmol nl chf low_dose ibtx sham moderate dose ibtx nmol nl chf moderate dose ibtx sham high_dose ibtx nmol nl chf high_dose ibtx n additional rat grouped follows sham vehicle sham kcnmb knockdown raav kcnmb shrna virus injection pvn chf vehicle chf kcnmb knockdown group_n cardiac_function determined echocardiography left_ventricular hemodynamics measured invasively renal sympathetic_nerve activity rsna recorded week coronary_artery ligation sham operation content norepinephrine ne n_terminal_pro_b_type_natriuretic_peptide nt_probnp plasma determined enzyme linked immunosorbent assay protein mrna expression kcnmb pvn measured immunofluorescence staining western_blot real_time pcr mrna expression bk ca pvn detected real_time pcr result compared sham operation group cardiac_function heart_failure group significantly_reduced p plasma ne serum nt_probnp significantly elevated p protein mrna expression kcnmb pvn obviously regulated chf rat p perfusion ibtx kcnmb knockdown microinjection raav kcnmb shrna virus right_ventricular weight body_weight lung weight body_weight ratio well left_ventricular_end_diastolic diameter increased left_ventricular_ejection_fraction decreased p sympathetic driving index increased sham rat change parameter aggravated chf rat p kcnmb knockdown downregulated protein_expression pvn chf rat conclusion downregulation blunted function bk ca pvn may_contribute sympathoexcitation deterioration cardiac_function rat chronic_heart_failure:0.0297903292574115"}, "Topic 23": {"114284": "objective_study sought investigate clinical_outcome associated left_atrial appendage occlusion laao versus direct oral anticoagulant doacs patient high_risk atrial_fibrillation_af background laao shown noninferior warfarin stroke prevention af however anticoagulation doacs preferred warfarin thromboprophylaxis af method patient_af enrolled amulet observational registry n successful laao amplatzer amulet device n compared propensity_score matched_control cohort incident af_patient n treated doacs identified danish national patient registry propensity_score_matching based covariates cha_d_vasc congestive_heart_failure hypertension age_year diabetes_mellitus prior stroke transient_ischemic_attack thromboembolism vascular_disease age_year sex category bled hypertension abnormal renal liver function stroke bleeding labile international normalized ratio elderly drug alcohol score predicting stroke bleeding primary_outcome composite ischemic_stroke major_bleeding bleeding academic research consortium cause_mortality follow year result af patient_treated laao significantly_lower risk primary composite_outcome compared patient_treated doacs hazard_ratio_hr_confidence_interval_ci total event event_rate per patient_year laao v doacs v_v respectively risk ischemic_stroke comparable group hr_ci risk major_bleeding hr_ci cause_mortality hr_ci significantly_lower patient_treated laao conclusion among high_risk af_patient laao comparison doacs may similar stroke prevention efficacy lower_risk major_bleeding mortality:0.0336124175272765", "107551": "observational_study investigate efficacy_safety nonvitamin k antagonist oral anticoagulant noacs atrial_fibrillation_af patient bioprosthetic valve prior surgical valve repair clinical_practice total_patient mean_age female bioprosthetic heart valve surgical valve repair af treated noacs included analysis mean cha_d_vasc congestive_heart_failure hypertension age_year diabetes_mellitus prior stroke transient_ischemic_attack vascular_disease bled hypertension abnormal renal liver function stroke bleeding labile inr international normalized ratio elderly drug alcohol score value respectively total study_population taking apixaban mg twice daily bid apixaban mg bid dabigatran mg bid dabigatran mg bid rivaroxaban mg daily qd rivaroxaban mg qd also study_population previously warfarin replaced noacs due lack compliance labile inr control time therapeutic range noac therapy af started average day bioprosthetic heart valve implantation surgical repair average duration day study_population included_patient bioprosthetic mitral_valve patient bioprosthetic aortic_valve patient previous surgical mitral repair patient previous surgical aortic repair concomitant use noacs patient evaluated thromboembolic event ischemic_stroke transient_ischemic_attack systemic embolism well major_bleeding event follow_period study_population recorded low mean annual incidence thromboembolism major_bleeding according data anticoagulation therapy noacs seems effective safe treatment_strategy nonvalvular af_patient bioprosthetic valve prior surgical valve repair:0.0325765132765547", "99307": "atrial_fibrillation_af prevalent arrhythmic disease tends foster thrombus formation due hemodynamic disturbance leading severe disabling even fatal thromboembolic disease meanwhile patient_af may_also present acute_coronary_syndrome_ac coronary_artery_disease_cad requiring stenting creates clinical dilemma considering majority patient likely receive oral anticoagulant oacs stroke prevention require additional double antiplatelet treatment dapt reduce recurrent cardiac_event stent thrombosis case gentle balance bleeding risk atherothromboembolic event need carefully considered study shown congestive_heart_failure hypertension age_year doubled diabetes_mellitus previous stroke transient_ischemic_attack tia doubled vascular_disease age_year sex category female cha_d_vasc_score outperform scoring system asian population hypertension abnormal renal liver function point stroke bleeding history predisposition labile international normalized ratio inr elderly year drug alcohol concomitantly point bled score simple clinical score predicts bleeding risk patient_af particularly among asian performs better bleeding score high bled score used rule oac treatment instead prompt clinician address correctable risk_factor therefore current review attempted analyze available data_patient nonvalvular af underwent stenting ac cad elaborate direct acting oral anticoagulant doac antiplatelet management among_patient majority patient triple therapy comprising oac aspirin clopidogrel considered month following ac however optimal duration triple therapy would depend patient ischemic bleeding risk doacs obviously safer vitamin k antagonist:0.0317852148862888", "71057": "objective compare clinical_characteristic use oral anticoagulant oac therapy individual aged older atrial_fibrillation_af individual younger af clinical_practice design observational_study setting real life multicenter survey evaluating stroke prevention strategy turkey trial nct national observational registry participant turkish adult nonvalvular af nvaf measurement age data_collected time entry registry octogenarian subgroup included_patient aged_year compared background management octogenarian non octogenarian af_patient result fifty seven cardiology unit enrolled individual month participant aged older n likely female v_p higher_prevalence persistant permanent af comorbidities history cerebral vascular accident major_bleeding consequence comorbidities congestive_heart_failure hypertension aged older diabetes_mellitus prior stroke transient_ischemic_attack thromboembolism vascular_disease aged female_sex cha_d_vasc v_p hypertension abnormal renal liver function stroke bleeding labile international normalized ratio elderly drug alcohol bled v_p score higher aged older mean time therapeutic range individual taking warfarin lower aged older younger p anticoagulant therapy prescribed participant younger aged older p_higher cha_d_vasc_score lower bled score independent_predictor oac prescription participant aged older conclusion nearly one fifth individual nvaf real_world sample aged older participant aged older likely female comorbidities younger aged older af less_likely receive anticoagulant younger comorbidities individual level characteristic may explain difference prescribed oacs participant aged older poorer quality anticoagulation younger suggesting opportunity improvement:0.0317495306626128", "73123": "background management atrial_fibrillation_af evolved development direct oral anticoagulant doacs data clinical effectiveness safety outside clinical_trial setting limited method raffine registry observational multicenter prospective registry japanese patient_af designed follow clinical_event year patient enrollment conducted university_hospital general hospital private clinic ensure inclusion broad spectrum representative af_patient primary_outcome event study ischemic_stroke systemic embolism major_bleeding result enrolled ambulatory patient_af university_hospital general hospital clinic japan mean patient age_year male type af paroxysmal persistent permanent major coexisting disease hypertension diabetes_mellitus congestive_heart_failure history ischemic_stroke transient_ischemic_attack coronary_artery_disease entire cohort treated warfarin treated doacs prescription doacs exceeded warfarin general hospital clinic risk_score chad score cha_d_vasc_score bled score higher patient university_hospital patient general hospital clinic conclusion raffine registry baseline described current status anticoagulation therapy japan long_term_follow data identify outcome vary stratified group_patient af doac era umin clinical_trial registry umin:0.0312978062375501", "729": "atrial_fibrillation_af common cardiac_arrhythmia af paroxysmal persistent becomes permanent convert sinus_rhythm spontaneously attempted cardioversion fails prevalence af general_population increase age octogenarian men age adjusted prevalence generally higher woman af synchronous mechanical atrial activity disturbed resulting haemodynamic impairment give rise thrombus formation embolism systemic circulation thrombus associated af arises frequently left_atrial appendage cerebrovascular embolus af_patient often manifest transient ischaemic attack ischaemic stroke overall rate ischaemic stroke among_patient nonrheumatic af average per_year rate increase age patient_af higher_risk cerebrovascular event cause stroke one every six occurs patient_af including transient ischaemic attack silent stroke detected radiographically overall rate cerebrovascular event af_patient rise per_year although approximately one third due cause secondarily incidentally associated af related anticoagulant therapy antiarrhythmic therapy useful improve cardiac rate function af however reduce first recurrent embolus antithrombotic therapy paramount importance result several randomized_clinical_trial antithrombotic therapy shown adjusted dose warfarin reduces first recurrent stroke compared_placebo patient nonvalvular af anticoagulated odds ischaemic stroke intracranial bleeding favour inr acetylsalicylic acid less efficacious warfarin af_patient reducing risk stroke therefore antiplatelet agent used af_patient low_risk anticoagulation current treatment modality af_patient high intermediate risk e patient history transient ischaemic attack stroke aged_year history hypertension_diabetes heart_failure structural heart_disease valvular disease significant systolic_dysfunction benefit dual antiplatelet regimen af_patient unknown combining antiplatelet agent different mechanism_action important topic future investigation:0.0309355041504989", "142208": "objective identified factor_associated thromboembolic bleeding event two contemporary cohort anticoagulated patient atrial_fibrillation_af treated either vitamin k antagonist vka non vka oral anticoagulant noacs design prospective multicentre observational_study setting centre seven european country participant patient_receiving vka prevention thromboembolic event european registry atrial_fibrillation prefer af derivation cohort patient_receiving noac prefer af prolongation validation cohort stroke prevention af outcome_measure risk_factor thromboembolic event ischaemic stroke systemic embolism major_bleeding gastrointestinal bleeding intracerebral haemorrhage life_threatening bleeding result mean_age patient_enrolled prefer af registry year female mean cha_d_vasc_score incidence thromboembolic major_bleeding event ci_ci year_follow respectively abnormal liver function prior stroke transient ischaemic attack labile international normalised ratio inr concomitant therapy antiplatelet non steroidal anti_inflammatory drug heart_failure older age_year independently_associated thromboembolic major_bleeding event exception unstable inr value risk_factor validated patient_treated noacs prefer af prolongation study year female cha_d_vasc single point decrease modifiable bleeding risk scale observed lower_risk major_bleeding event ci_p lower rate thromboembolic event ci_p_conclusion attending modifiable risk_factor important treatment target anticoagulated af_patient reduce thromboembolic bleeding event initiation anticoagulation risk stroke prevented elevated bleeding risk_score:0.0304452059151294", "182783": "result large randomized_trial update clinical guideline antithrombotic therapy following percutaneous_coronary_intervention_pci changed recent_year patient nonvalvular atrial_fibrillation nvaf purpose_study investigate real_world data antithrombotic regimen discharge evolving trend well compare effect different therapy incidence major cardiovascular cerebrovascular ischemic event macces bleeding event elderly_patient analysis stent implantation patient carried retrospectively atrial_fibrillation_af patient age older divided two_group according antithrombotic regimen prescribed hospital_discharge dual antiplatelet aggregation treatment_group dapt anticoagulant treatment antiplatelet aggregation treatment_group att baseline_characteristic efficacy endpoint macces cerebrovascular ischemic event safety endpoint bleeding event analysed compared different antithrombotic regiment use oral anticoagulant oac increased p trend since introduction non vitamin k antagonist oral anticoagulant noacs warfarin usage decreased noacs rapidly replaced warfarin rate persistent af att group significantly_higher rate dapt group_v_p att group used proton pump inhibitor ppi dapt group_v_p significant_decrease observed macces v_p cerebrovascular ischemic event v_p att group_compared dapt group according att subgroup_analysis significant_difference incidence overall bleeding triple anticoagulant therapy group dual anticoagulant therapy group dt v_p macces predicted independently att cha_d_vasc congestive_heart_failure hypertension age_year diabetes stroke transient_ischemic_attack vascular_disease age_year sex category score whereas bleeding predicted independently ppi use bled hypertension abnormal renal liver function stroke bleeding history predisposition labile international normalized ratio elderly drug alcohol score result noac introduction use combination antithrombotic regimen discharge elderly_patient af pci changed rapidly past year toward higher use atts whereas patient_af undergoing pci still rarely receive appropriate antithrombotic regimen essential conduct att elderly patient_undergoing pci dt may appropriate:0.0302423979497102", "110299": "background several non vitamin k antagonist oral anticoagulant noac alternative warfarin available stroke prevention atrial_fibrillation_af aimed describe factor_associated selection noacs versus warfarin patient new_onset af method orbit af ii study national u prospective observational cohort_study anticoagulation treatment patient_af receiving noacs warfarin united_state measured factor_associated oral anticoagulant selection patient recently diagnosed af result baseline patient started warfarin noacs latter started dabigatran rivaroxaban apixaban receiving noacs slightly younger patient median_age v_p less_likely prior stroke v_p prior bleeding v_p better kidney_function mean estimated_glomerular_filtration_rate ml_min v ml_min p fewer patient_high stroke risk cha_d_vasc_score congestive_heart_failure hypertension age_year diabetes_mellitus prior stroke transient_ischemic_attack tia thromboembolism vascular_disease age_year sex category female v_p multivariable_analysis factor_associated noac selection versus warfarin included renal_function prior stroke valve replacement rhythm_control af management_strategy treatment cardiologist higher patient education level conclusion contemporary clinical_practice three fourth patient new_onset af initially treated noac stroke prevention selected noac treatment lower stroke bleeding risk profile likely treated cardiologist higher socioeconomic status trial_registration clinicaltrials_gov identifier_nct:0.0296849660195813", "168319": "importance u approximately million adult atrial_fibrillation_af af associated significantly increased_risk stroke_heart_failure myocardial_infarction dementia chronic_kidney_disease mortality observation symptom af include palpitation dyspnea chest_pain presyncope exertional intolerance fatigue although approximately people af asymptomatic af detected incidentally clinical encounter wearable device interrogation cardiac implanted electronic device patient_presenting ischemic_stroke without diagnosed af implantable loop recorder ie subcutaneous telemetry device evaluate patient intermittent af american college cardiology acc american heart_association aha american college clinical pharmacy accp heart rhythm society hr guideline writing group proposed stage af evolution stage risk defined patient_af associated risk_factor eg obesity hypertension stage pre af sign atrial pathology electrocardiogram imaging without af stage presence paroxysmal recurrent af episode lasting day persistent continuous af episode lasting day af subtypes stage permanent af lifestyle risk_factor modification including weight_loss exercise prevent af onset recurrence complication recommended stage patient estimated risk stroke thromboembolic event greater per_year anticoagulation vitamin k antagonist direct oral anticoagulant reduces stroke risk compared_placebo patient direct oral anticoagulant apixaban rivaroxaban edoxaban recommended warfarin lower bleeding risk compared anticoagulation aspirin associated poorer efficacy recommended stroke prevention early rhythm_control antiarrhythmic drug catheter_ablation restore maintain sinus_rhythm recommended acc aha accp hr guideline patient_af catheter_ablation first_line therapy_patient symptomatic paroxysmal af improve symptom slow progression persistent af catheter_ablation also recommended patient_af heart_failure_reduced_ejection_fraction_hfref improve quality_life left_ventricular systolic_function cardiovascular_outcome rate mortality heart_failure_hospitalization conclusion relevance af associated_increased rate stroke_heart_failure mortality lifestyle risk_factor modification recommended prevent af onset recurrence complication oral anticoagulant recommended estimated risk stroke thromboembolic event greater per_year early rhythm_control using antiarrhythmic drug catheter_ablation recommended select patient_af experiencing symptomatic paroxysmal af hfref:0.0296643041177457"}, "Topic 24": {"23949": "recent trial helped clarify indication initial pharmacological therapy hypertension joint national committee prevention detection evaluation treatment high blood_pressure jnc vi world health organization international society hypertension ish recommendation revised recent trial indicate diuretic beta_blocker appear effective reducing overall morbidity_mortality agent swedish trial old patient hypertension stop united kingdom prospective diabetes study ukpds intervention goal hypertension treatment insight nordic diltiazem nordil use blocker result cardiovascular_event especially congestive_heart_failure compared diuretic antihypertensive therapy lipid lowering heart attack trial allhat use angiotensin_converting_enzyme ace_inhibitor result fewer myocardial_infarction episode heart_failure calcium_channel blocker elderly diabetic_patient fosinopril v amlodipine cardiovascular_event randomized_trial facet appropriate blood_pressure control diabetes abcd stop data captopril prevention project cappp suggest use ace_inhibitor preferred diabetic_patient overall cardiovascular_event similar calcium_channel blocker compared diuretic however fewer stroke non dihydropyridine calcium_channel blocker nordil trend towards increase heart_failure myocardial_infarction either dihydropyridine non dihydropyridine calcium_channel blocker compared diuretic insight nordil angiotensin_receptor_blocker arb decrease proteinuria slow progression renal_disease type diabetic_patient compared regimen include arb ace_inhibitor reduction endpoint niddm angiotensin_ii antagonist losartan renaal irbesartan type ii diabetic nephropathy trial idnt irbesartan type ii diabetes microalbuminuria irma il debate initial therapy may moot high_risk hypertensive_patient probably treated initially combination therapy one diuretic use diuretic beta_blocker well ace_inhibitor alone diuretic considered initial therapy change jncvi alpha blocker reserved special situation e prostatic hypertrophy contrast ish recommendation ace_inhibitor arb usually along diuretic considered preferred therapy hypertensive diabetic_patient data_suggest equal greater reduction stroke calcium_channel blocker medication:0.0400858772128748", "2667": "angiotensin_ii receptor_blocker arb represent new class effective well_tolerated orally active antihypertensive agent recent clinical_trial shown added benefit arb hypertensive_patient reduction left_ventricular_hypertrophy improvement diastolic_function decrease ventricular_arrhythmia reduction microalbuminuria improvement renal_function cardioprotective_effect patient_heart_failure several large long_term study progress assess beneficial_effect arb cardiac_hypertrophy renal_function cardiovascular cerebrovascular morbidity_mortality hypertensive patient_without diabetes_mellitus value drug patient heart_disease diabetic nephropathy arb specifically block interaction angiotensin_ii receptor thereby relaxing smooth_muscle increasing salt water excretion reducing plasma volume decreasing cellular hypertrophy agent exert blood_pressure lowering effect mainly reducing peripheral vascular_resistance usually without rise heart_rate commercially available arb control blood_pressure h daily dosing sustained efficacy blood_pressure control without evidence tachyphylaxis demonstrated long_term administration year arb efficacy arb similar thiazide diuretic beta_blocker angiotensin_converting_enzyme_inhibitor calcium_channel blocker patient similar degree hypertension higher daily dos dietary salt restriction concomitant diuretic ace_inhibitor administration amplify antihypertensive effect arb arb low incidence adverse_effect headache upper respiratory infection back pain muscle cramp fatigue dizziness even elderly_patient approval losartan five arb candesartan cilexetil eprosartan irbesartan telmisartan valsartan three combination hydrochlorothiazide irbesartan losartan valsartan approved antihypertensive agent compound various stage development arb non peptide compound varied structure candesartan losartan irbesartan valsartan common tetrazolo biphenyl structure except irbesartan active arb carboxylic acid group candesartan cilexetil prodrug losartan metabolite exp active parent drug metabolite arb contribute significantly antihypertensive effect variation molecular structure arb result difference binding affinity receptor pharmacokinetic profile difference observed lipid solubility absorption distribution plasma protein binding bioavailability biotransformation plasma half life systemic elimination influence time onset duration action efficacy arb basis daily mg dose antihypertensive potency arb follows sequence candesartan cilexetil telmisartan approximately losartan irbesartan approximately valsartan eprosartan oral administration arb rapidly absorbed time peak plasma_level h wide range bioavailability low eprosartan high irbesartan food influence bioavailability except valsartan reduction eprosartan increase limited dose peak plasma_level area plasma_level time curve proportionality observed arb drug high plasma protein binding irbesartan lowest binding among group steady state volume distribution vary low l candesartan high l telmisartan abstract truncate:0.0394186156577195", "17014": "cardiovascular cardiorenal disease continuum comprises transition cardiovascular_risk_factor endothelial_dysfunction atherosclerosis clinical complication myocardial_infarction_mi stroke development persistent target organ damage ultimately chronic congestive_heart_failure_chf end_stage_renal_disease premature death renin_angiotensin_aldosterone_system raas involved step along pathway raas blockade ace_inhibitor angiotensin receptor_antagonist angiotensin_receptor_blocker arb turned beneficial patient_outcome throughout disease continuum ace_inhibitor arb prevent reverse endothelial_dysfunction atherosclerosis thereby reducing risk cardiovascular_event drug shown reduce end organ damage heart kidney brain aldosterone antagonist spironolactone eplerenone increasingly recognized third class raas inhibitor potent risk reducing property especially solely respect inhibition cardiac remodelling possible prevention heart_failure secondary_prevention head head comparison ace_inhibitor arb recent ontarget study provided evidence addition better tolerability arb non inferior ace_inhibitor prevention clinical endpoint mi stroke cardiovascular high_risk_patient however combination ramipril telmisartan maximally tolerated dosage achieved benefit associated adverse_event symptomatic hypotension renal_dysfunction acute mi complicated heart_failure valiant trial shown similar effect ace inhibition captopril arb treatment valsartan dual raas blockade reduce event chf meta_analysis resolvd valheft charm added shown combined raas inhibition ace_inhibitor arb significantly_reduced morbidity endpoint certain patient subgroup compared standard therapy however clinical_practice dual raas blockade rarely employed seen instance corona trial rale ephesus trial investigating effect aldosterone blockade cardiovascular_outcome chf_patient revealed addition aldosterone antagonist standard heart_failure therapy conferred powerful relative_risk reduction morbidity_mortality future study elucidate whether also hold true patient asymptomatic heart_failure_preserved_ejection_fraction selected patient renal_disease several study suggested combined raas blockade brings additional renoprotective antiproteinuric effect independent blood_pressure reduction large trial robust endpoint underway summary combined therapy several raas inhibitor recommended patient along cardiorenovascular continuum patient_chf incomplete neuroendocrine blockade indicated example repetitive cardiac decompensation refractory symptom might benefit dual therapy long safety issue well controlled finally novel pharmacological agent direct renin inhibitor aliskiren may_provide additional therapeutic tool role yet established:0.0390509773002930", "44000": "role renin_angiotensin_aldosterone_system raas regulating volume composition extracellular fluid blood_pressure bp well onset progression cardiovascular renal_disease studied year compound block vital stage raas cascade ace_inhibitor acei receptor_blocker arb aldosterone receptor_antagonist importantly extended treatment_option however positive therapeutic effect compound also certain negative consequence administration aceis arb interrupt physiological feedback renal renin release lead reactive elevation circulating active renin greater production angiotensin angiotensin_ii subsequent return aldosterone secretion pre treatment level escape phenomenon possible adverse_effect intermediary product incomplete raas blockade leading organ complication facilitated effort develop compound blocking initial stage renin_angiotensin cascade e direct renin blocker several year unsuccessful attempt recent_year seen development first non peptide orally long_term effective renin inhibitor aliskiren fumarate monotherapy combination antihypertensive hydrochlorothiazide arb acei aliskiren reduces bp dose dependent manner mg den aliskiren reduces plasma renin activity pra neutralises hydrochlorothiazide induced raas activation daily administration drug lead longer hour activity prolonged blocking effect kidney basis renoprotectivity addition significant antihypertensive effect clinical_study also showed range organoprotective property patient left_ventricle hypertrophy allay study heart_failure aloft study diabetic nephropathy avoid study similar blocker aliskiren minimum adverse side_effect aliskiren hypertension therapy launched clinical_practice usa tekturna combination formulation tekturnahcl respectively shortly european union rasilez czech republic aliskiren rasilez released clinical use diabetologists nephrologists patient hypertension concomitant diabetes nephropathy proteinuria dos mg per day recommended monotherapy combination antihypertensive treat condition elevated pra including pra elevation following diuretic acei_arb administration aliskiren might used patient tolerate aceis well patient angiotensin_ii participates pathogenesis disease reno protective property leading reduction proteinuria delaying renal_failure progression observed_patient diabetic well non diabetic nephropathy drug subject similar precaution contraindication aceis arb e pregnancy bilateral renal artery stenosis make meaningful conclusion far positive contribution new treatment class broad applicability therapy hypertension cardiovascular_disease imperative assess long_term effect morbidity_mortality well compare agent raas blocker long_term clinical_study represents research effort another year:0.0388785097105938", "20057": "hypertension control rare clinical_practice particularly high_risk_patient large factor therapeutic inertia deriving poorly prescribed lifestyle change excess monotherapy use scarce treatment modification use drug combination significantly improves blood_pressure bp control particular fixed combination improve therapy without increasing daily pill intake thereby favouring patient compliance therapy continuation widely_used fixed combination based thiazide diuretic added either angiotensin_converting_enzyme ace_inhibitor angiotensin_ii receptor_blocker arb several large_scale clinical_trial conducted showing combination effective lowering bp however thiazide diuretic reduce metabolic benefit derived renin_angiotensin_aldosterone_system raas inhibitor high metabolic risk patient contrast ace_inhibitor arb combined dihydropyridine calcium_channel antagonist dhpcas exert marked antihypertensive effect without decreasing metabolic protection raas blockade recent jikei heart study approximately patient affected hypertension_heart_failure coronary_heart_disease combination valsartan arm simultaneously treated dhpcas note reduction primary_endpoint combined morbidity_mortality reported valsartan compared_non valsartan arm furthermore recent multinational study hypertensive patient_treated valsartan dhcpa amlodipine reported concontrolled bp week treatment expected amlodipine negatively influence metabolic profile patient thereby supporting role arb dhpca combination effective promising tool hypertension treatment summary combination arb dhpcas effective strategy hypertension treatment synergy antihypertensive vascular protective action persistent metabolic benefit deriving raas inhibition reduced incidence side_effect:0.0388050006098858", "20080": "cardiovascular_disease represents continuum start risk_factor hypertension progress atherosclerosis target organ damage ultimately myocardial_infarction_heart_failure stroke death renin_angiotensin_system ra blockade angiotensin_converting_enzyme ace_inhibitor angiotensin_receptor_blocker arb turned beneficial stage continuum class agent prevent reverse endothelial_dysfunction atherosclerosis thereby reducing risk cardiovascular_event reduction shown mainly ace_inhibitor patient coronary_artery_disease recent_study revealed arb inferior respect however data currently available combination drug ace_inhibitor arb shown reduce target organ damage organ kidney brain heart decrease cardiovascular_mortality morbidity patient congestive_heart_failure experimental data point influence ace_inhibitor arb number function endothelial progenitor cell revealing additional mechanism_action drug valiant trial shown equivalent effect arb valsartan ace_inhibitor captopril patient post myocardial_infarction dual ra blockade compared monotherapy reduce event secondary_prevention recently published ontarget study provides evidence top better tolerability receptor_antagonist equal ace_inhibitor prevention clinical endpoint like cardiovascular_mortality morbidity myocardial_infarction_stroke combined ra blockade however achieved benefit vascular high_risk_patient associated adverse_event chronic_heart_failure valheft charm added shown combined ra inhibition ace_inhibitor valsartan candesartan reduced morbidity_mortality certain patient subgroup accumulating evidence also point benefit combination therapy individual proteinuric nephropathy conclusion combined ra inhibition generally indicated patient along cardio reno vascular continuum already proven effective heart_failure_patient incomplete neuroendocrine blockade secondary_prevention monotherapy either ra inhibitor equally efficacious furthermore novel pharmacologic agent renin inhibitor may prove useful preventing common side_effect ra blockade angiotensin escape receptor upregulation giving clinician additional therapeutic tool optimally treat individual patient:0.0384911580807252", "14723": "systolic_blood_pressure sbp increase age hypertension affect approximately two third adult u aged_year blood_pressure bp increase consequence age related structural change large artery lead loss elasticity reduced vascular compliance increased pulse wave velocity augments sbp resulting high_prevalence isolated systolic hypertension age elevates cardiovascular_risk effective_treatment hypertension older aged_year patient_population prevents many event per patient_treated treatment younger hypertensive_patient recommendation treating hypertension similar older_patient compared general_population seventh report joint national committee detection prevention evaluation treatment high blood_pressure recommends target bp goal mmhg patient uncomplicated hypertension mmhg diabetes_mellitus renal_disease recent guideline position paper extended aggressive treatment goal include patient coronary_artery_disease type vascular_disease heart_failure randomized_clinical_trial demonstrated efficacy calcium_channel antagonist calcium_channel blocker ccbs low_dose diuretic ace_inhibitor angiotensin_ii type receptor_antagonist angiotensin_receptor_blocker arb reducing risk stroke adverse cardiovascular_outcome older_patient beta adrenoceptor antagonist less effective term endpoint reduction majority older_patient require two drug achieve bp goal despite active treatment half patient achieve target bp part reluctance physician intensify treatment phenomenon referred clinical inertia arb effective antihypertensive agent older_patient shown reduce cardiovascular endpoint patient hypertension diabetic nephropathy cerebrovascular_disease heart_failure arb produce additive bp reduction combined diuretic ccbs also advantage placebo like tolerability contributes favourably patient compliance long_term treatment prerequisite reducing morbidity_mortality:0.0384883822694360", "57804": "background renin_angiotensin_system ra major regulator blood_pressure bp vascular response injury increasing evidence ra inhibition may_provide end organ protection independent bp lowering two drug class directly target angiotensin_ii complementary mechanism angiotensin_converting_enzyme ace_inhibitor block conversion angiotensin active peptide angiotensin_ii increase availability bradykinin angiotensin_receptor_blocker arb selectively antagonize angiotensin_ii receptor may_also increase activation receptor modulate effect angiotensin_ii breakdown product objective paper present overview clinical_data supporting use ra inhibitor ace_inhibitor arb monotherapy combination therapy based known role ra bp regulation vascular response injury considers implication data future treatment method relevant experimental clinical_study identified searching medline june using primary search term renin_angiotensin_system angiotensin_converting_enzyme_inhibitor angiotensin_ii receptor_blocker dual ra blockade trial included review large patient prospective randomized controlled study evaluating effect ra inhibition end organ protection various high_risk population result eleven clinical_trial identified evaluated effect ace_inhibitor arb monotherapy end organ protection five trial identified evaluated effect combination therapy ace_inhibitor arb compared treatment either agent alone different patient_population using different end_point hypertensive_patient type_diabetes microalbuminuria combination ace_inhibitor arb therapy resulted better bp control either agent alone mean_difference mm_hg systolic p mm_hg diastolic p well greater reduction microalbuminuria mean_difference albumin creatinine ratio p compared monotherapy dual ra inhibition reduced occurrence doubling serum_creatinine concentration end_stage_renal_disease patient nondiabetic renal_disease p v ace_inhibitor alone p v arb alone recently published study reported nonsignificant benefit combination therapy monotherapy subset hypertensive_patient high_level microalbuminuria baseline v reduction respectively patient_heart_failure left_ventricular_ejection_fraction relative_risk cardiovascular_death hospitalization_heart_failure reduced received arb added ace_inhibitor compared received placebo added ace_inhibitor p another study found benefit mortality cardiovascular end_point combination therapy compared ace_inhibitor monotherapy ongoing study investigating dual ra blockade patient high_risk end organ damage well effective dos use combination regimen conclusion accumulating evidence antihypertensive regimen inhibit ra may_provide incremental end organ protection combining ace_inhibitor arb provide extensive ra inhibition may_provide greater antihypertensive efficacy end organ protection use either class alone future strategy treating high_risk_patient focus early intervention prevent delay end organ damage:0.0376022230939386", "66678": "hypertension major risk_factor stroke coronary event elderly people clinical_trial shown treatment hypertension various drug result substantial reduction cerebrovascular cardiovascular_event angiotensin_ii type receptor_antagonist newest class antihypertensive agent used widely clinical_practice receptor_antagonist generally given daily also extremely well_tolerated minimal first dose hypotension incidence adverse_effect similar seen placebo adverse_event rate significantly_lower class antihypertensive drug including ace_inhibitor factor result improved compliance increased rate continuance therapy receptor_antagonist show similar efficacy lowering blood_pressure class antihypertensive agent antihypertensive effect potentiated given concomitantly low_dose thiazide diuretic receptor_antagonist eliminated predominantly hepatic route subject extensive metabolism interaction drug uncommon advantage elderly often receiving multiple medication increase_risk adverse drug interaction dose adjustment usually required elderly unless plasma volume depletion although plasma receptor_antagonist concentration generally higher elderly younger subject pharmacokinetic difference may balanced decreased activation circulating renin_angiotensin_aldosterone_system elderly recent clinical_study high_risk hypertensive_patient left_ventricular_hypertrophy patient diabetic nephropathy heart_failure demonstrated receptor_antagonist improve clinical_outcome similar sometimes greater extent antihypertensive agent many study_included large number older_patient confirmed excellent tolerability profile drug thus receptor_antagonist considered possible first_line treatment component combination therapy_patient type_diabetes_mellitus microalbuminuria nephropathy alternative additional treatment ace_inhibitor patient_heart_failure left_ventricular_dysfunction receptor_antagonist also appear reduce onset new diabetes compared antihypertensive drug benefit term organ protection mainly seen study using higher dos particular receptor_antagonist certain present whether result extrapolated member class elderly likely developed organ damage related hypertension_heart_failure diabetes concomitant condition receptor_antagonist represent appropriate option many elderly_patient main disadvantage drug cost medication may offset improved tolerability fewer adverse reaction thus increased compliance resulting better blood_pressure control fewer clinical_event overall receptor_antagonist well_tolerated efficacious blood_pressure lowering given single daily dose elderly_patient many potential benefit high_risk hypertensive subject:0.0369678432216341", "42520": "elevated blood_pressure level highly prevalent major reason cardiovascular_event thus place significant financial burden healthcare system worldwide guideline recommend five first_line anti hypertensive drug class compelling indication may indicate favoring one drug class another angiotensin_receptor_blocker arb demonstrated blood_pressure lowering efficacy least comparable drug class including ace_inhibitor ace beta_blocker calcium_channel blocker diuretic addition lower side_effect profile drug class patient arb persistent therapy compelling indication use arb heart_failure post myocardial_infarction diabetic nephropathy proteinuria microalbuminuria left_ventricular_hypertrophy atrial_fibrillation metabolic_syndrome ace induced cough arb irbesartan demonstrated high efficacy lowering blood_pressure shown least comparable ace superior arb losartan valsartan translated better cost_effectiveness irbesartan valsartan losartan treatment hypertension addition irbesartan shown effective early late stage diabetic nephropathy demonstrated considerable cost saving standard therapy including beta_blocker diuretic non dihydropyridine calcium_channel blocker stage kidney_disease based efficacy data irbesartan diabetic nephropathy trial reduction endpoint niddm non insulin dependant diabetes melitis angiotensin_ii antagonist losartan study also demonstrated cost saving losartan late stage renal_disease losartan irbesartan registered treatment late stage diabetic nephropathy irbesartan also registered early_stage diabetic nephropathy eu summary data randomized_clinical_trial efficacy antihypertensive drug provides indication real value patient addition observational data clinical_practice proven end organ protection diabetic nephropathy provides evidence true value irbesartan compared arb treatment hypertension:0.0369301834342056"}, "Topic 25": {"186716": "objective modified item frailty index mfi comorbidity based risk_stratification tool predict adverse_event following various neurologic surgery study_aim quantify association increased mfi postoperative complication mortality following surgical fixation traumatic thoracolumbar fracture method american college surgeon national surgical quality improvement program ac nsqip dataset used_identify patient_undergoing fusion surgery thoracolumbar spine fracture mfi score calculated based presence major comorbidities congestive_heart_failure within_day surgery insulin dependent noninsulin dependent diabetes_mellitus chronic_obstructive_pulmonary_disease partially dependent totally dependent functional health_status time surgery hypertension requiring medication multivariate_analysis assessed independent impact increasing mfi score postoperative day morbidity_mortality controlling baseline clinical_characteristic result_total_patient included analysis female mean_age_year univariate_analysis higher mfi score significantly_associated increased_risk superficial surgical site infection deep surgical site infection wound dehiscence unplanned reoperation pneumonia unplanned intubation postoperative ventilator use progressive renal_insufficiency acute renal_failure urinary tract infection stroke myocardial_infarction cardiac_arrest pulmonary_embolism deep vein thrombosis bleeding requiring transfusion sepsis septic shock longer hospital length_stay los multivariate logistic_regression increasing mfi score versus mfi score zero associated_higher odds overall complication mfi odds_ratio ci_p mfi ci_p day_mortality mfi ci_p conclusion_study demonstrates frailty measured_using mfi independently predicts postoperative complication hospital los day_mortality surgical repair thoracolumbar fracture finding important risk_stratification patient_undergoing thoracolumbar fusion surgery standardization reporting outcome procedure:0.0332590639939568", "160212": "objective_study sought determine incidence risk_factor blood transfusion among_patient undergoing total knee revision tkr using nationwide database method_retrospective data analysis conducted based nationwide inpatient sample ni enrolling patient_underwent tkr complete information patient_divided two_group based whether received blood transfusion demographic characteristic race sex age length_stay los total charge hospitalization hospital characteristic admission type insurance type bed size teaching status location region hospital hospital_mortality comorbidities perioperative complication analyzed finally conducted univariate multivariate logistic_regression identify factor_associated tkr patient require blood transfusion result ni database included patient_underwent tkr among_patient received blood transfusion incidence blood transfusion dramatic decrease incidence year dropping tkr patient requiring transfusion experienced longer los incurred higher total medical expense utilized medicare frequently increased hospital_mortality rate p independent_predictor blood transfusion included advanced age female gender iron_deficiency anemia rheumatoid disease chronic blood loss anemia congestive_heart_failure coagulopathy uncomplicated diabetes lymphoma fluid electrolyte disorder metastatic carcinoma neurological disease paralysis peripheral vascular disorder pulmonary circulation disorder renal_failure valvular disease weight_loss addition risk_factor transfusion tkr surgery included sepsis acute_myocardial_infarction deep vein thrombosis pulmonary_embolism gastrointestinal bleeding heart_failure renal_insufficiency pneumonia wound infection lower limb nerve injury hemorrhage seroma hematoma wound rupture non healing urinary tract infection acute renal_failure postoperative delirium conclusion finding highlight importance recognizing risk_factor blood transfusion tkr reduce occurrence adverse_event:0.0329701965719061", "192009": "introduction cardiac_surgery play crucial role treating wide range cardiovascular condition offering life saving intervention patient disease coronary_artery_disease heart valve disorder heart_failure however procedure without significant risk including complication stroke acute_kidney_injury respiratory_failure infection important recognize potential complication associated procedure also identify high_risk_patient early treatment process aging population increasing burden comorbidities growing number_patient likely present suboptimal functional_status prior cardiac_surgery incorporating functional_status preoperative evaluation healthcare provider improve patient_selection enhance perioperative care improve_outcome high_risk patient_population therefore study_aim investigate whether preoperative dependent functional_status associated_increased_risk postoperative major_adverse outcome patient_undergoing cardiac_surgery method performed retrospective cohort analysis adult cardiac_surgery patient based american college surgeon national surgical quality improvement program ac nsqip database compared primary composite_outcome consisting post surgery outcome independent partially totally dependent patient primary_outcome defined experiencing following adverse_event superficial incisional deep incisional organ space surgical site infection death within_day post operation stroke cerebral vascular accident cva cardiac_arrest requiring cardiopulmonary resuscitation cpr myocardial_infarction pulmonary_embolism pe deep vein thrombosis dvt thrombophlebitis progressive renal_insufficiency ventilator use hour post operation unplanned intubation reoperation sepsis septic shock pneumonia confounding variable age_gender race emergency case comorbidities baseline laboratory marker used multivariable logistic_regression_analysis obtain adjusted_odds_ratio confidence_interval_ci result_patient included_study female male group year_old prevalence dependent status compared independent patient dependent higher incidence primary_outcome v yielding crude ci association remained significant ci adjustment age_gender race body_mass_index_bmi emergency case comorbidities diabetes hypertension_heart_failure preoperative blood transfusion sepsis laboratory marker conclusion_patient preoperative dependent functional_status found significantly_greater risk complication cardiac_surgery even adjusting demographic comorbidities laboratory marker perioperative characteristic investigation needed explore development clinical_application predictive tool includes functional_status could help identify high_risk_patient facilitate timely intervention prehabilitation program enhance functional_capacity:0.0324509078286700", "128629": "objective calculate risk postoperative complication mortality corrective surgery adult spinal deformity asd patient using american college surgeon national surgical quality improvement program ac nsqip surgical risk calculator src method_patient aged_year undergoing corrective surgery asd identified current procedural terminology cpt code assessed patient international classification disease ninth revision icd scoliosis diagnosis calculated perioperative complication risk average via ac nsqip surgical calculator compared observed complication rate outcome assessed follows serious complication complication pneumonia cardiac_complication surgical site infection urinary tract infection venous thromboembolism renal_failure readmission return operating room death discharge nursing rehabilitation sepsis total length hospital_stay predictive performance calculator analyzed computation brier score brier score sum squared difference binary outcome predicted risk range maximum brier score mean observed outcome mean observed outcome value closer suggestive better predictive performance length_stay los assessed bland altman plot plot average observed los x axis difference observed predicted los axis result_total asd patient_year female kg identified procedure involved decompression involved fusion mean individual patient_characteristic entered online risk calculator interface follows functional_status independent partially dependent totally dependent emergent case wound class clean clean contaminated contaminated dirty infected american society anesthesiologist class ii iii_iv v steroid use chronic_condition ascites within_day prior surgery systemic sepsis within hour surgery ventilator dependent disseminated cancer diabetes_mellitus use hypertensive medication congestive_heart_failure dyspnea history smoking within_year chronic_obstructive_pulmonary_disease dialysis acute renal_failure predictive day postoperative complication ranged across cpt code actual rate cohort demonstrated good predictive performance via brier score maximum predicted observed percentage outcome assessed associated brier score brier maximum calculated mean_difference observed predicted los day ci_conclusion ac nsqip src predicts surgical risk patient_undergoing asd corrective surgery tool used resource preoperative optimization deformity surgeon level evidence:0.0314001735770976", "170705": "background past decade prevalence obesity risen united_state parallel demand anterior cervical discectomy fusion acdf prior study_evaluated role obesity class cervical spine surgery smaller patient_population aimed evaluate potential correlation national population sample utilizing large multicenter database purpose purpose_study analyze obesity level influence perioperative complication rate patient_undergoing acdf study_design setting retrospective cohort large multicenter database study_patient sample american college surgeon national surgical quality improvement program ac nsqip database queried identify_patient undergone elective acdf procedure using current procedural terminology cpt code outcome_measure medical surgical complication within thirty day operation method_patient categorized four bmi group nonobese bmi kg obese class bmi kg obese class ii bmi kg obese class iii bmi kg univariate_analysis conducted demographic variable preoperative comorbidities identified age_sex race smoking status hypertension requiring medication diabetes history congestive_heart_failure history bleeding disorder chronic_obstructive_pulmonary_disease risk_factor chi square test used compare incidence complication among group multivariable logistic_regression_analysis subsequently performed adjust preoperative risk_factor compare obesity class iii nonobese patient result_patient identified nonobese obese class obese class ii obese class iii obese class iii patient higher incidence surgical site infection v_p pulmonary_embolism pe v_p obese class iii lower incidence blood transfusion v_p obese class obese class ii obese class iii independently increased_risk pe ci_ci ci_ci respectively_conclusion risk postoperative pe acdf significantly_higher obese class iii compared nonobese patient finding may support use additional prophylaxis measure precaution perioperative setting:0.0312855279068592", "145638": "objective examine incidence risk_factor hospital prosthesis related complication prc following total knee arthroplasty tka using large_scale national database method_retrospective database analysis_performed based nationwide inpatient sample ni patient_underwent tka included recruited case divided two_group according occurrence prc patient demographic age_sex race hospital characteristic type admission payer bedsize teaching status location region hospital length_stay los total charge hospitalization hospital_mortality comorbidities perioperative complication analyzed result_total tkas captured ni database case hospital prc tka overall incidence slight downward trend annually periprosthetic joint infection pji main category among prc followed mechanical loosening dislocation periprosthetic fracture ppf patient suffered hospital prc year younger year v_year likely male v compared nonaffected population p additionally patient experiencing hospital prc tka less_likely elective admission v likely teaching hospital v without complication p furthermore occurrence hospital prc associated longer los day v day_p total charge v_p higher hospital_mortality v_p multivariate logistic_regression performed identify independent_risk_factor hospital prc tka included younger age male non elective admission teaching hospital deficiency chronic blood loss anemia coagulopathy congestive_heart_failure depression diabetes chronic complication fluid electrolyte disorder pulmonary circulation disorder metastatic cancer weight_loss besides hospital prc tka associated secondary osteoarthritis inflammatory arthritis prior knee arthroscopy acute renal_failure acute_myocardial_infarction deep vein thrombosis sepsis transfusion wound dehiscence conclusion beneficial study risk_factor hospital prc tka ensure appropriate management optimize consequence although relatively low incidence identified:0.0307136825893199", "184539": "objective explore association diabetes outcome thyroidectomy patient method_retrospective cohort analysis used american college surgeon national surgery quality improvement program database current procedural terminology cpt code used_identify thyroidectomy case demographic comorbidities complication incidence compared diabetic nondiabetic patient using pearson chi square test fisher exact test appropriate independent effect diabetes outcome analyzed_using binary logistic_regression result_total nondiabetic diabetic patient_undergoing thyroidectomy identified chi square analysis demonstrated diabetic_patient higher incidence obesity v_p dyspnea v_p poor functional_status v_p ventilator dependence v_p chronic_obstructive_pulmonary_disease_copd v_p congestive_heart_failure v_p acute renal_failure v_p hypertension v_p dialysis v_p open wound v_p steroid use v_p bleeding disorder v_p preoperative blood transfusion v_p systemic sepsis v_p demographic characteristic significantly_different cohort including gender p age p race p hispanic ethnicity p adjusting factor logistic_regression_analysis showed diabetes associated acute renal_failure ci_p wound disruption ci_p prolonged length_stay ci_p unplanned readmission ci_p superficial incisional surgical site infection ci_p urinary tract infection occurrence ci_p organ space surgical site infection occurrence ci_p pneumonia occurrence ci_p medical complication ci_p complication ci_p_conclusion diabetes_mellitus significant factor associated_increased odds complication following thyroidectomy level evidence laryngoscope:0.0305950668331909", "193673": "background frailty become increasingly recognized perioperative risk_stratification tool frailty strongly correlated worsening surgical outcome individual determinant frailty rarely investigated setting aortic disease aim_study examine determinant factor modified frailty index mfi mortality postoperative complication patient_undergoing endovascular aortic aneurysm repair evar method data national surgical quality improvement program database queried patient_undergoing nonemergent evar univariate logistic_regression used_assess association mfi variable complication occurring within_day surgery significant variable used multivariate_analysis variable included mfi scoring diabetes nonindependent functional_status chronic_obstructive_pulmonary_disease congestive_heart_failure myocardial_infarction_mi previous percutaneous_coronary_intervention cardiac_surgery angina hypertension requiring medication peripheral vascular_disease impaired sensorium previous transient_ischemic_attack cerebrovascular accident overall complication included superficial surgical site infection deep incisional surgical site infection deep vein thrombosis readmission reintervention bleeding requiring transfusion major adverse_event maes mortality maes included classified clavien dindo grade iv defined life_threatening complication requiring intensive_care_unit level management single multiple organ failure odds_ratio or calculated using spss result_total_patient identified resulting cohort male average age_year binary regression revealed significant_increase day_mortality confidence_interval_ci_p overall complication ci_p maes ci_p stroke ci_p prolonged mechanical_ventilation ci_p acute_kidney_injury ci_p cardiac_arrest ci_p mi ci_p per point increase mfi score multivariate_analysis demonstrated functional dependency highly associated_increased odds outcome except stroke cardiac_arrest mi impaired sensorium highly associated day_mortality conclusion mfi strong predictor postoperative complication mortality patient_undergoing nonemergent evar measurement frailty considered preoperative assessment patient evaluated evar particular attention risk benefit aortic repair dependent functional_status impaired sensorium:0.0303997978230256", "160806": "introduction laminectomy one common orthopedic spine surgery performed united_state compared spine operation fusion laminectomy isolation lower morbidity however complication may arise result readmission inpatient healthcare facility purpose_study identify demographic risk_factor associated unplanned day_readmission following laminectomy method american college surgeon national surgical quality improvement program ac nsqip database queried patient_underwent laminectomy procedure using cpt code query yielded case demographic lifestyle comorbidity peri operative factor recorded independent sample student test chi squared appropriate fisher exact test used univariate_analysis identify demographic lifestyle peri operative variable related day_readmission following laminectomy procedure multivariate logistic_regression modeling subsequently performed odds_ratio or confidence_interval_ci calculated reported result_patient included sample readmitted within_day surgery corresponding readmission_rate result univariate analysis_revealed statistically_significant relationship readmission status following patient variable patient age_sex bmi asa classification race bleeding disorder chronic_obstructive_pulmonary_disease_copd diabetes hypertension congestive_heart_failure_chf chronic steroid use total operative time tobacco use p multivariate logistic_regression modeling confirmed following patient variable associated statistically significantly_increased odds readmission age greater p female_sex p bleeding disorder p diabetes p current smoker p copd p steroid use p asa class ii p total operative time p_conclusion unplanned day_readmission laminectomy infrequent however increasing age female_sex steroid use current smoker bleeding disorder diabetes copd chf higher asa classification longer operative time independent_risk_factor readmission following laminectomy:0.0302386465652069", "117131": "background hospital_readmission associated_increased mortality_morbidity cost also current health_care reform tied significant financial administrative penalty study show patient_undergoing vascular surgery may higher average readmission_rate recently released nationwide readmission database nrd comprehensive national source readmission data gathering discharge information geographically dispersed state accounting total u resident population u hospitalization aim_study use power nrd obtain nationally representative readmission information patient_admitted claudication critical limb ischemia cli underwent revascularization procedure method nrd queried patient_admitted claudication international classification disease ninth revision icd cli icd underwent percutaneous transluminal angioplasty peripheral bypass aortofemoral bypass patient demographic comorbidities length_stay los mortality readmission_rate associated cost collected univariable multivariable logistic_regression_analysis implemented claudication cli group outcome interest common readmission diagnosis code diagnosis group also identified result_total_patient admitted peripheral vascular_disease claudication cli day_readmission readmission_rate claudication cli respectively significant_difference found claudication cli respectively initial cost admission v_p readmission cost v_p los day v day_p day_readmission day v day_p mortality initial admission v_p mortality admission v_p univariate multivariate logistic_regression_analysis found claudication cli angioplasty peripheral bypass aortofemoral bypass female_sex age charlson comorbidity index los primary expected payer status significant_predictor day overall readmission varying degree common disease readmission group found vascular procedure amputation lower limb except toe sepsis heart_failure postoperative device infection abovementioned group common diagnosis included postoperative infection sepsis atherosclerosis native artery gangrene complication due vascular device implant graft conclusion_result demonstrate significant_difference readmission_rate cost morbidity patient_admitted claudication cli furthermore based regression_analysis multiple clear risk_factor associated_worse clinical economic outcome study_needed predict patient require increased vigilance hospital_stay prevent readmission worse outcome level evidence care management epidemiological level iv:0.0299033312933427"}, "Topic 26": {"171754": "introduction kansa city cardiomyopathy questionnaire kccq one widely_used instrument measuring health_related_quality_life patient_heart_failure_hf however item version kccq sufficiently tested european population invariance patient reduced midrange preserved_ejection_fraction never assessed aim purpose_study examine validity reliability kccq large cohort italian patient_hf assess measurement invariance across level ejection_fraction method total_patient mean_age_year_male completed kccq alongside measure depression anxiety quality_life hf symptom burden construct validity assessed mean confirmatory factor analysis testing association kccq score clinical parameter ie ejection_fraction mortality month well measure anxiety depression symptom burden general quality_life multigroup confirmatory factor analysis implemented investigate invariance property across reduced midrange preserved_ejection_fraction omega model based internal consistency coefficient computed investigate internal consistency reliability result confirmatory factor analysis specified according original factor model ie physical social limitation symptom frequency quality_life yielded satisfactory fit index root mean square error approximation comparative fit index moderate high correlation found kccq mental physical component score short form well conceptually related construct indicating adequate facet construct validity multigroup confirmatory factor analysis tested across patient different ejection_fraction group established kccq invariant partial scalar level omega model based internal consistency coefficient adequate ranging subscales whole scale confirming strong internal consistency reliability conclusion kccq demonstrated satisfactory psychometric property european sample patient_hf providing evidence support use practice research:0.0347090208788172", "129452": "background health_related_quality_life hrqol known impaired individual coronary_artery_disease_cad especially recent acute_coronary_syndrome_ac heart_failure_hf common burden population significantly contributes worsening hrqol accurately measure level hrqol individual cad ac disease specific scale minnesota living_heart_failure questionnaire mlhfq recommended nevertheless date study would comprehensively evaluate psychometric property mlhfq large sample individual cad ac debate regarding internal structure mlhfq also still present hence study_aimed translate mlhfq evaluate internal structure reliability precision validity individual cad following ac lithuania method cross_sectional_study participant men age sd evaluated sociodemographic clinical_characteristic hrqol measured_using mlhfq short form health survey sf addition exercise_capacity ec also evaluated study_patient using standardized computer driven bicycle ergometer result internal consistency mlhfq subscales found good confirmatory factor analysis cfa provided support three factor model physical domain social domain emotional domain mlhfq showed acceptable fit comparative fit index cfi goodness fit gfi non normal fit index nfi root mean square error approximation rmsea regarding convergent evidence significant_association found mlhfq domain sf domain ec r range conclusion current study completed cultural validation provided information psychometric characteristic mlhfq lithuania suggesting mlhfq valid reliable instrument measure hrqol lithuanian version mlhfq best described three factor solution measuring physical social emotional dimension hrqol among individual cad following ac:0.0335630421466588", "51352": "background assessment health_related_quality_life widely recommended european health agency relevant research study well clinical care aim validate french version macnew heart_disease health_related_quality_life questionnaire method part international heartqol project french speaking patient ischaemic_heart_disease angina n myocardial_infarction_mi n heart_failure n mean_age_year recruited seven cardiac_rehabilitation centre patient completed french version macnew questionnaire short form health survey sf hospital anxiety depression scale evaluate psychometric property french version macnew instrument result mean macnew global scale score patient angina mi heart_failure respectively_p mi versus angina observed minimal missing item ceiling effect floor effect factor analysis confirmed three factorial structure explaining observed variance internal consistency reliability cronbach alpha ranged test retest reliability ranged convergent validity confirmed total group diagnosis although correlation macnew physical subscale sf mental component summary higher expected discriminative validity partially confirmed sf health transition item fully confirmed anxiety depression predictor variable conclusion french version macnew questionnaire recommended assessing health_related_quality_life french speaking patient ischaemic_heart_disease:0.0330384731736640", "62081": "aim patient_heart_failure_hf commonly suffer severe impairment quality_life qol one main goal hf treatment improvement qol physical well essential component qol enable assessment physical well hf_patient validated questionnaire prospective_study patient cardiac insufficiency bisoprolol study elderly method_result hf_patient age_year male new_york_heart_association_class ii left_ventricular_ejection_fraction measured physical well qol item short form health survey sf depressive_symptom prime md patient health questionnaire german short version depression phq baseline two follow visit correlated score qol data clinical parameter mean score baseline_month year assessed data quality scale assumption construct validity reliability cronbach alpha subscales resilience ability enjoy vitality inner peace total score intraclass correlation coefficient icc ci icc pearson correlation sf phq significant six minute walking distance heart_rate correlated significantly total score conclusion showed good reliability internal consistency intraclass correlation score correlated well psychological physical well sf clinical marker exercise_tolerance min walk test heart_rate result indicate strong correlation self_reported physical well psychological factor value baseline predicted development several aspect qol beta_blocker titration:0.0326556766880174", "2273": "objective create valid sensitive disease specific health_status measure patient congestive_heart_failure_chf background quantifying health_status becoming increasingly important chf kansa city cardiomyopathy questionnaire kccq new self administered item questionnaire quantifies physical limitation symptom self efficacy social interference quality_life method establish performance characteristic kccq two distinct patient cohort recruited stable decompensated chf_patient ejection_fraction upon entry study_patient administered kccq minnesota living_heart_failure questionnaire short form sf questionnaire repeated three month later result convergent validity kccq domain documented comparison available criterion standard r_p among stable chf remained stable predefined criterion n minimal change kccq domain detected three month observation mean change point p n contrast large change score observed among_patient whose decompensated chf improved three month later n mean change point p sensitivity kccqwas substantially greater minnesota living_heart_failure sf questionnaire conclusion kccqis valid reliable responsive health_status measure patient_chf may serve clinically meaningful outcome cardiovascular research patient management quality assessment:0.0324850501535352", "135782": "purpose aim_study_evaluate psychometric property core disease specific item german heartqol questionnaire method extension international heartqol project cross_sectional longitudinal health_related_quality_life hrql data_collected patient angina n myocardial_infarction n ischemic heart_failure n austria switzerland using german version heartqol short form health survey sf hospital anxiety depression scale underlying factor structure examined mokken scaling analysis convergent divergent discriminative validity internal consistency reliability responsiveness assessed result highest hrql score reported patient myocardial_infarction followed ischemic heart_failure angina two factor structure confirmed strong physical emotional global scale h coefficient divergent convergent validity r shown diagnosis discriminative validity verified well partially age_sex disease_severity largely sf health_status transition totally anxiety depression internal consistency reliability excellent cronbach alpha term responsiveness physical global scale score improved significantly percutaneous_coronary_intervention p cardiac_rehabilitation scale score improved significantly p_conclusion german heartqol questionnaire valid reliable hrql instrument data supporting potential use clinical_practice research assess compare hrql german speaking patient ischemic_heart_disease shortness tool may prove helpful particularly clinical_practice:0.0319276199145677", "155859": "background health_related_quality_life hrqol important outcome indicator chronic_disease study_aimed develop new instrument assessment hrqol chronic_heart_failure_chf evaluate psychometric property method_study included two step conceptualization item generation assessment psychometric property instrument measuring hrqol patient_chf sample patient confirmed diagnosis heart_failure participated study addition content validity exploratory confirmatory factor analysis concurrent validity convergent validity known group comparison performed assess construct validity internal consistency stability estimated cronbach alpha macdonal omega intraclass correlation coefficient result content validity developed chronic_heart_failure quality_life questionnaire assessed expert exploratory factor analysis indicated four factor solution instrument containing item jointly accounted variance observed confirmatory factor analysis confirmed four factor solution following fit index chi df cfi nfi tli ifi gfi agfi rmsea however stage one item removed concurrent convergent validity chfqolq established using short form health survey sf macnew heart_disease quality_life questionnaire respectively known group validity assessed_using new_york_heart_association nyha functional classification showed questionnaire discriminated well patient differed functional classification internal consistency test retest reliability chfqolq satisfactory cronbach alpha intraclass correlation coefficient icc value respectively_conclusion result confirmed chfqolq valid reliable instrument measuring quality_life qol patient_chf short easy use instrument also capable assessing cognitive functioning overlooked previous questionnaire:0.0313162220761330", "99742": "objective patient_reported outcome implantable_cardioverter_defibrillator_icd patient describe experience living heart_disease icd however little_known patient_outcome among chinese patient may limit effective patient discussion intervention patient purpose_study examine device related experience e_g device acceptance shock anxiety chinese icd patient identify potential variable influence health_related_quality_life hrqol compare hrqol outcome healthy heart_failure population method_study used cross_sectional research design serially recruited icd patient_n clinic china participant completed survey including item short form health survey questionnaire sf florida patient acceptance survey fpas florida shock anxiety scale fsas type scale d general information questionnaire result participant icd patient china mean_age sd mean score sf physical component summary pc mental component summary mc icd patient respectively lower chinese general_population p general health social functioning role emotional score lower chronic_heart_failure patient_p multiple linear regression_analysis indicated lvef positive shock history age shock anxiety significant_predictor physical function accounted adjusted variance type personality shock history shock anxiety predictor mental health component accounted variance shock history age type personality shock anxiety significantly predicted device acceptance fpas total accounted variance conclusion icd patient_reported health_outcome generally lower chinese general_population patient_heart_failure relation general health social functioning role emotional generic disease specific hrqol influenced medical psychosocial predictor suggests current western society based comprehensive model patient hrqol patient care need may extend chinese patient icds:0.0310995339680333", "32117": "background assessment health_related_quality_life hrql using generic measure may optimally responsive treatment intervention disease specific instrument macnew heart_disease hrql questionnaire macnew designed specifically evaluate hrql among heart patient aim validate hebrew version macnew report hrql israeli chronic cardiac patient_method generic sf macnew hrql questionnaire administered hebrew speaking heart patient_treated outpatient clinic sheba medical_center result according sf hrql relatively low cardiac patient compared israeli norm comparable norm american heart patient according macnew heart_failure_patient lowest hrql score three dimension physical mental social total score identified macnew confirmatory factor analysis verified good model fit physical emotional domain item supporting structural validity spearman coefficient correlating macnew parallel sf domain moderate high r_p supported convergent validity cronbach alpha total macnew score dimension supporting internal reliability test retest reliability examined month later among_patient different scale discriminated heart_failure angina pectoris heart patient supporting criterion validity multilinear regression_model showed significant_correlation heart_failure past myocardial_infarction_mi year schooling duration heart_disease hrql conclusion among_patient heart_disease macnew highly acceptable maintains good psychometric property comparing favorably sf discussion conclusion finding_suggest macnew utility measuring disease specific hrql israeli heart patient:0.0306718390773153", "49742": "background limited evidence exists nature degree emotional problem pulmonary_arterial_hypertension pah association patient health_related_quality_life hrqol method cross_sectional_study examined presence depression anxiety stress symptom association disease specific generic hrqol total_patient woman pah age_year new_york_heart_association_nyha_class ii completed depression anxiety stress scale generic medical outcome study short form item sf health survey disease specific minnesota living_heart_failure questionnaire mlhfq hrqol instrument association emotional problem hrqol determined using multivariable linear regression_analysis controlling demographic disease related characteristic result_patient experienced depressive anxiety stress symptom respectively hrqol standard_deviation population norm sf physical component summary depressive_symptom nyha_class disabled explained total variance mlhfq emotional problem contribute sf physical component summary explained part variance physical sub scale sf role limitation due physical problem bodily pain general health conclusion high presence emotional problem warrant regular screening appropriate psychotherapeutic pharmacological treatment_strategy could improve pah patient hrqol remains investigated:0.0305573666669084"}, "Topic 27": {"128384": "left_ventricular non compaction lvnc rare genetically heterogeneous cardiomyopathy disorder vastly affect infant young child severe neonatal lvnc relatively rare prevalence genetic defect underlying pediatric adult onset lvnc mutation myh mybpc sarcomeric gene found vast majority positive pediatric case pkp encodes plakophilin non sarcomeric desmosomal protein multiple role cardiac_myocytes including cell cell adhesion tightening gap junction transcriptional factor reported pkp mutation heterozygous missense truncating variant associated adult onset autosomal dominant disorder namely arrhythmogenic right_ventricular dysplasia cardiomyopathy arvd c homozygous pkp mutation rarely described herein present rare case infant neonatal onset congestive_heart_failure owing severe lvnc multiple muscular vsd medical_treatment failed control heart_failure_patient died month age whole exome sequencing identified novel homozygous pkp variant c g c patient mrna analysis_revealed aberrant transcript lacking exon predicted cause frameshift truncated peptide p gly glufster heterozygous parent normal cardiac structure_function demonstrated electrocardiogram echocardiography pathogenic variant sarcomeric gene analyzed found patient conducted literature review identified eight family biallelic pkp mutation observed three family included null variant linked lethal phenotype homozygous missense mutation resulted less severe manifestation adolescent onset arvd c childhood onset dcm data support previous notion severe neonatal lvnc might represent unique entity distinct genetic spectrum conclusion present_study extended phenotype genotype pkp related disorder lethal lvnc:0.0427718666329444", "105878": "background dilated_cardiomyopathy_dcm heritable genetically heterogeneous disorder typically exhibit autosomal dominant inheritance genomic strategy enable discovery novel unsuspected molecular underpinnings familial dcm performed genome wide mapping exome sequencing unique family wherein dcm segregated autosomal recessive ar trait method_result echocardiography adult descendant first cousin revealed dcm female sibling idiopathic left_ventricular enlargement brother genotyping linkage analysis mapped ar dcm locus chromosome arm q validated refined high density homozygosity mapping exome sequencing affected sister used complementary strategy mutation discovery iterative bioinformatics process used filter genetic variant revealing single shared homozygous missense mutation localized q critical region mutation absent hapmap genome ethnically matched_control altered conserved residue gatad encoding gata zinc finger domain containing protein thirteen relative heterozygous mutation carrier evidence myocardial disease even advanced age immunohistochemistry demonstrated nuclear localization gatad left_ventricular myocytes yet subcellular expression nuclear morphology aberrant proband conclusion linkage analysis exome sequencing used synergistic genomic strategy identify gatad gene ar dcm gatad bind histone modification site regulates gene_expression consistent murine dcm caused genetic disruption histone deacetylases data implicate inherited basis epigenetic dysregulation human heart_failure:0.0414666182884546", "58426": "inherited cardiomyopathy major cause sudden_cardiac_death scd heart_failure_hf disease associated extensive genetic heterogeneity pathogenic mutation cardiac sarcomere protein gene cytoskeletal protein gene nuclear envelope protein gene linked etiology early_diagnosis conducive clinical monitoring allows presymptomatic intervention needed present_study entire coding sequence flanking region major disease cardiomyopathy related gene namely myosin heavy chain cardiac muscle beta myh myosin binding protein c cardiac mybpc lamin c lmna troponin type cardiac tnni troponin type cardiac tnnt actin alpha cardiac muscle actc tropomyosin alpha tpm sodium channel voltage gated type v alpha subunit scn myosin light chain regulatory cardiac slow myl myosin heavy chain cardiac muscle alpha myh myosin light chain alkali ventricular skeletal slow myl protein_kinase amp activated gamma non catalytic subunit prkag patient dilated_cardiomyopathy_dcm patient hypertrophic_cardiomyopathy hcm amplified sequenced using ion torrent personal genome machine pgm system result novel heterozygous mutation myh p asn thr variant uncertain significance tnnt p arg identified_patient hcm missense mutation absent sample obtained healthy_control subject altered amino acid evolutionarily conserved among number vertebrate specie illustrates non synonymous mutation play_role pathogenesis hcm moreover double heterozygous mutation prkag p gly ser plus myh p arg trp identified patient_severe familial hcm first_time best knowledge patient provided u information regarding genotype phenotype correlation mutation myh prkag taken together finding provide insight molecular_mechanism underlying inherited cardiomyopathy mutation identified study may investigated future order improve diagnosis treatment_patient inherited cardiomyopathy furthermore finding indicated sequencing using ion torrent pgm system useful approach identification pathogenic mutation associated inherited cardiomyopathy may used risk evaluation individual possible susceptibility inherited cardiomyopathy:0.0401608454065145", "93988": "background familial dilated_cardiomyopathy_dcm genetically heterogeneous associated mutation least different gene apart ttn encoding giant protein titin none gene expected diagnostic yield complicating genetic diagnosis whole exome sequencing wes powerful alternative identification causal gene however variant interpretation remains challenging report wes large family autosomal dominant dcm complicated end_stage_heart_failure non sustained ventricular_arrhythmia causative mutation identified using targeted gene panel including gene method_result wes applied affected cousin stringent filtering identified genetic variant performed including population variant frequency silico analysis orthologous paralogous conservation subsequently sanger sequencing performed potential disease causing variant order confirm presence variant evaluate co segregation one variant exon rbm gene c p met lys nm showed full co segregation affected family member resulting maximum point lod score suggesting pathogenic mutation responsible phenotype recently mutation rbm linked arrhythmogenic dilated_cardiomyopathy caused defective splicing giant sarcomere protein titin abnormal calcium handling conclusion report identification novel mutation rbm wes large pedigree dcm:0.0391682050959723", "138426": "hypertrophic_cardiomyopathy hcm common inherited disease prevalence worldwide cause hcm usually present autosomal dominant mutation gene encoding one sarcomeric protein incomplete penetrance variable expressivity hcm classically manifest unexplained thickness interventricular septum iv left_ventricular_lv wall without obstruction lv outflow tract lvot variable cardiac_arrhythmia present rare case mixed cardiomyopathy cardiac_hypertrophy dilation erythrocytosis young patient year_old_man admitted clinic due biventricular heart_failure_hf nyha_class iii personal medical_record included diagnosis dilated_cardiomyopathy_dcm since age_year time considered outcome myocarditis severe respiratory infection led circulatory decompensation acute femoral thrombosis combination non obstructive lv hypertrophy lv wall mm lv dilatation decreased contractility lv ef lv apical thrombosis seen cardiac mri showed complex pattern late gadolinium enhancement lge endomyocardial_biopsy emb revealed primary cardiomyopathy intravascular coagulation inflammatory_response viral genome detected plasma emb sample whole exome sequencing wes revealed homozygous frame deletion p del mybpc gene clinically unaffected mother heterozygous carrier deletion father unavailable clinical genetic testing essential erythrocytosis remains unexplained significant_improvement achieved conventional treatment including prednisolone mg therapy icd implanted due sustained vt high_risk scd orthotopic heart_transplantation htx considered optimal early manifestation combined hypertrophic dilated phenotype progression may reflect complex genotype one pathogenic allele combination genetic disease one_patient:0.0379790575367548", "51971": "dilated_cardiomyopathy_dcm common form primary myocardial disease important cause sudden_cardiac_death heart_failure leading indication heart_transplantation child adult worldwide recent_study revealed strong genetic basis idiopathic dcm many distinct gene causally implicated nevertheless dcm genetically heterogeneous disorder genetic determinant underlying dcm substantial proportion_patient remain unclear study whole coding exon flanking intron gata binding protein gata gene code zinc finger transcription_factor essential cardiovascular development structural remodeling sequenced unrelated patient idiopathic dcm available relative index patient carrying identified mutation unrelated ethnically matched healthy individual used control genotyped gata functional characteristic mutant gata analyzed contrast wild_type counterpart using dual luciferase reporter assay system result novel heterozygous gata mutation p g identified family dcm inherited autosomal dominant pattern co segregated dcm family complete penetrance missense mutation absent reference chromosome altered amino acid completely conserved evolutionarily across specie functional analysis_revealed gata mutant associated significantly diminished transcriptional activity study firstly link gata mutation dcm provides novel insight molecular_mechanism dcm suggesting potential molecular target prenatal prophylaxis allele specific treatment dcm:0.0371170568695726", "51733": "dilated_cardiomyopathy_dcm prevalent type primary myocardial disease third common cause_heart_failure frequent reason heart_transplantation aggregating evidence demonstrates genetic risk_factor involved pathogenesis idiopathic dcm nevertheless dcm remarkable genetic heterogeneity genetic defect underpinning dcm overwhelming majority patient remain unknown present_study whole coding exon splice junction site nkx gene encodes homeodomain transcription_factor crucial cardiac development structural remodeling sequenced unrelated patient idiopathic dcm available relative index patient harboring identified mutation unrelated ethnically matched healthy individual used control genotyped nkx gene functional effect mutant nkx characterized contrast wild_type counterpart using dual luciferase reporter assay system result novel heterozygous nkx mutation p w identified family dcm inherited autosomal dominant trait co segregated dcm family complete penetrance notably mutation carrier also arrhythmia paroxysmal atrial_fibrillation atrioventricular block missense mutation absent reference chromosome altered amino acid completely conserved evolutionarily among specie functional analysis_revealed nkx mutant associated significantly_reduced transcriptional activity finding expand mutational spectrum nkx linked dcm provide novel insight molecular_mechanism underlying dcm contributing antenatal prophylaxis allele specific management dcm:0.0366246229383837", "123394": "familial hypertrophic_cardiomyopathy hcm one common type genetic heart disorder feature high genetic heterogeneity hcm major cause sudden_cardiac_death also important cause_heart_failure related disability pedigree suspected familial hcm recruited present_study identify genetic abnormality hcm confirmed echocardiography clinical_data family member collected genomic dna extracted peripheral blood sequenced based standard whole exome sequencing wes protocol sanger sequencing performed verify mutation site association hcm wes sanger sequencing revealed heterozygous missense mutation c c p r c myosin heavy chain myh identified three family member arg cys mutation located exon best knowledge previously reported familial hcm furthermore family member carrying mutated gene different sex clinical phenotype included proband year_old survivor sudden cardiac_arrest ventricular systolic_dysfunction proband maternal uncle presented ventricular diastolic_dysfunction proband mother obvious clinical symptom present cardiac_dysfunction however echocardiology indicated proband mother enlarged left_atrium slightly thicker right anterior wall anterior septum expanded atrial septum therefore hcm exhibited obvious genetic phenotypic heterogeneity best knowledge present_study first report mutation myh gene familial hcm addition present_study demonstrated wes powerful tool identifying genetic variant hcm:0.0365767449032614", "173929": "background hypertrophic_cardiomyopathy hcm autosomal dominant genetic heart_disease wide range clinical_manifestation asymptomatic case heart_failure sudden_cardiac_death objective identify disease causing variant patient_severe hcm carrying clinical examination genetic analysis generation single family patient_method family member underwent comprehensive cardiovascular examination whole exome sequencing carried proband girl five year_old followed co segregation silico analysis result proband harboured homozygous variant nm c delinsta p trp delinscysasn mrpl gene leading shorter protein variant novel absent clinvar human gene mutation database hgmd classified vus according american college medical genetics genomics acmg criterion co segregation analysis_revealed proband parent sister heterozygous carrier sister wild_type affected brother homozygous mutation silico analysis_showed significant structural difference mutated ml protein disrupting interaction ribosomal complex component impairing translation protein synthesis conclusion_study report novel mrpl variant associated hcm tunisian family finding expands current knowledge genetic variation linked mitochondrial cardiomyopathy highlight importance genetic testing diagnosis management cardiomyopathy:0.0364141871638889", "145510": "background arrhythmogenic cardiomyopathy acm genetic disorder estimated prevalence characterized fibrofatty replacement cardiomyocytes predisposes malignant arrhythmia heart_failure sudden_cardiac_death diagnosis based task force criterion including family history electrocardiographic trait arrhythmogenic pattern specific gene mutation structural histological abnormality acms display autosomal dominant mode inheritance often incomplete penetrance variable expressivity genetic screening patient acm identifies pathogenic likely pathogenic variant prevalently gene encoding cardiac desmosome pkp dsp dsc dsg jup less frequently non desmosomal gene ctnna pln tmem ryr scn cdh de method present_study performed molecular autopsy boy died suddenly physical exertion addition post mortem examination dna sample analyzed next generation sequencing ng result genetic analysis_revealed presence pathogenic heterozygous c del p pro leufs frameshift variant pkp gene cascade screening family member allowed u identify mutation carrier intervene subject risk many athlete conclusion molecular autopsy establish cardiogenetic diagnosis allow appropriate preventative measure high_risk relative:0.0359501720478246"}, "Topic 28": {"156858": "background although previous observational_study shown association anemia cardiovascular_disease_cvd underlying causal relationship anemia cvd remains uncertain method_result conducted sample bidirectional mendelian randomization mr study assess causal association anemia cvd extracted summary statistic data anemia heart_failure_hf coronary_artery_disease_cad atrial_fibrillation stroke ischemic_stroke ai relevant published genome wide association study rigorous quality control step independent single nucleotide polymorphism disease selected instrumental variable inverse variance weighting used primary method estimate causal association anemia cvd sample mr analysis simultaneously performed series multiple method analysis median weighting maximum likelihood mr robust adjusted profile score sensitivity_analysis cochran q test mr egger intercept leave one test mr pleiotropy residual sum outlier instrumental variable strength evaluation f statistic statistic power estimate verify robustness reliability result furthermore association anemia cvd different study including uk biobank finngen study combined meta_analysis mr analysis_showed genetically predicted anemia significantly_associated hf_risk bonferroni corrected significance level odds_ratio ci_p suggestively associated cad risk ci_p however association anemia atrial_fibrillation stroke ai statistically_significant reverse mr analysis found genetic susceptibility hf cad ai significantly_associated anemia risk or hf cad ai ci_p e ci_p e ci_p respectively genetically predicted atrial_fibrillation suggestively associated anemia ci_p sensitivity_analysis found weak evidence horizontal pleiotropy heterogeneity ensured robustness reliability result meta_analysis also showed statistically_significant association anemia hf_risk conclusion_study support bidirectional causality anemia hf significant_association genetic predisposition cad ai anemia contributes clinical management disease:0.0649714355683862", "174334": "uterine fibroid uf common benign tumor woman associated cardiovascular_disease_cvd observational_study yet causal inference remains_unclear due confounding mendelian randomization mr study leveraged genetic variant instrumental variable iv evaluate causal relationship genetically predicted uf cvd risk exposure data derived uk biobank genome wide association study european uf case outcome data cvd subtypes obtained finngen ebi consortium sample size fourteen independent single nucleotide polymorphism strongly_associated uf p x selected iv pruned linkage disequilibrium r f statistic inverse variance weighted method_used primary analysis supplemented sensitivity approach weighted median mr egger mr presso robustness evaluated via cochran q test heterogeneity mr egger intercept pleiotropy leave one analysis genetically predicted uf showed causal effect ischemic_heart_disease e ci e_e p heart_failure e ci e_e p venous thromboembolism e ci e_e p stroke e ci e_e p sensitivity_analysis confirmed consistency p heterogeneity cochran q p horizontal pleiotropy mr egger intercept p leave one analysis indicated stable estimate mr study found insufficient evidence support causal link uf cvd contrasting previous observational report:0.0642723676011948", "165655": "background evidence_suggests coronavirus disease covid associated risk cardiovascular_disease cvds however result inconsistent causality remains established aimed investigate potential causal relationship covid cvds using two sample mendelian randomization mr analysis method summary level data covid cvds including myocarditis heart_failure_hf acute_myocardial_infarction_ami arrhythmia venous thromboembolism vte obtained ieu opengwas project public genome wide association study gwas single nucleotide polymorphism snp used instrumental variable five complementary mr method performed including inverse variance weighted ivw mr egger weighted median weighted mode simple mode method ivw method considered primary approach besides sensitivity_analysis including cochran q test mr egger intercept test leave one analysis_performed evaluate robustness result result according ivw result mr study indicated genetically predicted covid causally connected risk cvds myocarditis odds_ratio confidence_interval_ci_p value hf ci_p value ami ci_p value arrhythmia ci_p value vte ci_p value supplementary mr method showed similar result sensitivity_analysis suggested causal estimate robust conclusion two sample mr analysis provide sufficient evidence causal relationship covid risk acute cvds may_provide new insight prevention acute cvds covid patient:0.0627443460817591", "166883": "background extensive epidemiological study highlighted correlation serum phosphate cardiovascular_disease present_study aim determine_whether genetically predicted serum phosphate causally associated distinct subtypes cardiovascular_event use mendelian randomization mr analysis method independent strongly correlated single nucleotide polymorphism snp serum phosphate extracted publicly available genome wide association study summary statistic cardiovascular_disease derived large_scale consortium including hermes finngen biobank mr egger weighted median inverse variance weighted pleiotropy residual sum outlier mr presso method mr using robust adjusted profile score mr rap employed analyze causality sensitivity_analysis comprised heterogeneity horizontal pleiotropy leave one approach used ensure stability result result_study demonstrated increased genetically predicted serum phosphate causally associated_higher_risk valvular_heart_disease vhd vhd including rheumatic fever odds_ratio confidence_interval_ci_p non rheumatic vhd ci_p however causal association detected serum phosphate common cardiovascular_disease including coronary_heart_disease heart_failure atrial_fibrillation essential hypertension conclusion_result indicate strong causality serum phosphate valvular_heart_disease serum phosphate lowering therapy within physiological range may represent novel therapeutic method valvular_heart_disease:0.0626134461258331", "165813": "background numerous study_conducted investigate relationship tea consumption risk cardiovascular_disease_cvd however conclusive result achieved conducted mendelian randomization mr study elucidate causal association tea consumption several cvd outcome including coronary_artery_disease_cad myocardial_infarction_mi atrial_fibrillation_af heart_failure_hf method independent single nucleotide polymorphism snp genome wide significantly_associated tea consumption used instrumental variable iv summary statistic cvd outcome obtained corresponding genetic consortium finngen consortium inverse variance weighted ivw method primary analytical method mr estimate different data source combined using fixed effect meta_analysis supplementary mr analysis including weighted median mr egger mr pleiotropy residual sum outlier method_conducted evaluate robustness result mr analysis repeated including genetic variant higher p_value threshold result found genetically predicted tea consumption causally associated cvd outcome ivw method using data large genetic consortium cad odds_ratio confidence_interval_ci_p mi ci_p af ci_p hf ci_p finngen consortium cad ci_p mi ci_p af ci_p hf ci_p result robust consistent across meta_analysis supplementary mr analysis analysis iv included conclusion mr study revealed causal association tea consumption four cvd outcome suggesting tea consumption may beneficial primary_prevention cvd:0.0622332413164871", "168555": "recent_study explored impact personality trait including mood swing physical health however remains_unclear whether direct cause effect link mood swing cardiovascular_disease cvds strobe compliant cross_sectional observational_study conducted analyzed_using two sample mendelian randomization mr approach examine potential causal relationship mood swing range cvds arrhythmia artery aneurysm coronary_heart_disease chd heart_failure hypertension stroke ischemic_stroke peripheral artery disease sourced genome wide association study gwas summary data mood swing uk biobank cvds gwas catalog finngen database excluded single nucleotide polymorphism snp linked potential confounders obesity smoking sex diabetes well snp suspected horizontal pleiotropy identified mr presso mr pleiotropy method prior final analysis sensitivity_analysis conducted using mr egger inverse variance weighted leave one method screening snp identified instrumental variable mood swing snp related confounding factor excluded increase mood swing frequency correlated significant_increase likelihood various condition notably arrhythmia finngen dataset showed odds_ratio confidence_interval_ci_p atrial_fibrillation ci_p chd risk elevated ieu opengwas project ci_p gwas catalog ci_p increased_risk also noted heart_failure gwas catalog ci_p hypertension finngen ci_p however significant_association found condition arterial aneurysm ischemic_stroke combined analysis mood swing associated_higher_risk chd ci_p heart_failure ci_p cvds study revealed causal link mood swing various cvds highlighting intriguing finding suggests implementing proper psychological intervention stabilize mood may beneficial preventing negative cardiovascular_event:0.0615986179336754", "171010": "although observational_study linked primary aldosteronism pa cardiovascular_disease cvds causality remains uncertain study_aimed_investigate whether pa causally associated cvd risk cardiac_magnetic_resonance cmr parameter using mendelian randomization mr method independent genome wide significant single nucleotide polymorphism pa extracted genome wide association study gwas summary statistic genetic association cvds cmr parameter obtained recent large_scale gwass genetic consortium inverse variance weighted ivw method utilized preliminary estimate multiple sensitivity_analysis including weighted median cochran q test mr egger mr presso leave one analysis conducted verify robustness result mr analysis using ivw method showed genetically predicated pa significantly_associated atrial_fibrillation ci padj myocardial_infarction ci padj heart_failure ci padj stroke ci padj ischemic_stroke ci padj small vessel stroke ci padj notably pa also causal effect adverse cardiac_remodeling including larger ventricular atrial volume higher ventricular stroke_volume reduced left_atrial emptying fraction finding support causal role pa higher cardiovascular_disease risk adverse cardiac_remodeling given diagnostic delay disease burden pa attention paid screening treatment pa reduce incidence cardiovascular_outcome:0.0612538816817060", "195939": "background causal relationship chronic venous insufficiency cvi cardiovascular_disease cvds yet elucidated herein implement mendelian randomization mr analysis investigate causal association method two sample mr approach using genetic data finngen genome wide association study gwas catalog applied investigate causal relationship cvi cvds study assessed single nucleotide polymorphism snp instrumental variable employing random_effect inverse variance weighted mr weighted median egger regression mendelian randomization pleiotropy residual sum outlier mr presso robust adjusted profile score rap method multivariable mr mvmr considered confounding factor result genetically predicted cvi associated_reduced heart_failure risk odds_ratio confidence_interval_ci_p increased atrial_fibrillation risk ci_p mvmr adjusting venous thromboembolism vte lower limb ulceration obesity smoking alcohol attenuated association significant link found hypertension aortic aneurysm coronary_artery_disease myocardial_infarction valvular_heart_disease stroke conclusion mr study support association cvi cvds may imply cvi monitored treatment_heart_failure atrial_fibrillation:0.0611925227644873", "181705": "background observational finding_suggest patient narcolepsy higher_risk cardiovascular_disease cvds potential causal relationship narcolepsy cvds unclear therefore mendelian randomization mr used explore association narcolepsy cvds method summary statistic related narcolepsy coronary_artery_disease_cad myocardial_infarction_mi heart_failure_hf stroke ischemic_stroke ai extracted public database relevant published genome wide association study gwas independent single nucleotide polymorphism selected instrumental variable strict quality control criterion inverse variance weighted ivw main analytical method assess causal effect addition conducted mr pleiotropy residual sum outlier mr presso weighted median mr egger leave one sensitivity_analysis verify robustness reliability result result result mr study revealed narcolepsy significantly_associated increased_risk hf ci_p cad ci_p statistically_significant causal association narcolepsy mi ai addition sensitivity analysis_showed robust result conclusion_result two sample mr study reveal potential causal relationship increased_risk hf cad narcolepsy finding emphasize importance early monitoring assessment cardiovascular_risk patient narcolepsy:0.0608977018589091", "128060": "background previous_study observed inconsistent association coronavirus disease covid heart_failure_hf study prone bias based reverse causality residual confounding factor aimed investigate genetic liability covid heart_failure using bidirectional mendelian randomization study method causal relationship covid including covid hospitalized covid compared general_population severe covid hf determined using bidirectional mendelian randomization analysis drew summary statistic largest hf genome wide association study gwas meta_analysis individual european ancestry included hf_patient control inverse variance weighted ivw adaption egger regression mr egger weighted median weighted model conducted mendelian randomization analysis estimate causal effect confirm stability performed leave one approach sensitivity_analysis result genetically predicted severe covid significantly_associated risk_hf odds_ratio confidence_interval_ci_p ivw demonstrated association genetically hospitalized covid infection hf_risk ci_p evidence support association genetically determined covid risk_hf ci_p addition genetically predicted hf also causally associated covid ci_p mr egger analysis indicated evidence directional pleiotropy conclusion current bidirectional mendelian randomization analysis overcomes limitation observational_study finding indicated causal association covid hf:0.0600738382601083"}, "Topic 29": {"168502": "importance anorexia nervosa commonly associated cardiovascular_complication objective investigate trajectory risk cardiovascular condition nationwide cohort_patient taiwan design setting_participant population_based health insurance database january_december longitudinal cohort_study identified_patient control propensity_score_matching ratio according sex age urbanization level residence socioeconomic status year diagnosis data analyzed june february exposure first_time diagnosis psychiatrist study_period main_outcome_measure incidence risk composite cardiovascular condition kaplan_meier curve used estimate cumulative incidence major_adverse_cardiovascular_event_mace cardiovascular condition adjustment psychiatric comorbidities conditional cox_proportional_hazard regression_analysis performed estimate risk cardiovascular_event presented hazard_ratio hr_ci relative comparison group risk individual cardiovascular condition calculated follow_period diagnosis result_study population included_patient matched_control total participant mean_sd age_year female total_patient mace v control patient cardiovascular condition v control year_follow cumulative incidence_rate mace ci cardiovascular condition ci compared control_group group significantly_higher risk mace adjusted hr ahr ci cardiovascular condition ahr ci significantly increased_risk congestive_heart_failure conduction disorder structural heart_disease occurred initial follow_period disappeared month_follow notably patient increased_risk ischemic_heart_disease month_follow ahr ci_conclusion relevance national matched cohort_study increased_risk cardiovascular condition found different period diagnosis clinician monitor comorbid cardiovascular condition among_patient initial presentation treatment follow:0.0369469342350839", "77067": "background cardiovascular_event associated oral hypoglycemic agent ohas raised significant safety concern study assessed association dipeptidyl peptidase inhibitor dpp risk cardiovascular_event patient type_diabetes_mellitus without chronic_kidney_disease_ckd study_design retrospective_cohort_study using taiwan national_health insurance research database setting_participant study included_patient type_diabetes received ohas march december eligible subject classified ckd non ckd cohort categorized dpp non dpp user cohort method dpp non dpp group matched propensity_score attenuate potential selection bias propensity_score estimated logistic_regression using demographic co medication comorbidities adapted diabetic complication severity index baseline outcome outcome interest included composite_endpoint ischemic_stroke myocardial_infarction cardiovascular_death major_adverse_cardiac_event mace hospitalization_heart_failure hhf cox_proportional_hazard_model applied examine association dpp outcome interest result identified_patient type_diabetes without ckd respectively propensity_score_matching pair ckd patient pair non ckd patient_included analysis ckd cohort dpp associated_increased_risk hhf dpp v non dpp incidence person_year v hr_ci_p risk mace hr_p non ckd cohort dpp associated_lower risk mace dpp v non dpp incidence person_year v hr_ci_p risk hhf hr p_conclusion dpp found associated decreased risk mace non ckd cohort_study however dpp associated_increased_risk hhf ckd cohort dpp ckd cohort used cautiously:0.0364371481666833", "99792": "objective explore association nontyphoidal salmonellosis nt risk acute ischemic_stroke using nationwide population_based study method_retrospective cohort_study using claim data taiwan national_health insurance research database nhird patient_aged_year older history nt n included january_december non nt group_n without nt matched propensity_score follow_period defined time initial diagnosis nt date development death december patient previously diagnosed stroke excluded cox_proportional_hazard_model robust sandwich estimator used estimate hazard_ratio_hr_confidence_interval_ci adjusting demographic clinical covariates result adjusted_hazard_ratio ahr nt group_compared non nt group confidence_interval_ci overall stroke furthermore nt cohort increased_risk compared_non nt group ahr ci stratified analysis_showed compared propensity_score matched non nt group subject aged_year female hypertension hyperlipidemia copd cancer heart_failure higher_risk developing stroke fold significant increase_risk stroke observed first month_follow ci conclusion_patient nt associated_increased_risk developing ischemic_stroke compared_non nt patient timely mindful treatment plan nt may milestone stroke prevention especially subpopulation:0.0361607441594989", "175982": "background individual schizophrenia substantially elevated cardiovascular morbidity_mortality disparity exacerbated coexisting type_diabetes_mellitus_dm impact specific antipsychotic long_term cardiovascular outcome_patient dm remains_unclear aimed compare major_adverse_cardiovascular_event_mace patient co occurring dm schizophrenia treated aripiprazole versus risperidone method_conducted multi center retrospective_cohort_study within trinetx u collaborative network adult year diagnosis dm schizophrenia new user aripiprazole risperidone identified aripiprazole risperidone cohort propensity_score matched n demographic age_sex race ethnicity body_mass_index healthcare utilization socioeconomic lifestyle factor comorbidities baseline medication primary_outcome time first major_adverse_cardiovascular_event defined composite myocardial_infarction ischemic hemorrhagic stroke_heart_failure ventricular_arrhythmia sudden_cardiac_death cause_mortality kaplan_meier estimation cox_proportional_hazard_model used compare outcome year_follow subgroup_analysis sex age race time stratified analysis year v year_follow performed result matching baseline_characteristic well balanced mean_age_year female median hba_c approximately group aripiprazole associated significantly elevated hazard mace compared risperidone hazard_ratio_hr confidence_interval risk difference emerged primarily beyond first_year treatment excess risk aripiprazole driven largely higher_rate heart_failure ventricular_arrhythmia whereas risk myocardial_infarction ischemic_stroke similar group significant heterogeneity treatment_effect observed across sex age racial subgroup conclusion large real_world cohort_patient dm schizophrenia aripiprazole use associated modest significant increase_risk mace compared risperidone clinician remain vigilant cardiovascular_risk management population regardless antipsychotic choice research needed elucidate mechanism confirm observation prospective_study:0.0355704729592721", "161284": "importance sodium_glucose_cotransporter type inhibitor sglt revolutionary treatment type_diabetes cardiovascular kidney serum urate lowering benefit objective compare risk incident gout rate recurrent flare patient initiating sglt v sulfonylurea common second line glucose lowering therapy added metformin monotherapy design setting_participant sequential propensity_score matched new user comparative effectiveness study using target trial emulation framework included adult receiving metformin monotherapy canadian general_population database january june exposure initiation sglt v sulfonylurea main_outcome_measure primary_outcome incident gout diagnosis ascertained emergency_department ed hospital outpatient medication dispensing record secondary_outcome gout primary hospitalization ed visit major_adverse_cardiovascular_event_mace well recurrent flare rate among prevalent gout patient_heart_failure_hf hospitalization assessed positive control outcome osteoarthritis encounter negative control target trial emulation used cox_proportional_hazard poisson regression propensity_score_matching primary analysis overlap weighting sensitivity_analysis analysis conducted september december result_among propensity_score matched adult initiating sglt sulfonylurea male mean_sd age_year incidence gout lower among sglt initiator event per_person_year sulfonylurea initiator event per_person_year hazard_ratio hr_ci rate difference rd ci per_person_year association persisted regardless sex age baseline diuretic use sglt use also associated fewer recurrent flare among gout patient rate ratio ci rd ci per_person_year hr rd mace associated sglt use ci_ci per_person_year control outcome sglt user lower_risk hf hr_ci expected difference osteoarthritis hr_ci result similar applying propensity_score overlap weighting conclusion population_based cohort_study gout cardiovascular benefit associated sglt target trial emulation may guide selection glucose lowering therapy_patient risk already gout:0.0352510756707384", "61088": "objective elderly aged_year population type_diabetes growing substantially evidence association use dipeptidyl peptidase inhibitor dpp novel incretin based antidiabetic drug clinical hard endpoint group remains inconclusive aimed assess safety cardiovascular effect dpp use nationally representative sample elderly adult design setting_participant conducted nationwide observational propensity_score matched study using taiwan national_health insurance research database total_patient aged_year patient_receiving initial dpp prescription march june included dpp user matched nonuser control using propensity_score endpoint cause_mortality major_adverse_cardiovascular_event_mace including ischemic_stroke myocardial_infarction potential adverse_effect hospitalization_heart_failure hypoglycemia also evaluated result compared matched_control cohort risk cause_mortality hazard_ratio_hr_confidence_interval_ci mace hr_ci myocardial_infarction hr_ci ischemic_stroke hr_ci lower dpp cohort dpp use affect risk hospitalization_heart_failure hypoglycemia stratified analysis produced consistent result across age_sex comorbidity subgroup conclusion prescription dpp associated_reduced risk cause_mortality mace patient_aged_year:0.0348287266668008", "59428": "background recent clinical_trial evaluated cardiovascular_outcome dipeptidyl peptidase dpp inhibitor patient type_diabetes_mellitus_dm end_stage_renal_disease esrd ineligible participation trial aimed characterize impact dpp inhibitor major_adverse_cardiovascular_event_mace patient dm esrd undergoing chronic dialysis method nationwide observational_study utilized data patient_aged_year dm esrd initiated treatment dpp inhibitor march june retrieved taiwan national_health insurance research database dpp inhibitor user matched non user control subject using propensity_score primary_outcome cause_mortality mace ischemic_stroke myocardial_infarction secondary_outcome hospitalization_heart_failure hypoglycemia subject followed death december result compared_non user dpp inhibitor user lower_risk cause_mortality hazard_ratio_hr_confidence_interval_ci mace hr_ci ischemic_stroke hr_ci risk myocardial_infarction hospitalization_heart_failure hypoglycemia differ treatment_effect remained consistent subgroup_analysis according age_sex comorbidities dialysis modality insulin use conclusion nationwide esrd cohort dpp inhibitor use associated_reduced risk cause_mortality ischemic_stroke:0.0345245936169772", "146280": "objective_determine risk time trend heart_failure_hf leading hospitalization individual newly_diagnosed polymyositis dermatomyositis pm dm relative non pm dm control general_population level method_retrospective cohort_study conducted using data nationwide insurance database taiwan patient incident pm dm without history hf selected unmatched propensity_score matched cohort established separately multivariable cox_proportional_hazard regression_model used estimate adjusted hazard_ratio_hr risk_hf unmatched cohort propensity_score matched cohort general_population control selected matched ratio patient pm dm based propensity_score accounted confounding factor age_sex index date year first diagnosis comorbidities medication usage cumulative incidence hf estimated using kaplan_meier method stratified cox_proportional_hazard_model used calculate hr risk_hf event different follow time_point among_patient pm dm compared_non pm dm control propensity_score matched cohort result unmatched cohort_study assessed patient pm dm general_population control result multivariable cox_regression_analysis adjusted age_sex comorbidities medication usage revealed greater risk_hf leading hospitalization pm dm group control_group adjusted hr confidence_interval_ci matching based propensity_score total pair pm dm patient general_population control identified propensity_score matched cohort cumulative incidence hf_patient pm dm year_year year_year respectively absolute difference hf_risk pm dm group_compared control_group year_year year_year compared general_population control patient pm dm exhibited augmented risk_hf hr_ci analysis stratified according follow time_point revealed increased_risk hf persisted year pm dm diagnosis conclusion_result indicate risk_hf leading hospitalization increased patient pm dm throughout study_period supporting need greater vigilance monitoring patient pm dm development potentially lethal complication:0.0341395598363964", "131080": "importance controversy exists regarding whether statin therapy benefit patient kidney failure consequence statin therapy_patient kidney failure concomitant peripheral artery disease pad particularly uncertain objective_evaluate association statin therapy cardiovascular_cv limb outcome among_patient kidney failure concomitant pad dyslipidemia receiving long_term maintenance dialysis design setting_participant retrospective_cohort_study used data taiwan national_health insurance research database total_patient kidney failure receiving long_term maintenance dialysis diagnosed pad dyslipidemia january_december identified_patient met study criterion data analyzed june june main_outcome_measure primary_outcome cause_death composite endovascular therapy evt amputation outcome interest included cv_event cv_death acute_myocardial_infarction ischemic_stroke hospitalization_heart_failure major_adverse limb event new_onset claudication new_onset critical limb ischemia evt nontraumatic amputation cause readmission outcome examined year year_follow minimize selection bias propensity_score_matching ratio performed among_patient receiving statin therapy statin group_patient receiving statin therapy nonstatin group defined daily dose ddd approach used_evaluate whether association statin therapy risk primary_outcome dose dependent result among_patient kidney failure concomitant pad dyslipidemia receiving long_term maintenance dialysis patient woman mean_sd age_year taiwanese ethnicity met predetermined study criterion patient_receiving statin therapy total_patient mean_sd age_year woman included propensity_score matched cohort patient_group statin nonstatin incidence risk cv cause_death significantly_lower statin group_v nonstatin group year_follow cv_death patient v patient hazard_ratio hr_ci_p cause_death patient v patient hr_ci_p statin use also associated significantly_lower incidence risk composite adverse limb outcome evt amputation year_follow patient v patient subdistribution hr_ci_p result subgroup_analysis consistent primary analysis across subgroup variable adjusted dose response analysis risk reduction associated statin use increased dose dependent manner cause_death hr ddd ddd ddd ddd p trend composite_outcome evt amputation subdistribution hr ddd ddd ddd ddd p trend compared statin therapy however finding ddd analysis statistically_significant conclusion relevance cohort_study statin therapy associated reduction risk cause_death cv_death composite adverse limb outcome evt amputation finding_suggest statin therapy may protective cv limb benefit patient kidney failure concomitant pad receiving long_term maintenance dialysis:0.0337419829003741", "130471": "background evaluate comparative cardiovascular_cv safety febuxostat versus allopurinol among_patient gout following recent accumulated use febuxostat method using korea national_health insurance database conducted cohort_study comparing gout patient initiating febuxostat versus allopurinol matched propensity_score p covariates primary_outcome composite_endpoint myocardial_infarction coronary revascularization stroke secondary_outcome individual component primary_outcome hospitalized heart_failure cause_mortality subgroup_analysis done high cv risk long_term user follow year without chronic_kidney_disease used cox_proportional_hazard_model estimate hazard_ratio_hr_confidence_interval_ci result included p matched pair febuxostat allopurinol user mean_age_year_male incidence_rate primary_outcome per_person_year febuxostat allopurinol user respectively hr_ci comparing febuxostat versus allopurinol initiator also observed similar risk secondary_outcome except reduced cause_mortality among febuxostat user hr_ci subgroup_analysis also showed non inferior cv safety febuxostat conclusion population_based cohort_study including largest number febuxostat user date found non inferior cv safety febuxostat versus allopurinol reduction cause_mortality among febuxostat user:0.0332559134646868"}, "Topic 30": {"38325": "objective_determine short_term effect cardiac_resynchronization_therapy_crt measurement left_ventricular_lv diastolic_function patient_severe heart_failure background cardiac_resynchronization_therapy improves systolic performance however effect diastolic_function load dependent pulsed wave doppler transmitral index variable method fifty patient_severe heart_failure evaluated two dimensional doppler echocardiography immediately prior month crt measurement included lv volume ejection_fraction_ef pulsed wave doppler pwd derived transmitral filling index e wave velocity e ratio deceleration time dt diastolic filling time dft isovolumic relaxation time tissue_doppler imaging used measurement systolic_diastolic em velocity four mitral annular site mitral e wave em ratio calculated estimate lv filling_pressure color mode flow propagation velocity also obtained result crt lv volume decreased significantly p lvef increased patient accompanied reduction pwd mitral e wave velocity e ratio p increased dt dft p lower filling_pressure e_e wave em septal p_patient lvef response crt significant_change measurement diastolic_function lv relaxation e em velocity worsened group_conclusion heart_failure_patient receiving crt improvement lv diastolic_function coupled improvement lv systolic_function:0.0470995428778840", "18901": "introduction isolated diastolic heart_failure dhf defined heart_failure preserved left_ventricular_lv systolic_function absence valve disease dhf clinical diagnosis confirmed echocardiography presumed due diastolic_dysfunction dd dd characterized abnormality relaxation distensibility restriction left_ventricle lv dhf account patient_heart_failure independent_predictor atrial_fibrillation_af elderly aim paper describe diagnosis dd sinus_rhythm af well report agent used treatment dhf prevention af dhf diagnosis sinus_rhythm early dd identified doppler determined mitral inflow measurement ratio peak velocity early filling e wave atrial contraction wave e deceleration time dt slow m isovolumic relaxation period irp prolonged m moderate dd lv stiffens elevated left_atrial pressure resulting pseudonormal filling pattern e ratio unmasked pulmonary vein measurement systolic forward flow less approximately diastolic forward flow wave retrograde flow wave r increased lv stiffens restrictive feature develop resulting rapid early filling e ratio shortened dt m irp m r wave increased amplitude duration m early diastolic filling reflected tissue_doppler determination mitral annulus motion velocity e reduced dd e_e ratio correlate well filling_pressure diagnosis af atrial contraction absent therefore measurement independent atrial influence dt irp e_e ratio wave used therapy dhf af prevention well_established treatment ace_inhibitor angiotensin_receptor_blocker arb aldosterone antagonist shown objective improvement dhf arb found decrease incidence af candesartan decrease incidence af_patient symptomatic heart_failure preserved lv systolic_function ongoing study irbesartan spironolactone evaluate effect dhf treatment conclusion diagnosis dd made echocardiography patient sinus_rhythm patient_af randomized_controlled_trial patient dhf way treatment dhf af prevention continue evolve:0.0444933697425771", "53974": "pulsed doppler derived transmitral flow tmf widely_used evaluating left_ventricular_lv diastolic_function grading lv diastolic_dysfunction feasible ratio early late diastolic inflow velocity e normal e grade e abnormal relaxation pattern grade ii e pseudonormal pattern grade iii e restrictive pattern grade iv e irreversible restrictive pattern pulmonary venous flow pattern also used evaluation lv diastolic_dysfunction especially differentiate normal pseudonormal tmf pattern ratio systolic_diastolic pulmonary venous flow normal regarded pseudonormal recently tissue_doppler imaging tdi introduced new diagnostic tool lv diastolic_dysfunction mitral annular velocity obtained tdi used preload independent index lv diastolic_function ratio early transmitral inflow mitral annular velocity e ea related well pulmonary_capillary wedge_pressure particular e ea strongly suggested elevated pcwp lv filling_pressure therefore analysis tmf pvf pattern pulsed doppler ea tdi useful diagnosing uncompensated state heart_failure furthermore tmf pattern utilized predict prognosis patient_heart_failure patient irreversible restrictive filling pattern high mortality whereas reversible restrictive filling high probability improvement heart_failure:0.0438403192796072", "15233": "background process myocardial remodelling start onset symptom recent heart_failure_hf guideline place special emphasis detection subclinical left_ventricular_lv systolic diastolic_dysfunction timely identification risk_factor hf goal describe prevalence determinant risk_factor lv diastolic_dysfunction general_population compare amino terminal probrain natriuretic_peptide level across group without diastolic_dysfunction method_result randomly recruited population sample n woman mean_age_year measured early late diastolic peak velocity mitral inflow e pulmonary vein flow pulsed wave doppler mitral annular velocity ea aa site tissue_doppler imaging healthy subsample subject mean_age_year provided age specific cutoff limit normal e_e ea ratio difference duration mitral reverse pulmonary vein flow atrial systole deltaad ard number subject diastolic_dysfunction group impaired relaxation elevated lv_end_diastolic filling_pressure elevated e ea abnormally low e respectively used delta ad ard confirm possible elevation lv filling_pressure group_compared subject normal diastolic_function n group versus pmol l p group versus pmol l p group versus pmol l p significantly_higher adjusted nt probrain natriuretic_peptide higher age body_mass_index heart_rate systolic_blood_pressure serum insulin creatinine significantly_associated higher_risk lv diastolic_dysfunction conclusion overall prevalence lv diastolic_dysfunction random sample general_population estimated echocardiographic measurement high:0.0434216383888929", "80576": "background study_aimed_investigate whether endogenous active level mmp tissue inhibitor metalloproteinases timp related index diastolic_dysfunction dd setting contemporary treatment coronary_artery_disease_cad method_result prospectively studied patient cad preserved left_ventricular_lv systolic_function ejection_fraction patient free heart_failure_symptom recruitment underwent percutaneous intervention pci culprit lesion demographic angiographic characteristic collected plasma sample analysed active form mmp timp using enzyme linked immunosorbent assay based isoform sensitive assay conventional tissue_doppler echocardiographic assessment diastolic filling undertaken measurement maximal early e late transmitral velocity diastole e ratio e wave deceleration time isovolumic relaxation time peak systolic_diastolic atrial reversal velocity pulmonary venous flow fraction time difference duration atrial reversal flow early diastolic peak velocity lateral mitral annulus e_e e_e active mmp level higher patient_severe phase dd normal n median ng_ml mild n ng_ml mild_moderate n ng_ml moderate_severe n ng_ml p trend three month post pci elevated level active mmp adjusted_odds_ratio p association moderate_severe dd conclusion elevated active mmp level associated severe dd patient cad preserved systolic_function may indicate abnormal extracellular_matrix metabolism myocardial ischaemia:0.0433641687250963", "58843": "background_aim two dimensional doppler echocardiography main method non_invasive evaluation ventricular_function child study monitored evaluation systolic diastolic_function pediatric patient using classical echocardiographic_parameter pulsed tissue_doppler parameter well correlation method_study included healthy child child diagnosed congestive_heart_failure secondary congenital heart malformation parameter systolic diastolic_function measured echocardiography guided mode color pulsed doppler well pulsed tissue_doppler level mitral tricuspid annulus result relaxation alteration pattern pseudonormal pattern e diastolic velocity compared wave found e_e group subject heart_failure e wave deceleration time significantly_increased value case patient_chf correlated diastolic_dysfunction left_ventricular flow propagation velocity vp decreased patient_heart_failure e vp ratio maintained relatively constant subject congestive_heart_failure healthy_subject probably account concomitant change e wave association severity systolic_dysfunction diastolic_dysfunction found pediatric patient_diagnosed congestive_heart_failure student test p_conclusion tissue_doppler measurement proved useful evaluation pediatric patient altered ventricular geometry secondary congenital_heart_disease systolic diastolic_dysfunction heart_failure:0.0426809691808307", "3403": "left_ventricular diastolic_dysfunction lvdd frequent cause_heart_failure doppler echocardiography become method choice noninvasive evaluation lvdd however pseudonormalization pn mitral inflow often present diagnostic challenge clinical_practice setting sought define role tissue_doppler imaging tdi septal mitral annulus echocardiography performed consecutive subject age_year eighteen diagnosed coronary_artery_disease_cad recent onset symptom within_month clinical suspicion cad symptom heart_failure new_york_heart_association_nyha_class mitral inflow profile e_e measured pulsed doppler deceleration time dt isovolumic relaxation time ivrt calculated peak diastolic velocity septal mitral annulus e_e time interval q ecg onset e derived pulsed tdi left heart catheterization performed direct measurement left_ventricular_end_diastolic pressure lvedp pn defined e ratio lvedp mmhg found nine patient_patient pn symptom heart_failure nyha_class patient_without pn differ respect e ratio v_p n dt msec v msec p n ivrt msec v msec p n group pn significant_reduction e cm sec v cm sec p e v_p detected pn group q e interval prolonged msec v msec p receiver_operating_characteristic_curve analysis e yielded area_curve p separating patient versus without pn combination e cm sec e used cutpoint pn could identified sensitivity_specificity significant relation lvedp either e r_p q e interval r p_conclusion e q e interval appear useful parameter assessing lv diastolic_dysfunction symptomatic patient pseudonormal mitral inflow pattern elevated filling_pressure:0.0422233282943781", "10282": "objective cardiac deposition aa amyloidosis may result increasing left_ventricular mass systolic diastolic_dysfunction dd aim_study investigate left_ventricular systolic diastolic_function tissue_doppler imaging tdi pulsed wave doppler echocardiography pwd patient aa amyloidosis without congestive_heart_failure symptom arrthymia method_result twenty four patient aa amyloidosis without congestive_heart_failure symptom arrthymia men nine woman mean_age_year healthy_subject men six woman mean_age_year control included_study mode two dimensional pwd tdi performed peak transmitral filling velocity e wave peak transmitral atrial filling velocity wave deceleration time isovolumic relaxation time measured pwd recording peak myocardial systolic velocity sm peak myocardial early em late diastolic velocity also recorded tdi e ratio less one accepted dd method ejection_fraction_ef calculated teicholtz method subject divided three_group follows healthy control_group patient_without dd group_patient dd group according pwd finding pwd echocardiography showed dd present patient whereas tdi showed dd case subgroup_analysis sm wave systolic_function index lower group group whereas mean ef value similar group_conclusion although aa amyloidosis uncommonly cause cardiac symptom finding according result_patient aa amyloidosis may systolic diastolic_dysfunction eventhough asymptomatic also tissue_doppler imaging reliable method early_detection cardiac_dysfunction patient:0.0416159389515630", "21578": "b_type_natriuretic_peptide bnp_level increase systolic heart_failure_hf however value bnp hypertensive_patient suspected diastolic hf symptom suggestive hf normal ejection_fraction relation myocardial function patient unclear prospectively studied ambulatory hypertensive subject woman mean_age_year exertional dyspnea ejection_fraction diastolic_function evaluated transmitral pulmonary venous doppler mitral annular velocity pulsed wave tissue_doppler flow propagation velocity color mode systolic_function assessed strain strain rate derived color tissue_doppler imaging bnp related myocardial function presence absence global diastolic_dysfunction conventional doppler criterion patient normal left_ventricular diastolic_function isolated diastolic_dysfunction bnp value higher patient diastolic_dysfunction v pg_ml_p related independently blood_pressure systolic strain rate left_atrial function p age p_patient diastolic_dysfunction pseudonormal filling higher bnp_level compared impaired relaxation v pg_ml_p however patient diastolic_dysfunction bnp_level within normal range conclude ambulatory hypertensive_patient symptom suggestive mild hf normal ejection_fraction bnp related atrial ventricular systolic parameter blood_pressure age although elevated presence diastolic_dysfunction bnp_level mostly normal range therefore limited diagnostic value stable patient suspected diastolic hf:0.0412476071844817", "41838": "arterial_hypertension associated accelerated atherosclerosis resulting increased arterial stiffness well_known left_ventricular diastolic_function decline patient hypertension study_aim determine relationship arterial stiffness left_ventricular diastolic_dysfunction patient hypertension preserved left_ventricular_ejection_fraction using newly developed ultrasonic imaging method performed cross_sectional_study including patient hypertension left_ventricular systolic diastolic_function evaluated mode measuring transmitral flow velocity mitral annular motion velocity using conventional tissue_doppler tdi ultrasonic system asymptomatic atherosclerosis also determined measuring intima medium thickness stiffness common carotid artery using mode tissue_doppler ultrasonography result according conventional doppler echocardiography transmitral tissue_doppler diastolic_function classified normal patient abnormal patient diastolic_dysfunction mild impaired relaxation advanced pseudonormal filling dysfunction univariate analysis_revealed index negatively associated em r_p well em ratio r_p moreover multivariate_analysis showed tdi derived em ratio significantly_associated age p relative wall_thickness p index beta_p conventional doppler derived e ratio significantly_associated age p arterial stiffness index highest patient hypertension normal function progressively increased patient impaired relaxation pseudonormal filling stepwise multiple regression_analysis model including age systolic_diastolic blood_pressure pulse pressure body_mass_index beta index factor independently correlated arterial stiffness left_ventricular average peak systolic velocity conclusion data confirm positive correlation diastolic_dysfunction arterial stiffness suggest non_invasive assessment index might useful studying effect arterial stiffness treatment designed optimize cardiac performance patient hypertension arterial stiffness independent_predictor diastolic_dysfunction hypertensive_patient considered potential target intervention diastolic heart_failure tdi detected left_ventricular diastolic_dysfunction accompanied increased arterial stiffness newly_diagnosed essential hypertension:0.0412145457490195"}, "Topic 31": {"60073": "adult mammal massive sudden loss cardiomyocytes infarction overwhelms limited regenerative capacity myocardium resulting formation collagen based scar necrotic cell release danger signal activating innate immune pathway triggering intense inflammatory_response stimulation toll like receptor signaling complement activation induces expression proinflammatory cytokine interleukin tumor_necrosis_factor alpha chemokines monocyte chemoattractant protein chemokine c c motif ligand ccl inflammatory signal promote adhesive interaction leukocyte endothelial_cell leading extravasation neutrophil monocyte infiltrating leukocyte clear infarct dead cell mediator repressing inflammation released anti_inflammatory mononuclear cell subset predominate suppression inflammatory_response associated activation reparative cell fibroblast proliferate undergo myofibroblast transdifferentiation deposit large amount extracellular_matrix protein maintaining structural integrity infarcted ventricle renin_angiotensin_aldosterone_system member transforming growth_factor beta family play_important_role activation infarct myofibroblasts maturation scar follows network cross linked collagenous matrix formed granulation tissue cell become apoptotic review discusses cellular effector molecular signal regulating inflammatory reparative response myocardial_infarction dysregulation immune pathway impaired suppression postinfarction inflammation perturbed spatial containment inflammatory_response overactive fibrosis may cause adverse remodeling patient infarction contributing pathogenesis heart_failure therapeutic modulation inflammatory reparative response may hold promise prevention postinfarction heart_failure:0.0389928251812545", "187642": "adult mammalian heart limited endogenous regenerative capacity heals activation inflammatory fibrogenic cascade ultimately result formation scar infarction massive cardiomyocyte death release broad range damage associated molecular pattern initiate myocardial systemic inflammatory_response tlrs toll like receptor nlrs nod like receptor recognize damage associated molecular pattern damp transduce downstream proinflammatory signal leading upregulation cytokine interleukin tnf_alpha tumor_necrosis_factor alpha interleukin chemokines ccl cc chemokine ligand recruitment neutrophil monocyte lymphocyte expansion diversification cardiac macrophage infarcted heart play major role clearance infarct dead cell subsequent stimulation reparative pathway efferocytosis trigger induction release anti_inflammatory mediator restrain inflammatory reaction set stage activation reparative fibroblast vascular cell growth_factor mediated pathway neurohumoral cascade matricellular protein deposited provisional matrix stimulate fibroblast activation proliferation myofibroblast conversion deposition well organized collagen based extracellular_matrix network protects heart catastrophic rupture attenuates ventricular dilation scar maturation requires stimulation endogenous signal inhibit fibroblast activity prevent excessive fibrosis moreover mature scar infarct neovessels acquire mural cell coat contributes stabilization microvascular network excessive prolonged dysregulated inflammatory fibrogenic cascade accentuate adverse remodeling dysfunction moreover inflammatory leukocyte fibroblast contribute arrhythmogenesis inflammatory fibrogenic pathway may promising therapeutic_target attenuate heart_failure progression inhibit arrhythmia generation patient surviving myocardial_infarction:0.0373831031906174", "4181": "one major therapeutic goal modern cardiology design strategy aimed minimizing myocardial necrosis optimizing cardiac repair following myocardial_infarction however sound understanding biology necessary specific intervention pursued therapeutic basis review summarizes current understanding cellular molecular_mechanism regulating inflammatory_response following myocardial_ischemia reperfusion myocardial necrosis induces complement activation free radical generation triggering cytokine cascade initiated tumor_necrosis_factor tnf_alpha release reperfusion infarcted area initiated attended intense inflammatory reaction interleukin il synthesis c activation crucial role recruiting neutrophil ischemic reperfused myocardium neutrophil infiltration regulated complex sequence molecular step involving selectins integrins mediate leukocyte rolling adhesion endothelium marginated neutrophil exert potent cytotoxic effect release proteolytic enzyme adhesion intercellular adhesion molecule icam expressing cardiomyocytes despite potential injury substantial evidence_suggests reperfusion enhances cardiac repair improving patient survival effect may part related inflammatory_response monocyte chemoattractant protein mcp also markedly upregulated infarcted myocardium inducing recruitment mononuclear cell injured area monocyte derived macrophage mast cell may produce cytokine growth_factor necessary fibroblast proliferation neovascularization leading effective repair scar formation stage expression inhibitory cytokine il may role suppressing acute inflammatory_response regulating extracellular_matrix metabolism fibroblast healing scar undergo phenotypic change expressing smooth_muscle cell marker previous review journal focused almost exclusively reduction inflammatory injury current update prompted potential therapeutic opportunity open vessel offer promoting effective tissue repair may possible reduce deleterious remodeling leading_cause heart_failure death elucidating complex interaction regulatory mechanism responsible cardiac repair may allow u design effective inflammation related intervention treatment myocardial_infarction:0.0351456494941634", "112291": "lipopolysaccharide lp induced endothelial_dysfunction play_important_role pathogenesis cardiovascular_disease lcz dual acting angiotensin_receptor_blocker neprilysin_inhibitor used treatment_heart_failure reduced_ejection_fraction recent work suggests lcz therapy might anti_inflammatory effect cardiovascular tissue current study show lcz attenuates lp induced oxidative_stress reducing production intracellular reactive_oxygen_specie ro measurement malonyl dialdehyde mda level human umbilical vascular endothelial_cell huvecs lcz inhibits lp induced expression secretion pro inflammatory cytokine interleukin il interleukin alpha il alpha tumor_necrosis_factor beta tnf beta well chemokines monocyte chemotactic protein mcp chemokine c x c motif ligand protein cxcl additionally found lcz reduces lp induced expression vascular cell adhesion molecule vcam p selectin attachment u monocyte huvecs mechanistically lcz prevents lp induced activation tlr myd pathway nuclear translocation nuclear factor kappa b nf_kappab p factor based finding conclude lcz capable ameliorating lp induced endothelial_dysfunction via anti_inflammatory property:0.0342118782176497", "46694": "rate erectile dysfunction ed heart_failure_hf extremely high limited capacity patient_hf exercise coronary_artery_disease considered main causative mechanism hf ed associated_increased level proinflammatory cytokine tumor_necrosis_factor alpha tnf_alpha interleukin il interleukin il increased level proinflammatory cytokine ed suggest inflammatory marker act important active agent ed development innate immune system also reacts danger signal released damaged cell damage associated molecular pattern damp molecule released result tissue injury acting immune activation non infectious inflammation damp may_also reach circulation mediate pathophysiological process occur distant organ injured site cardiomyocytes possess abundant mitochondrion tissue damage likely heart release high amount mitochondrial dna mtdna act potent ligand toll like receptor tlr accordingly present manuscript review literature pertaining relationship hf ed subjacent inflammatory process associated disease addition propose hypothesis tlr activation damp released hf lead inflammation vascular dysfunction functional change cavernosal tissue providing additional mechanism connects hf ed since tnf_alpha usually product tlrs activation seems common link hf ed hypothesis provide two possible target treat ed associated hf may important preventative therapeutic implication:0.0338676816095103", "96923": "heart_failure exhibit remarkable pathophysiologic heterogeneity large body evidence_suggests regardless underlying etiology heart_failure associated induction cytokine chemokines may_contribute pathogenesis adverse remodeling systolic diastolic_dysfunction pro inflammatory cytokine tumor_necrosis_factor tnf_alpha interleukin il il extensively implicated pathogenesis heart_failure inflammatory cytokine modulate phenotype function myocardial cell suppressing contractile_function cardiomyocytes inducing inflammatory activation macrophage stimulating microvascular inflammation dysfunction promoting matrix degrading phenotype fibroblast moreover cytokine induced growth_factor synthesis may exert chronic fibrogenic action contributing pathogenesis heart_failure_preserved_ejection_fraction_hfpef addition role adverse cardiac_remodeling inflammatory cytokine may_also exert protective action cardiomyocytes condition stress chemokines ccl also upregulated failing_heart may stimulate recruitment pro inflammatory leukocyte promoting myocardial_injury fibrotic remodeling dysfunction although experimental evidence_suggests cytokine chemokine targeting may hold therapeutic promise heart_failure clinical translation remains challenging review manuscript summarizes knowledge role tnf_alpha il il ccl pathogenesis heart_failure discusses promise challenge targeted anti cytokine therapy dissection protective maladaptive cellular action cytokine failing_heart identification patient subset overactive dysregulated myocardial inflammatory_response required design successful therapeutic_approach:0.0336545931304351", "32757": "myocardial necrosis trigger inflammatory reaction clear wound dead cell matrix debris activating reparative pathway necessary scar formation growing body evidence_suggests accentuation prolongation expansion postinfarction inflammatory_response result worse remodeling dysfunction following myocardial_infarction review manuscript discusses cellular effector endogenous molecular signal implicated suppression containment inflammatory_response infarcted heart clearance apoptotic neutrophil recruitment inhibitory monocyte subset regulatory cell macrophage differentiation pericyte endothelial interaction may play active role restraining postinfarction inflammation multiple molecular signal may involved suppressing inflammatory cascade negative regulation toll like receptor signaling downmodulation cytokine response termination chemokine signal may mediated concerted action multiple suppressive pathway prevent extension injury protect adverse remodeling expression soluble endogenous antagonist decoy receptor posttranslational processing bioactive molecule may limit cytokine chemokine action interleukin member transforming growth_factor beta family proresolving lipid mediator lipoxins resolvins protectins may suppress proinflammatory signaling human patient myocardial_infarction defective suppression impaired resolution inflammation may important mechanism pathogenesis remodeling progression_heart_failure understanding inhibitory proresolving signal infarcted heart identification patient uncontrolled postinfarction inflammation defective cardiac repair needed design novel therapeutic_strategy:0.0334493836930616", "27586": "left_ventricular_lv remodeling lead congestive_heart_failure main determinant morbidity_mortality following myocardial_infarction therapeutic_option prevent lv_remodeling limited necessitates exploration alternative therapeutic_target toll like receptor tlrs serve pattern recognition receptor within innate immune system activation tlr result inflammatory_response involved extracellular_matrix degradation key process lv_remodeling following myocardial_infarction establish role tlr postinfarct lv_remodeling myocardial_infarction induced wild_type balb c mouse tlr defective c h tlr lp mouse without affecting infarct_size tlr defectiveness reduced extent lv_remodeling end_diastolic volume microl versus microl p preserved systolic_function ejection_fraction versus_p assessed mri noninfarcted area interstitial fibrosis myocardial hypertrophy reduced c h tlr lp mouse infarcted area however collagen density increased accompanied fewer macrophage reduced inflammation regulating cytokine expression_level interleukin il alpha il il il il il il tumor_necrosis_factor alpha interferon gamma granulocyte macrophage colony stimulating factor reduced matrix metalloproteinase versus_p matrix metalloproteinase activity versus_p data provide direct evidence causal role tlr postinfarct maladaptive lv_remodeling probably via inflammatory cytokine production matrix degradation tlr may therefore constitute novel target treatment ischemic heart_failure:0.0329442791555447", "131796": "severe acute respiratory syndrome coronavirus sars_cov caused novel global coronavirus disease covid disease outbreak pathogenesis mostly located respiratory tract however organ also affected hence realising complex disturbance affect patient recovery crucial regarding significance control covid related complication recovery current study designed review cellular molecular_mechanism linking covid significant long_term sign including renal cardiac_complication cutaneous neurological manifestation well blood coagulation disorder virus directly influence cell angiotensin_converting_enzyme ace induce cytokine storm acute release interleukin il il plasminogen activator inhibitor pai related elevating risk heart_failure also inflammatory cytokine like il tumour necrosis_factor alpha cause secretion von willebrand factor vwf human endothelial_cell vwf bind neutrophil extracellular trap induce thrombosis hand virus damage blood brain barrier increasing permeability subsequently enters central nervous_system systemic circulation furthermore sars induced ace deficiency decrease de arg bradykinin desarg bk degradation kidney induce inflammation thrombotic problem fibrosis necrosis notably angiotensin_ii angiotensin_ii type receptor binding cause increase aldosterone mineralocorticoid receptor surface dendritic cell cell leading recalling macrophage monocyte inflammatory site skin conclusion pathway play key role pathogenesis disturbance nevertheless investigation necessary determine pathogenetic mechanism virus:0.0326718351250058", "48911": "heart_failure related cardiac_complication remains great health challenge investigated effect upregulating heme oxygenase ho myocardial histo pathological lesion proinflammatory cytokine chemokines oxidative mediator important marker heart_failure osteopontin osteoprotergerin n omega nitro l arginine methyl ester l name induced hypertension treatment ho inducer heme arginate improved myocardial morphology l name hypertensive rat attenuating subendocardial injury interstitial fibrosis mononuclear cell infiltration cardiomyocyte hypertrophy associated reduction several inflammatory oxidative mediator including chemokines cytokine macrophage inflammatory protein alpha mip alpha macrophage chemoattractant protein mcp tumor_necrosis_factor alpha tnf_alpha interleukin il il beta endothelin isoprostane nitrotyrosine aldosterone similarly heme arginate abated elevated level extracellular_matrix remodeling protein including transforming growth_factor beta tgf_beta collagen iv myocardium accompanied significant_reduction protein heart_failure osteopontin osteoprotegerin interestingly cardio protective_effect heme arginate associated potentiation adiponectin atrial natriuretic_peptide anp ho ho activity cyclic gnanosine monophosphate cgmp total anti oxidant capacity whereas ho inhibitor chromium mesoporphyrin nullified effect heme arginate exacerbating inflammatory injury oxidative insult conclude heme arginate therapy protects myocardial damage potentiating ho adiponectin anp axis turn suppressed elevated level aldosterone pro inflammatory chemokines cytokine mononuclear cell infiltration oxidative_stress concomitant reduction extracellular_matrix remodeling protein heart_failure protein data_suggest cardio protective role ho system l name induced hypertension could explored design novel strategy cardiomyopathy:0.0326000584027532"}, "Topic 32": {"60079": "heart_failure remains leading_cause_death worldwide burgeoning problem public_health due limited capacity postnatal heart self renew pathophysiological change injured heart sometimes manifested scar formation myocardial degradation rather supplemental muscle regeneration replenish lost tissue healing process stem_cell therapy investigated possible treatment approach child adult potentially fatal cardiovascular_disease respond current medical_therapy although heart one least regenerative organ mammal discovery made past decade improved understanding cardiac development resident stem progenitor pool may lineage restricted subpopulation post neonatal stage cardiac morphogenesis recently investigation specifically focused factor activate either endogenous progenitor cell preexisting cardiomyocytes regenerate cardiovascular cell replace damaged heart tissue discovery induced pluripotent stem_cell advanced technological capability direct cardiac reprogramming essential factor crucial heart field completion stage cardiac_tissue engineering technology recently shown progress generating myocardial_tissue human native cardiac extracellular_matrix scaffold review summarizes recent advance field cardiac cell therapy emphasis cellular mechanism bone_marrow stem_cell cardiac progenitor cell show high potential success preclinical clinical meta_analysis study expanding current understanding mechanism self renewal neonatal mammalian heart may_lead development novel cardiovascular regenerative medicine pediatric heart_disease:0.0396474315832180", "731": "congestive_heart_failure remains major public_health problem frequently end result cardiomyocyte apoptosis fibrous replacement myocardial_infarction process referred left_ventricular remodeling cardiomyocytes undergo terminal differentiation soon birth generally considered irreversibly withdraw cell cycle response ischemic insult adult cardiomyocytes undergo cellular hypertrophy nuclear ploidy high degree apoptosis small number human cardiomyocytes retain capacity proliferate regenerate response ischemic injury however whether cell derived resident pool cardiomyocyte stem_cell renewable source circulating bone_marrow derived stem_cell home damaged myocardium present known replacement regeneration functional cardiac muscle ischemic insult heart could achieved either stimulating proliferation endogenous mature cardiomyocytes resident cardiac stem_cell implanting exogenous donor derived allogeneic cell fetal embryonic cardiomyocyte precursor bone_marrow derived mesenchymal stem_cell skeletal myoblasts newly formed cardiomyocytes must integrate precisely existing myocardial wall order augment synchronized contractility avoid potentially life_threatening alteration electrical conduction heart major impediment survival implanted cell altered immunogenicity prolonged ex vivo culture condition addition concurrent myocardial revascularization required ensure viability repaired region prevent scar tissue formation human adult bone_marrow contains endothelial precursor resemble embryonic angioblasts used induce infarct bed neovascularization experimental myocardial_infarction result protection cardiomyocytes apoptosis induction cardiomyocyte proliferation regeneration long_term salvage survival viable myocardium prevention left_ventricular remodeling sustained improvement cardiac_function reasonable anticipate cell therapy strategy ischemic_heart_disease need incorporate renewable source proliferating functional cardiomyocytes b angioblasts generate network capillary larger size blood vessel supply oxygen nutrient chronically ischemic endogenous myocardium newly implanted cardiomyocytes:0.0364165618932897", "99550": "cardiovascular_disease represent major cause morbidity_mortality worldwide multiple study_conducted far order develop treatment able prevent progression pathology despite progress made last decade current therapy still hampered poor translation actual clinical_application major drawback strategy represented limited regenerative capacity cardiac_tissue indeed ischaemic insult formation fibrotic scar take place interfering mechanical electrical function heart hence ability heart recover ischaemic injury depends several molecular cellular pathway imbalance result adverse remodeling culminating heart_failure complex scenario new chapter regenerative medicine opened past year discovery induced pluripotent stem_cell ipscs cell share characteristic embryonic stem_cell escs generated patient specific somatic cell overcoming ethical limitation related esc use providing autologous source human cell similarly escs ipscs able efficiently differentiate cardiomyocytes cm thus hold real regenerative potential future clinical_application however cell based therapy subjected poor grafting may cause adverse_effect failing_heart thus last year bioengineering technology focused attention improvement survival functionality ipsc derived cm combination two field study burst development cell based three dimensional structure organoids mimic realistically vivo cell behavior toward path possibility directly induce conversion fibroblast cm recently emerged promising area situ cardiac regeneration review provide date overview latest advancement application pluripotent stem_cell tissue engineering therapeutically relevant cardiac regenerative approach aiming highlight outcome limitation future perspective clinical translation:0.0360850719041995", "131892": "cardiomyocyte death dysfunction frequently caused myocardial_infarction_mi heart_failure leading_cause morbidity_mortality modern society paradoxically limited non curative therapy heart_failure mi currently available result past two decade research focused developing cell based approach promoting regeneration infarcted tissue cell based therapy myocardial regeneration include powerful candidate multipotent stem_cell mesenchymal stem_cell msc bone_marrow derived stem_cell endothelial progenitor cell hematopoietic stem_cell induced pluripotent stem_cell ipscs possess unique property potency differentiate desired cell type proliferation capacity patient specificity preclinical clinical_study demonstrated modest improvement myocardial regeneration reduced infarcted area upon transplantation pluripotent multipotent stem_cell another cell population need considered potential source cardiac regeneration telocytes found different organ including heart therapeutic effect studied various heart pathology mi arrhythmia atrial amyloidosis recent cell free therapeutic tool relies cardioprotective_effect complex cargo carried small membrane bound vesicle exosomes released stem_cell via exocytosis msc ipsc derived exosomes could considered novel exosome based therapy cardiovascular_disease thanks unique content also cell free approach e_g gene therapy acellular cardiac patch therefore review provides recent insight novel strategy myocardial repair based regenerative potential different cell type cell free approach:0.0359396887979018", "174273": "cardiovascular_disease cvds remain leading_cause global mortality myocardial_infarction_mi subsequent heart_failure_hf posing significant clinical challenge despite advancement pharmacological surgical intervention limited regenerative capacity adult human_heart necessitates innovative therapeutic_strategy stem_cell based therapy emerged promising approach cardiac regeneration aiming restore damaged myocardial_tissue cell replacement paracrine mediated repair mechanism review provides comprehensive overview current landscape stem_cell therapy cardiac regeneration focusing molecular_mechanism cell type delivery technique recent clinical advancement highlight role key signaling_pathway including notch pi k akt wnt beta catenin hippo yap mapk regulating cardiomyocyte proliferation angiogenesis fibrosis inflammation additionally discus therapeutic potential various stem_cell type mesenchymal stem_cell msc cardiac progenitor cell cpcs induced pluripotent stem_cell ipscs embryonic stem_cell escs promoting cardiac repair despite promising preclinical result challenge low cell retention immune rejection inconsistent clinical_outcome persist recent advancement genetic engineering innovative delivery method including transendocardial intracoronary injection offer new avenue enhancing therapeutic efficacy review underscore need research optimize stem_cell based therapy improve clinical_trial design translate innovative approach effective_treatment heart_disease addressing challenge stem_cell therapy hold potential revolutionize cardiac regeneration improve outcome_patient ischemic_heart_disease heart_failure:0.0359392140486325", "85009": "cardiovascular_disease remain leading_cause_death worldwide burden equally shared men_woman around globe cardiomyocytes die response disease process aging replaced scar tissue instead new muscle cell although recent report suggest intrinsic capacity mammalian myocardium regenerate via endogenous stem progenitor cell magnitude response appears minimal yet realized fully cardiovascular patient despite advance pharmacotherapy new biomedical technology prognosis patient_diagnosed end_stage_heart_failure appears grave heart_transplantation viable option life saving intervention suffers acute shortage cardiac organ donor view existing issue donor cell transplantation emerging promising strategy regenerate diseased myocardium study multiple laboratory shown transplantation donor cell e_g fetal cardiomyocytes skeletal myoblasts smooth_muscle cell adult stem_cell improve function diseased heart short period time week long_term_follow study warranted generally perceived beneficial_effect transplanted cell mainly due increased angiogenesis favorable scar remodeling engrafted myocardium although skeletal myoblasts bone_marrow stem_cell hold highest potential implementation autologous therapy initial result phase trial promising contrast transplantation fetal cardiomyocytes shown confer protection induction ventricular_tachycardia experimental myocardial_injury model furthermore result multiple laboratory suggest fetal cardiomyocytes couple functionally host myocytes stimulate formation new blood vessel improve myocardial function neither practical ethical test potential fetal cardiomyocytes clinical_trial embryonic stem e cell serve novel source generation unlimited quantity cardiomyocytes myocardial repair initial success application e cell partially repair improve myocardial function experimental model heart_disease quite promising however multiple hurdle need crossed potential benefit e cell translated clinic review summarize current knowledge cardiomyocyte derivation enrichment e cell culture provide brief survey factor increasing cardiomyogenic induction mouse human e culture subsequently summarize current state research using mouse human e cell treatment heart_disease various experimental model furthermore discus challenge need overcome prior successful clinical utilization e derived cardiomyocytes treatment end_stage heart_disease optimistic researcher field sail across hurdle also suggest cautious approach validation e cardiomyocytes experimental model would certainly prevent future disappointment seen skeletal myoblast study:0.0356179582891955", "184628": "cardiovascular_disease leading cause_mortality morbidity worldwide despite improvement standard_care patient heart_disease including innovation pharmacotherapy surgical intervention none yet proven effective prevent progression_heart_failure cardiac_transplantation last resort patient_severe heart_failure donor shortage remain roadblock cardiac regenerative strategy include cell based therapeutic gene therapy direct reprogramming non cardiac cell acellular biologics tissue engineering method restore damaged heart significant advancement made past several decade within field review_focus advancement cell based cardiac regenerative therapy use noncoding rna induce endogenous cell proliferation application bioengineering method promote retention integration engrafted cell different cell source investigated including adult stem_cell derived bone_marrow adipose cell cardiosphere derived cell skeletal myoblasts pluripotent stem_cell addition cell based transplantation approach accumulating interest past decade inducing endogenous cm proliferation heart regeneration particularly use noncoding rna mirnas lncrnas bioengineering application focused combining cell transplantation approach fabrication porous vascularized scaffold using biomaterials advanced bio fabrication technique may offer enhanced retention transplanted cell hope cell would better engraft host tissue improve cardiac_function review summarizes present status future challenge cardiac regenerative therapy:0.0351393037782314", "146694": "cardiac muscle limited proliferative capacity regenerative therapy highly demand new treatment_strategy pharmacological non pharmacological therapy developed medical_therapy limited effect cure patient_severe heart_failure moreover heart_transplantation limited due low number donor organ thus heart regeneration hold great potential offer innovative therapy treat heart_failure_patient currently several strategy heart regeneration transplantation somatic stem_cell safe modestly improved cardiac_function myocardial_infarction mainly paracrine mechanism alternatively new cardiomyocytes could generated induced pluripotent stem_cell ipscs transplant injured heart however several issue remain resolved prior using ipsc derived cardiomyocytes potential risk tumorigenesis poor survival transplanted cell injured heart recently direct cardiac reprogramming emerged novel technology regenerate damaged myocardium directly converting endogenous cardiac_fibroblast induced cardiomyocyte like cell restore cardiac_function following first report cardiac reprogramming improvement cardiac reprogramming efficiency vivo direct cardiac reprogramming cardiac reprogramming human cell reported many investigator previous_study advanced regenerative research many challenge remain review current status cardiac regenerative technology great hope treat cardiovascular_disease:0.0347229249810377", "175120": "myocardial_infarction_heart_failure remain among leading global cause morbidity_mortality mainly due irreversible loss cardiomyocytes human_heart inherently limited regenerative capacity cardiac regeneration emerged transformative frontier cardiovascular medicine response clinical biological impasse review examines current approach rebuilding damaged heart tissue improving cardiac_function early investigation cell based therapy particularly mesenchymal stem_cell bone_marrow derived mononuclear cell showed modest improvement heart_function benefit appeared arise primarily paracrine signaling rather direct tissue regeneration recently researcher focused extracellular vesicle exosomes acellular messenger deliver molecular signal encourage new blood vessel growth reduce inflammation promote cell survival breakthrough direct cardiac reprogramming make possible convert fibroblast cardiomyocyte like cell induced pluripotent stem_cell derived cardiomyocytes open new door personalized disease modeling potential myocardial reconstruction advance gene editing notably clustered regularly interspaced short palindromic repeat ca elevating precision efficiency regenerative intervention finally synthetic biology tissue engineering innovation accelerating development physiological cardiac_tissue patch driving aspiration fully implantable bioartificial heart multidisciplinary innovation redefining boundary cardiac care bringing prospect myocardial regeneration increasingly within reach:0.0346885188123424", "99127": "true cardiac regeneration injured heart broadly described lower vertebrate active replacement lost cardiomyocytes functionally structurally restore myocardial_tissue contrary following severe injury e myocardial_infarction adult mammalian heart endowed impaired reparative response mean meager wound healing program detrimental remodeling lead time cardiomyopathy heart_failure lately growing body basic translational clinical_study supported therapeutic use stem_cell provide myocardial regeneration working hypothesis stem_cell delivered cardiac_tissue could result new cardiovascular cell replenish lost one nevertheless multiple independent evidence demonstrated injected stem_cell likely modulate cardiac_tissue via beneficial paracrine effect enhance cardiac repair reinstate embryonic program cell cycle activity endogenous cardiac stromal cell resident cardiomyocytes therefore increasing interest addressed therapeutic profiling stem_cell derived secretome namely total cell secreted soluble factor specific attention cell released extracellular vesicle including exosomes carrying cardioprotective regenerative rna molecule addition use cardiac decellularized extracellular_matrix recently suggested promising biomaterial develop novel therapeutic_strategy myocardial repair either source molecular cue regeneration biological scaffold cardiac_tissue engineering biomaterial platform functional release factor review specifically address translational relevance two approach ad hoc interest feasibility rejuvenate endogenous mechanism cardiac repair functional regeneration:0.0344057797490351"}, "Topic 33": {"139134": "heart energy consuming organ human body heart_failure homeostasis energy supply demand endangered increase cardiomyocyte workload insufficiency energy providing process energy_metabolism directly associated mitochondrial redox homeostasis production toxic reactive_oxygen_specie ro may overwhelm mitochondrial cellular ro defense mechanism case heart_failure mitochondrion essential cell organelle provide required energy heart metabolic remodeling change mitochondrial structure_function alteration mitochondrial calcium signaling diminish mitochondrial energy provision many form cardiomyopathy mitochondrial respiratory chain creates proton gradient across inner mitochondrial membrane couple respiration oxidative phosphorylation preservation energy chemical bond atp akin mitochondrial enzyme respiratory chain integrated inner mitochondrial membrane tight association mitochondrial phospholipid cardiolipin cl ensures structural integrity coordinate enzymatic activity review_focus change mitochondrial cl may associated heart_failure dysfunctional cl found diabetic_cardiomyopathy ischemia_reperfusion injury aging heart barth syndrome bths caused inherited defect biosynthesis cardiolipin moreover dysfunctional cl pool cause type rare inherited cardiomyopathy sengers syndrome dilated_cardiomyopathy ataxia dcma review impact cardiolipin deficiency mitochondrial_function cellular animal_model describe molecular_mechanism concerning mitochondrial_dysfunction incitement cardiomyopathy discus potential therapeutic_strategy:0.0338697924936985", "195339": "aging major risk_factor cardiovascular_disease driving progressive structural_functional decline myocardium mitochondrion primary source atp oxidative phosphorylation essential cardiac contractility calcium homeostasis redox balance aging heart mitochondrion show morphological alteration including cristae disorganization swelling fragmentation along reduced oxphos efficiency defect increase proton leak lower atp production elevate reactive_oxygen_specie ro causing oxidative damage concurrent disruption mitochondrial fusion fission impair turnover quality control exacerbating mitochondrial_dysfunction cardiac decline serum response factor srf signaling crucial regulator cytoskeletal metabolic gene_expression play key role modulating mitochondrial_function cardiac aging dysregulation srf impairs mitochondrial adaptability contributing dysfunction additionally reduced level nicotinamide adenine dinucleotide nad hinder sirtuin dependent deacetylation compromising mitochondrial efficiency stress resilience cumulative defect activate regulated cell_death pathway leading cardiomyocyte loss fibrosis impaired diastolic_function mitochondrial_dysfunction therefore serf driver amplifier cardiac aging accelerating transition toward heart_failure narrative review aim provide comprehensive overview mitochondrial remodeling aging myocardium examining mechanistic link mitochondrial_dysfunction myocardial_injury also discus emerging therapeutic_strategy targeting mitochondrial bioenergetics quality control promising approach preserve cardiac_function extend cardiovascular health span aging population:0.0336790183464066", "109770": "heart must function continuously responsible supplying oxygen nutrient throughout entire body well transport waste product excretory organ facing either physiological pathological increase cardiac demand heart undergoes structural_functional remodeling mean adapting increased workload adaptive response include change gene_expression protein composition structure sub cellular organelle involved energy production metabolism mitochondrion essential cardiac_function supply atp necessary support continuous cycle contraction relaxation addition mitochondrion carry important process including synthesis essential cellular component calcium buffering initiation cell_death signal surprisingly mitochondrial_dysfunction linked several cardiovascular disorder including hypertension cardiac_hypertrophy ischemia_reperfusion heart_failure present chapter discus change mitochondrial cristae structure fusion fission dynamic fatty_acid oxidation atp production generation reactive_oxygen_specie might impact cardiac structure_function particularly context pathological hypertrophy fibrotic response addition mechanistic role mitochondrion autophagy programmed cell_death cardiomyocytes addressed also review strategy improve mitochondrial_function discus cardioprotective potential:0.0335560720816207", "175198": "cardiovascular_disease cvds remain leading_cause global mortality yet pathogenesis fully elucidated particularly regarding role abnormal energy_metabolism major outstanding question pertain dynamic regulation metabolic reprogramming complex interplay mitochondrial_dysfunction previous_study demonstrated heart high energy demand organ relies dynamic equilibrium substrate fatty_acid fa glucose sustain adenosine triphosphate atp production metabolic disturbance characterized suppressed fa oxidation aberrant activation glycolysis directly contribute pathological progression various cvds including heart_failure_hf atherosclerosis myocardial_infarction_mi mechanism involving oxidative_stress inflammatory_response energy crisis review systematically examines core pathway cardiac energy_metabolism e_g mitochondrial oxidative phosphorylation oxphos regulation glucose lipid metabolism dysregulation disease state evaluating intervention strategy targeting metabolic pathway mitochondrial_function enhancement substrate utilization modulation future_research direction emphasize integration metabolomics clinical translational study comprehensively decipher multidimensional regulation metabolic network thereby facilitating development novel precision therapeutic_target:0.0335472934595219", "90878": "despite significant progress cardiovascular medicine myocardial_ischemia infarction progressing eventually final end_point heart_failure_hf remain leading_cause morbidity_mortality usa hf complex syndrome result structural_functional impairment ventricular filling blood ejection ultimately heart inability supply body tissue enough blood may_lead death mechanistically hallmark failing_heart include abnormal energy_metabolism increased production reactive_oxygen_specie ro defect excitation contraction coupling hf highly dynamic pathological process observed alteration cardiac metabolism function depend disease_progression early_stage cardiac_remodeling characterized normal slightly increased fatty_acid fa oxidation play compensatory cardioprotective role however upon progression hf fa oxidation mitochondrial oxidative activity decreased resulting significant drop cardiac atp level hf compensatory response decreased oxidative metabolism glucose uptake glycolysis upregulated upregulation sufficient compensate drop atp production elevated mitochondrial ro generation ro mediated damage overwhelm cellular antioxidant defense system induce heart injury contribute progression hf mitochondrial uncoupling protein ucps promote proton leak across inner mitochondrial membrane emerged essential regulator mitochondrial membrane potential respiratory activity ro generation although physiological role ucp ucp expressed heart clearly established increasing evidence_suggests protein promoting mild uncoupling could reduce mitochondrial ro generation cardiomyocyte apoptosis ameliorate thereby myocardial function investigation alteration cardiac ucp activity regulation advance understanding physiological role healthy diseased heart also may facilitate development novel efficient therapy:0.0328437372488430", "198780": "study metabolic abnormality regarding mitochondrial respiration energy production significantly advanced understanding cell biology molecular_mechanism underlying cardiovascular_disease cvds mitochondrion provide energy required maintaining normal cardiac_function central heart bioenergetics initial phase heart_failure mitochondrial number function progressively decline causing decrease oxidative metabolism increased glucose uptake glycolysis leading atp depletion bioenergetic starvation finally contributing overt heart_failure compromised mitochondrial bioenergetics associated vascular damage hypertension vascular remodeling pulmonary_hypertension acute cardiovascular_event thus mitochondrial_dysfunction leading impaired atp production excessive ro generation opening mitochondrial permeability transition pore activation apoptotic necrotic pathway revealed typical feature common cvds molecule able positively modulate cellular metabolism improving mitochondrial bioenergetics energy_metabolism inhibiting oxidative_stress production expected exert beneficial protective_effect heart vasculature review discusses recent advance cardiovascular research study cellular bioenergetics chronic acute cvds emerging therapeutic_strategy specifically targeting metabolic modulators mitochondrial_function quality control discussed:0.0326991892419027", "195337": "heart relentless contractile activity depends critically mitochondrial_function meet extraordinary bioenergetic demand mitochondrion oxidative phosphorylation supply atp also regulate metabolism calcium homeostasis apoptotic signaling ensuring cardiomyocyte viability cardiac_function mitochondrial_dysfunction hallmark cardiomyopathy heart_failure characterized impaired oxidative phosphorylation excessive production reactive_oxygen_specie ro dysregulated calcium handling disturbance mitochondrial dynamic mitophagy defect culminate energetic insufficiency cellular injury cardiomyocyte death driving heart_disease progression diverse cardiomyopathy phenotype exhibit distinct mitochondrial pathology acute ischemia induced mitochondrial collapse chronic remodeling seen dilated hypertrophic restrictive primary mitochondrial cardiomyopathy mitochondrion also orchestrate cell_death inflammatory pathway worsen cardiac_dysfunction therapeutic_strategy targeting mitochondrial_dysfunction including antioxidant modulators mitochondrial biogenesis metabolic therapy innovative approach mitochondrial transplantation show promise face challenge clinical translation advance biomarker discovery personalized medicine approach hold promise optimizing mitochondrial targeted therapy unlike previous review examined pathway intervention individually work summarizes insight mechanism emerging therapeutic_strategy sglt inhibition hfpef nad repletion mitochondrial transplantation biomarker driven precision medicine unified synthesis framework underscore novel contribution linking basic mitochondrial biology translational clinical opportunity cardiomyopathy heart_failure review synthesizes current understanding mitochondrial biology cardiac health disease delineates molecular_mechanism underpinning mitochondrial_dysfunction cardiomyopathy heart_failure explores emerging therapeutic avenue aimed restoring mitochondrial integrity improving clinical_outcome cardiac patient:0.0324388491193830", "172375": "mitochondrial_dysfunction increasingly recognized central contributor pathogenesis cardiovascular_disease cvds including heart_failure ischemic_heart_disease hypertension cardiomyopathy mitochondrion known powerhouse cell play vital role maintaining cardiac energy homeostasis regulating reactive_oxygen_specie ro production controlling cell_death pathway dysregulated mitochondrial_function result impaired adenosine triphosphate atp production excessive ro generation activation apoptotic necrotic pathway collectively driving progression cvds review provides detailed examination molecular_mechanism underlying mitochondrial_dysfunction cvds including mutation mitochondrial dna mtdna defect oxidative phosphorylation oxphos alteration mitochondrial dynamic fusion fission mitophagy additionally role mitochondrial_dysfunction specific cardiovascular condition explored highlighting impact endothelial_dysfunction myocardial remodeling arrhythmia emerging therapeutic_strategy targeting mitochondrial_dysfunction mitochondrial antioxidant metabolic modulators gene therapy also discussed synthesizing recent advance mitochondrial biology cardiovascular research review aim enhance understanding role mitochondrion cvds identify potential therapeutic_target improve cardiovascular_outcome:0.0322893571505469", "184965": "mitochondrion cellular organelle generate adenosine triphosphate atp molecule maintenance cellular energy oxidative phosphorylation also regulate variety cellular process including apoptosis metabolism interest inner part mitochondrion mitochondrial matrix contains circular molecule dna mtdna characterised transcriptional machinery genomic dna mtdna may_also undergo nucleotide mutation shown responsible mitochondrial_dysfunction physiological aging mitochondrial membrane potential decline associate enhanced mitophagy avoid accumulation damaged organelle moreover dysfunctional mitochondrion properly cleared could lead cellular dysfunction subsequent development several comorbidities cardiovascular_disease cvds diabetes respiratory cardiovascular_disease well inflammatory disorder psychiatric disease reported genomic dna mtdna also amenable chemical modification namely dna methylation change mtdna methylation shown associated altered transcriptional program mitochondrial_dysfunction aging addition epigenetic signal observed mitochondrion particular interaction mtdna methylation non coding rna mitoepigenetic modification also involved pathogenesis cvds oxygen chain disruption mitochondrial fission ro formation alter cardiac energy_metabolism leading hypertrophy hypertension_heart_failure ischemia_reperfusion injury present review summarize current evidence growing importance epigenetic change modulator mitochondrial_function aging better understanding mitochondrial epigenetic landscape may pave way personalized therapy prevent age related disease:0.0320810734324621", "174899": "heart_failure represents terminal stage development many cardiovascular_disease pathological mechanism closely related disturbance energy_metabolism mitochondrial_dysfunction cardiomyocytes recent_year nicotinamide adenine dinucleotide nad core coenzyme involved cellular energy_metabolism redox homeostasis shown potentially ameliorate heart_failure regulation mitochondrial_function review systematically investigates four core mechanism mitochondrial_dysfunction heart_failure imbalance mitochondrial dynamic excessive accumulation reactive_oxygen_specie ro leading oxidative_stress injury dysfunction mitochondrial autophagy disturbance ca homeostasis abnormality collectively exacerbate progression_heart_failure disrupting atp production inducing apoptosis myocardial_fibrosis nad shown regulate mitochondrial biosynthesis antioxidant defence activation deacetylase family e_g silent information regulator homolog sirt sirt increase mitochondrial autophagy remove damaged mitochondrion thus restoring energy_metabolism redox balance cardiomyocytes addition inhibition nad degrading enzyme e_g poly adp ribose polymerase parp cluster differentiation cd selective androgen receptor modulators sarms increase tissue intracellular nad content supplementation nad precursor e_g beta nicotinamide mononucleotide nmn nicotinamide riboside etc also significantly elevates myocardial nad level ameliorate heart_failure study provides theoretical basis understanding central role nad mitochondrial homeostasis development targeted therapy heart_failure:0.0312639773498068"}, "Topic 34": {"103487": "pulmonary_arterial_hypertension pah also classified group pulmonary_hypertension ph rare debilitating progressive life_threatening disease pulmonary vasculature characterized vascular proliferation remodelling small pulmonary_artery pah defined increase mean pulmonary arterial_pressure mpap mm_hg pulmonary wedge_pressure mm_hg left untreated lead right_heart_failure premature death prior availability pah drug_therapy median survival time year survival_rate one three five year following diagnosis respectively survival patient pah improved since introduction advanced pah therapy current average survival adult reaching five seven year following diagnosis recent survival data_patient idiopathic pah ipah familial pah fpah two largest subgroup pah american registry estimate one three five seven year survival_rate respectively health canada approved eight treatment_option covering four different class drug pah world health organization group prostanoids epoprostenol treprostinil endothelin receptor_antagonist era bosentan ambrisentan macitentan phosphodiesterase type pde inhibitor sildenafil tadalafil soluble guanylate cyclase sgc stimulator riociguat macitentan orally active non peptide potent dual era et et b canada macitentan indicated long_term treatment pah group reduce morbidity patient whose functional_class fc ii_iii whose pah either idiopathic heritable associated connective tissue disease congenital_heart_disease macitentan available mg film coated tablet taken orally dose mg daily without food objective review evaluate beneficial harmful effect macitentan opsumit monotherapy combination drug treatment pah patient_group fc ii_iii:0.0433176893316792", "163359": "importance pulmonary_arterial_hypertension pah subtype pulmonary_hypertension ph characterized pulmonary arterial remodeling prevalence pah approximately case per million adult u untreated pah progress right_heart_failure death observation pulmonary_hypertension defined mean pulmonary_artery_pressure greater mm_hg classified clinical group based etiology pathophysiology treatment pulmonary_arterial_hypertension group ph hemodynamically defined right_heart_catheterization demonstrating mean pulmonary_artery_pressure greater mm_hg pulmonary_artery wedge_pressure mm_hg lower pulmonary_vascular_resistance wood unit greater pulmonary_arterial_hypertension divided subgroup based underlying etiology consisting idiopathic pah heritable pah drug toxin associated pah pulmonary veno occlusive disease pah long_term responder calcium_channel blocker persistent ph newborn well pah associated medical condition including connective tissue disease hiv congenital_heart_disease early presenting symptom nonspecific typically consist dyspnea exertion fatigue currently approved therapy pah consists drug enhance nitric_oxide cyclic guanosine monophosphate biological pathway sildenafil tadalafil riociguat prostacyclin pathway agonist epoprostenol treprostinil endothelin pathway antagonist bosentan ambrisentan pah specific therapy year_survival improved current treatment consists combination drug_therapy target biological pathway nitric_oxide cyclic guanosine monophosphate endothelin pathway eg ambrisentan tadalafil shown demonstrable improvement morbidity_mortality compared previous conventional single pathway targeted monotherapy conclusion relevance pulmonary_arterial_hypertension affect estimated per million adult u without treatment typically progress right_heart_failure death first_line therapy drug combination target multiple biological pathway associated_improved survival:0.0423910730565680", "36018": "pulmonary_arterial_hypertension pah progressive disorder poor_prognosis characterized sustained elevation pulmonary_artery_pressure pap pulmonary_vascular_resistance pvr defined hemodynamically mean pap mm_hg pulmonary arterial wedge_pressure mm_hg less excludes left_sided lesion pvr wood unit dyn sec cm patient limited exertional dyspnea pre true syncope chest_pain edema ascites right_heart_failure supervenes pah afflicts predominantly young woman diagnosis often delayed three process contribute progressive arterial narrowing vasoconstriction vascular remodeling thrombosis situ diagnosis pah must confirmed etiology must identified appropriate therapy instituted right_heart_catheterization necessary establish diagnosis severity prognosis pah ascertain etiology evaluate vasoreactivity guide therapy treatment pah includes vasodilator supplemental anticoagulation diuretic digoxin intravenous inotropic therapy decompensated right_ventricular failure lung combined heart lung transplantation patient continue deteriorate poor quality_life despite pharmacologic therapy calcium_channel blocker beneficial small minority patient prospective controlled randomized_trial approved vasodilator agent enrolled large proportion woman agent endothelin receptor_antagonist bosentan phosphodiesterase inhibitor sildenafil prostanoids shown improve symptom exercise_capacity instance delay clinical worsening clinical_outcome patient pah improved judicious use contemporary therapy:0.0412421143186524", "49178": "pulmonary_arterial_hypertension pah defined intractable disease characterized progressive elevation pulmonary_vascular_resistance pvr pulmonary arterial_pressure pap leading right_heart_failure premature death five year survival_rate diagnosis approximately although extensive research identified factor_associated cause pah etiology pathogenesis remain unclear addition ca channel blocker nifedipine diltiazem three category drug developed treatment pah based pathological mechanism prostacyclin analogue epoprostenol treprostinil iloprost endothelin receptor_antagonist bosentan ambrisentan phosphodiesterase type inhibitor sildenafil tadalafil however screening novel type drug acting signal pathway associated pathological mechanism_underlying pah ongoing recently found extracellular ca sensing receptor casr belongs family c g_protein coupled receptor gpcr superfamily upregulated pulmonary arterial smooth_muscle cell pasmcs patient idiopathic pah ipah upregulated casr necessary enhanced ca signaling augmented cell proliferation pasmcs ipah patient importantly blockage casr antagonist np prevents development pulmonary_hypertension right_ventricular hypertrophy animal_model pulmonary_hypertension use calcilytics antagonist casr may novel therapeutic_approach pah patient:0.0411289282705345", "181090": "background pulmonary_arterial_hypertension pah group pulmonary_hypertension ph type pulmonary vascular_disease characterized abnormal contraction remodeling pulmonary arteriole manifested pulmonary_vascular_resistance pvr increased pulmonary arterial_pressure eventually leading right_heart_failure even death mechanism involved process include inflammation vascular matrix remodeling endothelial_cell apoptosis proliferation vasoconstriction vascular smooth_muscle cell proliferation hypertrophy study review mechanism_action prostaglandin receptor pah main body pah targeted therapy endothelin receptor_antagonist phosphodiesterase type inhibitor activator soluble guanylate cyclase prostacyclin prostacyclin analog improve pvr mean pulmonary arterial_pressure six minute_walk distance cardiac_output exercise_capacity licensed patient pah however shown reduce mortality current treatment pah primarily focus inhibiting excessive pulmonary vasoconstriction however vascular remodeling recalcitrant currently available therapy lung transplantation remains definitive treatment_patient pah therefore imperative identify novel target improving pulmonary vascular remodeling pah study confirmed prostaglandin receptor play_important_role occurrence development pah vasoconstriction vascular smooth_muscle cell proliferation migration inflammation extracellular_matrix remodeling conclusion prostacyclin related drug used clinical treatment pah prostaglandin also potential treat pah review provides idea treatment pah discovery new drug target:0.0409575386630522", "58663": "pulmonary_arterial_hypertension pah progressively worsening disorder characterized increased pulmonary_vascular_resistance leading increased afterload right_ventricular hypertrophy ultimately right_heart_failure death current pharmacologic treatment primarily act reduce pulmonary_vascular_resistance pvr provide benefit cure pah canonical vasodilator therapy involving nitric_oxide soluble guanylate cyclase sgc cgmp pathway demonstrated efficacy pathologic state endothelial_dysfunction within pulmonary vasculature lead reduced synthesis bioavailability acting downstream sgc stimulators activator restore endogenous function exploit positive effect sgc stimulation various organ system including heart riociguat bay first agent class sgc stimulators receive fda approval treatment pah chronic thromboembolic hypertension cteph riociguat demonstrated significant benefit assessed mwd pvr n_terminal_pro_brain_natriuretic_peptide nt_probnp_level time clinical worsening world health organization functional_class quality_life measure clinical_trial monotherapy combination endothelin receptor_antagonist non intravenous prostanoids riociguat first fda approved treatment_option inoperable persistent cteph add new effective drug available treatment_option pulmonary_hypertension ph question whether riociguat superior available treatment_option unanswered present time requires study:0.0407222600394225", "56400": "pulmonary_arterial_hypertension pah rare condition characterised elevated pulmonary arterial resistance leading right_heart_failure pah sporadic idiopathic pah primary pulmonary_hypertension familial caused germline bmpr mutation type ii member tgfbeta receptor superfamily related condition including connective tissue disease congenital_heart_disease human immunodeficiency virus infection portal hypertension appetite suppressant exposure idiopathic pah prevalence per million per_year france lack specificity pah symptom mostly dyspnea presumably lead underdiagnosis condition echocardiography investigation choice non_invasive screening measurement hemodynamic parameter right_heart catheterism mandatory establish diagnosis mean pulmonary_artery_pressure mmhg pulmonary_artery wedge_pressure mmhg acute pulmonary vasodilator testing performed nitric_oxide prostacyclin right_heart_catheterization recent advance management pah including continuous intravenous prostacyclin infusion endothelin receptor_antagonist improved markedly patient prognosis novel treatment inhaled iloprost type phosphodiesterase inhibitor evaluated setting lung transplantation last option patient deteriorating despite medical_treatment:0.0404606414463949", "198761": "pulmonary_hypertension ph broadly defined mean pulmonary arterial_pressure mpap exceeding mm_hg rest pulmonary_arterial_hypertension pah specific subset ph characterized normal pulmonary arterial wedge_pressure pawp combined elevated mpap increased pulmonary_vascular_resistance pvr without cause pre capillary hypertension lung_disease chronic thromboembolic pulmonary_hypertension majority pah case idiopathic common etiology include connective tissue disease associated pah congenital_heart_disease portopulmonary hypertension lesser extent genetic familial form pah also occur pathophysiology pah involves following four primary pathway nitric_oxide endothelin prostacyclin activin bone morphogenetic protein bmp dysregulation pathway lead progressive vasculopathy marked vasoconstriction vascular proliferation elevated right_heart afterload ultimately right_sided heart_failure diagnosing pah challenging often occurs advanced stage gold_standard diagnosis remains invasive right_heart_catheterization along invasive hemodynamic measurement several noninvasive imaging modality echocardiography ventilation perfusion scanning key adjunct technique also recent advancement cardiac_magnetic_resonance cmr opened new era pah management additionally cmr echocardiography enable diagnosis also aid evaluating disease_severity monitoring treatment response current pah treatment focus targeting molecular pathway reducing inflammation inhibiting right_sided heart_failure integrating imaging basic science technique crucial enhanced patient diagnosis precision medicine emerging key strategy pah management additionally incorporation artificial intelligence molecular imaging approach hold significant potential growing need integrate new imaging modality high resolution reduced radiation exposure clinical_practice review discus molecular pathway involved pah imaging modality utilized diagnosis monitoring current targeted therapy advance molecular understanding imaging technology coupled precision medicine could hold promise improving patient_outcome revolutionizing management pah patient:0.0403868402777354", "124670": "pulmonary_hypertension ph defined disorder mean pulmonary arterial_pressure mpap greater mmhg rest pulmonary_arterial_hypertension pah considered mpap mmhg pulmonary_vascular_resistance pvr wu pah chronic progressive disease resulting right_heart_failure premature death postulated due inactivating mutation gene named bone morphogenetic protein receptor type bmpr whose predominant function halting vascular proliferation lamentable prognosis rapidly diagnosed adequately treated treatment pah evolved past decade since many related pathway potential therapeutic_target explored parenteral prostanoids effective therapeutic_option pah epoprostenol synthetic analog prostacyclin potent vasodilator food drug administration fda approved december intravenous use treat pah also used treat different pah subtypes including connective tissue related pah like lupus systemic sclerosis congenital_heart_disease drug induced pah effective reducing mortality_rate improving survival_rate although use epoprostenol pah challenging one successful therapy used manuscript review pathophysiology pah risk_stratification tool also discus mechanism_action pah targeted therapy focusing role epoprostenol investigated many clinical_trial finally discus two ongoing clinical_trial highlight potential therapeutic_option:0.0403563827057734", "82643": "pulmonary_arterial_hypertension pah chronic progressive disease leading right_heart_failure ultimately death untreated first classification ph proposed fourth world symposium ph held dana point california usa revised previous classification currently ph devided five subgroup group includes patient suffering idiopathic familial pah without germline mutation patient diagnosis pah systematically screened regarding underlying mutation bmpr gene bone morphogenetic protein receptor type rarely acvrl activine receptor like kinase type eng endogline smad gene pulmonary veno occusive disease pulmonary_capillary hemagiomatosis individualized designated clinical group group pulmonary_hypertension due left heart_disease divided three sub group systolic dysfonction diastolic dysfonction valvular dysfonction group pulmonary_hypertension due respiratory disease includes heterogenous subgroup respiratory disease like ph due pulmonary fibrosis copd lung emphysema interstitial lung_disease exemple group includes chronic thromboembolic pulmonary_hypertension without distinction proximal distal form group regroup ph patient unclear multifactorial mechanism invasive hemodynamic assessment right_heart_catheterization requested confirm definite diagnosis ph showing resting mean pulmonary_artery_pressure mpap mmhg normal pulmonary_capillary wedge_pressure pcwp mmhg assessment pcwp may allow distinction pre capillary post capillary ph pcwp mmhg echocardiography important tool management_patient underlying suspicion ph european society_cardiology european respiratory society esc er guideline specify role essentially screening proposing criterion estimating presence ph mainly based tricuspid_regurgitation peak velocity systolic artery pressure spap therapy pah consists non specific drug including oral anticoagulation diuretic well pah specific therapy diuretic one important treatment setting ph right_heart_failure lead fluid retention hepatic congestion ascites peripheral edema current recommendation propose oral anticoagulation aiming targeting international normalized ratio inr target inr patient displaying chronic thromboembolic ph better understanding pathophysiological mechanism ph past quarter century led development medical therapeutic even though cure pah exists several specific therapeutic agent developed medical management pah including prostanoids epoprostenol trepoprostenil iloprost endothelin receptor_antagonist bosentan ambrisentan phosphodiesterase type inhibitor sildenafil tadalafil review discusses current state art regarding epidemiologic aspect ph diagnostic approach current classification ph addition currently available specific pah therapy discussed well future treatment:0.0402325183636023"}, "Topic 35": {"56418": "background positron emission tomography pet flow metabolic mismatch considered nuclear medicine gold_standard assessment myocardial viability aim_study investigate whether baseline nitrate technetium tetrofosmin single photon emission computed_tomography spect mismatch may_provide equivalent clinical information method_result studied patient_aged_year men previous myocardial_infarction anterior inferior anterior plus inferior postischemic heart_failure gated spect g spect ejection_fraction patient_underwent tc tetrofosmin g spect rest nitrate intravenous isosorbide dinitrate mg ml ml h well fluorine fluoro deoxy glucose fdg pet scan regional wall motion analysis_performed quantitative g spect qgs myocardial dysfunction defined regional qgs score greater regional perfusion assessed quantitative perfusion score qps providing percent tc tetrofosmin uptake segment model semiquantitative analysis fdg uptake performed use polar map generated siemens ecat hr software area perfusion rate lower pet viability identified normalized fdg percent uptake baseline tc tetrofosmin percent uptake ratio greater analyzed segment dysfunctional qgs analysis viable pet imaging whereas nonviable regional tc tetrofosmin uptake higher viable nonviable segment rest v_p nitrate v_p according receiver_operating_characteristic_curve analysis cutoff value resting well post nitrate g spect provided highest diagnostic accuracy detection myocardial viability rest nitrate respectively algorithm used comparison pet normalized nitrate percent uptake baseline percent uptake applied g spect obtained highest agreement pet accuracy sensitivity_specificity conclusion patient_severe left_ventricular_dysfunction perfusion data alone rest nitrate allow accurate estimate myocardial viability dysfunctioning segment analysis rest post nitrate tc tetrofosmin mismatch provides result similar obtained pet flow metabolic mismatch:0.0550488685746805", "176410": "ischemic_cardiomyopathy icm leading_cause heart_failure globally myocardial viability testing aim identify dysfunctional potentially reversible myocardium patient icm review examines clinical_application diagnostic performance radionuclide imaging technique including thallium tl technetium tc single positron emission tomography spect flourine flourodeoxyglucose f fdg positron emission tomography pet assessing myocardial viability ti spect assesses viability via active myocardial uptake delayed redistribution limited prolonged protocol suboptimal image quality tc labeled agent sestamibi tetrofosmin offer improved spatial resolution shorter half life higher photon energy enabling faster imaging better image quality combined nitrate augmentation gated imaging tc spect enhances detection viable perfused myocardium f fdg pet considered gold_standard modality viability assessment due superior sensitivity image quality quantitative capability myocardial blood_flow observational_study associate viability improved outcome revascularization randomized_trial yielded mixed result however contemporary guideline continue support viability testing selected high_risk_patient emerging technology including novel pet tracer artificial intelligence hybrid imaging may_improve diagnostic accuracy clinical utility radionuclide viability testing radionuclide imaging remains valuable tool assessing myocardial viability icm pet offer superior diagnostic accuracy spect remains widely_used given accessibility future study incorporating modern imaging technology contemporary heart_failure therapy needed clarify role viability testing guiding revascularization strategy:0.0541298035532448", "85430": "purpose_review transthoracic_echocardiography echo single photon emission computed_tomography spect routine many heart_failure_patient recently imaging test emerged heart_failure management cardiovascular magnetic_resonance cmr positron emission tomography pet computed_tomography ct article_review recent development_heart_failure imaging recent_finding longitudinal left_ventricular systolic strain echo speckle_tracking imaging detects subclinical cardiomyopathy predicts survival symptomatic heart_failure late gadolinium enhancement myocardial scar independent_predictor death transplantation ischemic nonischemic cardiomyopathy contrast earlier report echo cmr contrast negligible risk adverse_outcome stress perfusion imaging spect pet pet flow quantification prognostic_value ischemic_cardiomyopathy f fluoro deoxyglucose fdg pet directed management impact outcome abnormal myocardial neuronal activity metaiodobenzylguanidine mibg imaging associated_increased_risk ventricular_arrhythmia death cardiac ct potentially could assess heart_failure etiology coronary_angiography myocardial_tissue characterization precise role remains undetermined summary several exciting development imaging modality large multicenter trial image heart_failure required standardize measure establish benefit widespread use heart_failure recommended:0.0538826373464962", "64018": "background outcome_patient severe ischaemic left_ventricular_lv dysfunction determined extent myocardial viability presence lv dyssynchrony aimed assessing parameter imaging method e gated positron emission tomography pet f fluorodeoxyglucose fdg scan method phase analysis emory cardiac toolbox applied gated pet fdg scan assess histogram bandwidth standard_deviation sd measure lv dyssynchrony heart_failure_patient mean ejection_fraction referred evaluation myocardial viability cut value single photon emission computed_tomography myocardial perfusion imaging spect mpi best predicting cardiac_resynchronization_therapy_crt response served standard reference bandwidth degree phase sd degree severe lv dyssynchrony diagnosed spect mpi value limit intraclass correlation clinical agreement detection severe lv dyssynchrony pet v spect assessed result significant_correlation pet fdg spect mpi bandwidth r_p phase sd r_p resulting excellent clinical agreement two method conclusion accurate lv dyssynchrony assessment phase analysis gated pet fdg scan feasible allowing assessing myocardial viability severe lv dyssynchrony one scan:0.0538699725293091", "95891": "purpose objective_study assess incremental value myocardial wall motion thickening compared perfusion alone obtained gated single photon emission computed_tomography spect myocardial perfusion imaging mpi diagnosing myocardial viability patient ischemic heart_failure method eighty three consecutive_patient ischemic heart_failure underwent tc mibi gated spect mpi f fdg positron emission tomography pet myocardial metabolic imaging retrospectively enrolled spect pet myocardial viability defined reference standard segmental myocardial perfusion wall motion thickening measured automated algorithm gated spect mpi univariate stepwise multivariate_analysis conducted establish optimal multivariate model predicting hibernating myocardium scar result_among segment evaluated segment normal perfusion segment decreased perfusion latter classified f fdg pet hibernating segment scarred segment multivariate regression_analysis showed model combined myocardial perfusion uptake wall motion thickening score optimal predictive efficiency distinguish hibernating myocardium scar segment decreased perfusion model largest c_statistic v_p global chi square increased compared perfusion alone p_conclusion assessment myocardial wall motion thickening addition conventional perfusion uptake segment decreased perfusion enables better differentiation hibernating myocardium scar patient ischemic heart_failure considering wide availability high cost_effectiveness regional myocardial function integrated perfusion gated spect mpi great promise become clinical tool assessment myocardial viability:0.0529505120766062", "26459": "assessment myocardial viability important identifying patient likely benefit coronary revascularization clinical_study shown positron emission tomography pet using f fluoro deoxy glucose fdg accurately identify_patient viable myocardium likely benefit revascularization procedure term improvement left_ventricular_lv function alleviation heart_failure_symptom improvement long_term prognosis single photon emission computed_tomography spect using perfusion tracer tl tc mibi useful assess viability problem particularly low specificity fdg pet several advantage including higher sensitivity_specificity perfusion tracer article_review myocardial metabolism fdg pet protocol procedure interpretive criterion clinical_application well problem limitation literature regarding diagnostic prognostic_information viability using fdg pet summarized:0.0528020037136086", "2238": "positron emission tomography pet advanced scintigraphic imaging technique developed vivo assessment cardiac physiology biochemistry currently available pet technology allows measurement regional tracer activity high spatial temporal resolution several radiopharmaceutical introduced study myocardial perfusion enabling accurate diagnosis localization coronary_artery_disease_cad assessing myocardial blood_flow rest stress condition calculating regional coronary flow reserve n ammonia rb water pet sensitive mean detect abnormal vasoreactivity already found early_stage atherosclerotic process angiographic clinical evidence cad flow tracer provide also quantitative information hemodynamic effect local invasive angioplasty systemic risk_factor modification intervention metabolic imaging f deoxyglucose fdg pet represents currently gold_standard tissue viability assessment well validated information presence extent viable myocardium prognostic_information metabolic imaging extends preoperative risk_stratification patient congestive_heart_failure facilitates decision_making revascularization conservative management fdg also used combination spect providing comparable physiologic pathophysiologic information without need expensive rarely available imaging technology pet recently newer tracer radiolabeled catecholamine analog allowed evaluation cardiac autonomic innervation variety cardiac_disease involvement neuronal innervation c hydroxyephedrine hed enabled imaging alteration neuronal innervation diabetes congestive_heart_failure heart_transplantation unique functional prognostic potential provided pet imaging together expected easier access technology better availability lower cost instrumentation raise clinical acceptance near future:0.0525090187300913", "49723": "patient_heart_failure_hf due coronary disease combined evaluation perfusion glucose metabolism cardiac single photon emission computed_tomography spect positron emission tomography pet used distinguish viable non viable myocardium current guideline recommend cardiac spect fluorodeoxyglucose fdg pet viability assessment takotsubo cardiomyopathy ttc disease characterized acute reversible hf leaving scarring explore robust semi quantitative viability criterion used cardiac spect fdg pet stand ground population ttc september october patient suspected ttc enrolled multimodality cardiac imaging research project echocardiography tc spect f fdg pet performed acute admission follow month later nineteen patient final diagnosis ttc consistent mayo clinic diagnostic criterion three_patient excluded analysis since wall motion abnormality persistent time nuclear imaging remaining sixteen patient exhibited distinct pattern hf apical ballooning perfusion metabolism defect midventricular apical region viability criterion applied identified significant scarring limited hibernation akinetic part left_ventricle however full recovery found ttc patient follow using current guideline endorsed viability criterion semiquantitative cardiac spect fdg pet modality failed demonstrate presence viability acute state ttc:0.0524765263863508", "12829": "article role nuclear medicine modality assessing myocardial viability risk_stratification patient_advanced left_ventricular_lv dysfunction reviewed diagnosis reversible lv_dysfunction patient_heart_failure important clinical issue patient_severe lv_dysfunction viable myocardium patient highest risk potential ischemia time benefit form revascularization important identify viable myocardium patient nuclear medicine technique excellent tool single photon emission computed_tomography spect combination myocardial perfusion tracer play_important_role identification tissue viability myocardial segment imaging positron emission tomography pet tracer allow assessment physiologic process myocardial oxygen_consumption metabolic rate glucose utilization myocardial blood_flow metabolic imaging pet offer regional tissue viability patient_advanced coronary_artery_disease severely impaired lv_function:0.0522582273238570", "47621": "routine use cardiac positron emission tomography pet application increasing replaced cardiac single photon emission computerized tomography spect study yet majority cardiac pet tracer exception fluorine fluorodeoxyglucose f fdg widely available require either onsite cyclotron costly generator production f fdg pet imaging high_sensitivity detection hibernating viable myocardium replaced tl spect imaging center equipped pet ct camera pet myocardial perfusion imaging various tracer rb n ammonia h higher sensitivity_specificity myocardial perfusion spect detection coronary_artery_disease_cad particular quantitative pet measurement myocardial perfusion help identify subclinical coronary stenosis better define extent severity cad detect ischemia balanced reduction myocardial perfusion due three vessel main stem cad fusion image pet perfusion ct coronary_artery calcium scoring ct coronary_angiography provide additional complementary information improve detection cad pet study novel f labeled perfusion tracer f flurpiridaz f fbntp yielded high sensitivity_specificity diagnosis cad tracer still tested human approved clinical use commercially widely available addition viability study f fdg pet also utilized detect inflammation infection various condition endocarditis sarcoidosis atherosclerosis recent series obtained encouraging result detection endocarditis patient intracardiac device prosthetic valve pet tracer cardiac neuronal imaging c hed help assess severity heart_failure post transplant cardiac reinnervation understand pathogenesis arrhytmias uncommon application cardiac pet include naf imaging identify calcium deposition atherosclerotic plaque beta amyloid imaging diagnose cardiac amyloid involvement f fdg imaging novel pet mr camera reported sensitive specific differentiation malignant nonmalignant cardiac mass potential application pet mr cardiac infectious inflammatory condition endocarditis:0.0521235523117833"}, "Topic 36": {"119118": "underlying_mechanism clinical biochemical manifestation chronic heart_failure_hf may due part neurohumoral adaptation activation renin_angiotensin_aldosterone sympathetic nervous_system periphery brain internet search discussion colleague method_study since chronic_hf associated autonomic imbalance increased sympathetic_nerve activity withdrawal parasympathetic activity may considered brain disease phenomenon may result increased systemic cerebral angiotensin_ii signaling plasma angiotensin_ii increased human animal chronic_hf increase angiotensin_ii signaling enhances sympathetic_nerve activity action central peripheral site chronic_hf activation angiotensin_ii signaling different brain site paraventricular nucleus pvn rostral ventrolateral medulla rvlm area postrema ap may increase release norepinephrine oxidative_stress inflammation leading increased cardiac contractility possible blocking angiotensin_ii type receptor decrease sympathetic_nerve activity cardiac sympathetic afferent reflex therapy administered pvn administration angiotensin_receptor_blocker injection ap activates sympatho inhibitory baroreflex indicating receptor_blocker act increasing parasympathetic activity chronic_hf peripheral region angiotensin_ii elevates norepinephrine release synthesis inhibits norepinephrine uptake nerve ending may_contribute increase sympathetic_nerve activity increased circulating angiotensin_ii chronic_hf may enhance sympatho excitatory chemoreflex inhibit sympatho inhibitory baroreflex resulting worsening_hf increased circulating angiotensin_ii signaling directly act central nervous_system via subfornical organ ap increase sympathetic outflow resulting neurohumoral dysfunction resulting heart_failure:0.0447759620967590", "101383": "sympathetic nervous_system identified major contributor pathophysiology chronic_heart_failure_chf disease hypertension_diabetes experimental animal_model patient kidney dense afferent sensory innervation positioning origin multimodal input central nervous_system afferent renal nerve arn signal centrally integrated activation result general increase sympathetic tone directed toward kidney well peripheral organ innervated sympathetic_nerve central nervous_system stimulation arn increase neuronal discharge frequency neuronal activity paraventricular nucleus pvn hypothalamus activity neuron pvn attenuated iontophoretic application glutamate receptor_blocker ap enhanced afferent renal input pvn may critically involved dictating sympathoexcitation chf furthermore renal denervation abrogates enhanced neuronal activity within pvn rat chf thereby possibly contributing reduction sympathetic tone renal denervation also restores decreased endogenous level neuronal nitric_oxide synthase nnos pvn rat chf overall data demonstrate sensory information originating kidney excites pre autonomic sympathetic neuron within pvn renal pvn afferent pathway may_contribute elevated sympathetic_nerve activity hyper sympathetic disease condition chf hypertension:0.0413532315661833", "111535": "introduction angiotensin_ii ang_ii vasopressin vp interact several physiological mechanism playing role arterial_hypertension congestive_heart_failure aim method search overview primary mechanism involved regulation cardiovascular function pubmed medline searched author selected original article_review written english result angiotensin_ii ang_ii vasopressin vp involved several physiological mechanism ang_ii stimulates vp release via angiotensin_receptor ang_ii vp stimulate aldosterone synthesis secretion enhance action renal collecting duct level vp also involved cardiovascular reflex control sympathetic nervous_system sn also vp potentiates vasoconstriction cardiac contractility enhancing effect ang_ii sympathetic tone arterial_pressure hand ang_ii vp act antagonistically regulating baroreflex control sn evidence high vp plasma_level increase baroreflex sympatho inhibitory response arterial baroreflex response shifted lower pressure cardiovascular reflex control mediated mainly brain specifically circumventricular organ area postrema ap modulation cardiovascular reflex control induced vp abolished lesion ap vp modulation baroreflex function also control alpha adrenergic pathway arising nucleus solitary tract nt synapsing vp ergic neuron supraoptic paraventricular nucleus presynaptic alpha adrenergic stimulation within nt inhibits vp release induced hypovolemia effect vp ap baroreflex control sn thus showing baroreceptor afferent input processed within nt contribute increased baroreflex sympatho inhibitory response discussion patient congestive_heart_failure_chf plasma vp level elevated inducing regulation aquaporin water channel expression renal collecting duct cd cell provoking exaggerated water retention dilutional hyponatremia antagonist vp ang_ii receptor reduce edema body_weight dyspnea chf_patient conclusion hormonal imbalance ang_ii vp sn may induce hypertension impaired water electrolyte balance cardiovascular_disease:0.0413524123911888", "153040": "aging cardiovascular regulatory function manifest imbalance sympathetic parasympathetic vagal component autonomic nervous_system an characteristic change sympathetic overdrive manifested increase muscle sympathetic_nerve activity msna burst frequency age age related change occur vagal nerve activity less clear resting tonic parasympathetic activity estimated noninvasively measuring increase heart_rate occurring response muscarinic cholinergic receptor blockade animal study model shown diminish age humoral cellular neural mechanism work together prevent non resolving inflammation review_focus mechanism_underlying age related alternation an imbalance an evaluated msna heart_rate variability hrv potentially facilitates inflammation homeostatic mechanism reflex neural circuit immune system compromised particularly dysfunction cholinergic anti_inflammatory reflex physiologically efferent arm reflex act via formula see text nicotinic acetylcholine receptor expressed macrophage monocyte dendritic cell cell endothelial_cell curb release inflammatory cytokine inhibition nf_kappab nuclear translocation activation jak stat mediated signaling cascade macrophage immune cell implicated reflex likely become less adequate advanced age consequently pro inflammatory state induced reduced vagus output age associated endothelial_dysfunction may significantly contribute development propagation atherosclerosis heart_failure hypertension aim review summarize relationship an dysfunction inflammation endothelial_dysfunction context aging meanwhile review also attempt describe role hrv measure predictor level inflammation endothelial_dysfunction aged population explore possible therapeutical effect vagus nerve stimulation:0.0407299648878569", "85648": "topic review review give update cellular molecular_mechanism within autonomic nervous_system involved non pathological pathological cardiovascular regulation advance highlight cardiovascular homeostasis non pathological condition maintained discrete neural network using specified signalling mechanism cellular molecular level required heart_failure cell signalling protein partner capon pin decrease bioavailability nitric_oxide inhibiting neuronal nitric_oxide synthase activity leading removal tonic neuronal inhibition following myocardial_infarction pro inflammatory cytokine paraventricular nucleus subsequent generation reactive_oxygen_specie via angiotensin_ii activation angiotensin_ii type receptor increase neuronal excitability leading sympathetic excitation pathological feature heart_failure abnormal control sympathetic nervous_system paraventricular nucleus hypothalamus pvn one important central site involved regulating sympathetic tone part responsible dysregulation sympathetic nervous_system evident heart_failure generation sympathetic tone response fluctuation cardiovascular regulation us discrete anatomical pathway neurochemical modulators direct indirect projection pvn pre autonomic neuron innervate sympathetic preganglionic neuron spinal cord turn innervate sympathetic ganglion give rise sympathetic_nerve pre autonomic neuron pvn receive afferent input arising nucleus tractus solitarii viscerosensory receptor convey cardiovascular fluctuation nucleus tractus solitarii pvn contains excitatory inhibitory neuron whose balance determines sympathetic tone non pathological condition tonic inhibition pvn pre autonomic neuron mediated gaba releasing neuron heart_failure pre autonomic neuron disinhibited action excitatory neurotransmitter glutamate angiotensin_ii leading increased sympathetic activity key feature disinhibition reduction bioavailability consequence disrupted capon pin signalling mechanism within neuron another critical feature contributes increased neuronal excitation within pvn production pro inflammatory cytokine immediately following myocardial_infarction activation angiotensin_ii type receptor production reactive_oxygen_specie examining change associated sympathetic nervous_system pathway progress understanding sympathetic regulation heart_failure identify gap knowledge suggest new therapeutic_strategy:0.0394535096817793", "111107": "chronic_heart_failure common clinical condition characterized persistent excessive sympathetic nervous_system activation derangement sympathetic activity relevant implication disease_progression patient survival aiming positively impact patient_outcome autonomic nervous_system modulatory therapy developed tested animal clinical_study general gross assumption direct vagal stimulation baroreflex activation considered equivalent assumption take account fact direct cervical vagal nerve stimulation involves activation afferent efferent fiber innervating heart entire visceral system leading undesired response compartment different action baroreflex activation based generating centrally mediated reduction sympathetic outflow increasing parasympathetic activity heart via physiological reflex pathway thus baroreflex activation rebalances unbalanced autonomic nervous_system via specific path independent complementary investigation shown sympathetic_nerve activity rebalanced via control arterial baroreflex heart_failure_patient result recent pioneering research study support hypothesis baroreflex activation add significant therapeutic benefit top guideline_directed_medical_therapy patient_advanced_heart_failure present review baroreflex activation therapy result discussed focusing critical aspect like patient_selection rationale support clinician orientation opting baroreflex activation therapy top current guideline_directed medical_treatment therapy considered:0.0381188564164000", "83750": "long_term level arterial_pressure dependent relationship arterial_pressure urinary output salt water turn affected number factor including renal sympathetic_nerve activity rsna present brief review consider mechanism within brain influence rsna focusing particularly hypothalamic mechanism paraventricular nucleus pvn hypothalamus major direct indirect connection sympathetic outflow considerable evidence tonic activation pvn sympathetic pathway contributes sustained increased level rsna occurs condition heart_failure neurogenic hypertension tonic activity pvn sympathetic neuron turn depends upon balance excitatory inhibitory input number neurotransmitter neuromodulators involved tonic excitatory inhibitory effect including glutamate gaba angiotensin_ii nitric_oxide dorsomedial hypothalamic nucleus dmh also exerts powerful influence sympathetic activity including rsna via synapsis sympathetic nucleus medulla possibly also brainstem region dmh sympathetic pathway important component phasic sympathoexcitatory response associated acute stress evidence important component central pathway produce long_term change arterial_pressure nevertheless possible repeated episodic activation pathway could lead vascular hypertrophy thus sustained change vascular_resistance arterial_pressure recent_study reactivated old debate concerning possible role baroreceptor reflex long_term regulation sympathetic activity therefore central resetting baroreceptor sympathetic reflex may important component mechanism causing sustained change rsna however little_known cellular mechanism could cause resetting:0.0380131992555163", "91305": "review address primarily role asics determining sensory signal arterial baroreceptor peripheral chemoreceptor cardiopulmonary somatic afferent alteration sensory signal acute cardiovascular stress result change sympathetic parasympathetic activity restore cardiovascular homeostasis pathological state however chronic dysfunction afferent result serious sympatho vagal imbalance significant_increase mortality_morbidity identified role asic mechano sensitivity aortic baroreceptor asic ph sensitivity carotid body spontaneously hypertensive rat reported decreased expression asic nodose ganglion neuron overexpression asic carotid body reciprocal expression asic asic result reciprocal change sensory sensitivity baro chemoreceptor consequential synergistic exaggeration sympathetic_nerve activity similar reciprocal sensory dysautonomia prevails heart_failure increase_risk mortality also evidence asic heteromers skeletal_muscle afferent contribute significantly exercise pressor reflex cardiac muscle afferent dorsal root ganglion contribute nociception detrimental sympathetic activation ischemia finally report inhibitory influence asic mediated baroreceptor activity suppresses sympatho excitatory reflex chemoreceptor skeletal_muscle afferent well asic mediated excitation central neuron fear threat panic translational potential activation asic cardiovascular_disease state may beneficial sympatho inhibition parasympathetic activation article part special issue entitled acid sensing ion channel nervous_system:0.0379972899935503", "78977": "sympathetic_nerve activity reported increased human animal chronic_heart_failure one mechanism believed responsible phenomenon increased systemic cerebral angiotensin_ii signaling plasma angiotensin_ii increased human animal chronic_heart_failure increase angiotensin_ii signaling enhances sympathetic_nerve activity action central peripheral site chronic_heart_failure angiotensin_ii signaling enhanced different brain site paraventricular nucleus rostral ventrolateral medulla area postrema blocking angiotensin_ii type receptor decrease sympathetic_nerve activity cardiac sympathetic afferent reflex therapy administered paraventricular nucleus injection angiotensin_receptor_blocker area postrema activates sympathoinhibitory baroreflex peripheral region angiotensin_ii elevates norepinephrine release synthesis inhibits norepinephrine uptake nerve ending may_contribute increase sympathetic_nerve activity seen chronic_heart_failure increased circulating angiotensin_ii chronic_heart_failure may enhance sympathoexcitatory chemoreflex inhibit sympathoinhibitory baroreflex addition increased circulating angiotensin_ii directly act central nervous_system via subfornical organ area postrema increase sympathetic outflow inhibition angiotensin_ii formation type receptor shown beneficial_effect chronic_heart_failure patient:0.0375150171341549", "58904": "key point impairment baroreflex function associated progression chronic_heart_failure_chf poor_prognosis baroreflex desensitization chf least partly result central neuronal network dysfunction dorsal medial nucleus tractus solitarius dmnts long appreciated primary site baroreceptor afferent termination central nervous_system however influence neurotransmitter neuromodulators dmnts baroreflex function normal chf state fully understood present_study provides first evidence showing tonic sympatho inhibitory role brain derived neurotrophic factor bdnf neurotransmission dmnts importantly bdnf tyrosine receptor kinase b trkb signalling dmnts integral normal baroreflex function indicated blunting baroreflex sensitivity br following antagonization trkb inhibited baroreflex gain range furthermore found tonic sympatho inhibition bdnf withdrawn chf state thus contributing increased sympathetic tone associated chf consistent finding bdnf trkb antagonism little effect reducing br chf animal corroborated observation decreased trkb expression dmnts chf taken together result implicate reduction bdnf trkb signalling dmnts chf contributes sympatho excitation baroreflex desensitization observation bdnf trkb pathway impaired dmnts chf provides novel mechanism understanding central alteration contribute baroreflex desensitization chf abstract chronic_heart_failure_chf result blunting arterial baroreflex sensitivity br arises alteration peripheral baroreceptor central autonomic nucleus nucleus tractus solitarius nt although glutamate known important neurotransmitter released baroreceptor afferent synapsis nt influence neurotransmitter neuromodulators remains_unclear alteration nt signalling chf remain particularly undefined present study_aimed evaluate role brain derived neurotrophic factor bdnf tyrosine receptor kinase b trkb receptor signalling nt baroreflex control healthy chf rat end microinjected bdnf highly selective trkb receptor_antagonist n oxoazepan yl amino carbonyl phenyl benzo b thiophene carboxamide ana dorsal medial nt dmnts male sprague dawley rat coronary_artery ligation induced chf sham operated control recorded blood_pressure renal sympathetic_nerve activity response subsequently measured br bilateral dmnts microinjections ana sham rat bdnf evoked dose dependent depressor sympatho inhibitory effect ana produced opposite response response significantly blunted chf rat furthermore bilateral microinjection ana dmnts greatly diminished baroreflex sensitivity sham rat whereas less effect chf rat observed decreased level trkb protein mrna dmnts chf rat data indicate endogenous bdnf signalling nt integral maintenance br bdnf trkb signalling impaired nt chf state:0.0374783875567945"}, "Topic 37": {"122431": "background cardiomems r sensor wireless pulmonary_artery_pressure device used monitoring symptomatic heart_failure_hf use cardiomems associated reduction hospitalization hf_patient acquisition cost could high low middle income country evidence cost_effectiveness needed help decision maker allocate resource according value money study_aimed estimating cost_effectiveness cardiomems used hf_patient third party payer perspective social security s private sector p argentina method markov model developed estimate cost_effectiveness cardiomems versus usual medical care lifetime horizon model applied hypothetical population patient_hf functional_class iii least_one hospitalization previous month main outcome incremental cost_effectiveness ratio icer populate model retrieved clinical epidemiological utility parameter literature whilst direct medical cost estimated micro costing approach exchange rate usd ar uncertainty parameter assessed deterministic probabilistic scenario sensitivity_analysis result compared usual medical care cardiomems increased quality adjusted life year qaly increased cost per patient ar s ar p resultant icer ar per qaly ar per qaly s p respectively icer sensitive hazard_ratio hf hospital_admission acquisition price cardiomems probability cardiomems cost_effective one ar three ar five ar gross domestic product per caput s p_conclusion cardiomems effective costly usual_care class iii hf_patient since argentina current explicit threshold final decision determine cost_effectiveness depend willingness pay qalys health subsector:0.0624431921058284", "185765": "background heart_failure_preserved_ejection_fraction_hfpef imposes high disease burden patient primarily multimorbidity frequent hospitalization recently american college cardiology expert consensus recommended treating patient_diagnosed hfpef sodium_glucose_cotransporter_inhibitor dapagliflozin empagliflozin reduce_risk cardiovascular_death hospitalization improve health_status however managing hfpef expensive highlighting need assess therapeutic alternative minimize health_care cost optimizing patient_outcome objective compare cost_effectiveness dapagliflozin v empagliflozin managing patient_hfpef u health_care system perspective method developed markov model simulate cohort patient_hfpef defined left_ventricular_ejection_fraction treated dapagliflozin empagliflozin transition probability health state hfpef hospitalization_heart_failure death cost quality_life weight input variable obtained literature base case analysis estimated total expected cost quality adjusted life year qalys gained incremental cost_effectiveness ratio icer lifetime horizon future expected cost qalys discounted annual rate conducted sensitivity_analysis demonstrate robustness cost_effectiveness model finding result dapagliflozin incremental expected lifetime cost compared empagliflozin resulting icer qaly value based price threshold analysis suggested empagliflozin cost_effective would need discount annual price probabilistic sensitivity_analysis dapagliflozin would preferred cost_effective option willingness pay threshold qaly time conclusion cost_effectiveness analysis_showed u health_care system perspective dapagliflozin cost_effective empagliflozin uptake may enhance long_term outcome_patient hfpef:0.0615825562557104", "138473": "aim_study determine cost_effectiveness dapagliflozin heart_failure_reduced_ejection_fraction_hfref patient china perspective health_care payer method_result built markov model perform cost_effectiveness analysis comparing standard treatment dapagliflozin mg q standard treatment hfref base case simulation year_old hfref_patient modelled year input model derived dapagliflozin prevention adverse_outcome heart_failure trial relevant data china cost quality adjusted life year qaly incremental cost_effectiveness ratio icer estimated adding dapagliflozin relative standard treatment cost qaly discounted rate annually cost presented u dollar dapagliflozin would considered cost_effective icer lower willingness pay wtp threshold uncertainty assessed model using one way two way probabilistic sensitivity_analysis psa base case compared standard treatment adding dapagliflozin expensive v effective v qalys respondent icer per qaly gained year_follow simulated horizon longer year respondent icer became lower wtp threshold input largest impact icer cost dapagliflozin cardiovascular_mortality group cost hospitalization_heart_failure result sensitivity_analysis robust psa showed similar result base case icer per qaly gained monte carlo simulation wtp threshold per qaly dapagliflozin considered cost_effective simulation conclusion dapagliflozin cost_effective treatment_option hfref_patient china according result model finding help doctor health_care payer make decision clinical_practice future real_world study cost_effectiveness dapagliflozin based chinese population also needed:0.0604554723812697", "155731": "background_objective sacubitril_valsartan shown effectiveness reducing hospitalization compared valsartan hfpef patient_heart_failure preserved_ejection_fraction_hfpef aimed investigate cost_effectiveness sacubitril_valsartan alternative valsartan chinese patient_heart_failure hfpef method markov model built investigate cost_effectiveness sacubitril_valsartan alternative valsartan chinese patient_hfpef healthcare system perspective time horizon lifetime cycle length month cost obtained local information published paper discounted rate future cost transition probability utility based study primary_outcome study incremental cost_effectiveness ratio icer sacubitril_valsartan considered cost_effective icer obtained lower willingness pay threshold u dollar u per quality adjusted life year qaly one way probabilistic sensitivity_analysis well scenario analysis_performed test robustness result lifetime simulation year_old chinese patient_hfpef could gain qalys life year sacubitril_valsartan plus standard treatment administered qalys life year valsartan plus standard treatment prescribed corresponding cost group u u respectively icer u qaly u life year higher willingness pay threshold sensitivity_analysis scenario analysis_showed result robust conclusion adding sacubitril_valsartan standard treatment alternative valsartan treatment hfpef resulted effectiveness higher cost sacubitril_valsartan likely cost_effective chinese patient_hfpef cost sacubitril_valsartan need reduce current price cost_effective population study based real_world data needed confirm conclusion:0.0598555416175374", "143453": "purpose research examined cost_effectiveness adding empagliflozin standard_care soc compared soc alone treatment_heart_failure reduced_ejection_fraction_hfref perspective healthcare payer united kingdom uk spain france method lifetime markov cohort model developed simulate patient progression health state based kansa city cardiomyopathy questionnaire clinical summary score model predicted risk_death hospitalisation worsening_heart_failure hhf treatment related adverse_event treatment discontinuation monthly cycle clinical input utility derived emperor reduced trial data supplemented published literature national costing database cost pound sterling euro quality adjusted life year qalys discounted annually uk spain france result uk spain france empagliflozin plus soc yielded additional qalys higher cost pound euro euro per patient soc alone yielding incremental cost_effectiveness ratio pound qaly euro qaly euro qaly respectively reduced hhf incidence provided cost offset empagliflozin plus soc similar result obtained range subgroup sensitivity_analysis probabilistic sensitivity result indicated empagliflozin plus soc remained cost_effective v soc willingness pay threshold pound qaly euro qaly euro qaly model run uk spain france respectively_conclusion empagliflozin added soc lead health benefit patient_hfref cost_effective treatment_option payer multiple european country uk spain france:0.0598302547695310", "128083": "background effect empagliflozin cardiovascular_outcome consistent heart_failure_reduced_ejection_fraction_hfref patient regardless presence absence diabetes evidence needed regarding cost_effectiveness empagliflozin hfref_patient study sought evaluate economic outcome adding empagliflozin standard treatment hfref_patient perspective chinese healthcare system thus provide information decision maker method based emperor reduced clinical_trial published literature data direct medical cost quality adjusted life year qalys patient_hfref year study_period simulated markov model incremental cost_effectiveness ratio icer calculated price empagliflozin referred data released menet hospitalization expense utility value derived published study china one way sensitivity_analysis probabilistic sensitivity_analysis conducted evaluate robustness model result result cost_effectiveness analysis_showed cost combination arm utility qalys cost standard arm utility qalys equated icer per qaly gained subgroup analysis_showed patient_hfref diabetes empagliflozin group higher qaly v lower cost v standard group corresponding icer non diabetic_patient per qaly deterministic sensitivity analysis_showed robust result willingness pay threshold time gross domestic product gdp per caput almost scattered point three scenario threshold line conclusion willingness pay threshold adding empagliflozin standard treatment cost_effective option hfref patient_without diabetes china:0.0595184134834880", "185729": "introduction efficacy_safety empagliflozin treatment heart_failure_preserved_ejection_fraction_hfpef demonstrated emperor preserved trial showed reduction combined risk cardiovascular_death hf_hospitalization hazard_ratio_hr_confidence_interval_ci_p reduction total number hf_hospitalization hr_ci_p compared_placebo basis result present study_aimed assess cost_effectiveness empagliflozin standard_care soc compared soc alone treatment hfpef method published markov model adapted compare health economic outcome france considering collective perspective patient_treated empagliflozin addition soc versus patient_treated soc alone model simulated intention treat itt population trial transitioning four mutually exclusive health state representing quartile kansa city cardiomyopathy questionnaire clinical summary score kccq cs arm model estimated lifetime time horizon economics health_outcome hf_hospitalization avoided life year quality adjusted life year qalys gained calculate incremental cost_effectiveness ratio icers resource used derived pairing french survey hf fresh cohort data french health insurance claim data utility derived basis eq l questionnaire valued french tariff economic health_outcome discounted annual rate result model predicted treatment hfpef_patient empagliflozin would prevent patient_treated hf_hospitalization death attributable cardiovascular_event resulting average gain month overall survival versus year placebo qalys versus placebo empagliflozin cost partially offset cost saving avoided hospitalization icers euro per life year gained euro per qaly gained sensitivity_analysis conducted showed empagliflozin probability cost_effective euro qaly threshold conclusion base case result_showed empagliflozin cost_effective strategy management hfpef addition impact public_health preventing hf_hospitalization death france sensitivity_analysis suggest simulation euro qaly threshold:0.0589876180949808", "107309": "objective chronic_heart_failure reduced_ejection_fraction hf ref represents major public_health issue associated considerable morbidity_mortality evaluated cost_effectiveness sacubitril_valsartan formerly lcz compared ace_inhibitor acei enalapril treatment hf ref perspective healthcare provider uk denmark colombia method cost utility analysis_performed based data multinational phase iii randomised controlled_trial decision analytic model developed based series regression_model extrapolated health_related_quality_life hospitalisation rate survival lifetime horizon primary_outcome incremental cost_effectiveness ratio icer result uk cost per quality adjusted life year qaly gained sacubitril_valsartan using cardiovascular_mortality pound euro versus enalapril denmark icer sacubitril_valsartan kr euro colombia icer cop million euro per qaly gained deterministic sensitivity analysis_showed result sensitive extrapolation mortality duration treatment_effect time horizon robust structural change scenario associated icers willingness pay threshold three country setting probabilistic sensitivity_analysis suggested probability sacubitril_valsartan cost_effective conventional willingness pay threshold uk denmark colombia conclusion analysis suggests three country sacubitril_valsartan likely cost_effective compared acei current standard_care patient_hf ref:0.0589362577549054", "51670": "background objective_study assess cost_effectiveness ivabradine plus standard_care soc chronic_heart_failure chf_patient sinus_rhythm baseline heart_rate b p greece comparison current soc alone method existing cost_effectiveness model consisting two health state adapted greek health_care setting clinical input model e mortality_rate hospitalization rate nyha_class distribution utility value estimated shift trial data costing data used model reflects year euro incremental cost_effectiveness ratio icer per quality adjusted life year qaly gained calculated deterministic probabilistic sensitivity_analysis psa conducted horizon analysis patient life time cost outcome discounted per_year analysis conducted greek third party payer perspective result markov analysis_revealed discounted quality adjusted survival qalys ivabradine plus soc soc alone treatment arm respectively cumulative lifetime total cost per patient euro euro ivabradine plus soc soc alone respectively icer ivabradine plus soc versus soc alone estimated euro per qaly gained psa showed likelihood ivabradine plus soc cost_effective threshold euro qaly found conclusion ivabradine plus soc may regarded cost_effective option treatment chf_patient greece:0.0589216806720087", "198468": "purpose antiarrhythmic drug aad therapy foundational long_term management atrial_fibrillation_af yet remains uncertainty clinical reimbursement decision china study_aimed estimate cost_effectiveness dronedarone compare amiodarone sotalol treatment paroxysmal persistent af china health system perspective method markov decision model developed compare lifetime clinical efficacy cost three aad therapy associated af recurrence congestive_heart_failure stroke death due af af related complication model input derived athena trial result real_world database published literature supplemented expert opinion cost_effectiveness measured incremental cost_effectiveness ratio icer defined incremental cost per quality adjusted life year qaly gained among group one way sensitivity probabilistic sensitivity scenario analysis_performed explore uncertainty model finding study used simulated cohort baseline_characteristic patient ccc af project base case compared amiodarone sotalol dronedarone expected gain additional qalys v qalys v higher cost v_v lifetime horizon leading icers per qaly respectively one way sensitivity analysis_revealed result sensitive relative_risk cardiovascular_mortality discount rate qalys utility sinus_rhythm probabilistic sensitivity_analysis indicated probability cost_effectiveness dronedarone ranged threshold one three time china per caput gross domestic product whereas probability amiodarone ranged sotalol always scenario analysis confirmed base case result sufficiently reliable implication analysis suggests dronedarone cost_effective aad compared amiodarone sotalol patient paroxysmal persistent af china offering improvement life expectancy qaly long_term rhythm_control:0.0588456872990643"}, "Topic 38": {"52418": "objective examined whether presence extent late gadolinium enhancement lge cardiovascular magnetic_resonance cmr predict adverse_outcome nonischemic cardiomyopathy nicm patient background morbidity_mortality high nicm patient however clinical_course individual patient unpredictable current risk_stratification approach limited cardiovascular magnetic_resonance detects myocardial_fibrosis appears lge contrast administration may convey prognostic importance method prospective_cohort_study nicm patient left_ventricular_lv ejection_fraction underwent cmr placement implantable_cardioverter_defibrillator_icd primary_prevention sudden_cardiac_death cmr image analyzed presence extent lge lv_function volume mass patient_followed index composite end_point cardiac_event hospitalization_heart_failure appropriate icd firing cardiac_death result_total n patient cmr lge averaging lv mass month median_follow n patient lge index composite_outcome event versus n without lge p kaplan_meier survival curve adjustment lv volume_index functional_class patient lge fold higher_risk experiencing primary_outcome hazard_ratio_confidence_interval p_conclusion cmr lge nicm patient strongly predicts adverse cardiac outcome cmr lge may represent end organ consequence sustained adrenergic activation adverse lv_remodeling identification may significantly improve risk_stratification strategy high_risk population imaging technique identifying factor sudden_cardiac_death risk nct:0.0487714190236829", "172693": "objective myocardial_fibrosis significantly impact prognosis various cardiovascular_disease yet role alcoholic cardiomyopathy acm remains poorly_understood study evaluates prognostic_value myocardial_fibrosis detected cardiac_magnetic_resonance cmr acm patient_method conducted retrospective analysis consecutive acm patient_underwent enhanced cmr august october assessment myocardial_fibrosis performed using late gadolinium enhancement lge native extracellular volume ecv fraction primary_outcome composite cardiac related mortality heart_transplantation hospitalization_heart_failure life_threatening arrhythmia need implantable_cardioverter_defibrillator cardiac_resynchronization_therapy result_total male patient finally enrolled experiencing primary_outcome median_follow_month iqr lge found patient median extent compared dcm patient consume alcohol acm patient showed lower lge native ecv value multivariate_analysis showed lge hr_p native per m increase p ecv per increase p significant prognostic association adverse_outcome including myocardial_fibrosis parameter improved predictive accuracy beyond standard assessment nonlinear relationship found lifetime ethanol consumption myocardial_fibrosis plateau low exposure sharp increase higher_level conclusion cmr identified myocardial_fibrosis association major_adverse_cardiac_event acm patient underscoring utility risk_stratification key point question prognostic role myocardial_fibrosis alcoholic cardiomyopathy remains poorly_understood finding fibrosis detected cardiac mri good incremental value predictive model assessing risk adverse cardiovascular_event patient alcoholic cardiomyopathy clinical relevance cardiac mri may potential tool identify high_risk alcoholic cardiomyopathy patient cardiovascular adverse_event helpful early clinical treatment improves patient prognosis:0.0481625368281871", "102131": "objective_study sought examine prognostic relevance mapping parameter based mapping method nonischemic dilated_cardiomyopathy nidcm compare conventional marker adverse_outcome background nidcm recognized cause poor clinical_outcome nidcm characterized intrinsic myocardial remodeling due complex pathophysiological process affecting myocardium diffusely lack accurate noninvasive characterization diffuse myocardial disease limit recognition early cardiomyopathy effective clinical management nidcm cardiac_magnetic_resonance cmr support detection diffuse myocardial disease mapping method prospective observational multicenter longitudinal study consecutive_patient dilated nidcm mean_age_year interquartile_range year male undergoing cmr mapping late gadolinium enhancement lge primary_endpoint cause_mortality composite heart_failure_hf mortality hospitalization secondary_endpoint result median_follow period month interquartile_range month observed total death cardiac composite hf event mapping index native extracellular volume fraction well presence extent lge predictive cause_mortality hf endpoint p multivariable_analysis native sole independent_predictor cause hf composite_endpoint hazard_ratio_confidence_interval hazard_ratio_confidence_interval_p followed model including extent lge right_ventricular ejection_fraction respectively_conclusion noninvasive measure diffuse myocardial disease mapping significantly predictive cause_mortality hf event nidcm provide basis novel algorithm risk_stratification nidcm using complementary assessment diffuse regional disease mapping lge respectively:0.0479876458294770", "48013": "aim nonischaemic dilated_cardiomyopathy nicm replacement myocardial_fibrosis detected late gadolinium enhancement lge cardiovascular magnetic_resonance cmr associated poor_prognosis investigated yet unexplored prognostic significance interstitial fibrosis nicm using mapping cmr method eighty nine nicm patient men age_year left_ventricular_systolic_dysfunction ejection_fraction underwent comprehensive clinical cmr evaluation extracellular volume fraction ecv estimation pre postcontrast mapping fifteen healthy individual men mean_age_year used control end_point composite cardiovascular_death hospitalization_heart_failure appropriate defibrillator intervention result myocardial ecv higher nicm patient control p nicm patient myocardial ecv correlated left_ventricular_ejection_fraction r lge extent r doppler e_e r ventricular_tachycardia r h ecg monitoring p median_follow_month interquartile_range month event occurred higher myocardium ecv independently_associated occurrence composite end_point p_conclusion nicm patient myocardial ecv increased compared normal individual likely reflecting extracellular_matrix remodelling collagen deposition resulted independent prognostic predictor beyond conventional clinical electrocardiographic echocardiographic_parameter:0.0472107281878555", "147228": "aim non ischaemic dilated_cardiomyopathy_dcm concomitant right_ventricular_rv dysfunction frequently observed study sought determine correlation rv dysfunction several cardiac_magnetic_resonance cmr imaging characteristic patient dcm prognostic_value rv dysfunction cause_mortality ventricular_arrhythmia va evaluated method_result consecutive_patient dcm left_ventricular_lv dysfunction ejection_fraction cmr included retrospectively left_atrial la lv rv volume function quantified rv systolic_dysfunction defined rvef presence pattern late gadolinium enhancement lge cmr assessed visually septal midwall lge defined midmyocardial stripe like patchy hyperenhancement septal segment extent quantified using full width half maximum method primary_endpoint composite cause_mortality va including resuscitated cardiac_arrest sustained va appropriate implantable_cardioverter_defibrillator therapy secondary_endpoint time cause_mortality alone time va alone total dcm patient_included female age_year mean rvef rv dysfunction present rvef moderately correlated la dilation la minimal volume rho p strongly correlated la lv_dysfunction la emptying fraction r_p lvef rho p septal midwall lge often observed_patient rv dysfunction compared_patient preserved rv function respectively v_p correlation found rvef extent septal midwall lge rho p median_follow_year iqr patient_experienced primary_endpoint rv dysfunction significantly_associated shorter time composite primary_endpoint hr_ci_p secondary_endpoint va alone hr_ci_p trend towards increased mortality rv dysfunction present hr_ci_p_conclusion right_ventricular dysfunction predominantly observed_patient dcm advanced_heart_failure pronounced myocardial remodelling defined increased lv la dilation dysfunction presence septal midwall lge cmr follow rv dysfunction associated shorter time cause_mortality ventricular arrhythmic event:0.0471216532684706", "106522": "objective aim_study_evaluate whether native value myocardium cardiac_magnetic_resonance cmr could predict clinical_event patient significant aortic_stenosis background although previous_study demonstrated prognostic_value focal fibrosis using late gadolinium enhancement lge cmr patient prognostic implication diffuse myocardial_fibrosis noninvasive imaging remains unknown method prospective observational longitudinal study performed consecutive_patient moderate_severe year_age male age_sex matched_control underwent cmr degree diffuse myocardial_fibrosis assessed noncontrast mapping relaxation time using modified look locker inversion recovery sequence presence extent lge also evaluated patient_divided group native value primary_endpoint composite cause_death hospitalization_heart_failure result native value higher patient compared_control subject m v m p follow median month clinical_event including death pre operative post operative majority occurred_patient highest tertile group v_v lowest mid highest tertile group_p log_rank test total number event pre post operative event also occurred frequently patient highest tertile group euroscore ii presence extent lge native value predictor poor_prognosis adjusted_hazard_ratio every m increase native p particular highest native value provided risk_stratification regardless presence lge conclusion high native value noncontrast mapping cmr novel independent_predictor adverse outcome_patient significant:0.0471071502630593", "90660": "background suspected nonischemic cardiomyopathy nicm common clinical_setting highly variable prognosis early noninvasive risk_stratification important justification invasive examination specific treatment_patient surveillance studied additional prognostic_value late gadolinium enhancement lge segmental wall motion abnormality swma extent cardiovascular magnetic_resonance cmr compared traditional risk_factor suspected nicm method observational cohort_study enrolled consecutive_patient referred cmr due suspected nicm patient ischemic_cardiomyopathy excluded cmr image analysed left_ventricular lge swma extent patient_followed major_adverse_cardiac_event mace including cardiovascular_death aborted sudden_death cardiac_transplantation result_patient median_age_year female mainly presenting ventricular_arrhythmia congestive_heart_failure finally diagnosed nicm left_ventricle hypertrophy idiopathic arrhythmia cmr patient lge swma median_follow day patient reached mace univariant analysis lge volume hazard_ratio_hr per increase lge p left_ventricular_ejection_fraction_lvef hr_p swma score hr_p strongest association mace multivariate_analysis best overall model event prediction included lge volume hr_p sustained ventricular_tachycardia hr_p lvef hr_p among_patient lge event_rate versus patient_without lge p log_rank highest event_rate observed_patient lge volume patient_without swma experience mace p log_rank giving additional information subgroup patient preserved lvef conclusion suspected nicm presenting ventricular_arrhythmia heart_failure lge extent give additional prognostic_information compared traditional risk_factor absence swma may give prognostic_information beyond normal lvef even though final diagnosis uncertain nicm extensive amount lge considered sign poor_prognosis:0.0466976767086312", "34251": "objective study_aimed demonstrate presence late gadolinium enhancement lge predictor death adverse_event patient suspected cardiac sarcoidosis background cardiac sarcoidosis important cause patient mortality systemic sarcoidosis yielding year mortality_rate despite immunosuppressive treatment_group shown lge may hold promise predicting future adverse_event patient_group method included consecutive_patient systemic sarcoidosis underwent cardiac_magnetic_resonance cmr workup suspected cardiac sarcoid involvement median_follow time year primary_endpoint death aborted sudden_cardiac_death appropriate implantable_cardioverter_defibrillator_icd discharge secondary_endpoint ventricular_tachycardia vt nonsustained vt result lge present patient presence lge yield cox hazard_ratio_hr death aborted sudden_cardiac_death appropriate icd discharge event superior functional clinical parameter left_ventricular_lv ejection_fraction_ef lv_end_diastolic volume presentation heart_failure yielding hr per increase lvef presentation heart_failure potentially lethal adverse_event respectively except patient dying pulmonary infection patient_without lge died experienced event follow even lv enlarged lvef severely impaired conclusion among population sarcoid patient nonspecific symptom presence myocardial scar indicated lge best independent_predictor potentially lethal event well adverse_event yielding cox hr respectively data support necessity future large longitudinal follow study definitely establish lge independent_predictor cardiac_death sarcoidosis well evaluate incremental prognostic_value additional parameter:0.0465384088983529", "86400": "background current risk_stratification sudden_cardiac_death scd nonischemic dilated_cardiomyopathy nidc relies left_ventricular_lv dysfunction poor marker ventricular electrical instability contrast enhanced cardiac_magnetic_resonance ability accurately identify quantify ventricular myocardial_fibrosis late gadolinium enhancement lge objective_evaluate impact presence amount myocardial_fibrosis arrhythmogenic risk prediction nidc method one_hundred thirty seven consecutive_patient angiographically proven nidc enrolled study_patient followed combined arrhythmic end_point including sustained ventricular_tachycardia vt appropriate implantable_cardioverter_defibrillator_icd intervention ventricular fibrillation vf scd result lv lge identified_patient median_follow_year combined arrhythmic end_point occurred_patient sustained vt appropriate icd intervention either vf n vt n aborted scd died suddenly kaplan_meier analysis_revealed significant_correlation lv lge presence amount distribution malignant arrhythmic event p univariate cox_regression_analysis lv lge hazard_ratio_hr_confidence_interval_ci_p left_bundle_branch_block hr_ci_p found associated arrhythmia multivariable_analysis presence lge independent_predictor arrhythmia hr_ci_p_conclusion lv lge powerful independent_predictor malignant arrhythmic prognosis amount distribution provide additional prognostic_value contrast enhanced cardiac_magnetic_resonance may_contribute identify candidate icd therapy fulfilling current criterion based left_ventricular_ejection_fraction:0.0459409170357788", "160624": "aim alcoholic cardiomyopathy acm recognized type non ischemic dilated_cardiomyopathy_dcm date clinical prognosis acm remains topic debate previous_study limited study cardiac mri characteristic aim_study summarize clinical mri feature acm patient identify predictor adverse prognosis based clinical_characteristic mri imaging finding material_method adult_patient clinically diagnosed acm underwent enhanced cmr september august retrospectively enrolled primary_endpoint major_adverse_cardiovascular_event including cardiac related death heart_transplantation hospitalization_heart_failure life_threatening ventricular_arrhythmia sustained ventricular_tachycardia ventricular fibrillation icd shock risk_factor associated primary_end_point identified using multivariable cox analysis result_total acm patient_year men included majority patient_presented symptom heart_failure median_follow period month iqr month patient reached primary_endpoint clinical_variable multivariable analysis_showed drinking duration hr_ci_p persistent drinking hr_ci_p associated mace cmr variable late gadolinium enhancement lge percent hr_ci_p stood independent_predictor mace conclusion acm patient persistent drinking cardiac mri defined myocardial scar associated adverse_outcome cardiac_death heart_transplantation hospitalization_heart_failure life_threatening ventricular_arrhythmia:0.0459167654879996"}, "Topic 39": {"185703": "obstructive_sleep_apnea osa common medical condition increasing prevalence occurring men_woman osa defined upper airway collapse resulting decrease hypopnea airflow loss apnea least second repeated episode hypopnea apnea cause hypoxia hypercapnia sleep fragmentation result_patient suffer various symptom including snoring gasping air night excessive sleepiness headache irritability difficulty concentrating decreased libido traditionally diagnosis osa relied lab polysomnography however home sleep_apnea testing acceptable alternative diagnostic tool result either test determine severity osa using apnea hypopnea index ahi defined american academy sleep medicine severity level categorized follows mild osa ahi moderate osa ahi severe osa ahi untreated osa associated numerous adverse health_outcome including increased motor vehicle accident hypertension type_diabetes stroke atrial_fibrillation coronary_artery_disease heart_failure increased overall mortality gold_standard treating osa continuous positive airway pressure cpap administered via various face nasal mask treatment improves overall sleep quality proven effective reducing blood_pressure ahi compliance challenging many patient reporting hour cpap use per night compliance treatment especially challenging time noncompliance rate long_term use range hypoglossal nerve stimulation hgns surgical option treating osa procedure stimulator connected hypoglossal nerve control genioglossus muscle nerve stimulated trigger contraction muscle effectively preventing collapse upper airway study shown hgns significantly improves quality_life ahi oxygen desaturation index odi:0.0724141976541142", "6558": "obstructive_sleep_apnea osa syndrome highly prevalent disorder characterized recurrent upper airway collapse sleep associated repetitive episode transient oxygen desaturation sleep disrupts normal ventilation sleep architecture typically associated excessive daytime sleepiness snoring witnessed apnea besides associated neurocognitive impairment mood behavioral effect increased_risk work related traffic accident osa also implicated pathogenesis various cardiovascular_disease including systemic hypertension coronary_artery_disease congestive_heart_failure pulmonary_hypertension stroke cardiac_arrhythmia mechanism osa affect cardiovascular_system may involve mechanical effect intrathoracic pressure increased sympathetic activation intermittent hypoxia endothelial_dysfunction therapy continuous positive airway pressure cpap demonstrated improve cardiopulmonary hemodynamics patient osa may reverse endothelial_cell dysfunction:0.0699118621558564", "165266": "obstructive_sleep_apnea osa common disorder affect quality_life associated comorbidities hypertension atrial_fibrillation heart_failure coronary_heart_disease type_diabetes_mellitus stroke osa characterized reduction cessation breathing sleep resulting intermittent hypoxemia autonomic fluctuation sleep fragmentation u preventive service task force state insufficient evidence recommend routine screening osa absence symptom osa considered patient excessive daytime fatigue unrestful sleep persistent snoring nocturnal awakening gasping choking stop bang questionnaire sensitive screening tool osa diagnostic standard polysomnography observed apnea hypopnea index greater presence symptom greater without symptom home sleep_apnea testing useful diagnostic option patient symptom consistent moderate_severe osa without significant cardiopulmonary comorbidities positive airway pressure humidified nasal facial mask first_line treatment adult osa weight_loss beneficial adjunct treatment intensive lifestyle modification medication bariatric surgery alternative patient intolerant nonadherent positive airway pressure include changing type mask used mandibular advancement device hypoglossal nerve stimulation surgical intervention although many osa therapy effectively improve daytime sleepiness blood_pressure none demonstrated mortality benefit randomized_controlled_trial:0.0664644615413668", "169747": "sleep_apnea involves almost one billion individual throughout world including million american major medical concern fact prevalence sleep_apnea significantly increasing due epidemic obesity physical inactivity diabetes_mellitus important risk_factor development persistence sleep_apnea individual sleep_apnea characterized multiple episode apnea hypopnea sleep cause nocturnal arousal gasping breath night daytime sleepiness irritability forgetfulness fatigue recurrent headache obstructive_sleep_apnea occurs upper airway obstruction occurs individual sleep absent markedly reduced airflow presence continued activity inspiratory thoracic diaphragmatic muscle central sleep_apnea defined absence significant_reduction naso oral airflow due withdrawal sleep ponto medullary respiratory center stimulation nerve inspiratory thoracic diaphragmatic muscle absence contraction muscle apnea complex sleep_apnea occurs individual exhibit characteristic obstructive central sleep_apnea severity sleep_apnea measured polysomnography apnea hypopnea index ahi average number apnea hypopnea per hour sleep measured polysomnography sleep_apnea mild ahi h mild symptom moderate ahi h occasional daytime sleepiness severe ahi h frequent daytime sleepiness interferes normal activity daily life chronic sleep_apnea hypopnea followed compensatory hyperpnea associated significant adverse cardiovascular consequence including recurrent hypoxemia hypercarbia increased sympathetic_nerve activity decreased parasympathetic nerve activity oxidative_stress vascular endothelial_dysfunction cardiac_remodeling cardiovascular_disease moderate_severe sleep_apnea significantly increase_risk coronary_artery_disease congestive_heart_failure cerebral vascular event stroke cardiac dysrhythmias also increase morbidity_mortality disease nevertheless sleep_apnea currently underdiagnosed untreated many individual due challenge prediction detection sleep_apnea lack well defined optimal treatment guideline chronic continuous positive airway pressure h night night beneficial treatment_patient sleep_apnea cpap improves sleep quality reduces ahi augments cardiac_output increase oxygen delivery brain heart reduces resistant hypertension decrease cardiac dysrhythmias reduces daytime sleepiness present article discusses diagnosis obstructive_sleep_apnea central sleep_apnea complex apnea thereafter important pathophysiologic mechanism sleep_apnea relationship pathophysiologic mechanic atherosclerotic vascular_disease reviewed guideline provided treatment mild moderate_severe sleep_apnea order reduce cardiovascular morbidity_mortality caused sleep_apnea facilitate diagnosis long_term effective_treatment sleep_apnea patient close cooperation necessary cardiovascular specialist pulmonary specialist respiratory therapy rehabilitation specialist:0.0653782243284976", "6364": "sleep_apnea syndrome sa common disorder characterized repetitive episode cessation breathing sleep resulting hypoxemia sleep disruption consequence abnormal breathing sleep include daytime sleepiness neurocognitive dysfunction development cardiovascular disorder metabolic dysfunction impaired quality_life two type sa obstructive_sleep_apnea syndrome osas central sleep_apnea syndrome csas osas prevalent disorder snoring repetitive apneic episode daytime sleepiness anatomical condition causing upper airway obstruction obesity craniofacial abnormality retrognathia micrognathia cause osas csas much less common osas disorder characterized cessation breathing caused reduced respiratory drive central nervous_system muscle respiration latter condition common patient_heart_failure cerebral neurologic disease diagnosis sa requires assessment subjective symptom apneic episode sleep documented polysomnography treatment osas include continuous positive airway pressure cpap oral appliance surgery patient csas treated oxygen adaptive servo ventilation cpap assessment treatment sa patient usually resolution disabling symptom subsequently resulting improved quality_life:0.0648064978582178", "182002": "obstructive_sleep_apnea osa breathing disorder characterized recurrent apnea hypopnea associated complete partial obstruction upper airway sleep resulting disturbed sleep architecture repeated hypoxemia awakening daytime sleepiness osa syndrome affect men_woman western country abnormality upper airway anatomy frequently due obesity muscle tone neural control breathing main cause osa associated impaired cognitive function favor onset hypertension major determinant resistant hypertension may favor cardiovascular_disease e_g coronary_artery_disease heart_failure thereby increasing mortality polysomnography cardio respiratory portable system used diagnose determine severity osa management osa includes lifestyle modification weight_loss avoidance supine sleep position continuous positive airway pressure mandibular advancement device upper airway surgery may_also appropriate patient hypoglossal nerve stimulation pharmacological intervention currently investigated improve symptom outcome:0.0631605208948528", "30949": "obstructive_sleep_apnea osa syndrome common often unrecognized disorder caused pharyngeal collapse sleep characterized frequent awakening disrupted sleep consequent excessive daytime sleepiness increasing epidemic obesity important risk_factor osa prevalence disease increase coming year thus representing important public_health problem fact recognized association osa hypertension metabolic_syndrome diabetes heart_failure coronary_artery_disease arrhythmia stroke pulmonary_hypertension neurocognitive mood disorder diagnosis based combined evaluation clinical_manifestation objective sleep study finding cardinal symptom include snoring sleepiness significant report sleep_apnea episode polysomnography represents gold_standard confirm clinical suspicion osa syndrome assess severity guide therapeutic choice behavioral medical surgical option available treatment continuous positive airway pressure cpap represents treatment choice patient cpap demonstrated effective reducing symptom cardiovascular morbidity_mortality neurocognitive sequela often poorly tolerated result clinical_study support surgery pharmacological therapy first_line treatment approach might useful selected patient better understanding mechanism_underlying disease could improve therapeutic_strategy reduce social impact osa syndrome:0.0628605800711776", "37901": "obstructive_sleep_apnea osa common form sleep disordered breathing affecting population characterized intermittent episode partial complete obstruction upper airway sleep disrupts normal ventilation sleep architecture typically associated excessive daytime sleepiness snoring witnessed apnea patient obstructive_sleep_apnea present risk general public safety causing fold increase vehicle accident may_also suffer physiologic consequence osa include hypertension coronary_artery_disease stroke congestive_heart_failure pulmonary_hypertension cardiac_arrhythmia possible cardiovascular consequence association osa hypertension found convincing although exact mechanism understood evidence osa associated frequent apnea causing mechanical effect intrathoracic pressure cardiac_function intermittent hypoxemia may turn cause endothelial_dysfunction increase sympathetic drive therapy continuous positive airway pressure demonstrated improve cardiopulmonary hemodynamics patient osa may reverse endothelial_cell dysfunction despite availability diagnostic measure effective_treatment many patient sleep disordered breathing remain undiagnosed therefore osa continues significant health risk affected individual general public awareness timely initiation effective_treatment may prevent potential deleterious cardiovascular effect osa:0.0624552464216506", "92526": "obstructive_sleep_apnea osa characterized recurrent episode partial hypopnea complete interruption apnea breathing sleep due airway collapse pharyngeal region osa cardiovascular consequence widely explored observational prospective_study evidence verifies positive relationship osa hypertension coronary_artery_disease atrial_fibrillation stroke_heart_failure however study_needed better assess impact osa possible benefit treatment continuous positive airway pressure cpap dyslipidemia type_diabetes insulin_resistance cardiovascular_mortality leading pathophysiological mechanism involved change triggered osa include intermittent hypoxemia oxygenation arousal change intrathoracic pressure hypertension strongly related activation sympathetic nervous_system stimulation renin_angiotensin_aldosterone_system impairment endothelial_function high_prevalence osa general_population hypertensive_patient especially obese individual patient resistant antihypertensive therapy highlight need effective screening diagnosis_treatment osa decrease cardiovascular_risk:0.0620247924732792", "103642": "obstructive_sleep_apnea osa condition repetitive partial complete closure upper airway result repeated reversible blood oxygen desaturation sleep fragmentation prevalence osa defined apnea hypopnea index ahi event hour woman_men random sample wisconsin state employee age_year increased male gender obesity age defined clinical syndrome ahi event hour combined significant sleepiness osa prevalence woman_men canadian community health survey reported prevalence osa canadian adult osa determined number sleep parameter abnormality measured polysomnography ahi arousal index minimum oxygen saturation po osa associated neurobehavioral morbidity reflected reduction epworth sleepiness score es quality_life increased cardiovascular_disease high blood_pressure heart_failure metabolic morbidity oxidative_stress osa associated substantial cost society due morbidity cost untreated osa potentially doubling medical expense mainly cardiovascular_disease osa related motor vehicle collision estimated u billion damage health_related cost treatment osa includes wide range option change diet lifestyle reduce risk_factor osa pharmacotherapy use continuous airway pressure cpap various oral device splint airway open facilitate airflow upper airway surgical treatment ontario patient waited mean month time referred sleep clinic time medical_therapy initiation month surgical therapy initiation rapid response report aim review clinical cost_effectiveness cpap compared oral device lifestyle change treatment osa:0.0612767875066171"}, "Topic 40": {"74669": "background guideline strongly recommend patient_heart_failure reduced_ejection_fraction_hfref treated multiple medication proven improve clinical_outcome tolerated degree gap medication use dosing persist contemporary outpatient practice unclear objective_study sought characterize pattern factor_associated use dose hfref medication current practice method champ hf change management patient_heart_failure registry included outpatient united_state chronic hfref receiving least oral medication management hf_patient characterized baseline use dose angiotensin_converting_enzyme_inhibitor acei angiotensin_ii receptor_blocker arb angiotensin_receptor neprilysin_inhibitor arni beta_blocker mineralocorticoid_receptor_antagonist mra patient level factor_associated medication use examined result overall patient primary_care cardiology practice included mean_age_year female mean ef among eligible patient prescribed acei_arb arni beta_blocker mra therapy respectively medication prescribed patient_receiving target dos acei_arb arni beta_blocker whereas patient_receiving target dos mra therapy among_patient eligible class medication simultaneously receiving target dos ace arb arni beta_blocker mra adjusted model older_age lower blood_pressure severe functional_class renal_insufficiency recent hf_hospitalization generally favored lower medication utilization dose social economic characteristic independently_associated medication use dose conclusion contemporary outpatient hfref registry significant gap use dose guideline_directed_medical_therapy remain multiple clinical factor_associated medication use dose prescribed strategy improve guideline_directed use hfref medication remain urgently needed finding may inform targeted approach optimize outpatient medical_therapy:0.0467852458592126", "188558": "introduction although several guideline recommend patient_heart_failure reduced_ejection_fraction_hfref treated angiotensin_converting_enzyme_inhibitor angiotensin_ii receptor_blocker aceis arb angiotensin_receptor neprilysin_inhibitor arnis beta_blocker mineralocorticoid_receptor_antagonist mras sodium_glucose_cotransporter_inhibitor sglt still several gap prescription dosage colombia study_aimed describe use pattern hfref treatment colombian heart_failure registry recolfaca method patient_hfref enrolled recolfaca included heart_failure_hf medication prescription daily dose assessed_using absolute number proportion therapeutic scheme patient_treated internal medicine specialist compared treated cardiologist result_patient registry hfref among individual prescribed beta_blocker acei_arb mras arnis moreover less third total_patient reached target dos recommended european hf guideline significant_difference therapeutic scheme target dos observed patient_treated internal medicine specialist cardiologist conclusion prescription rate target dose achievement suboptimal colombia nevertheless recolfaca one highest prescription rate beta_blocker mras compared recent hf registry however arnis remain underprescribed continuous registry update improve identification patient suitable arni sglt therapy promote use clinical_practice:0.0463426880666710", "109075": "background guideline recommend patient_heart_failure reduced_ejection_fraction_hfref medical_therapy titrated target dos derived clinical_trial tolerated degree titration occurs contemporary u practice unknown objective_study sought characterize longitudinal titration hfref medical_therapy clinical_practice identify associated factor reason medication change method among u outpatient chronic hfref champ hf change management patient_heart_failure registry complete medication data contraindication medical_therapy use dose angiotensin_converting_enzyme_inhibitor acei angiotensin_ii receptor_blocker arb angiotensin_receptor neprilysin_inhibitor arni beta_blocker mineralocorticoid_receptor_antagonist mra examined baseline month_follow result baseline patient_receiving target dos mra beta_blocker acei_arb arni therapy respectively month proportion_patient medication initiation dose increase mra beta_blocker acei_arb arni corresponding proportion discontinuation dose decrease respectively month patient simultaneously treated target dos acei_arb arni beta_blocker mra multivariate_analysis across class medication multiple patient_characteristic associated_higher likelihood initiation dose increase e_g previous hf_hospitalization higher blood_pressure lower ejection_fraction discontinuation dose decrease e_g previous hf_hospitalization impaired quality_life severe functional_class medical reason common reason discontinuation dose decrease therapy relative contribution patient preference health team system based reason varied medication conclusion contemporary u registry eligible hfref_patient receive target dos medical_therapy point follow patient dos increased time although patient alteration medical_therapy multiple clinical factor independently_associated medication change quality improvement effort urgently needed improve guideline_directed medication titration hfref:0.0458841356764186", "179053": "introduction optimization guideline_directed_medical_therapy gdmt improve prognosis patient_heart_failure_hf one main goal chronic care objective aimed assess implementation recommendation regarding gdmt optimization hf_patient undergoing scheduled hospitalization particular emphasis patient reduced left_ventricular_ejection_fraction_lvef patient_method analysis included_patient known lvef mean_sd age men admitted elective hospitalization representing subset participant hero study heart_failure observational_study polish cardiac society recruitment across polish center took place april may result mean_sd lvef study group patient_hf reduced lvef hfref constituted n whole group subgroup use angiotensin_receptor neprilysin_inhibitor arni angiotensin_converting_enzyme_inhibitor acei angiotensin_receptor_blocker arb increased patient admission discharge beta_blocker mineralocorticoid_receptor_antagonist mra sodium_glucose_cotransporter_inhibitor sglt arni acei_arb therapy optimized participant rate optimization beta_blocker mra sglt respectively however patient attained pillar gdmt sglt arni acei_arb beta_blocker mra dos equal target dose conclusion polish multicenter hero registry patient_hfref discharged pillar gdmt nevertheless attainment target high_dose gdmt remained suboptimal finding provide new insight variability gdmt implementation national level underline need strategy improve dosing optimization:0.0455294203872971", "199684": "aim central eastern europe cee quality care centre qcc survey evaluated implementation guideline_directed_medical_therapy gdmt device use discharge heart_failure_hf hospitalization cee gdmt underutilization remains concern method_result march january patient mean_age_year_male enrolled discharge centre across cee country patient_population included hf reduced_ejection_fraction_hfref hf mildly reduced_ejection_fraction hf preserved_ejection_fraction total population admission discharge increase use angiotensin_receptor neprilysin_inhibitor arni beta_blocker mineralocorticoid_receptor_antagonist mra sodium_glucose co transporter inhibitor sglt reduction angiotensin_converting_enzyme_inhibitor acei use p similar trend observed across hf phenotype including hfref increased use arni beta_blocker mra sglt lower acei use p discharge patient_received quadruple therapy hfref target dos titratable drug achieved hfref predictor gdmt underuse included older_age lower education living alone non ischaemic hf higher ejection_fraction chronic_kidney_disease hypotension hyperkalaemia prolonged hospitalization residual oedema among eligible hfref_patient discharged referred implantable_cardioverter_defibrillator cardiac_resynchronization_therapy conclusion cee qcc survey highlight substantial hospital gdmt implementation titration though device use remains limited targeted strategy needed enhance guideline implementation ensure optimal hf care across cee region:0.0450637371088051", "156975": "multiple landmark trial helped advance treatment_heart_failure reduced_ejection_fraction_hfref significantly past decade trial led introduction four main drug class esc guideline namely angiotensin_receptor neprilysin_inhibitor angiotensin_converting_enzyme_inhibitor beta_blocker mineralocorticoid_receptor_antagonist sodium_glucose_cotransporter_inhibitor life saving effect therapy shown additive becomes apparent within week maximally tolerated target dos drug class strived quickly possible recent evidence strong hf trial demonstrated rapid drug implementation titration superior traditional gradual step step approach valuable time lost titration accordingly multiple rapid drug implementation sequencing strategy proposed significantly reduce time needed titration process strategy urgently needed since previous large_scale registry shown guideline_directed_medical_therapy gdmt implementation challenge challenge reflected generally low adherence rate attributed factor considering patient health_care system local hospital health_care provider review four medication class used treat hfref seek present thorough overview data supporting current gdmt discus obstacle gdmt implementation titration identify multiple sequencing strategy could improve gdmt adherence sequencing strategy gdmt implementation gdmt guideline_directed_medical_therapy acei angiotensin_converting_enzyme_inhibitor arb angiotensin_ii receptor_blocker arni angiotensin_receptor neprilysin_inhibitor bb beta_blocker mra mineralocorticoid_receptor_antagonist sglt sodium_glucose co transporter inhibitor:0.0445883170049401", "200214": "introduction guideline_directed_medical_therapy gdmt heart_failure_reduced_ejection_fraction_hfref includes combination angiotensin_converting_enzyme_inhibitor acei angiotensin_receptor_blocker arb angiotensin_receptor neprilysin_inhibitor arni beta_blocker mineralocorticoid receptor_agonist mra sodium_glucose co transporter inhibitor sglt despite mortality benefit implementation remains suboptimal method_retrospective observational_study conducted three outpatient internal medicine cardiology clinic within east tennessee state university health system adult aged_year ejection_fraction_ef least_one outpatient follow december november included_patient contraindication gdmt end_stage_renal_disease limited life expectancy excluded gdmt use dosing none target dose beta_blocker acei_arb arni mra sglt assessed descriptive statistic logistic_regression_model used examine patient_characteristic treatment pattern result_among eligible patient_receiving target dos beta_blocker acei_arb arni mra sglt respectively quadruple therapy prescribed patient fewer achieved target dosing four medication class mra use strikingly low patient therapy despite well_established mortality benefit relative affordability multivariable regression_analysis revealed several notable association increasing age linked lower odds acei_arb arni use higher systolic_blood_pressure sbp favored treatment mra use likely among_patient lower sbp non ischemic_cardiomyopathy obesity absence atrial_fibrillation_af obesity absence af associated achieving target dose sglt therapy common younger patient lower ejection_fraction lower sbp type_diabetes_mellitus strongest predictor initiation dose optimization conclusion finding highlight significant gap gdmt implementation despite favorable patient profile high cost benefit ratio mra use remains limited cohort targeted intervention support gdmt initiation optimization eligible patient may_help reduce disparity heart_failure care:0.0441177945539350", "181273": "aim persistent symptom despite guideline_directed_medical_therapy gdmt poor tolerance gdmt hallmark patient_advanced heart_failure_hf reduced_ejection_fraction_hfref however real_world data gdmt use dose prognostic implication lacking method_result included consecutive_patient hfref least_one need help marker advanced hf enrolled multicentre registry beta_blocker bb administered patient angiotensin_converting_enzyme_inhibitor angiotensin_receptor_blocker angiotensin_receptor neprilysin_inhibitor acei_arb arni administered patient_received mineralocorticoid_receptor_antagonist mra overall target dos reached patient bb acei_arb arni mra respectively hypotension bradycardia kidney dysfunction hyperkalaemia main cause underprescription underdosing half patient receive target dos unknown cause bb acei_arb arni mra respectively proportion patient_receiving bb acei_arb arni lower among fulfilling hfa esc criterion advanced hf treatment bb acei_arb arni associated_lower risk_death hf_hospitalization adjusted hazard_ratio_hr_confidence_interval_ci hr_ci respectively_conclusion large real_world contemporary cohort patient_severe hfref least_one marker advanced hf prescription uptitration gdmt remained limited significant proportion_patient undertreated due unknown reason suggesting potential role clinical inertia either prescribing healthcare professional patient treatment bb acei_arb arni associated_lower mortality_morbidity:0.0439443645864100", "195356": "background_objective urgent hospitalization due acutely decompensated_heart_failure adhf unfavorable event trajectory disease patient condition decompensation frequently limit opportunity implement optimize guideline_directed_medical_therapy gdmt define task post hospital care essential gain knowledge regarding extent gdmt implementation day discharge adhf episode purpose analisis evaluate gdmt change hospitalization due adhf particular emphasis patient reduced_ejection_fraction method analysis conducted group_patient hospitalized due adhf known left_ventricular_ejection_fraction_lvef hero study prospective multi center observational_study result mean_age study group men_woman year mean lvef six patient_died hospitalization analysis whole group regardless ejection_fraction_ef arni angiotensin_receptor neprilysin_inhibitor acei angiotensin_converting_enzyme_inhibitor arb angiotensin_receptor_blocker use increased subject admission discharge beta_blocker use increased mra mineralocorticoid_receptor_antagonist use increased sglt sodium_glucose co transporter inhibitor use increased arni acei_arb therapy optimized subject optimization rate beta_blocker mras sglt respectively however patient reached level treatment corresponding sglt arni acei_arb betablocker mra dos conclusion patient_hospitalized due adhf hero study use gdmt discharge significantly_higher admission patient reduced_ejection_fraction gdmts drug class prescribed patient however insufficient number_patient attained high dos gdmt emphasizes need effective dose titration outpatient setting:0.0438684658680380", "200415": "background evaluate implementation guideline_directed_medical_therapy identify associated clinical factor among patient_heart_failure reduced_ejection_fraction_hfref receiving follow asella referral teaching hospital ethiopia method_conducted hospital based cross_sectional_study involving patient_hfref attending follow asella referral teaching hospital october december eligible participant adult lvef monthly clinic visit recent echocardiogram within two year data_collected structured interview chart review analyzed_using spss version result prescription rate renin_angiotensin_system inhibitor rasi beta_blocker mineralocorticoid_receptor_antagonist mra respectively however achieved target dos rasi beta_blocker mra three therapy guideline recommended target dos patient_received angiotensin_receptor neprilysin_inhibitor arni sodium_glucose co transporter inhibitor sglt primarily due cost availability multivariable_analysis baseline bradycardia adjusted_odds_ratio aor ci_p diabetes_mellitus aor ci_p significantly_associated achieving rasi target dos absence prior heart_failure_hospitalization associated_lower likelihood achieving mra target dose aor ci_p_conclusion implementation guideline_directed_medical_therapy hfref_patient suboptimal achieving target dos three available therapy patient_received arni sglt_inhibitor due availability cost barrier key clinical factor baseline heart_rate diabetes hospitalization history influenced medication optimization gdmt optimization hfref remains inadequate ethiopia policy intervention e_g formulary expansion structured titration protocol urgently needed:0.0433418039404498"}, "Topic 41": {"182829": "aim emperor preserved trial empagliflozin improved clinical_outcome patient_heart_failure_hf preserved_ejection_fraction pre specified analysis aim_study effect empagliflozin cardiovascular kidney outcome across spectrum kidney_function method_result patient categorized presence absence chronic_kidney_disease_ckd baseline ckd defined estimated_glomerular_filtration_rate egfr_ml_min urine albumin creatinine ratio mg g primary key secondary_outcome composite cardiovascular_death first hf_hospitalization primary_outcome ii total number hf_hospitalization iii egfr slope pre specified exploratory composite kidney outcome including sustained decline egfr chronic dialysis renal transplant median_follow_month total_patient randomized empagliflozin placebo ckd irrespective ckd status empagliflozin reduced primary_outcome ckd hazard_ratio_hr_confidence_interval_ci without ckd hr_ci interaction p total first recurrent hospitalization_hf ckd hr_ci without ckd hr_ci interaction p empagliflozin slowed slope egfr decline ml_min year patient ckd ml_min year patient_without ckd interaction p empagliflozin reduce pre specified kidney outcome patient_without ckd ckd hr_ci without ckd hr_ci interaction p slowed progression macroalbuminuria reduced risk acute_kidney_injury effect empagliflozin primary composite_outcome key secondary_outcome consistent across five baseline egfr category interaction p empagliflozin well_tolerated independent ckd status conclusion emperor preserved empagliflozin beneficial_effect key efficacy outcome patient_without ckd overall benefit safety empagliflozin consistent across wide range kidney_function spectrum baseline egfr_ml_min:0.0393710574985964", "34219": "background purpose_study evaluate serum bicarbonate level risk_factor renal outcome cardiovascular_event mortality_patient chronic_kidney_disease_ckd study_design observational cohort_study setting_participant participant ckd stage enrolled chronic renal_insufficiency cohort cric june december predictor serum bicarbonate level outcome renal outcome defined end_stage_renal_disease either initiation dialysis therapy kidney transplantation reduction estimated_glomerular_filtration_rate egfr atherosclerotic event myocardial_infarction_stroke peripheral arterial disease congestive_heart_failure event death measurement time event result mean egfr sd ml_min median serum bicarbonate level iqr meq l median_follow_year participant died renal outcome experienced atherosclerotic event congestive_heart_failure event adjusted analysis risk developing renal end_point lower per meq l increase serum bicarbonate level hr_ci_p association stronger participant egfr_ml_min hr_ci_p risk heart_failure increased hr_ci_p per meq l increase serum bicarbonate level meq l serum bicarbonate level associated independently atherosclerotic event hr_ci_p cause_mortality hr_ci_p limitation single measurement sodium bicarbonate conclusion cohort participant ckd low serum bicarbonate level independent_risk_factor kidney_disease progression particularly participant preserved kidney_function risk heart_failure higher upper extreme serum bicarbonate level association serum bicarbonate level cause_mortality atherosclerotic event:0.0393329695601618", "162008": "aim according kidney_disease improving global outcome kdigo guideline definition chronic_kidney_disease_ckd requires presence abnormal kidney structure_function month implication health ckd patient_heart_failure_hf defined using definition less known true health implication ckd patient objective current study identify patient_hf met kdigo criterion ckd examine outcome method_result veteran hf receiving kidney replacement_therapy data ambulatory serum_creatinine day apart ckd defined estimated_glomerular_filtration_rate egfr_ml_min n urinary albumin creatinine ratio uacr mg g n present twice month apart normal kidney_function nkf defined egfr_ml_min present month without uacr mg g n patient egfr_ml_min categorized four stage n n n n ml_min five year cause_mortality occurred_patient nkf four egfr stage uacr mg g albuminuria respectively compared nkf hazard_ratio_hr_confidence_interval_ci cause_mortality associated four egfr stage albuminuria respectively respective age adjusted hr_ci multivariable adjusted hr_ci similar pattern observed association hospitalization conclusion data needed define ckd using kdigo criterion available six ten patient ckd could defined seven ten patient data hf_patient kdigo defined ckd higher_risk poor_outcome explained abnormal kidney structure_function future study need examine whether ckd defined using single egfr characteristically prognostically different ckd defined using kdigo criterion:0.0390099476829629", "165301": "rationale objective clinical trajectory normoalbuminuric chronic_kidney_disease_ckd particularly absence diabetes yet well studied study_evaluated association kidney cardiovascular_outcome level albuminuria cohort_patient nondiabetic ckd study_design prospective_cohort_study setting_participant adult nondiabetic ckd without known glomerulonephritis diagnosed hypertensive nephrosclerosis unknown cause ckd participating chronic renal_insufficiency cohort cric study exposure albuminuria stage study entry outcome primary_outcome composite kidney halving estimated_glomerular_filtration_rate egfr kidney transplantation dialysis secondary_outcome egfr slope composite cardiovascular_disease event hospitalization_heart_failure myocardial_infarction_stroke cause_death cause_death analytical approach linear mixed effect cox_proportional_hazard regression_analysis result lower level albuminuria associated female_sex older_age primary_outcome compared normoalbuminuria moderate_severe albuminuria higher_rate kidney outcome adjusted_hazard_ratio ahr ci ahr ci respectively cardiovascular_outcome ahr ci ahr ci respectively normoalbuminuria mug mg n slower decline egfr_ml_min per_year compared moderate mug mg n ml_min per_year severe albuminuria mug mg n ml_min per_year adjusted analysis kidney outcome occurred average sooner among moderate year severe year albuminuria compared normoalbuminuria year whereas average time cardiovascular_outcome similar across albuminuria group year respectively limitation self report ckd etiology without confirmatory kidney biopsy residual confounding conclusion participant normoalbuminuric nondiabetic ckd experienced substantially slower ckd progression modestly lower cardiovascular_risk high_level albuminuria finding inform design future study investigating intervention among individual lower level albuminuria plain language summary diabetes hypertension leading_cause chronic_kidney_disease_ckd urine albumin level associated cardiovascular kidney_disease outcome among individual ckd however previous_study long_term clinical_outcome ckd largely included_patient diabetes well study_evaluated long_term_outcome across different level urine albumin among people without diabetes study found individual nondiabetic ckd low urine albumin much slower decline kidney_function modestly lower_risk cardiovascular_event compared high_level urine albumin individual low urine albumin much likely cardiovascular_event progression kidney_disease finding inform design future study investigating treatment among individual lower level albuminuria:0.0389123603402161", "194204": "background chronic_kidney_disease_ckd defined kdigo kidney_disease improving global outcome guideline abnormal kidney structure_function present month implication health kdigo defined ckd associated poor outcome_patient heart_failure_hf less known whether association vary left_ventricular_ejection_fraction objective_study aim determine prevalence outcome kdigo defined ckd heart_failure_preserved_ejection_fraction_hfpef heart_failure mildly reduced_ejection_fraction hfmref heart_failure_reduced_ejection_fraction_hfref method veteran hf diagnosis national veteran affair electronic health record data data ef kdigo defined ckd normal kidney_function nkf ckd defined value measured day apart estimated_glomerular_filtration_rate egfr_ml_min categorized egfr stage based last egfr_ml_min ml_min ml_min ml_min urinary albumin creatinine ratio uacr mg g albuminuria nkf defined value measured day apart egfr_ml_min without egfr_ml_min albuminuria year hf diagnosis patient categorized hfpef ef n hfmref ef n hfref ef n hr_ci year cause_mortality hf_hospitalization december associated ckd group_v nkf estimated using cox_regression result_among patient_hf nkf mortality occurred hf_hospitalization occurred hfpef hfmref hfref respectively compared nkf ckd associated_higher multivariable adjusted risk_death patient_hfpef hfmref hfref respectively respective risk hf_hospitalization higher egfr associated risk incrementally higher decreasing egfr except egfr_ml_min likely initiation dialysis follow albuminuria associated_higher multivariable adjusted risk_death hf_hospitalization hfpef hfmref hfref respectively association statistically_significant conclusion finding based kdigo defined ckd nkf provide new information best estimate true prevalence outcome ckd hfpef hfmref hfref:0.0386732039352823", "187781": "background finerenone non steroidal mineralocorticoid_receptor_antagonist improved kidney cardiovascular outcome_patient chronic_kidney_disease_ckd type_diabetes two phase outcome trial finerenone addition standard_care progression kidney_disease patient_non diabetic chronic_kidney_disease find ckd study investigates effect finerenone adult ckd without diabetes method find ckd nct eu ct randomized double_blind placebo controlled phase trial patient ckd non diabetic aetiology adult urinary albumin creatinine ratio uacr mg g estimated_glomerular_filtration_rate egfr_ml_min receiving maximum tolerated dose renin_angiotensin_system inhibitor randomized daily placebo finerenone mg depending egfr_ml_min primary efficacy outcome total egfr slope defined mean annual rate change egfr baseline_month secondary efficacy outcome include combined cardiorenal composite_outcome comprising time kidney failure sustained decrease egfr hospitalization_heart_failure cardiovascular_death well separate kidney cardiovascular composite_outcome adverse_event recorded assess tolerability safety result across country patient screened randomized study treatment common_cause ckd chronic glomerulonephritis hypertensive ischaemic nephropathy immunoglobulin nephropathy common glomerulonephritis total population baseline mean egfr median uacr ml_min mg g respectively diuretic used participant statin calcium_channel blocker sodium_glucose co transporter sglt_inhibitor used patient individual similar mean egfr versus ml_min slightly higher median uacr versus mg g compared using sglt_inhibitor baseline conclusion find ckd first phase trial finerenone patient ckd non diabetic aetiology:0.0385508205042153", "130464": "objective finerenone reduced risk kidney cardiovascular_event people chronic_kidney_disease_ckd type_diabetes fidelio dkd figaro dkd phase study effect finerenone outcome_patient taking sodium_glucose_cotransporter_inhibitor sglt evaluated prespecified pooled analysis study research design method_patient type_diabetes urine albumin creatinine ratio uacr mg g estimated_glomerular_filtration_rate egfr_ml_min randomly_assigned finerenone placebo sglt permitted time outcome included cardiovascular composite cardiovascular_death nonfatal myocardial_infarction nonfatal stroke hospitalization_heart_failure kidney composite kidney failure sustained egfr decline renal death end_point change uacr egfr safety outcome result among_patient received sglt baseline initiated one trial cardiovascular composite hazard_ratio hr_ci without sglt ci sglt kidney composite hr_ci without sglt ci sglt baseline sglt use affect risk reduction cardiovascular kidney composite finerenone pinteraction respectively neither sglt use concomitant study treatment conclusion benefit finerenone compared_placebo cardiorenal outcome_patient ckd type_diabetes observed irrespective sglt use:0.0385439396678468", "151404": "rationale objective fidelity finerenone improved cardiorenal outcome_patient chronic_kidney_disease_ckd type_diabetes analysis explores efficacy_safety finerenone hispanic patient study_design post_hoc analysis fidelity prespecified pooled analysis fidelio dkd figaro dkd randomized control trial setting_participant patient type_diabetes ckd urinary albumin creatinine ratio uacr mg g estimated_glomerular_filtration_rate egfr_ml_min uacr egfr_ml_min optimized renin_angiotensin_system blockade intervention finerenone placebo outcome cardiovascular composite cardiovascular_death nonfatal myocardial_infarction nonfatal stroke hospitalization_heart_failure kidney composite kidney failure sustained egfr decline renal death change uacr result_patient self identified hispanic median_follow_year cardiovascular composite_outcome occurred hispanic patient_receiving finerenone hispanic patient_receiving placebo hr_ci consistent non hispanic patient hr_ci_p interaction kidney composite_outcome occurred hispanic patient finerenone placebo respectively hr_ci risk reduction consistent observed non hispanic patient hr_ci_p interaction finerenone reduced uacr month hispanic non hispanic patient versus placebo p patient_group safety profile finerenone incidence hyperkalemia similar hispanic non hispanic patient_group limitation small sample size short follow time lower treatment adherence hispanic population conclusion overall efficacy_safety finerenone similar hispanic non hispanic patient ckd type_diabetes funding bayer ag trial_registration clinicaltrials_gov identifier_nct nct plain language summary chronic_kidney_disease_ckd patient type_diabetes occurs frequently hispanic patient_non hispanic patient rapid progression kidney failure treatment finerenone reduces risk kidney heart event starting dialysis heart attack patient ckd type_diabetes clinical_trial investigate treatment ckd type_diabetes included enough hispanic patient benefit treatment particularly hispanic patient frequently unknown study explores benefit finerenone hispanic patient overall study show finerenone provide kidney heart benefit hispanic patient ckd type_diabetes non hispanic patient:0.0383616105193635", "144862": "background patient chronic_kidney_disease_ckd type_diabetes risk atrial_fibrillation flutter aff due cardiac_remodeling kidney complication finerenone novel selective nonsteroidal mineralocorticoid_receptor_antagonist inhibited cardiac_remodeling preclinical model objective work aim examine effect finerenone new_onset aff cardiorenal effect history aff finerenone reducing kidney failure disease_progression diabetic kidney_disease fidelio dkd study method_patient ckd randomized finerenone placebo eligible patient urine albumin creatinine ratio mg g estimated_glomerular_filtration_rate egfr_ml_min received optimized dos renin_angiotensin_system blockade effect new_onset aff evaluated pre specified outcome adjudicated independent cardiologist committee primary composite_outcome time first onset kidney failure sustained decrease egfr baseline death renal cause key secondary_outcome time first onset cardiovascular_death nonfatal myocardial_infarction nonfatal stroke hospitalization_heart_failure analyzed history aff result_patient history aff new_onset aff occurred_patient finerenone patient placebo hazard_ratio_confidence_interval_p effect finerenone primary key secondary kidney cardiovascular_outcome significantly impacted baseline aff interaction p_value respectively conclusion_patient ckd finerenone reduced risk new_onset aff risk kidney cardiovascular_event reduced irrespective history aff baseline eudract randomized double_blind placebo controlled parallel group multicenter event driven phase iii study investigate efficacy_safety finerenone addition standard_care progression kidney_disease subject type_diabetes_mellitus clinical diagnosis diabetic kidney_disease efficacy_safety finerenone subject type_diabetes_mellitus diabetic kidney_disease fidelio dkd nct:0.0378266861601453", "128410": "objective finerenone significantly_improved cardiorenal outcome_patient chronic_kidney_disease_ckd type_diabetes finerenone reducing kidney failure disease_progression diabetic kidney_disease trial explored whether baseline hba_c level insulin treatment influenced outcome research design method_patient urine albumin creatinine ratio uacr mg g estimated_glomerular_filtration_rate egfr_ml_min treated optimized renin_angiotensin_system blockade randomly_assigned receive finerenone placebo efficacy outcome included kidney kidney failure sustained decrease egfr baseline renal death cardiovascular cardiovascular_death nonfatal myocardial_infarction nonfatal stroke hospitalization_heart_failure composite_endpoint patient analyzed baseline insulin use baseline hba_c mmol mol result_patient received insulin baseline overall patient_included analysis hba_c baseline hba_c mmol mol finerenone significantly_reduced risk kidney composite_outcome independent baseline hba_c level insulin use pinteraction respectively cardiovascular composite_outcome incidence reduced finerenone irrespective baseline hba_c level insulin use pinteraction respectively although baseline hba_c level affect kidney event risk cardiovascular_risk increased higher hba_c level uacr reduction consistent across subgroup adverse_event similar group regardless baseline hba_c level insulin use finerenone treated patient discontinued treatment hyperkalemia conclusion finerenone reduces kidney cardiovascular_outcome risk patient ckd risk appear consistent irrespective hba_c level insulin use:0.0378012664678190"}, "Topic 42": {"36420": "myocytes failing myocardium exhibit depressed prolonged intracellular ca concentration ca transient part responsible contractile dysfunction unstable repolarization better understand molecular basis aberrant ca handling heart_failure_hf studied rabbit pacing tachycardia hf model induction hf associated action potential ap duration prolongation especially pronounced low stimulation frequency l type calcium_channel current ca l density v pa pf mv na ca exchanger ncx current v pa pf mv different myocytes control failing_heart amplitude peak ca depressed mv microm normal failing_heart respectively_p slowed rate decay reduced ca spark amplitude p myocytes isolated failing v control heart inhibition sarco endo plasmic reticulum ca atpase serca revealed greater reliance ncx remove cytosolic ca myocytes isolated failing v control heart p mrna level alpha c subunit ryanodine receptor ryr ncx unchanged control serca phospholamban plb significantly downregulated failing v control heart p alpha c protein_level unchanged ryr serca plb significantly downregulated p ncx protein significantly upregulated p result support prominent role sarcoplasmic_reticulum sr pathogenesis hf abnormal sr_ca uptake release synergistically contribute depressed ca altered ap profile phenotype:0.0423667684768265", "196975": "previous_study observed alteration excitation contraction ec coupling end_stage_heart_failure include action potential calcium ca transient prolongation reduction ca transient amplitude underlying phenomenon downregulation potassium k current downregulation sarcoplasmic_reticulum ca atpase serca increase ca sensitivity ryanodine receptor upregulation sodium calcium na ca exchanger however human heart_failure_hf debate continues relative contribution change calcium handling v change membrane current understand consequence change incorporated computational human ventricular myocyte hf model explore contribution spontaneous ca release sarcoplasmic_reticulum sr reduction transient outward k current main membrane current contributor decrease ryr open probability l type calcium_channel lcc density emphasizes importance phase action potential ap shape duration apd current clamp condition ryr hyperphosphorylation exhibit least amount ca release sr cytosol sr_ca fractional release dynamic slow rapid slow hz pacing display abundant lasting ca spark two fold longer normal cell hand voltage clamp condition hf decreased serca upregulated ncx show least sr_ca uptake ec coupling gain compared hf hyperphosphorylated ryr overall study demonstrates combined effect serca ncx b ryr dysfunction along downregulation cardiomyocyte potassium current could substantially contribute ca mishandling spark level lead heart_failure:0.0400354773405250", "15259": "background congestive_heart_failure_chf common_cause atrial_fibrillation focal source unknown mechanism described chf related atrial_fibrillation author hypothesized abnormal calcium ca handling contributes chf related atrial arrhythmogenic substrate method_result chf induced dog ventricular tachypacing bpm x week cellular ca handling property expression phosphorylation status key ca handling myofilament protein assessed control chf atrium chf decreased cell shortening increased left_atrial diastolic intracellular ca concentration ca ca transient amplitude sarcoplasmic_reticulum sr_ca load caffeine induced ca release sr_ca overload associated spontaneous ca transient event triggered ectopic activity suppressed inhibition sr_ca release ryanodine na ca exchange mechanism_underlying abnormal sr_ca handling studied chf increased atrial action potential duration action potential voltage clamp showed chf like action potential enhance ca loading chf increased calmodulin dependent protein_kinase ii phosphorylation phospholamban potentially enhancing sr_ca uptake reducing phospholamban inhibition sr_ca atpase affect phosphorylation sr_ca release channel ryr total ryr calsequestrin main sr_ca binding protein_expression significantly_reduced potentially contributing sr dysfunction chf decreased expression total protein_kinase phosphorylated myosin binding protein c key contractile filament regulator potentially accounting decreased contractility despite increased ca transient complex phosphorylation change explained enhanced calmodulin dependent protein_kinase iidelta expression function type protein phosphatase activity downregulated regulatory protein_kinase subunit conclusion chf cause profound change ca handling regulatory protein produce atrial_fibrillation promoting atrial cardiomyocyte ca handling abnormality arrhythmogenic triggered activity contractile dysfunction:0.0394881497567958", "13463": "micrornas small endogenous noncoding rna regulate protein_expression hybridization imprecise complementary sequence target mrna change abundance muscle specific microrna mir implicated cardiac_disease including arrhythmia heart_failure however specific molecular target cellular mechanism involved action mir heart beginning emerge study_investigated effect increased expression mir excitation contraction coupling ca cycling rat ventricular myocytes using method electrophysiology ca imaging quantitative immunoblotting adenoviral mediated overexpression mir myocytes resulted marked increase amplitude inward ca current flattening ca transient voltage dependence enhanced frequency spontaneous ca spark reducing sarcoplasmic_reticulum ca content compared_control presence isoproterenol rhythmically paced mir overexpressing myocytes exhibited spontaneous arrhythmogenic oscillation intracellular ca event occurred rarely control myocytes condition effect mir completely reversed camkii inhibitor kn although phosphorylation phospholamban altered mir overexpression increased phosphorylation ryanodine receptor ryr ca calmodulin dependent protein_kinase protein_kinase overexpression mir accompanied selective decrease expression protein phosphatase pp regulatory subunit b alpha involved pp targeting specialized subcellular domain conclude mir enhances cardiac excitation contraction coupling selectively increasing phosphorylation l type ryr channel via disrupting localization pp activity channel:0.0383368356318331", "3224": "progressive deterioration cardiac contractility central feature congestive_heart_failure_chf human report review study addressed idea alteration intracellular calcium ca regulation primarily responsible depressed contractility failing_heart review point ca transient contraction similar non failing failing myocytes slow frequency stimulation low stress environment faster pacing rate high ca beta_adrenergic stimulation reveal large reduction contractile reserve failing myocytes underlying cellular basis defect considered study showing change abundance l type ca channel ca transport protein sarcoplasmic_reticulum ca atpase serca phospholamban plb na ca exchanger ncx ca release channel ryr excitation contraction coupling ca release uptake sarcoplasmic_reticulum sr reviewed observation support hypothesis defective ca regulation involves multiple molecule process one molecule ii initiation progression chf inolves defective ca regulation iii prevention correction ca regulatory defect early_stage cardiac_disease delay prevent onset chf:0.0378190050384559", "82240": "sarcoplasmic_reticulum sr_ca release play essential role mediating cardiac myocyte contraction depolarization plasma membrane result influx ca l type ca channel ltccs turn trigger efflux ca sr ryanodine receptor type channel ryr process known ca induced ca release cicr occurs within dyadic region adjacent transverse tubule sr membrane allow ryr cluster release sr_ca following ca influx adjacent ltccs sr_ca released systole bind troponin c initiate actin myosin cross bridging leading muscle contraction diastole cytosolic ca concentration restored resequestration ca sr sr er ca atpase serca extrusion ca via na ca exchanger ncx whole process entitled excitation contraction ec coupling highly coordinated determines force contraction providing link electrical mechanical activity cardiac muscle response heart_failure_hf heart undergoes maladaptive change result depressed intracellular ca cycling decreased sr_ca concentration result amplitude cicr reduced resulting less force production ec coupling review discus specific protein alter regulation ca hf particular focus defect ryr mediated sr_ca release article part special issue entitled heart_failure pathogenesis emerging diagnostic therapeutic_intervention:0.0374455936758923", "143452": "type sarco endoplasmic reticulum ca atpase serca play central role intracellular ca homeostasis cardiac_myocytes pumping ca cytoplasm sarcoplasmic_reticulum sr lumen maintain relaxation diastole prepare contraction systole diminished serca function reported several pathological condition including heart_failure therefore development new drug improve serca ca transport great clinical significance study characterized effect recently identified n aryl n alkyl thiophene carboxamide compound serca ca atpase ca transport activity cardiac sr vesicle ca regulation hek cell expression system mouse ventricular myocytes found compound enhances serca ca atpase ca transport sr vesicle fluorescence lifetime measurement fluorescence resonance energy transfer serca phospholamban indicated compound interacts serca phospholamban complex measurement endoplasmic reticulum ca dynamic hek cell expressing human serca showed compound increase endoplasmic reticulum ca load enhancing serca mediated ca transport analysis cytosolic ca dynamic mouse ventricular myocytes revealed compound increase action potential induced ca transient sr_ca load negligible effect l type ca channel na ca exchanger however adrenergic receptor activation compound increase ca transient sr_ca load decreased propensity toward ca wave suggestive concurrent desirable effect compound ryr h ryanodine binding cardiac sr vesicle show small decrease nm ca small increase mum ca accordingly compound slightly decreased ca spark permeabilized myocytes thus novel compound show promising characteristic improve intracellular ca dynamic cardiomyocytes exhibit reduced serca ca uptake found failing_heart:0.0372401267394788", "34576": "alteration excitation contraction coupling recently shown play crucial role pathogenesis heart_failure_hf failing_heart abnormality neurohormonal mechanism included chronic activation sympathetic nervous_system renin_angiotensin_system result structural_functional change calcium ca regulatory protein change include decreased sarcoplasmic_reticulum sr load could caused reduced sr_ca atpase serca function increased sr_ca leak via cardiac ryanodine receptor ryr functional defect l type ca channel activation reversal mode na ca exchanger abnormal regulation intracellular ca affect troponin c binding actin myosin cross bridging modulates post signaling_pathway turn contributes contractile dysfunction heart hence progression hf moreover diastolic ca leak may develop delayed depolarization triggered activity substrate lethal arrhythmia sudden_cardiac_death review_focus underlying_mechanism defective ca regulation hf possibility proceeding clinical_application new treatment hf targeting ca regulatory protein:0.0368776072082187", "57258": "cardiomyocytes isolated failing human_heart characterized contractile dysfunction including prolonged relaxation reduced systolic force elevated diastolic force contractile abnormality paralleled abnormal ca homeostasis reduced sarcoplasmic_reticulum sr_ca release elevated diastolic ca reduced rate ca removal addition failing human myocardium characterized frequency dependent decrease systolic force ca opposed normal myocardium increase pacing rate result potentiation contractility increase sr_ca release failing_heart decrease sr_ca load linked decrease sr_ca atpase serca function recently shown overexpression serca adenoviral gene transfer restores contractile_function cardiac_myocytes failing human_heart addition shown overexpression serca model pressure_overload hypertrophy transition failure improves contractile_function reserve animal currently exploring effect long_term expression serca failing animal along energy cost serca expression using nmr method also using different strategy improve sr_ca atpase activity involves decreasing expression phospholamban antisense strategy enhance sr_ca atpase activity na ca exchanger also targeted enhance calcium removal failing_heart action potential prolongation attributed reduction transient outward current ito density human heart_failure prolongation alter contractility also cause afterdepolarization using gene transfer various k channel responsible ito investigating molecular ionic basis action potential prolongation cardiac_hypertrophy failure examining intracellular calcium handling change response alteration action potential duration gene transfer serf initially experimental tool may_provide novel therapeutic_approach:0.0363439081717809", "594": "calcium ca ion currency heart muscle activity excitation contraction coupling ca rapidly cycled cytosol activates myofilaments sarcoplasmic_reticulum sr_ca store flux occur transient activity ca pump channel failing human_heart change activity expression profile ca handling protein particular sr_ca atpase serca thought cause overall reduction amount sr_ca available contraction steady state ca content sr essentially balance ca uptake via serca pump ca release via cardiac sr_ca release channel complex ryanodine receptor ryr review discusses current pharmacological option available enhance cardiac sr_ca content implication approach inotropic therapy heart_failure two option considered activation serca pump increase sr_ca uptake ii reduction sr_ca leakage ryr ryr form macromolecular complex number regulatory protein either remain permanently bound interact time ca dependant manner regulatory protein dramatically affect ryr function e_g expression accessory protein fk binding protein fkbp recently shown reduce sr_ca leak recent attempt design positive inotropes chronic administration focussed use phosphodiesterase iii inhibitor pde iii inhibitor compound increase intracellular camp level failed clinical_trial therefore medical researcher seeking new drug act alternative pathway novel cardiac inotropes targeting sr_ca cycling protein may potential fill gap:0.0359298687156484"}, "Topic 43": {"30074": "background sleep disordered breathing sdb including cheyne stokes respiration central sleep_apnea csr csa cause deterioration prognosis_patient chronic_heart_failure_chf adaptive servo ventilation asv oxygen therapy useful improving csr csa chf purpose present_study examine short_term effect asv suppressing sdb csr csa dominant chf accompanying neurohumoral abnormality cardiac overload sympathetic nervous activation myocardial damage method_result forty two patient_chf sdb mean lvef apnea hypopnea index ahi h central apnea index cai h obstructive apnea index oai h enrolled performed polysomnography baseline asv consecutive day measured level atrial natriuretic_peptide anp b_type_natriuretic_peptide_bnp noradrenalin urinary catecholamine high_sensitivity troponin asv reduced ahi cai arousal index mean heart_rate sleep level noradrenalin urinary catecholamine high_sensitivity troponin however asv decreased level anp bnp conclusion asv reduces cardiac overload attenuates sympathetic nervous activity ongoing myocardial damage effectively chf_patient sdb patient cannot use asv alternative therapy:0.0660305959115548", "38465": "background effect nasal oxygen supply night using conventional home oxygen therapy hot equipment quality_life qol sleep disordered breathing sdb evaluated patient congestive_heart_failure_chf nasal nocturnal therapy stabilizes sdb also reduces sympathetic activity improves exercise_capacity patient_chf however effect oxygen cardiac_function qol heart_failure_patient fully elucidated method_result fifty six patient_chf new_york_heart_association_class ii_iii left_ventricular_ejection_fraction_lvef central sleep_apnea csa cheyne stokes respiration csr randomly_assigned receive either nocturnal hot group_n usual breathing control_group n week respiration airflow arterial oxygen level monitored determination apnea hypopnea index ahi oxygen desaturation index odi sleep lv_function determined radionuclide angiography echocardiography qol assessed specific activity scale questionnaire hot group nocturnal resulted significant_improvement ahi event h mean_sd p odi dip h p specific activity scale mets p lvef also increased baseline end study p_conclusion patient_stable chf csr hot night improves sdb lv_function qol thus valuable nonpharmacological option treatment patient_chf csr csa:0.0613785556735395", "21150": "study objective central sleep_apnea csa associated cheyne stokes respiration patient congestive_heart_failure_chf thought acquired pattern respiratory control instability related least part elevated sympathetic nervous_system activity effect restoring heart_function normal heart_transplantation patient_chf csa reported within week transplant varying result purpose_study evaluate impact successful heart_transplant sympathetic nervous_system activity csa severity patient_chf design controlled prospective trial setting university_hospital patient twenty two_patient chf_patient csa patient sleep disordered breathing sdb intervention measurement polysomnography left_ventricular_ejection_fraction_lvef overnight urinary norepinephrine excretion une measured month successful heart_transplantation result csa group fall apnea hypopnea index ahi mean_sd h p une nmol mmol creatinine p associated normalization lvef p month following heart_transplantation csa group following transplantation seven patient sdb ahi h three_patient persistent csa ahi h four patient acquired obstructive_sleep_apnea osa ahi h comparison none control_group acquired csa osa transplantation conclusion conclude csa may persist despite normalization heart_function sympathetic_nerve activity:0.0605166642934145", "56865": "adaptive servo ventilation asv novel method ventilatory support designed cheyne stokes respiration csr heart_failure aim_study compare effect one night asv sleep breathing effect treatment fourteen subject stable cardiac_failure receiving optimal medical_treatment tested untreated four treatment night random order nasal oxygen l_min continuous positive airway pressure cpap mean cm h bilevel mean cm h asv largely default setting mean pressure cm h polysomnography thermistor apnea hypopnea index ahi declined h sem untreated h oxygen h cpap p versus control h bilevel h asv p versus bilevel effort band ahi behaved similarly arousal index decreased h untreated h oxygen h cpap h bilevel h asv p versus except bilevel large increase slow wave rapid eye movement rem sleep asv oxygen cpap subject preferred asv cpap one night asv suppresses central sleep_apnea csr csa csr heart_failure improves sleep quality better cpap l_min oxygen:0.0578903334105174", "44681": "background manifestation central sleep_apnea csa cheyne stokes respiration major prognostic impact chronic_heart_failure_chf inflammatory process linked progression cardiovascular_disease including heart_failure association c_reactive_protein crp level obstructive_sleep_apnea documented lack information regarding variation crp level patient csa objective objective_study investigate potential association crp level csa severity chf_patient method high_sensitivity crp level analyzed patient_chf bmi new_york_heart_association_class left_ventricular_ejection_fraction n_terminal_pro_brain_natriuretic_peptide nt_probnp_level pg_ml without sleep disordered breathing sdb apnea hypopnea index ahi h various degree csa documented hospital cardiorespiratory polygraphy polysomnography result crp concentration chf_patient mg_dl patient_without sdb ahi h n versus mg_dl patient mild csa ahi h n p n mg_dl patient moderate csa ahi h n p n patient_severe csa ahi h n significantly_higher crp concentration documented mg_dl p stepwise regression_analysis revealed ahi nt_probnp heart_rate independently_associated elevated crp level conclusion severe csa chf_patient associated elevated level crp systemic marker inflammation cardiovascular_risk might explain part negative prognostic impact csa patient:0.0573438120459970", "33095": "background coexistence obstructive_sleep_apnea osa central sleep_apnea csa cheyne stokes respiration csr common patient_heart_failure_hf cpap improves csa csr maximal suppression crucial improving clinical_outcome auto servoventilation asv effectively suppresses csa csr hf trial performed_patient coexisting osa csa csr objective_evaluate randomized_controlled_trial compare efficacy asv cpap reducing breathing disturbance improving cardiac parameter patient_hf coexisting sleep disordered breathing method mode delivered using bipap autosv philip respironics month period seventy patient men bmi kg coexisting osa csa csr arterial_hypertension coronary_heart_disease cardiomyopathy clinical sign heart_failure new_york_heart_association_class ii_iii polysomnography brain_natriuretic_peptide_bnp spiroergometry echocardiography performed baseline_month treatment result mode therapy significantly_improved respiratory disturbance oxygen desaturations arousal study_period asv reduced central apnea hypopnea index baseline cpap asv month cpap asv p bnp_level baseline cpap ng_ml asv month cpap asv p significantly effectively compared cpap relevant difference exercise performance echocardiographic_parameter group_conclusion asv improved csa csr bnp month period effectively cpap:0.0571674390062481", "16175": "cheyne stokes respiration csr form central sleep disordered breathing sdb cyclical fluctuation breathing lead period central apnea hypopnea alternate period hyperpnea crescendo decrescendo pattern respiration csr compensation changing level blood oxygen carbon dioxide severe congestive_heart_failure seems important risk_factor development csr number pathophysiologic change sleep disruption arousal hypoxemia reoxygenation hypercapnia hypocapnia change intrathoracic pressure harmful effect cardiovascular_system presence csr associated_increased mortality_morbidity subject variable degree heart_failure management csr involves optimal control underlying heart_failure oxygen therapy positive airway pressure support review initially define describe epidemiology central sleep_apnea csa csr pathogenesis clinical_presentation diagnostic method discus recent development management patient_heart_failure:0.0571611842013945", "68695": "objective_determine sleep disordered breathing patient decompensated hf dhf altitude method polysomnogram first hour admission patient_hospitalized dhf sleep_apnea sa defined apnea hypopnea index ahi hour central sleep_apnea csa central apnea index cai ahi result sixteen participant lvef patient sa severe csa presented cheyne stokes respiration csr eight patient obstructive sa five central component cai h spo decreased sleep patient csr conclusion altitude patient dhf presented sleep_apnea severe csa significant percentage csr associated_higher oxygen desaturation:0.0564484641523757", "51025": "purpose adaptive servo ventilation asv positive pressure ventilator support system normalize ventilation patient cheyne stokes respiration csr latest generation enhanced asv device pacewave resmed new feature auto adjustment epap study tested hypothesis enhanced asv auto adjustment epap pacewave non inferior conventional asv autosetcs method prospective randomized crossover single_center study enrolled adult_patient stable heart_failure_hf moderate_severe sleep disordered breathing sdb receiving conventional asv therapy least week patient_received conventional asv one night enhanced asv another night support setting two asv device similar fixed expiratory positive airway pressure epap set cm h variable epap set cm h full polysomnography performed asv therapy night endpoint number nocturnal respiratory event oxygen desaturations change blood_pressure bp result level epap comparable use enhanced conventional asv minimum maximum inspiratory pressure support value significantly_higher pacewave device measure apnea hypopnea oxygen saturation significantly_improved asv therapy either device significant_change bp heart_rate conclusion enhanced asv non inferior asv fixed epap patient_chronic hf csr trend towards better control respiratory event:0.0559518125756053", "63558": "background sleep disordered breathing sdb cheyne stokes respiration csr particular associated_reduced survival patient_acute decompensated_heart_failure adhf csr cycle length cl shown mirror heart_failure severity therefore may predictor outcome however study characterizing csr adhf rare study_investigated change csr admission discharge adhf patient_method consecutive_patient admitted academic medical_center adhf eligible study patient_underwent two multichannel cardiorespiratory polygraphy pg recording one admission another recompensation result_patient age_year male nyha_class left_ventricular_ejection_fraction brain_natriuretic_peptide pg_ml two fully analyzable pg recording csa prevalence first pg based apnea hypopnea index ahi csa mild moderate_severe patient respectively adhf treatment ahi decreased non significantly h h p central hypopnea index h h p time spent csr min p oxygenation improved p significant_change cl conclusion_patient adhf high_prevalence central respiratory event decreased cardiac recompensation cardiac recompensation also non significantly_improved ahi time spent csr oxygenation clear impact csr cl leaf clinical account open investigation:0.0556532566197364"}}